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Abstract
Neurodegenerative diseases are progressive, incurable conditions characterized by neuronal
degeneration and protein aggregation, resulting in cognitive decline and/or motor
dysfunction. Over half a million Canadians are affected with these diseases, and the number
of cases is expected to rise as the aging population grows and average lifespans continue to
increase. There are currently no curative treatments, and only few therapeutics are available
to target disease symptoms or slow disease progression. Further, diagnosis can be
challenging, relying on clinical features that are often highly heterogeneous between patients.
Gaining a greater understanding of the full spectrum of genetic factors contributing to these
diseases may offer the opportunity to more accurately assess risk of disease development,
improve diagnosis, and identify potential therapeutic targets. By leveraging the unique study
design of the Ontario Neurodegenerative Disease Research Initiative (ONDRI) — a multiplatform study characterizing neurodegenerative diseases and cerebrovascular disease (CVD)
— I have made significant progress in the elucidation of overlapping genetic determinants
across neurodegenerative diagnoses. Using a targeted next-generation sequencing (NGS)
approach, I comprehensively genetically characterized the ONDRI cohort (n = 519),
including participants diagnosed with: 1) Alzheimer’s disease (AD); 2) amyotrophic lateral
sclerosis (ALS); 3) frontotemporal dementia (FTD); 4) mild cognitive impairment (MCI); 5)
Parkinson’s disease (PD); and 6) CVD. I identified associations between common genotypes
or haplotypes of high phenotypic effect and neurodegenerative disease presentation and
features. I also assessed novel gene-disease relationships and the potential genetic overlap
between neurodegenerative and cerebrovascular diagnoses through the assessment of rare
genetic variation captured by the targeted NGS panel and gold-standard Sanger sequencing
methods. Finally, I identified a novel association between Notch receptor 3 (NOTCH3) rare
variants and CVD burden in participants with PD. The work presented throughout this
Dissertation highlights the complexity of neurodegenerative disease genetic risk factors by
demonstrating a large amount of overlap between specific diagnoses. The findings contribute
to the longstanding effort to fully understand the genetic architecture of neurodegenerative
diseases and improve therapeutic development, diagnostic tools, and progression prediction.
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Summary for Lay Audience
Neurodegenerative diseases are conditions characterized by progressive deterioration of brain
cells resulting in memory loss, behavioural changes, and lack of muscle control. It was
projected that more than 500,000 Canadians were affected with these diseases in 2016 — a
number that will continue to rise in tandem with the aging population. Currently,
neurodegenerative diseases lack treatment options with no ability to stop progression or even
slow it to a manageable capacity, and accurate diagnosis can be difficult. To mitigate these
issues, the Ontario Neurodegenerative Disease Research Initiative (ONDRI) study is aiming
to gain a greater understanding of the risk factors and disease course of multiple
neurodegenerative diseases including: 1) Alzheimer’s disease; 2) amyotrophic lateral
sclerosis; 3) frontotemporal dementia; 4) mild cognitive impairment; and 5) Parkinson’s
disease, as well as determining how cerebrovascular incidents, such as strokes, may influence
neurodegeneration. Within this Dissertation, I present my work studying the DNA changes,
or “genetic variants,” that may be increasing the participants’ risk of disease. To do this, I
applied a DNA sequencing method to look for genetic changes within 80 genes that are
known to contribute to the risk of neurodegenerative disease or stroke. In doing so, I
determined that genetic risk for the various neurodegenerative diseases is complex, with
some individuals carrying common variants that increase their disease risk and others
carrying DNA variants that are much rarer. I also identified new associations between genetic
variants in specific genes and individual neurodegenerative diseases. Finally, my results
suggested that in addition to genetic variants that increase risk of disease, there may be
genetic variants that cause individuals with the same diagnosis to present differently from
one another. The application of my findings may provide further insight into what is causing
neurodegenerative diseases on a molecular level and will allow for the development of new
treatments and gene-sequencing-based early-diagnosis and risk-assessment tools.
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Chapter 1 – Introduction
1.1

Overview

Neurodegenerative diseases are a collection of progressive and incurable conditions
characterized by neuron degeneration and resulting in cognitive decline — also referred
to as dementia — and/or motor dysfunction. It was projected that, in 2016, more than
500,000 Canadians were affected by the diseases, and worldwide prevalence is predicted
to double within the next 20 years ("Chapter 3: Mapping Connections: An understanding
of neurological conditions in Canada – Scope (prevalence and incidence)," 2014;
Dudgeon, 2010). Similarly, when considering dementia patients alone, care costs totaled
over $10 billion in 2016 and are estimated to double by 2031, including direct costs to the
healthcare system and out of pocket costs of patients and their loved ones. Aside from
these financial burdens, caregivers of individuals with dementia performed a collective
19.2 million hours of unpaid care across Canada in 2011 (Chambers, Bancej, &
McDowell, 2016). Further, the World Health Organization has estimated that, by 2040, as
the aging population is increasing, neurodegenerative diseases will overtake cancer as the
second leading cause of death worldwide, only behind cardiovascular disease (Gammon,
2014).
Although encompassing a wide variety of specific diagnoses, all neurodegenerative
diseases share common features, most notably, the greatest risk factor for the diseases’
developments — increasing age (Hou et al., 2019). The specific diagnoses can be
categorized into two main subtypes: 1) motor/movement disorders and 2) cognitive
and/or behavioural disorders. The former encompasses diseases characterized by motor
impairment as a result of progressive neuronal loss, including amyotrophic lateral
sclerosis (ALS) and Parkinson’s disease (PD). In contrast, cognitive and/or behavioural
disorders are largely caused by protein aggregates within the brain and/or cerebral small
vessel pathology and result in progressive cognitive decline, changes to personality, and
language impairment. Alzheimer’s disease (AD), frontotemporal dementia (FTD), and
vascular cognitive impairment (VCI), are all examples of common cognitive and/or
behavioural disorders.
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A second notable similarity between neurodegenerative diagnoses is the presence of
misfolded proteins and their resultant aggregates within the brain and central nervous
system. Although the specific proteins involved vary between diagnoses, all
neurodegenerative diseases are characterized by these aberrant accumulations (Dugger &
Dickson, 2017). Common examples of the protein inclusions include amyloid plaques,
neurofibrillary tau tangles, and α-synuclein-based Lewy bodies. Importantly, the
aggregates present within the brains of neurodegenerative disease patients are considered
the best indication of an individual’s true diagnosis, as clinical presentations of the
different diseases are highly variable with many overlapping features (Dugger &
Dickson, 2017). Upon postmortem pathologic analysis, it is not uncommon to observe
aggregates of multiple neurodegenerative diseases, indicating co-pathologies. Further, it
is estimated that protein aggregation may begin 10–20 years prior to clinical onset of
disease features (Katsuno, Sahashi, Iguchi, & Hashizume, 2018).
While a considerable amount of effort has been put into understanding the pathogenesis
of neurodegenerative diseases, there is still an absence of appropriate treatment options.
Currently, no neurodegenerative diseases are curable, and the majority of available
therapeutics are only able to target specific symptoms and slow disease progression to a
minimal degree (Duraes, Pinto, & Sousa, 2018). It is postulated that the lack of
appropriate treatment options is a direct result of a lack of full understanding regarding
the neuropathologic mechanisms of the diseases (Duraes et al., 2018).
Interestingly, neurodegenerative disease diagnosis also remains a challenge, particularly
in the early stages, without the ability to accurately detect all protein aggregates while
patients are still alive. Current diagnostic approaches rely on clinical features of disease;
however, these are often highly variable with large amounts of heterogeneity within and
between disease cohorts. As a result, misdiagnoses are, unfortunately, not uncommon
(Beber & Chaves, 2013; Bicchi, Emiliani, Vescovi, & Martino, 2015; Selvackadunco et
al., 2019). Yet, early and accurate diagnosis is critical, as the therapeutics that are
available to patients must begin as early as possible to be most effective at mitigating
symptoms and slowing disease progression (Agrawal & Biswas, 2015).
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By elucidating the entire genetic landscape of the neurodegenerative disease continuum,
we may not only identify more appropriate therapeutic targets by gaining a better
understanding of the pathologic mechanisms involved, but we may also improve our
ability to diagnose individuals, both early and accurately. Genetic analysis offers a
promising opportunity for diagnosis, as heritability estimates — or the amount of risk
estimated to be from genetic variation — across the diseases are relatively high
(Bocchetta et al., 2016; Pang et al., 2017; Postuma et al., 2016; Strong et al., 2017). We
may also be able to leverage an individual’s genetic profile to gain a better understanding
of how they may progress through their disease. However, to utilize genetic testing for
diagnosis or progression prediction, greater understanding regarding the types of
variation that contribute to neurodegeneration is necessary. Additionally, the large
amount of overlap between neurodegenerative disease intermediate phenotypes and
neuropathological hallmarks suggests that we must thoroughly define the potential
overlap of genetic risk factors contributing to multiple diagnoses.
The Ontario Neurodegenerative Disease Research Initiative (ONDRI) is a longitudinal,
observational cohort study that has aimed to fully elucidate the spectrum of
neurodegenerative diseases, as well as the potential involvement of cerebrovascular
disease (CVD) within the diagnoses (S. M. K. Farhan et al., 2017; Sunderland et al.,
2020). With the recognition that much remains to be known regarding the large amount
of genetic and phenotypic heterogeneity within and between the different
neurodegenerative diseases, ONDRI proposed a novel study design providing both a
longitudinal nature of assessment and follow-up, as well as simultaneous analysis of
patients across five neurodegenerative phenotypes, including AD, ALS, FTD, mild
cognitive impairment (MCI), and PD. The model is in contrast to the majority of prior
work within the field that has taken a reductionist approach, staying within individual
diagnostic silos and failing to account for the entire spectrum of neurodegeneration.
ONDRI also takes a multimodal approach with multiple assessment platforms, which
include neuroimaging, neuropsychology, clinical assessment, gait and balance, ocular
control and morphology, and genomics, allowing for large-scale collaborative efforts to
characterize the full presentation of the diseases under the ONDRI mandate.
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The genomics platform of ONDRI specifically aimed to begin mitigating the gaps in the
current understanding of the genetic underpinnings of neurodegenerative diseases. By
leveraging the broad range of neurodegenerative diseases under study, we may be able to
identify overlapping genetic risk factors not previously considered by researchers
studying only individual neurodegenerative disease cohorts, thereby accounting for a
portion of the missing heritability. Further, the rich phenotypic assessment of participants
may allow for the identification of genetic determinants contributing to the heterogenous
phenotypic intermediates observed across neurodegenerative cohorts.

1.2 Human genetics
Human genetics encompasses the study of variation in human deoxyribonucleic acids
(DNA), how that variation is inherited, and the contribution of DNA variation to traits
and disease. By studying our DNA, not only are we able to gain a greater understanding
of how the human body functions, but also a critical knowledge regarding why and how
traditional human function can go wrong, leading to important breakthroughs in disease
prediction, diagnosis, and treatment.
The DNA molecule, often referred to as the building block of human life, is structured as
a double-stranded helix composed of two strands of alternating phosphate and
deoxyribose groups with nitrogen bases attached to each deoxyribose (Youssef, Budd, &
Bielawski, 2019). There are four nitrogen groups, including adenine (A), cytosine (C),
guanine (G), and thymine (T), and each base is able to form a specific covalent bond with
another base, such that the two strands of DNA are held together. A always bonds with T,
and C bonds with G. Together, the deoxyribose, phosphate, and base make up a single
“nucleotide.” Importantly, the order in which the nucleotides appear within a strand of
DNA is referred to as the “DNA sequence” (Youssef et al., 2019).
Each cell in the human body contains two copies of DNA that, if stretched out, would be
approximately 2 m in length; therefore, it is important that the DNA is effectively
packaged within the cell nucleus. The molecules are tightly wound around histone
proteins, forming chromatin that is further wound into chromosomes (Youssef et al.,
2019). Humans cells are “diploid,” meaning that the two copies of DNA are organized
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into two sets of chromosomes. There are 22 autosomal chromosomes in each set,
numbered one through 22, as well as a pair of sex chromosomes — two X in females and
an X and a Y in males.
A single copy of human DNA encompasses approximately 3,200,000,000 nucleotides, or
“base pairs” (bp) (Piovesan et al., 2019). The nucleotides are organized such that certain
regions are protein coding, otherwise referred to as “genes.” The genes are often
separated by stretches of non-coding DNA of varying length, called “intergenic regions.”
Within a gene, each triplet of nucleotides, or “codon,” encodes a specific amino acid, that
when read together results in the production of a protein specific to the gene in question
(Nirenberg & Matthaei, 1961). Notably, multiple different codons can encode the same
amino acid, often referred to as “redundancy” in the genetic code. In this way, genes are
transcribed into strands of messenger ribonucleic acid (mRNA) that are further translated
into protein products. The resulting proteins will perform highly specific functions on a
cellular level within the human body (Saier, 2019).
There are approximately 24,000 protein-coding genes in the human genome that are
further organized into multiple “exons,” referring to the regions of the gene that encode
the protein product, and “introns,” which are non-coding regions and are spliced out of
the mRNA before it is translated into a protein (International Human Genome
Sequencing, 2004). During the process of mRNA splicing, certain exons may or may not
also be included or excluded resulting in different mRNA isoforms that encode variations
of the protein product, referred to as “alternative splicing” and resulting in “differential
transcripts” (Figure 1.1) (Berget, Moore, & Sharp, 1977; Chow, Gelinas, Broker, &
Roberts, 1977; Moraes & Goes, 2016). The human “exome” refers to all protein-coding
exons of all genes in the human genome.
In April 2003, the Human Genome Project was completed, which produced the first
readout of nearly the entire human genome sequence, including the identification and
mapping of almost all genes (International Human Genome Sequencing, 2004; Lander et
al., 2001). The completion of this endeavour was monumental and resulted in a turning
point in the field of human genetics. With the full sequence, researchers were finally able
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to have a complete picture of the complexity of the human genome and could use it as a
reference to aid in the identification of changes within the DNA sequence that could
contribute to various traits and disease states. Although further studies were needed to fill
in the small number of remaining gaps of the human genome since the Human Genome
Project was released (Chaisson et al., 2015; Dolgin, 2009; Miga et al., 2020), and a recent
preprint suggests the final components have now been completed (Nurk et al., 2021),
multiple nearly complete versions of the human reference genome are widely available
and considered highly accurate for use in human genetic studies.
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Figure 1.1 Alternative mRNA splicing of transcribed precursor mRNA to produce
differential mRNA transcripts.
Genes are organized into multiple exons, which encode the resulting protein product, and
introns, which are spliced out of the mRNA before it is translated into a protein. During
the process of mRNA splicing, certain exons may be included or excluded resulting in
different mRNA isoforms that encode variations of the protein product. The process is
referred to as alternative splicing and results in differential transcripts.
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1.2.1

Genetic variation

Quite remarkably, a person’s DNA sequence shares > 99% similarity with any other
person’s DNA sequence; however, the ~1% of differences within the genome distinguish
individuals from one another (Auton et al., 2015). Deviations in a person’s DNA
sequence from the generally accepted human reference genome are referred to as “genetic
variants.” These variants exist on a spectrum of consequence ranging from no effect to
lethality. Variants may contribute to a certain trait, cause or increase risk of disease, or
even be protective against disease. Variants also exist in a variety of sizes — ranging
from single nucleotide variations affecting only one base in the genome, to structural
variants affecting multiple bases or entire exons, genes, or chromosomes — and
frequencies in the general population (Auton et al., 2015).
Although variants occurring in the intergenic region of the genome or intronic region of a
gene may be of some consequence (F. Zhang & Lupski, 2015; Zou, Wu, Tan, Shang, &
Zhou, 2020), they remain relatively difficult to interpret. In contrast, variants occurring in
the human exome, or within ten nucleotides of an intron-exon junction (the “splicing
region”) are considered those most likely to be of consequence due to their potential
direct effect on the encoded protein.

1.2.1.1

Single nucleotide variation

A “single nucleotide variant” (SNV) consists of a single base pair that deviates from the
expected nucleotide based on the human reference genome. SNVs are first classified into
two categories: 1) “transitions” and 2) “transversions” (Shastry, 2009b). A transition is a
substitution between the nucleotides A and G — the “purine” nucleotides — or between
C and T — the “pyrimidine” nucleotides. Conversely, a transversion is a substitution
from one purine nucleotide to a pyrimidine, or vice-versa.
SNVs can be further classified based on their resulting “sequency ontology”, referring to
the impact the SNV has on a protein product of a gene (Figure 1.2). Although SNVs
located within the intronic region of a gene are often not of consequence, some can
dysregulate mRNA splicing, particularly those occurring within the splicing region (Nik
& Bowman, 2019; Pagani & Baralle, 2004). mRNA splicing variants located at the
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beginning of an intron are referred to as “splice-donor” variants, and mRNA splicing
variants located at the end of an intron are referred to as “splice-acceptor” variants (Anna
& Monika, 2018). SNVs located within an exon can have a variety of consequences on
the protein. Due to redundancy in the genetic code, an SNV may result in a
“synonymous” variant that does not change the amino acid at the corresponding protein
position (Saier, 2019). However, if the SNV results in a new codon that does not encode
the same amino acid at the corresponding position in the protein, the variant is referred to
as “nonsynonymous”. More specifically, a nonsynonymous SNV may be of three types:
1) a “missense” variant resulting from the substitution of one amino acid for another; 2) a
“nonsense” variant resulting from the substitution of the original amino acid for a
premature stop codon, and therefore, a truncated protein product; or 3) a “nonstop”
variant resulting from the substitution of the original stop codon for an amino acid, and
therefore, a longer-than-normal protein product.
SNVs that occur outside of the coding region or splicing region of a gene are also widely
prevalent, including those within introns, untranslated regions (5’ and 3’ UTRs),
promoters, enhancers, silencers, non-coding genes, or intergenic regions, but are much
more difficult to interpret.
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Figure 1.2 Various types of possible single nucleotide variants (SNVs), classified
based on sequence ontology.
Sequence ontology refers to the impact an SNV may have on the resulting protein. A) A
splicing variant a variant is located in an intron of a gene, but is within 10 nucleotides of
the nearest exon-intron junction. Splicing variants located at the beginning of an intron
are splice-donor variants, and those located at the end of an intron are splice-acceptor
variants. Importantly, these variants can result in changes to how mRNA is spliced,
thereby resulting in mRNA that may be missing or including entire exons that the
transcript would or would not normally have, respectively. B) Nonsynonymous variants
refer to SNVs resulting in changes to the amino acid encoded at that location. Missense
variants are SNVs that result in the change of a single amino acid to another amino acid.
Nonsense variants are SNVs that result in the change of a single amino acid into a stop
codon. Nonstop variants are SNVs that result in the change of a stop codon into an amino
acid. C) Synonymous variants are SNVs that do not change the encoded amino acid due
to the redundancy of the genetic code.
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1.2.1.2

Structural variation

Generally, all genetic variation can be included in the category of “structural variation”,
aside from SNVs (Ku, Loy, Salim, Pawitan, & Chia, 2010). The umbrella term
encompasses variants ranging from insertions or deletions of only a few nucleotides to
large-scale insertions, deletions, or transversions of entire pieces of chromosomes
(Figure 1.3). Structural variants may be “balanced,” such that the number of nucleotides
is unchanged, but the location of the nucleotides changes (for example, in inversions and
translocations) or the variants may be “unbalanced,” resulting in the loss or gain of
nucleotides (for example, in insertions, deletions, tandem repeat expansions, or copy
number variants (CNVs)). Typically, the structural variants occur as a result of
inaccuracies during DNA replication or recombination (Hurles, Dermitzakis, & TylerSmith, 2008).
It is largely accepted that structural variants tend to be more deleterious than SNVs due to
the greater number of nucleotides affected (Sudmant et al., 2015). In fact, the larger the
variant, the more likely it is predicted to be deleterious, with the largest structural variants
(>250,000 bp) almost exclusively occurring in the general population at frequencies of
<1% (Conrad, Andrews, Carter, Hurles, & Pritchard, 2006). Structural variants are also of
greater likelihood to be deleterious when encompassing protein-coding genes or
regulatory regions. Yet, there remains many reports of structural variants that have no
effect or protective effects against certain conditions (Feuk, Marshall, Wintle, & Scherer,
2006).
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Figure 1.3 Different types of potential structural variation.
Structural variants generally encompass all variants aside from single nucleotide variants
(SNVs). A) Insertion/deletions (InDels) range in size from 1–50 nucleotides and result in
a gain or loss of nucleotides, respectively. B) Tandem repeats are a subset of repetitive
DNA elements that consist of a repeating motif of bases in a localized region of the
genome. Motifs of 1–6 nucleotides are called microsatellites, motifs > 6 nucleotides are
called minisatellites. C) Copy number variants (CNVs) are large-scale deletions or
duplications of DNA greater than 50 nucleotides in length. Duplications may occur in
tandem, be interspersed to a different region of the same chromosome, or be considered
complex and located on a different chromosome than the original sequence. Finally, D)
inversions and E) translocations are balanced structural variants, such that copy number
of the locus does not change, but the position does.
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1.2.1.2.1

Insertions and deletions

“Insertions” or “deletions” of nucleotides (InDels) can range in size from 1–50 bases;
although, most common are those one to three nucleotides in length, which make up
~70% of all InDels (Figure 1.3A) (Lin et al., 2017). Although there are multiple
mechanisms that can cause InDels to occur within the genome, typically they are a result
of polymerase slippage during DNA replication processes (Taylor, Ponting, & Copley,
2004).
As with all genetic variation, InDels can occur at any location, or “locus,” throughout the
genome, but are of particular interest when located within an exonic region of a gene. In a
coding region, if an InDel’s length is a multiple of three nucleotides, it is referred to as an
“in-frame” variant, and it results in the insertion or deletion of one or more amino acids
within a protein. In contrast, if the length of the InDel is not a multiple of three, it is
called a “frameshift” variant, as all downstream nucleotides will be shifted in position
resulting in disruption of the remaining codon sequence (Kuntzer, Eggle, Klostermann, &
Burtscher, 2010). Ultimately, this results in variation with all downstream amino acids in
the corresponding protein and often also introduces an unexpected stop codon. The
premature termination of the protein may trigger a nonsense-mediated decay pathway
during mRNA translation, which results in degradation of the mRNA and no production
of the protein (Kuntzer et al., 2010). For these reasons, frameshift variants typically result
in a large amount of biological consequence and are considered “loss-of-function” (LOF)
variants.

1.2.1.2.2

Tandem repeats

Over 50% of the human genome is comprised of repetitive sequences of DNA, including
many located within genes or regulatory regions (Liang, Tseng, Tsai, & Sun, 2015).
“Tandem repeats” are a subset of repetitive DNA elements that consist of a repeating
motif of bases in a localized region of the genome (Figure 1.3B). The repeats can be
further subclassified into “microsatellites” with motifs of 1–6 bp and “minisatellites”
with motifs of >6 bp (Hannan, 2018).
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Tandem repeats are highly unstable, meaning they are prone to additional variation,
typically encompassing increases or decreases to the number of repeated motifs (Fan &
Chu, 2007). Although there are multiple events that may result in changes to the number
of repeats, similarly to InDel variants, the main pathway is polymerase slippage during
DNA replication. Briefly, during this process the two DNA strands are separated, but
when they re-pair, one strand “slips” and mispairing occurs. This creates a loop of DNA
at the mismatch site (Figure 1.4). The loops are often recognized by DNA repair
systems; however, when those mechanisms fail, the number of repeats is altered (Fan &
Chu, 2007).
Tandem repeat disorders are caused by tandem repeats located in specific regions or
genes that have exceeded lengths considered to be of generally accepted normalcy,
although these thresholds vary based on a variety of factors. Often, the disorders do not
present as binary phenotypes, rather are expressed across a spectrum of disease states,
typically with more severe outcomes directly correlated to the length of the associated
tandem repeat (Hannan, 2018). Section 1.2.1.1.1 will introduce a hexanucleotide tandem
repeat expansion in the 5’ regulatory region of the chromosome 9 open reading frame 72
gene (C9orf72) that is the most frequently inherited genetic cause of ALS and FTD
(DeJesus-Hernandez et al., 2011; Renton et al., 2011).
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Figure 1.4 Contraction and expansion of a tandem repeat during DNA replication.
During DNA replication of an existing tandem repeat, when the DNA strands are
separated, one of the strands may slip prior to re-annealing due to the inherent instability
of these regions. Depending on which strand experiences the slippage, the tandem repeat
will contract or expand in length. Adapted from (Bush & Moore, 2012).
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1.2.1.2.3

Copy number variants

CNVs are large-scale deletions or duplications of DNA of at least 50 nucleotides in
length (Figure 1.3C) (Feuk, Carson, & Scherer, 2006). As previously described, humans
are diploid, harbouring both a maternal and paternal copy of their nuclear genome.
Deletions occur when there is a loss of DNA, or loss of copy number, in comparison to
the reference genome, whereas duplications occur when there is repetition of DNA, or
gain of copy number, in comparison to the reference genome. However, unlike tandem
repeats, a CNV duplication does not always occur in tandem to the original DNA
sequence — the duplication may be located in an entirely different region of the genome
(Feuk, Carson, et al., 2006). Although approximately 12% of the human genome is
comprised of CNVs, and they contribute to normal phenotypic variation between
individuals (Redon et al., 2006), CNVs may also affect gene expression, organization,
and dosage (Stranger et al., 2007). Therefore, particularly when involving genes, CNVs
can increase susceptibility to disease (Shastry, 2009a).

1.2.1.2.4

Chromosome alterations

“Chromosomal alterations” were some of the first variants observed in the human
genome, as identification did not require the availability of sequencing technology.
Rather, the variants are identifiable using a microscope to examine all 46 chromosomes,
otherwise referred to as a “karyotype” (Feuk, Carson, et al., 2006). Other cytogenetic
techniques are also now routinely used to identify these variants, including fluorescent in
situ hybridization (FISH), comparative genomic hybridization (CGH) (Thompson &
Gray, 1993), and, more recently, next-generation sequencing (NGS) (Iacocca et al.,
2017).
There are several types of chromosomal alterations including, but not limited to,
aneuploidies and rearrangements. “Aneuploidy” refers to an abnormal number of
chromosomes due to an extra or missing copy. The majority of aneuploidies are trisomic
or monosomic and one third of miscarriages are due to aneuploidy, highlighting their
high potential for clinical consequence (Hassold & Hunt, 2001). “Rearrangements” can
be further subclassified into unbalanced rearrangements, such as deletions or insertions of
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large chromosomal segments, or balanced rearrangements, such as inverted or
translocated chromosomal regions (Figure 1.3D-E) (Morin, Eccles, Iturriaga, &
Zimmerman, 2017).

1.2.1.3

Frequency of variants

The success of the Human Genome Project, combined with the quick advancement of
genetic sequencing technologies over the last 20 years, has resulted in the identification
of millions of variants of unknown clinical relevance. This rapidly led to the development
of complete databases of genomic variation from large cohorts of ancestrally diverse
individuals to fully understand the role of both common and rare variants in phenotypic
presentation (Auton et al., 2015; Karczewski et al., 2020; Lek et al., 2016). Based on the
frequency at which a variant is observed in each of these databases, it is assigned a
“minor allele frequency” (MAF), defined as the percentage of the population that carries
the variant. The use of minor in MAF refers to the second most common allele that may
appear at a genetic locus, whereas the major allele refers to the first most common allele,
or the allele displayed in the human reference genome. Depending on the database, or
subpopulation within the database, the MAF may be in reference to the global population,
a population of individuals with or without a particular trait or diagnosis, or a specific
ancestral population (Auton et al., 2015; Guerreiro et al., 2018; Karczewski et al., 2020;
Lek et al., 2016).
MAFs vary widely throughout the genome, often dictated by the location of the variant,
the deleteriousness of the variant, and evolutionary constraints (Subramanian & Kumar,
2006). Within populations, there are also further factors at play, such as genetic selection,
migration, and drift that may cause a variant to be more or less common in a specific
ancestral group (Tishkoff & Verrelli, 2003; Zlotogora, 1994). For this reason, it is
imperative that genetic analyses control for ancestral populations, particularly when
performing genetic association analyses — which correlate differences in phenotypic
frequencies to allele frequencies and are discussed further in Section 1.1.4.2 — as MAFs
between ancestries can vary widely (Cardon & Palmer, 2003; Taioli, Pedotti, & Garte,
2004).

18

Common variants are generally defined as those with an MAF > 1% in the general
population and are often referred to as “polymorphisms.” Although polymorphisms exist
in all variant types, a common SNV is given the specific designation of “single
nucleotide polymorphism” (SNP). Typically, common variants are predicted to be of
neutral or very low phenotypic effect, due to their general abundance in the genome
(Figure 1.5) (Gibson, 2012); however, exceptions do exist, such as the apolipoprotein E
(APOE) genotype and its high phenotypic effect in Alzheimer’s disease risk, which is
discussed further in Section 1.2.2.1.1.
In contrast, rare variants are classically defined as variants with an MAF ≤ 1%. Although
individually not common, as a result of ancient population bottlenecks and the morerecent rapid increase in population size, the majority of variants that have been identified
in the general population are rare, as new variants are introduced with each generation
(Lappalainen, Scott, Brandt, & Hall, 2019). It is generally accepted that the most
deleterious of genetic variants are rare, due to the effects of natural selective pressures
(Figure 1.5). More specifically, variants of high deleterious effect will undergo negative
natural selection, as they are less advantageous to survival, and the variants will become
less frequent in the general population (Karczewski et al., 2020).
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Figure 1.5 Typical range of potential phenotypic effect size, based on a variant's
minor allele frequency (MAF) in the general population.
It is generally accepted that rare variants (MAF ≤ 0.01) tend to be of higher phenotypic
effect, usually acting as highly penetrant monogenic disease-causing mutations. In
contrast, common variants (MAF > 0.05) are typically considered to be of small
phenotypic effect, as demonstrated by the low effect sizes associated with the variants in
genome-wide association analyses. However, these generalizations do not always hold
true and some rare variants may be of smaller phenotypic effect, yet their rarity and low
impact cause them to be difficult to detect with typical genetic analytic approaches. In
contrast, there are a few known cases of common variants that demonstrate high
phenotypic effect, such as the apolipoprotein E (APOE) E4 genotype. Adapted from
(Bush & Moore, 2012).
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1.2.2

Transmission of genetic traits and disease

As previously described, every somatic cell in the human body contains two copies of the
genome — otherwise referred to as the diploid genome — of which one copy was
maternally inherited and the other paternally inherited (Georgadaki, Khoury, Spandidos,
& Zoumpourlis, 2016). During fertilization, an egg cell from the biological mother
containing one copy of DNA and a sperm cell from the biological father containing one
copy of DNA combine to form the diploid zygote. As the zygote replicates throughout
human development to form each cell in the human body, the cells all retain the same two
inherited copies of the human genome (Georgadaki et al., 2016). In this way, genetic
variation is inherited from an individual’s biological parents. Any genetic variant present
from the time the zygote was formed is called a “germline variant” and can be passed on
to further offspring of an individual.
During the formation of gamete cells within the gonads, or during the early stages of
embryogenesis, genetic variants may occur spontaneously as a result of errors in DNA
replication, DNA damage such as double-strand breaks, or crossover interference during
gamete formation (Goldmann, Veltman, & Gilissen, 2019). The resulting variants are
called “de novo variants” and while they were not present within the genome of the
biological mother or father, they can still be passed on to an individual’s offspring. More
simply stated, de novo variants are spontaneously developed within a single generation,
but are able to be passed on to future generations (Goldmann et al., 2019). Prior to the
introduction of large-scale sequencing techniques, the identification of disease-causing de
novo variants was difficult, as they defy the typical inheritance patterns required when
performing linkage analysis, as described further in Section 1.1.4.1. Importantly,
incidence of de novo variants is very low, and for this reason, they are often considered to
have a high likelihood of being pathogenic (Mani, 2017).
Spontaneous variants may also occur in later stages of embryogenesis or throughout an
individual’s development or lifespan. These “somatic variants” result in mosaicism, with
only a subset of an individual’s cells harbouring the variant (Poduri, Evrony, Cai, &
Walsh, 2013). In a similar manner to germline de novo variants, somatic variants may be
a result of errors in DNA replication or DNA damage from either endogenous sources,
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such as oxidation, or exogenous sources, such as ultra-violet radiation or exposure to
certain chemicals (Saini & Gordenin, 2018). Although they are well known for their
contribution to many cancers, somatic mutations can also contribute to non-cancerous
diseases as well, depending on the genes affected and the cells in which they are
harboured.

1.2.2.1

Genotypes, haplotypes, and zygosity

A selection of genetic information that defines a trait or disease is referred to as a
“genotype,” while alternative variants of a gene, genotype, or variant, are called “alleles.”
The allele that is present within the human reference genome is considered the “wildtype” allele, or the “major allele.” When referring to the trait or disease influenced by a
genetic marker, it is called a “phenotype.” Therefore, certain alleles of a genotype define
a phenotype.
In some instances, groups of alleles are inherited together at a genetic locus and are called
a “haplotype.” Typically, haplotypes result from a lack of recombination occurring
between the alleles upon gamete formation, which may be due to the close proximity of
alleles. Although, some haplotypes can encompass tens of kilobases (Wall & Pritchard,
2003). In particular, the phenomenon of non-random co-occurrence of alleles is known as
“linkage disequilibrium” (LD) (Lewontin & Kojima, 1960). LD can reflect population
histories, evolution, and patterns of geographic subdivision and has allowed for major
advancements in the study of human genetics, particularly in linkage analysis and the
defining of haplotype blocks, which have aided in the mapping of SNPs in large-scale
association studies (Wall & Pritchard, 2003). Approaches to genetic analysis will be
discussed further in Section 1.1.4.
“Zygosity” refers to the degree to which the two alleles — each from one copy of the
diploid genome — at a given locus are similar. If the two alleles are identical, the
genotype is referred to as “homozygous,” whereas if they are different, the genotype is
“heterozygous” (Winsor, 1988). In some cases, there may be two different variants
inherited at the same genetic locus, such as within the same gene, but on different alleles
in which case the genotype is referred to as a “compound heterozygote.” And finally, the
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sex chromosomes offer interesting cases of zygosity called “hemizygosity,” which
describes males carrying a variant on their single X chromosomes, or females carrying a
loss of one of their X chromosomes.

1.2.2.2

Monogenic inheritance of Mendelian phenotypes

“Mendelian inheritance” derives its name from the first description of the pattern by
Gregor Mendel, who proposed a model for genes and inheritance as a result of his studies
on pea plants. Ultimately, his work resulted in the “Law of Segregation” and “Law of
Independent Assortment” (Mendel, 1865; H. Zhang, Chen, & Sun, 2017). The Law of
Segregation described that upon gamete formation, only one of two gene copies are
passed on to potential offspring. Closely tied to that, the Law of Independent Assortment
described that alleles of different genes are independently sorted into the gametes,
resulting in potential offspring diversity. Mendel was also responsible for the coining of
the terms “recessive” and “dominant,” which are still used today in the description of
inheritance patterns ( Mendel, 1865; H. Zhang et al., 2017).
Mendelian inheritance refers to a genotype at a single genetic locus driving phenotypic
presentation, otherwise referred to as a “monogenic variant.” The monogenic variants
may be inherited in the various zygosity states described previously; however, whether
they result in presentation of a phenotype depends on the “inheritance pattern” of the
genotype-phenotype relationship. Monogenic phenotypes may follow a variety of
inheritance patterns, including dominant, recessive, co-dominant, and sex linked (Figure
1.6).
“Autosomal dominant” inheritance refers to phenotypes that present when an individual
carries only one copy of the genetic variant. Typically, heterozygous variant would have
been inherited from a single parent, who also would have presented with the associated
phenotype (Winsor, 1988). Alternatively, autosomal dominant phenotypes may result
from de novo genetic variants, as previously described, in which case neither of the
parents carried the variant or presented with the associated phenotype. Multiple
mechanisms may underlie the presentation of an autosomal dominant phenotype,
including dominant negativity, haploinsufficiency, and increased gene dosage (Veitia,
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Caburet, & Birchler, 2018). Both dominant negative and haploinsufficiency models are a
result of heterozygous LOF variants, yet differ in pathogenic mechanism. In a “dominant
negative” model, the heterozygous variant results in a protein product that actively
interferes with the wild-type protein product, whereas in “haploinsufficiency” models a
single wild-type copy of a protein product cannot compensate for the variant protein
product that cannot perform its usual function. Conversely, “increased gene dosage”
models are a result of gain-of-function variants that increase the production or
functioning of a gene’s protein product. The excess protein production may result in
dysregulation of mechanistic pathways or expression in inappropriate pathways or during
inappropriate times of development (Veitia et al., 2018).
“Autosomal recessive” inheritance refers to phenotypes that present when an individual
carries two copies of the genetic variant as a result of the inheritance of one copy from
each parent (Winsor, 1988). In this case, each parent harbouring a single copy of the
variant would be referred to as a “carrier” of the variant, but neither would present with
the phenotype as they would not be homozygous for the allele.
“Autosomal co-dominant” inheritance is an interesting case in which both the variant
allele and the wild-type allele are expressed. This may result in an intermediate
phenotype in heterozygous carriers of the variant, otherwise known as “incomplete
dominance,” and more severe phenotypes in homozygous carriers (Moldovan, Banescu,
& Dobreanu, 2020). Alternatively, autosomal co-dominance can result in the presentation
of both phenotypes simultaneously, such as in the case of ABO blood groups.
“X-linked” inheritance refers to variants located on the X chromosome that contribute to
a phenotype. X-linked inheritance may also be dominant or recessive, but it is important
to recognize that these variants will have different effects in males and females (Winsor,
1988). Females have two copies of the X chromosome, so if only one of their X
chromosomes harbours a variant, they may only be a carrier if the phenotype is inherited
in a recessive manner. However, males only have a single X chromosome, so no matter if
the phenotype is inherited in a dominant or recessive manner, if they harbour a
phenotype-associated variant on the X chromosome, there is no other wild-type copy of
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the allele to compensate, and they will present with the phenotype (Winsor, 1988).
Similarly, “Y-linked” inheritance is the result of genetic variants present on the Y
chromosome. As only males have the Y chromosome, the variants can only be paternally
passed on to all male offspring.
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Figure 1.6 Potential inheritance patterns of Mendelian phenotypes from monogenic
variants.
The inheritance pattern of Mendelian phenotypes can be determined based on pedigrees
of a family, which depict those that do and do not present with the phenotype of interest.
A) Autosomal dominant phenotypes are those that present when an individual is
heterozygous for the variant of interest. B) Autosomal recessive phenotypes are those that
only present when an individual is homozygous for the variant of interest. All
heterozygotes are considered variant carriers. C) Autosomal co-dominance refers to
phenotypes that are influenced by the presence of both the variant and wild-type allele
such that it may result in an intermediate phenotype in heterozygous carriers of the
variant, otherwise known as incomplete dominance, or heterozygous carriers may display
both phenotypes simultaneously. D) Y-linked refers to phenotypes that are caused by
variants on the Y chromosome, whereas X-linked phenotypes are those caused by
variants on the X chromosome and may be E) dominant or F) recessive.
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1.2.2.2.1

Variable penetrance

An important caveat when studying seemingly monogenic phenotypes is that there may
be underlying genetic complexity complicating the analysis of phenotype-causing genetic
variation, such as that introduced by incomplete penetrance. “Penetrance” is defined as
the probability that individuals carrying a disease-causing genetic variant fully express
the associated phenotype (Cooper, Krawczak, Polychronakos, Tyler-Smith, & KehrerSawatzki, 2013). “Complete penetrance” is the term used to describe a phenotype that
always presents itself in an individual that carries the associated genetic variant. When
penetrance is “incomplete” it means that individuals may carry a variant known to cause
a certain phenotype, but they may not express the expected phenotype (Figure 1.7).
Similarly, variable expressivity of a genetic variant can complicate the seemingly
straight-forward model of monogenic inheritance. “Variable expressivity” is used to
describe instances where multiple individuals carry the same genetic variant, but display
varying degrees of phenotypic presentation, otherwise referred to as “phenotypic
heterogeneity” (Figure 1.7) (Schacherer, 2016). Finally, “pleiotropy” refers to genes, or
even specific variants, that cause or increase risk of multiple different phenotypes that
may or may not be related (Hemani, Bowden, & Davey Smith, 2018).
Variable penetrance and expressivity may be a result of a variety of mechanisms,
including: influence from additional genetic variants, the age or sex of the individual,
epigenetic changes, or environmental factors (Cooper et al., 2013). Due to the potential of
influence from other genetic factors to variants displaying either of these phenomena, the
variants begin to blur the line between true monogenic inheritance patterns and polygenic
inheritance (Schacherer, 2016). For this reason, penetrance and expressivity introduce
great complexity in the interpretation of genetic variants, which is an important
component of genetic analyses and will be discussed further in Section 1.1.5.
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Figure 1.7 Examples of incomplete penetrance and variable expressivity of a
phenotype.
Incomplete penetrance refers to phenotypes that are not always expressed when an
individual carries the associated genetic variant, whereas variable expressivity refers to
phenotypes that are expressed, but to varying degrees across individuals who carry the
same associated genetic variant. It is also possible for a variant to exemplify both
incomplete penetrance and variable expressivity.
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1.2.2.3

Polygenic inheritance of complex disease

In contrast to monogenic inheritance, “polygenic inheritance” refers to traits that are
influenced by more than one genetic variant, which have an additive effect on phenotypic
presentation. Typically, these phenotypes are referred to as “complex” and the many
genetic variants that contribute to the trait or disease are located at a variety of loci
throughout the genome (Dron & Hegele, 2018). A complex phenotype may also be
considered “multifactorial” if influenced by both polygenic and environmental factors.
Classically, polygenic phenotypes are considered to be influenced by SNPs of small
phenotypic impact; however, variants contributing to complex traits or disease may be
common or rare, and include both SNVs and structural variants. In general, rare variants
tend towards larger phenotypic impact compared to common variants, yet exceptions do
exist and variants of any frequency can contribute to the cumulative sum of phenotypic
risk (Figure 1.5) (Crouch & Bodmer, 2020). The variants may also reside within coding
regions of genes or in non-coding regions of the genome, and although variants located
within coding regions often have larger phenotypic impact, complex phenotypes are often
driven by noncoding variants that contribute to gene expression (Crouch & Bodmer,
2020).
One complication of polygenic inheritance models is the difficulty in assessing the
functional impact of genetic variants and understanding their combined contribution to
phenotypic presentation. Further, even when the additive impact of polygenic variants is
considered, there often remains a large proportion of unexplained genetic variance,
referred to as an issue of “missing heritability” (Boyle, Li, & Pritchard, 2017).
To assess overall risk from polygenic contributors to disease, a “polygenic risk score”
(PRS) can be employed. Although PRSs were not used for the purposes of this
Dissertation, their importance in understanding overall genetic risk of disease cannot be
discounted. Overall, they are a measure of genetic risk of a specific complex phenotype
based on an individual’s accumulation of genetic risk variants. Typically, the weighted
scores are calculated from the summation of effect size estimates of various SNPs
associated with a phenotype of interest, obtained from large genome wide association
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studies (GWASs) (Dron & Hegele, 2018). Although rare variants can also be included in
a PRS, rare variants of small to moderate effect remain difficult to identify using GWAS,
and therefore are largely unknown (Choi, Mak, & O'Reilly, 2020). The score can
encompass tens to thousands of genetic variants, with larger scores often able to capture a
greater amount of genetic risk. Although PRSs have allowed the ability to assess genetic
risk from multiple small effect SNPs, they are not without their limitations. The design of
a reliable PRS requires the results from many GWASs with large sample sizes, which
still remain limited for many phenotypes. Further, it is imperative that PRSs have been
replicated in multiple cohorts, as false positive claims of genetic risk using a PRS can be
relatively common (Nalls et al., 2019). PRSs are also often specific to the ancestral
population of the experimental cohorts with which they were designed, as common
genetic architecture between ancestral populations can vary widely. Unfortunately, many
of the currently designed PRSs were built using cohorts of European ancestry and fail to
account for ancestral diversity (Martin et al., 2019). Finally, in many cases, PRSs have
failed to fill the gap between the amount of heritability accounted for by monogenic
variants’ contribution to disease and overall disease heritability estimates, leaving
missing heritability, which will be discussed further below. Nonetheless, PRSs are
becoming a promising tool to predict individual disease risk, and can also be employed to
study overlap in genetic determinants of different diseases (Bellou, Stevenson-Hoare, &
Escott-Price, 2020).

1.2.2.3.1

Heritability

“Heritability” is defined as the amount of phenotypic variance in a population that is
attributable to genetic variance (Manolio et al., 2009). Typically, heritability is expressed
by a number ranging from zero to one, where the former describes phenotypes that are
not explained by genetics at all, and the latter describes phenotypes completely explained
by genetics. If a complete understanding of the genetic contributors to a certain
phenotype were understood, heritability would estimate how well we could predict a
phenotype based on genetic factors.
Unfortunately, many complex phenotypes still display a large gap between the estimated
heritability determined by family-based studies, such as twin studies, and the phenotypic
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variance explained by associated genetic variants, which is defined as the “missing
heritability” (Uricchio, 2020). There are many potential explanations for missing
heritability, including the proposition that there remain variants contributing to complex
phenotypes that are yet to be discovered, such as common variants of smaller impact, rare
variants of smaller impact that are difficult to detect even with large samples sizes, and
ultra-rare variants of large impact. However, as phenotype-associated genetic variation is
continuously discovered, other considerations have come to light. One hypothesis is that
current heritability estimates may be inflated, potentially due to non-additive genetic
effects or shared environmental influence in families. Others suggest that the nonadditive genetic effects of gene-gene interactions are difficult to capture and potentially
account for the missing heritability (Manolio et al., 2009). Regardless, identifying the
remaining genetic factors that contribute to complex traits is imperative as we
continuously move towards a precision medicine model of diagnosis, progression
prediction, and treatment for many complex phenotypes.

1.2.3

Methods to identify genetic variation

The ability to identify variation within the human genome is relatively new, with methods
only being developed over the last 50 years. In 1977, Frederick Sanger published his
methodology for DNA sequencing, later named “Sanger sequencing,” that to this day
remains the gold-standard approach to obtain the exact readout of a selection of DNA
(Sanger, Nicklen, & Coulson, 1977). The method also underwent important technological
improvements during the completion of the Human Genome Project (Lander et al., 2001).
Along with its conclusion, technological advances have allowed for a new era of genetic
analysis encompassing high-throughput massively parallel DNA sequencing, referred to
as NGS, as well as advancements in the ability to perform large-scale genotyping arrays.

1.2.3.1

Sanger sequencing

Sanger sequencing, otherwise referred to as “chain-termination” or the “dideoxy
technique,” remains one of the most reliable sequencing approaches, even almost 50
years after it revolutionized the field of human genetics (Sanger et al., 1977).
Traditionally, the method utilizes analogues of the deoxyribunucleotides (dNTPs) found
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in DNA that lack the 3’ hydroxyl group, called dideoxyribonucleotides (ddNTPs) that
result in the inability to form bonds with the next dNTP in a sequence. Using these, four
parallel polymerase chain reactions (PCR) are run, each containing only one set of
radiolabeled ddNTPs corresponding to a single base — A, C, G, or T — and resulting in
DNA strands of each possible length being produced. The DNA strands then undergo
size-separation-based capillary gel electrophoresis, and the 5’ to 3’ DNA sequence can be
read based on the radioactive label in the corresponding position on the gel (Heather &
Chain, 2016).
Over the years, methodologies have been improved, resulting in the ability to automate
Sanger sequencing using machines, and the accuracy of the method remains a goldstandard in the field. Yet Sanger sequencing does not come without its limitations, as
even with automation, the use of the method remains tedious, time consuming, and cost
prohibitive. Sanger sequencing lacks practicality when studying large sample sizes or
regions of the genome much greater than 1 kb.

1.2.3.2

Next-generation sequencing

Following the completion of the Human Genome Project, there became a striking need
for the ability to sequence large cohorts of individuals quickly and at low cost. In 2005,
the shift to the “next-generation” of sequencing began under the basic premise that the
methods sequence DNA in a massively parallel manner (Margulies et al., 2005; Shendure
et al., 2005). By shearing the DNA into small overlapping fragments, or “reads,” millions
of nucleotide sequences can be determined simultaneously. Not only does this speed up
the process of sequencing and decrease cost, but it also results in high coverage, or “read
depth”, at each sequenced nucleotide, thereby increasing the confidence of the
sequencing calls made by NGS methods and allowing for the determination of allele
zygosity and dosage. Further, while Sanger sequencing is restricted to identifying smallscale SNVs and InDels in regions already known to be of interest, NGS offers the ability
to identify a wide range of genetic variation, including large-scale CNVs (Iacocca et al.,
2017). NGS can also interrogate the human genome without the bias needed for Sanger
sequencing, as full exomes or genomes may be sequenced at once (Behjati & Tarpey,
2013).
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NGS can be subcategorized based on specific technologies as well as the regions of the
genome that are captured. Whole genome sequencing (WGS) refers to NGS of the entire
human genome, providing an unbiased assessment of the genetic variation harboured by
an individual. While there are obvious benefits to this approach, such as the ability to
identify variants within intergenic, intronic, and regulatory regions of the genome, and
the continuously decreasing costs of the sequencing itself, limitations also exist. Due to
the length of the full human genome sequence, WGS data processing and analyses are
computationally intensive, requiring the ability to store extremely large file sizes. Further,
genetic variation located in non-coding regions of the genome remain difficult to
interpret, and related genetic association analyses require very large sample sizes for the
power to detect variants of interest. Alternatively, there is whole exome sequencing
(WES), which targets the exonic regions of all genes in the human genome, resulting in
~1% of the content than that covered by WGS (Rabbani, Tekin, & Mahdieh, 2014).
While WES obviously limits the ability to detect genetic variation to the coding regions
of the genome, it is predicted that between 60–85% of disease-associated genetic variants
are restricted to these regions (Rabbani et al., 2014; Ross, Dion, & Rouleau, 2020), and
the decreased content coverage of WES limits both the computational resources
necessary for analysis, as well as the associated costs of the sequencing. WES can also
produce sequencing data of greater read depth than WGS, providing a higher degree of
confidence in allele calls (LaDuca et al., 2017; Sims, Sudbery, Ilott, Heger, & Ponting,
2014). Read depth can be even greater if a targeted NGS approach is used. Targeted NGS
refers to sequencing panels designed to target specific genomic content, including any
genes or regions of particular interest. Targeted panels offer further decreases in cost and
computational processing power, and are of particular benefit when certain genes are
known or predicted to be associated with a phenotype of interest.
While NGS offers its clear advantages, there are important limitations to consider. Due to
the short-read lengths of the DNA fragments being sequenced, highly repetitive regions
of the genome remain difficult to map back to the human reference genome, specifically
when the repeats are longer than each individual read itself (Xuan, Yu, Qing, Guo, & Shi,
2013). Further, GC-rich regions of the genome often result in decreased read depth of
NGS data, and confidence in allele calls becomes uncertain (Chen, Liu, Yu, Chiang, &
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Hwang, 2013). Yet, it is widely recognized that NGS approaches have revolutionized the
study of human genetics and are continuously becoming more approachable. Not only are
bioinformatics processes able to handle the data being refined, but costs continue to
decrease, with the first genome sequence costing over $100,000,000 to complete and
WGS now offered for under $1,000 per sample in some instances (Wetterstrand, 2020).

1.2.3.3

Genotyping

Unlike NGS, which sequences full genomic regions, “genotyping” is the targeting of
specific genetic coordinates. Genotyping may be performed on a variety of known
genetic loci at once using a microarray or may be performed on individual alleles using
single SNP quantitative PCR (qPCR)-based assays, such as a TaqMan allelic
discrimination assay. Although genotyping does not offer the ability to assess the full
spectrum of genetic variants an individual may carry, targeting specific loci can offer the
ability to scan a population for SNVs known to be pathogenic, to characterize the
ancestry of a population, or to perform genome-wide association studies and identify
novel phenotype-associated regions in the genome (Ragoussis, 2009).
Microarrays offer a unique approach to genetic analysis, as they can cover up to millions
of SNVs. Often considered an intermediate between cytogenic analysis of chromosomal
karyotypes and complete DNA sequencing, microarrays provide a scan of the entire
genome to identify genomic variation (Page et al., 2007). Further, the phenomenon of LD
allows for the imputation of additional SNVs that are within the same haplotype blocks of
alleles that have been genotyped. The coverage of such a large amount of the genome
allows for the detection of CNVs based on the signal intensity of the data; however, the
locations of the SNVs on the microarray limit resolution and CNV breakpoints must be
further discerned (Coughlin, Scharer, & Shaikh, 2012). Microarrays also offer the
opportunity to perform GWAS, which are used to identify novel loci associated with
phenotypes of interest (Ragoussis, 2009). GWAS will be discussed further in Section
1.1.4.2.1.
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1.2.3.4

Repeat-primed PCR

When studying tandem repeats, obtaining an accurate detection of expansion size is
imperative, as there are often well-defined thresholds for the number of repeats that cause
a phenotype. But it is difficult to detect these variants with Sanger sequencing and NGS,
due to the imbalances they often introduce in GC content or their inherent length.
Although there are many alternatives to detect these variants — such as capillary
electrophoresis, Southern blot analysis, or mass spectrometry — the most commonly
used approach is repeat-primed PCR, due to its relative simplicity and feasibility (Liu,
Zhang, Wang, Gu, & Wang, 2017).
Briefly, repeat-primed PCR utilizes a pair of reverse primers that can bind at various
locations throughout the tandem repeat, amplifying DNA of various lengths, along with a
fluorescently labelled forward primer. The resulting DNA fragments are then able to be
analyzed using the fluorescence trace, creating a “ladder” and allowing for the
identification of large pathogenic repeats (Renton et al., 2011; Warner et al., 1996).
Unfortunately, the method is limited to only determine the length of a tandem repeat up
to a certain size, for example 60 copies of a hexanucleotide repeat; however, it is still able
to determine that the number of repeats are above the length threshold.

1.2.4

Approaches to identify genetic contributors of disease

The analytic approaches used to map genetic loci to associated human phenotypes can be
largely categorized by two main groups, including: 1) “linkage analysis” that relies on cosegregation of genotype and phenotype throughout a pedigree and 2) “population
genetics”, also referred to as “association analyses”, which study genetic variation in
large populations of unrelated individuals. The approaches each have their own
advantages and limitations, and the choice of which to utilize is dictated by the data
available, the phenotype severity and transmission pattern, and the goals of the study.

1.2.4.1

Linkage analysis

As previously described, Mendel’s Laws stated that alleles at different loci will segregate
independently during gamete formation; however, there are genes — typically in close
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proximity on the same chromosome — that are “linked”, resulting in phenotypes being
inherited together. Linkage analysis relies on these exceptions to Mendel’s law in order to
identify genetic markers that are linked to genes driving a phenotype, and to ultimately
map genes to their associated phenotype ( Mendel, 1865; Elston, 1998).
Prior to the availability of large-scale sequencing methods, the identification of genes
contributing to a phenotype of interest relied on the use of SNPs with known positions
within the genome and analyzing co-segregation of the SNPs throughout a family’s
pedigree (Morton, 1955). Specifically, “co-segregation” refers to genotypes that are only
carried by individuals in a pedigree that also present with the phenotype being studied. A
map of the SNP positions within the genome can then be generated and, based on the
SNPs that co-segregated, regions of interest likely to be associated with the phenotype
can be identified (Elston, 1998).
Classically, linkage analyses were used for the identification of rare, monogenic variants
of high penetrance, and this application is still widely accepted, as the inherent rarity of
these variants result in detection difficulty with other methods, such as GWAS (Bush &
Haines, 2010). The wide-availability of NGS data coupled with linkage analysis now
allows for a narrowed approach to identifying genetic markers of disease by directing
which genomic loci should be prioritized for further analysis (Ott, Wang, & Leal, 2015).
Although linkage analysis has been successful in mapping disease-causing genes for
decades, it is still important to recognize its limitations. Most importantly, the approach
relies on the availability of genetic and phenotypic data of entire families, with larger
pedigrees being most optimal (Bush & Haines, 2010). Unfortunately, large pedigrees
with family members all willing and available to be involved in genetic analyses can be
difficult to find, particularly in diseases with onset later in adult life. Additionally, there
is always the, albeit unlikely, potential that linked genetic loci will experience
recombination between them and the region will be eliminated from consideration.
Finally, although not impossible, the identification of common genetic variants of small
or modest phenotypic impact remains difficult with linkage analysis, due to the often
lower penetrance of these variants (Bush & Haines, 2010).
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1.2.4.2

Association analyses

Association analyses encompass a wide-range of approaches all aimed at detecting
associations between genetic variants and phenotypes of interest at a population level.
Importantly, they rely on the use of populations of unrelated individuals and the same
genetic markers contributing to a phenotype across the various individuals (RodriguezMurillo & Greenberg, 2008). Association analyses have risen in popularity over the last
two decades due to the availability and feasibility of large-scale NGS sequencing and
genome-wide microarrays. The approaches are advantageous, as family data is often
difficult to obtain, and the analyses offer a high level of granularity to detect variants of
relatively small phenotypic impact, while simultaneously producing quantitative
estimates of that impact (Rodriguez-Murillo & Greenberg, 2008).
An important caveat to association analyses is the need to accurately account for
differential ancestry within the population under study. As early humans spread around
the world and settled into different geographic locations, they faced differential
environments, catastrophic events, and geographic isolation often resulting in gene pool
isolation and, in some cases, interbreeding. All of these factors resulted in highly
differential MAFs across different populations (Hellwege et al., 2017). Therefore, when
performing association analyses, it is important to either have ancestrally homogenous
cohorts to compare or to apply corrections for the effects of population stratification, as
not to identify false positive genetic associations that are actually a result of confounding
from population heterogeneity. To stratify a cohort into differential populations,
statistical methods such as principal component analysis (PCA) can be used to assess the
variance in SNPs harboured by individuals within a population and determine their
ancestral “distance” from one another (Hellwege et al., 2017).

1.2.4.2.1

Genome wide association studies

GWAS are aimed at identifying associations between SNPs and complex traits and
diseases in large population-based studies. Over the past 15 years the approach has
revolutionized the study of the small phenotypic impacts of relatively common genetic
variation (Visscher, Brown, McCarthy, & Yang, 2012).
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The method builds upon the long acknowledged understanding that genes can be
effectively mapped by relying on population-based LD; however, it has done so by
leveraging the insights of the human genome brought forth by the Human Genome
Project (Visscher et al., 2012). More specifically, the subsequent HapMap project
(International HapMap, 2005) investigated the degree of LD between SNPs throughout
the genome. The map of LD can now be exploited to ensure that the SNPs analyzed
across a GWAS analysis are not redundant, as SNPs in LD would give the same signal in
the analysis.
The GWAS itself requires large populations comprised of both individuals with a
phenotype of interest and controls, all genotyped using a genome-wide SNP array.
Analyses are then able to identify SNPs highly associated with the trait of interest, based
on their frequency in the cases in comparison to the controls, and produce an effect size
relative to how much impact the SNP contributes to the phenotype under study (Bush &
Moore, 2012). Following the identification of significant SNPs, the results may be further
analyzed to determine if the association was ‘direct’, meaning as a result of the SNP
genotyped itself, or ‘indirect’, meaning as a result of another genetic variant in high LD
with the SNP that was genotyped (Bush & Moore, 2012).
Any direct associations identified using GWAS contribute to the common-diseasecommon-variant hypothesis. It is unclear who the true founders of this hypothesis were,
as multiple researchers first proposed the theory in the mid- to late-1990s (Chakravarti,
1999; Lander, 1996; Risch & Merikangas, 1996). Briefly, the hypothesis proposes that all
common diseases, with a population frequency >1–5% are driven by common genetic
variation. The common variation may exhibit monogenic inheritance, such is the case
with APOE and AD, or polygenic inheritance with many SNPs of small-to-modest
phenotypic effect driving phenotypic presentation. Yet, further research over the last 20
years has proven there are very few complex phenotypes that can be substantially
explained solely by common variation, leading to missing heritability and giving rise to
the competing common-disease-rare-variant hypothesis (Gibson, 2012).

38

1.2.4.2.2

Rare variant association analysis

In contrast to the common-disease-common-variant hypothesis, the rare variant
counterpart suggests that rare genetic variants of high phenotypic impact are driving
phenotypic presentation (Gibson, 2012). The theory has also been expanded by some to
include the possibility that there are many rare variants of small-to-modest phenotypic
impact that are unable to be easily detected with GWAS or linkage approaches and may
account for some of the missing heritability of disease. In turn, this hypothesis has led to
the development of rare variant association analysis (RVAA).
As previously explained, GWAS are largely underpowered to detect rare, diseaseassociated variants without extravagant sample sizes, unless a variant’s phenotypic
impact is very large. Further, there is difficulty performing indirect association mapping
on GWAS identified disease-associated SNPs to rare variants, as two variants must have
similar MAFs to be in high LD (Asimit & Zeggini, 2010). In contrast, RVAAs capitalize
on the understanding that although rare variants are individually infrequent, when binned
together, they may be common enough to harness the statistical power for novel
associations to be made. When performing RVAA, rare variants are collapsed into variant
groups, which can be dictated by a variety of factors, including, but not limited to:
general genomic region, individual genes, pathways of interest, MAFs, or functional
consequence (Asimit & Zeggini, 2010). Importantly, when rare variants are binned based
upon specific genes or pathways, novel disease-associations may be identified.
Akin to GWAS, RVAAs also utilize large populations of individuals both with a
phenotype of interest and controls; however, in contrast to GWAS, typically RVAAs
employ NGS data, as microarrays cannot capture the full breadth of possible rare
variation in a population (Asimit & Zeggini, 2010). Following NGS, variants are
prioritized using quality control metrics, MAFs, in silico prediction algorithms, and/or
previous disease associations — all of which are discussed further in Section 1.1.5. Rare
variants are then binned into their respective groups, and various methods can be used to
identify associations between the rare variant groups and the phenotype of interest. The
methods vary widely and can include various types of univariate or multivariate
regression models customized for the individual study, or standardized models, such as
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burden tests or the optimal unified sequence kernel association test (SKAT-O) (Lee,
Emond, et al., 2012).
Burden tests collapse rare variants based on genomic region under the assumption that
the rare variants all contribute to the phenotype in the same direction (i.e. they all
increase risk for the phenotype). The approach can be useful when the genes under study
are known to contribute to the phenotype in a similar manner, but it is generally accepted
that at least a portion of variants, if not the general majority identified in a region, will
have little to no phenotypic impact. Unfortunately, this can introduce noise in the
analysis, as well as a loss of statistical power (Wu et al., 2011). On the contrary, sequence
kernel association testing (SKAT) uses a kernel function and variance component tests to
identify phenotypic associations with rare variants binned, again, based on genomic
region, but also accounts for variants with differential phenotypic impact magnitudes and
directions (Wu et al., 2011). The approach was further refined to produce SKAT-O,
which was used in the methodology of Chapter 4, and builds upon SKAT by including
the ability to identify the optimal testing strategy between burden tests and SKAT to
maximize statistical power. More specifically, when the effects of variants are correlated,
SKAT-O will employ a burden method, rather than the SKAT approach (Lee, Wu, & Lin,
2012).

1.2.5

Genetic variant interpretation

When studying how genetic variation can contribute to disease, an important aspect to
consider is interpretation of the variants. As described above, prior to RVAAs, variants
are prioritized to identify those that are rare in the general population (commonly MAF <
1%), and may be further filtered based on the goals of the study. Additionally, following
the identification of gene-disease associations using linkage analysis or association
analysis, assessing the deleteriousness of different variants within a gene becomes the
new challenge, particularly when there is interest in implementing clinical genetic testing.
One of the first steps in this process is the interpretation of identified gene-disease
relationships themselves. With such rapid advances in genomic technologies, there has
been an exponential increase in gene-disease correlations, yet the levels of evidence
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behind these correlations may differ widely. Online Mendelian in Man (OMIM) ("Online
Mendelian Inheritance in Man, OMIM®,") is a freely available resource that has
amalgamated information regarding human genes and associated phenotypes in a
comprehensive manner. Although the compendium only originally included genes
definitively carrying Mendelian disease-causing variants, the collection has broadened to
include genes with varying degrees of disease-association evidence. While this is an
excellent resource to clinicians and researchers alike, standard guidelines were necessary
for evaluating the strength of gene-disease correlations, especially for use in the clinical
setting. In 2017, the NIH-funded Clinical Genome Resource (ClinGen) published a
standard framework for the evaluation of these gene-disease correlations and efforts are
ongoing to classify gene associations across many diseases by Gene Curation Expert
Panels (GCEPs) (Strande et al., 2017).
When interpreting genetic variants themselves, there are multiple approaches that may be
taken. A customized approach may be used, based on the goals of a study, or a validated
framework may be applied, such as the American College of Medical Genetics and
Genomics (ACMG) Standards and Guidelines for Interpretation of Sequence Variants
(Richards et al., 2015), which is beneficial in clinical settings. Customized strategies tend
towards variant filtration to prioritize those likely-to-be or known-to-be disease causing
or risk associated, whereas the ACMG guidelines classify all variants using the
framework of: “benign,” “likely benign,” “uncertain significance,” “likely pathogenic,”
and “pathogenic.”
In addition to the approach, many different factors go into interpreting genetic variants,
including, but not limited to, variant zygosity, sequence ontology, MAFs, in silico
prediction scores, and previous disease associations. To begin, it is important to consider
the zygosity of the variants of interest, as for an established gene-disease association
there is often an accepted inheritance model for the relationship, such as autosomal
dominant or autosomal recessive, especially in cases of Mendelian inheritance. Sequence
ontology refers to the type of genetic variation, typically defined by the resulting change
to the protein encoded by the gene of interest. Sequence ontologies are binned into two
general categories: 1) nonsynonymous, or variants that change the resulting protein code
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and 2) synonymous, or variants that do not change the resulting protein code.
Nonsynonymous variants can be further subdivided, based on sequence ontology, to
include: 1) putative LOF variants, including nonsense, splicing, and frameshift InDels; 2)
missense variants, referring to those that change a single amino acid in the protein to a
new amino acid; and 3) in-frame InDels. MAFs have heretofore been comprehensively
covered in this Dissertation, but it is important to recognize that these variant frequencies
can be obtained from a variety of population databases. The first example of a general
population database is the 1000 Genomes Project (1000G) (Auton et al., 2015), which
launched in 2008 and aimed to identify most common genetic variation within
populations from across the world using WGS. In total, the final 1000G dataset is
comprised of 2,504 samples that have all been well defined ancestrally, allowing the data
to be quite useful when performing genetic ancestral estimation. Another example of a
general population database is the Exome Aggregation Consortium (ExAC) (Lek et al.,
2016), which was produced by the Broad Institute of MIT and Harvard and included the
WES data from over 60,000 samples. The database was later updated into the Genome
Aggregation Database (gnomAD) (Karczewski et al., 2020), to reflect the inclusion of
WGS data. Version 2.1.1 of gnomAD includes SNV and InDel data from WES of over
125,000 samples and structural variation data from WGS of over 15,000 samples.
Version 3.1 of gnomAD includes SNV and InDel variant data from WGS of over 76,000
samples. Although larger datasets provide the obvious advantage of a greater ability to
capture a wider range of human genetic variation, the choice of general population
database is dependent on the specifications of the study. For example, while ExAC is a
smaller dataset than either version of gnomAD, it does not include samples from
individuals with neurological conditions, whereas gnomAD does include some
individuals with these conditions. In silico predictions are algorithms that are able to
predict how deleterious a nonsynonymous variant may be by considering the
conservation of the affected amino acid(s) and/or the biochemical properties and location
of the amino acid change. When employing in silico predictions, it must be understood
that they are not able to definitively determine variant pathogenicity, rather they provide
a prediction of how deleterious a variant may be. In fact, in many cases different in silico
prediction algorithms may not agree and one must consider the factors contributing to
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each individual algorithm in order to assess validity of prediction calls. Examples of in
silico algorithms used within this Dissertation include: Polymorphism Phenotyping v2
(PolyPhen-2) (Adzhubei et al., 2010), Sorting Intolerant from Tolerant (SIFT) (Kumar,
Henikoff, & Ng, 2009), and Combined Annotation Dependent Depletion (CADD)
(Kircher et al., 2014). Finally, when interpreting genetic variation, we must consider
previous disease associations of the individual variants, which may be described within
the relevant literature, or captured by databases such as ClinVar (Landrum et al., 2014).

1.3

Neurodegenerative disease

Neurodegenerative diseases are a collection of progressive, debilitating conditions
characterized by the degeneration of neurons, either within the brain or peripheral
nervous system. Upon pathological examination, neurodegenerative disease patients
present with protein aggregates within the brain that classically define their diagnosis
(Table 1.1). Although clinical presentations differ widely between different
neurodegenerative disease diagnoses, features do tend to overlap, and even within single
neurodegenerative disease cohorts, such as AD, presentations between patients is highly
heterogenous. Further, very few individuals have pure forms of their diagnosis; rather,
many exist on a continuum of neurodegenerative phenotypes, and mixed pathologies are
common (Dugger et al., 2014). Importantly, the greatest risk factor for neurodegenerative
disease development is increasing age.
Neurodegenerative diseases are largely grouped into two categories: 1) motor/movement
disorders and 2) cognitive and/or behavioural disorders. The former includes motor
neuron diseases, such as ALS, and parkinsonisms, such as PD (Trojsi, Christidi,
Migliaccio, Santamaria-Garcia, & Santangelo, 2018). As the name suggests,
motor/movement disorders principally affect a patient’s mobility, including decreased
motor control, apraxia, and speech/swallowing difficulties, although cognitive features or
mixed pathologies with cognitive and/or behavioural disorders are not infrequent. In a
similar manner, cognitive and/or behavioural disorders are mainly defined by the
presentation and progression of decline in cognitive functioning across a variety of
domains and/or severe changes in behaviour. Yet, again, patients may also present with
features of impaired movement (Trojsi et al., 2018).
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A third group of neurodegenerative diseases that is often discounted, or even ignored, is
vascular cognitive impairments (VCIs). Although not always defined as a
neurodegenerative disease, it is important to account for the role that cerebrovascular
disease (CVD) plays in neurodegeneration phenotypes. In fact, Alois Alzheimer himself,
who first defined AD, suggested involvement of the circulatory system in the disease’s
pathology (Raz, Knoefel, & Bhaskar, 2016). Further, damage within the neurovasculature has been observed across neurodegenerative diagnoses, including white
matter hyperintensities, cerebrovascular lesions, cerebral amyloid angiopathy (CAA), and
enlarged perivascular spaces (Ramirez et al., 2015; Raz et al., 2016). However, VCIs are
defined as cognitive dysfunction as a direct result of vascular dysfunction and include
diagnoses such as vascular dementia and cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy (CADASIL).
For the purposes of this Dissertation, five neurodegenerative diseases will be described in
detail (Table 1.1), as well as the potential involvement of CVD in neurodegeneration
pathology and presentation.
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Table 1.1 Breakdown of the general characteristics of various neurodegenerative disease diagnoses.
Neurodegenerative
disease

Prevalence
(per 1000)

Early-onset
age (years)

Late-onset
age (years)

Alzheimer’s disease
(AD)

13.81,2

< 65

≥ 656

Amyotrophic lateral
sclerosis (ALS)

0.044

< 45

≥ 45

0.5911,4

< 65

≥ 65

Mild cognitive
impairment (MCI)

1605

< 65

≥ 65

Parkinson’s disease
(PD)

1

Frontotemporal
dementia (FTD)

3

4.2

< 40

≥ 60

Common features
Cognitive decline and memory
impairment disrupting daily
functioning
Loss of upper and lower motor
neurons resulting in progressive
muscle weakness and eventual
paralysis; in some cases,
concurrent FTD
Frontal and anterior temporal lobe
atrophy resulting in severe
behaviour changes, language
impairment, and cognitive
decline; in some cases, concurrent
ALS
Memory impairment and/or
impaired language and executive
function that does not disrupt
daily functioning
Loss of dopaminergic neurons,
resulting in bradykinesia, rigidity,
resting tremor, and postural
instability; in some cases,
dementia

Classical neuropathology
hallmarks
Amyloid-β plaques; neurofibrillary
tau tangles; in some cases, Lewy
bodies, cerebral amyloid
angiopathy, and TDP-43 inclusions
TDP-43 ubiquitinated inclusions;
FUS ubiquitinated inclusions; p62
ubiquitinated inclusions

TDP-43 ubiquitinated inclusions;
hyper-phosphorylated tau; in rare
cases, FUS ubiquitinated inclusions

Amyloid-β plaques; neurofibrillary
tau tangles
Lewy bodies (with α-synuclein
aggregates); amyloid-β plaques;
neurofibrillary tau tangles

Presented prevalences were per 1000 people. The AD, FTD, and PD prevalences were all based on individuals over the age of 40 years. The ALS prevalence was
based on individuals of any age. The MCI prevalence was based on individuals over the age of 50 years.
1
(Ng et al., 2015); 2("2020 Alzheimer's disease facts and figures," 2020); 3("Chapter 3: Mapping Connections: An understanding of neurological conditions in
Canada – Scope (prevalence and incidence)," 2014); 4(Hogan et al., 2016); 5(R. Roberts & Knopman, 2013).
Abbreviations: FUS, Fus RNA binding protein; p62, nucleoporin 62; TDP-43, TAR DNA-binding protein 43.
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1.3.1
1.3.1.1

Motor/movement disorders
Amyotrophic lateral sclerosis (ALS)

ALS is a neuromuscular disorder characterized by the loss of upper and lower motor
neurons, referring to the neurons connecting the cortex and brainstem/spinal cord and the
neurons connecting the spinal cord and muscles/glands, respectively. Generally, the
neuronal degeneration results in progressive, severe muscle weakness and eventual
paralysis, although presentation is highly heterogeneous with mixed features of muscle
atrophy, fasciculations, and spasticity. With a mean age of onset of roughly 61 years,
classic cases display a median survival period of 2–4 years (Grad, Rouleau, Ravits, &
Cashman, 2017). ALS is also considered relatively uncommon compared to other
neurodegenerative diseases, with prevalence estimate of 0.044 per 1,000 individuals,
although this considers individuals of any age ("Chapter 3: Mapping Connections: An
understanding of neurological conditions in Canada – Scope (prevalence and incidence),"
2014). Upon neuropathological analysis, a classic feature of ALS is the identification of
ubiquitinated inclusions in the motor neuron cytoplasm, yet the etiology and components
of the inclusions can vary, with some heterogeneity attributable to specific monogenic
genetic variants. In turn, potential mechanisms of disease are quite complex and may also
vary between patients, suggesting a spectrum of phenotypes under the umbrella of ALS
(Mejzini et al., 2019).
Generally, ALS onset begins with muscle weakness within the face, arms, and/or legs,
and steadily spreads and advances throughout the body. The majority of typical ALS
patients present with a spinal form of the disease with asymmetrical muscle weakness
onset in the distal or proximal upper or lower limbs; however, muscle weakness spreads
rather quickly to other limbs, as well as bulbar symptoms affecting speech and
swallowing, and eventually respiratory symptoms, although order of onset may vary
(Wijesekera & Leigh, 2009). The development of limb spasticity is also common, and
bladder dysfunction and behavioural or cognitive impairments have also been reported. In
fact, a report by Strong et al. found that based on clinically accepted diagnostic criteria,
over 50% of ALS patients present with a form of FTD or other dementia, such as AD
(Strong et al., 2017).
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1.3.1.1.1

Genetic determinants of ALS

ALS cases are largely classified as either familial (fALS) or sporadic (sALS), referring to
the ~10% of cases with a family history and ~90% of cases without a family history,
respectively. Interestingly, only 40–55% of fALS cases can be explained by dominant
monogenic variants in known ALS-associated genes, with variants in the genes
superoxide dismutase (SOD1), C9orf72, FUS RNA binding protein (FUS), and TAR
DNA binding protein (TARDBP) being most common (Mejzini et al., 2019). A small
fraction of sALS patients have also been found to harbour monogenic variants in fALSassociated genes, yet over 90% of cases remain genetically unexplained in spite of sALS
heritability estimates of ~60% (Mejzini et al., 2019). Importantly, patient neuropathology
and clinical presentation is highly dependent on the genetic factors contributing to their
ALS diagnosis, although presently, genetics fail to account for all disease heterogeneity.

1.3.1.1.1.1 Monogenic determinants of ALS
For the purposes of brevity, the effects of variants in the four most common genes
associated with fALS will be discussed further; however, there are many other genes that
have now been associated with the phenotype.
Monogenic variants in SOD1 account for approximately 20% of fALS cases and are
thought to induce excitotoxicity, oxidative stress, endoplasmic reticulum stress,
mitochondrial disfunction, and prion-like propagation, although exact pathological
mechanisms are still under study (Mejzini et al., 2019). Neuropathological analysis has
identified aggregates of SOD1 within immunoreactive inclusions of the motor neurons of
ALS patients harbouring SOD1 pathogenic variants, yet the aggregates have also been
observed in sALS patients without SOD1 variants and in patients carrying a C9orf72
repeat expansion or variants in other ALS-associated genes (Bosco et al., 2010; Mejzini
et al., 2019). TARDBP encodes the protein TDP-43, which is the main component of
ubiquitinated inclusions in ALS patients that are distributed in neurons throughout the
central nervous system. Normally, TDP-43 is involved in mRNA stability, processing,
and transport, but when mutated the protein no longer localizes to the nucleus and instead
aggregates in the cytoplasm. Yet, these aggregates are not unique to those carrying
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TARDBP variants and TDP-43 inclusions are now considered a hallmark of a majority of
ALS cases (Mejzini et al., 2019). In contrast, ALS patients carrying pathogenic FUS
variants do not typically present with TDP-43 inclusions, rather they harbour unique FUS
aggregation within ubiquitinated neuronal cytoplasmic inclusions throughout the central
nervous system. FUS shares many gene expression roles with TDP-43, although with
different targets. FUS variants have also been implicated in cases of concurrent ALS and
FTD (Mejzini et al., 2019; Saberi, Stauffer, Schulte, & Ravits, 2015; Snowden et al.,
2011).
The C9orf72 gene contains a hexanucleotide repeat expansion (GGGGCC) in its noncoding region, and an expansion on at least one allele of >30 copies — although more
often the pathogenic repeats are present in hundreds to thousands of copies — accounts
for one of the most commonly inherited forms of ALS in Europeans, including cases of
sALS. The repeat expansion also increases risk of FTD development, both with or
without ALS (DeJesus-Hernandez et al., 2011; Renton et al., 2011; Shatunov et al.,
2010). Again, exact mechanisms are unclear, but patients present with ubiquitinated
TDP-43 aggregates in neuronal cells; however, repeat expansion carriers are unique as
the TDP-43 positive inclusions are outnumbered by nucleoporin 62 ubiquitinated
neuronal inclusions, as well as dipeptide repeats protein aggregates most commonly
found within the frontal, occipital, temporal, and motor cortices (Saberi et al., 2015).
As previously described, sALS cases remain mostly genetically undefined, yet
heritability estimates are ~60%; therefore, there is a large amount of missing heritability
for this phenotype. GWAS analyses have been used to account for some of this missing
heritability, but many have only identified genes associated with fALS or rare subtypes of
the disease (Rich, Roggenbuck, & Kolb, 2020). RVAAs have also been used to identify
genes harbouring rare variation that may be contributing to the phenotype (S. M. K.
Farhan et al., 2019; Nicolas et al., 2018). Yet replication of associations remains difficult,
and relatively small sample sizes of ALS cohorts are likely limiting the ability to identify
novel genetic associations, such as ultra-rare SNVs or structural variants in novel disease
genes (Theunissen et al., 2020).
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1.3.1.1.1.2 Polygenic contributors to ALS
The aforementioned GWAS analyses of ALS have also successfully identified a selection
of common SNPs with small contributions to genetic risk (Nicolas et al., 2018).
Unfortunately, there are relatively few of these studies, as obtaining large cohorts of ALS
patients, along with appropriate replication cohorts, remains difficult. In time, enough
associated SNPs may be identified that the generation of an accurate PRS score is
possible, particularly for the sporadic forms of disease with a large amount of remaining
missing heritability. With that said, an interesting pattern has emerged in the literature
with regard to the identification of polygenic contributors to phenotypic modifiers of
ALS, rather than the disease state itself. For example, a SNP in the gene Unc-13
Homolog A (UNC13A) was associated with cognitive decline, prefrontal and temporal
cortex degeneration, and burden of hyperphosphorylated TDP-43 in patients with ALS
and FTD (Placek et al., 2019), while another recent study created a PRS for cognitive
dysfunction in ALS that also predicted atrophy severity in the frontal and temporal lobes
(Placek et al., 2021). Overall, these studies suggest that in addition to polygenic
contributors to overall ALS diagnosis, variants of small to moderate effect — both
common and rare — may contribute to the heterogeneous presentation between ALS
patients as well.

1.3.1.2

Parkinson’s disease (PD)

PD is the most common movement disorder, with a prevalence of 4.2 per 1,000
individuals over the age of 40 in Ontario (Ng et al., 2015). The phenotype is
characterized by loss of dopaminergic neurons in the substantia nigra pars compacta,
resulting in motor features, such as bradykinesia, rigidity, resting tremor, and postural
instability (Kalia & Lang, 2015). Presentation between PD patients is highly
heterogeneous and sub-typing is not uncommon — for example, differentiating tremordominant PD from non-tremor dominant PD. Non-motor features are also not uncommon
in PD patients and may present before or after the onset of motor features. Cognitive
impairment and dementia, psychiatric disorders, sleep disruptions, and olfactory
dysfunction can all appear up to 12–14 years prior to the motor symptoms of PD, yet
often remain unexplained until diagnosis (Kalia & Lang, 2015). Additionally, although
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there are therapies that can manage disease symptoms, such as dopamine replacement
therapy, patients’ conditions continue to worsen. With an average disease duration of 17
years, late-stage patients present with severe, debilitating treatment-resistant symptoms,
including freezing of gait and falls, dysphagia, speech impairment, urinary incontinence,
and dementia (Kalia & Lang, 2015).
As with other neurodegenerative diseases, PD displays a hallmark of protein aggregates,
most notably aggregates of α-synuclein that form inclusions within neurons called “Lewy
bodies” (Spillantini et al., 1997). Lewy bodies do not stay centralized to the brain, but can
also be found in both the spinal cord and peripheral nervous system, and it is
hypothesized that these inclusions induce the onset of motor symptoms. It is also well
established that Lewy bodies contribute to late-stage cognitive phenotypes within PD
patients, and the inclusions are often used to define “Lewy body diseases” under the PD
spectrum, including Lewy body dementia and PD dementia (Gomperts, 2016). In addition
to α-synuclein, other proteins are also known to aggregate in the neurons of PD patients,
including amyloid-β plaques and neurofibrillary tau tangles, both of which contribute to
an earlier onset of dementia symptoms. Aside from the protein aggregates, PD pathology
has been found to involve dysfunction in the ubiquitin-proteosome system, mitochondrial
function, the lysosome-autophagy pathway, protein trafficking, synaptic response, and, of
course, dopamine neurotransmission (Kalia & Lang, 2015).

1.3.1.2.1

Genetic determinants of PD

Approximately 20% of PD cases are considered familial, although only 5–10% of all PD
cases have a known monogenic cause, leaving most of the remaining familial cases
genetically undefined (Ohnmacht, May, Sinkkonen, & Kruger, 2020). Genetic risk
factors of low penetrance and polygenic risk factors have also been associated with a
small fraction of sporadic PD cases. Including all PD cases, both seemingly familial and
sporadic, heritability estimates are approximately 30%, which may increase as
understanding of the complex nature of PD continues to develop (Keller et al., 2012;
Nalls et al., 2014). Therefore, a relatively large amount of heritability remains
unaccounted for. Importantly, PD associated genetic variants often display a large

50

amount of variable expressivity, including variation in age of onset, features of disease,
and rates of progression.

1.3.1.2.1.1 Monogenic determinants of PD
More than 20 years ago, the first gene to be associated with PD was identified as
synuclein alpha (SNCA), which encodes the α-synuclein protein and has a role in synaptic
vesicle trafficking (Polymeropoulos et al., 1997). Rare pathogenic variants in the gene
result in autosomal dominant PD; however, common non-coding variants have also been
identified at the locus attributable to sporadic PD (Maraganore et al., 2006; SimonSanchez et al., 2009). All PD patients harbouring monogenic SNCA variation display
hallmarks of Lewy bodies, Lewy neurites, and dopaminergic neuronal loss, yet clinical
manifestation of disease can vary widely depending on the variant. Although many of the
variants within SNCA previously associated with PD are nonsynonymous SNVs,
duplications and triplications of the entire gene are also causative of the disease (Lunati,
Lesage, & Brice, 2018). Autosomal dominant variants in the genes leucine-rich repeat
kinase 2 (LRRK2), VPS35 retromer complex component (VPS35), GTP cyclohydrolase 1
(GCH1), and Ataxin 2 (ATXN2) also display well-established associations with PD.
Other genes have been identified that display an autosomal recessive inheritance pattern
for PD; listed in order of variant frequency in PD, the genes include parkin RBR E3
ubiquitin protein ligase (PARK2), PTEN induced kinase 1 (PINK1), and parkinsonism
associated deglycase (DJ1) (Lunati et al., 2018). PD patients carrying homozygous
variants in these genes typically present with an early-onset form of disease (<40 years).
Additionally, all three genes are involved in mitochondrial quality control, and
pathogenic variants within the genes result in mitochondrial and mitophagy dysfunction
(Ryan, Hoek, Fon, & Wade-Martins, 2015). Many other genes have been identified
through both family studies and GWAS as potentially associated with either autosomal
dominant or autosomal recessive PD, yet a large portion have yet to be fully validated.
Generally accepted as the most common genetic risk factor for PD is variation in the
glucocerebrosidase gene (GBA). Originally, the gene was associated with autosomal
recessive Gaucher’s disease; however, patients were identified that presented with
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generalized parkinsonism, and, upon further review, family members of patients with
Gaucher’s disease displayed increased incidence of PD, and many were identified as
heterozygous GBA variant carriers (Halperin, Elstein, & Zimran, 2006; Tayebi et al.,
2001). Aside from a lower frequency of resting tremor and a much greater risk of
cognitive impairment and motor dysfunction, GBA variant carriers display relatively
“typical” sporadic PD presentation (Sidransky et al., 2009). The variants themselves have
been associated with lysosomal dysfunction, ultimately resulting in increased α-synuclein
aggregation. Neuroinflammation and mitochondrial dysfunction have also been observed
in these patients (Gegg & Schapira, 2018). The association between GBA and PD will be
explored further in Chapter 6.

1.3.1.2.1.2 Polygenic contributors to PD
Although there are a small portion of PD patients that have monogenic forms of disease,
largely patients are considered complex, with likely polygenic inheritance models. Recent
estimates indicate that heritability of PD attributable to common variants may be between
16–36% (Goldman et al., 2019; Nalls et al., 2019). Specifically, 90 SNPs have now been
associated with PD; however, the PRS that was created using these SNPs was predicted
to lead to a high rate of false positive associations if applied to a general population,
creating concerns for the clinical application of a PRS in PD (Nalls et al., 2019). Yet,
further analysis of polygenic contributors to PD may allow for the development of a more
accurate PRS.
In a similar manner to ALS, polygenic contributors have also been identified in PD to
modify classical disease presentation. Shared genetic loci have been identified to
associate with both PD and schizophrenia, suggesting common mechanisms underlying
clinical features of the diseases (Smeland et al., 2021). Further, a weighted PRS of 23
GWAS identified SNPs was associated with faster cognitive and motor decline in patients
with PD (Paul, Schulz, Bronstein, Lill, & Ritz, 2018). Again, these studies suggest that
genetic variants with small to moderate phenotypic impact may not only contribute to
risk of PD, but to the differential presentation between PD patients.
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1.3.2
1.3.2.1

Cognitive and/or behavioural disorders
Alzheimer’s disease (AD)

As the most common neurodegenerative disease, AD has a prevalence across Ontario of
13.8 per 1,000 individuals over the age of 40 years and up to 50.4 per 1,000 individuals
over the age of 65 years ("2020 Alzheimer's disease facts and figures," 2020; Ng et al.,
2015). The disease is characterized by progressive cognitive decline and severe memory
impairment that disrupts daily functioning. As patients progress through the course of
AD, they become more dependent on external care and may experience behavioural
changes, mobility impairment, and/or psychosis. The mean age of diagnosis is ~75 years
— with early-onset (EOAD) cases defined as onset < 65 years of age and late-onset
(LOAD) defined as onset ≥ 65 years of age — and the disease has an average duration of
~8.5 years, although duration is often longer in early-onset and/or familial cases (Jost &
Grossberg, 1995). Similar to most neurodegenerative diseases, available treatments and
interventions are only able to marginally slow disease progression and mitigate
symptoms (Weller & Budson, 2018).
AD neuropathology is largely defined by amyloid-β plaques and neurofibrillary tau
tangles. Amyloid-β plaques are extracellular inclusions of amyloid-β-40 and amyloid-β42, which are the by-products of aberrant amyloid precursor protein (APP) metabolism,
and the latter of which is of higher abundance in resulting plaque deposits (Tiwari, Atluri,
Kaushik, Yndart, & Nair, 2019). The amyloid-β first forms fibrils that oligomerize and
diffuse into the extracellular space. There, the fibrils interrupt synaptic signaling and
polymerize further to form plaques. Interestingly, the accumulation of amyloid-β plaques
activates the hyperphosphorylation of microtubule-associated tau proteins, resulting in
the formation of neurofibrillary tau tangles (Tiwari et al., 2019). While amyloid-β
plaques have long been associated with AD, deposition of amyloid-β has also been
observed in cognitively normal elderly individuals, suggesting amyloid-β cannot drive
disease presentation in singularity; in contrast, neurofibrillary tau tangle load has been
directly associated with degree of cognitive impairment (Lane, Hardy, & Schott, 2018).
Although it is well established that amyloid-β and neurofibrillary tau tangles have a large
role in AD pathology, precise mechanisms are yet to be elucidated. Neuropathological
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markers such as neuropil threads, dystrophic neurites, and CAA, or co-pathologies such
as vascular disease, Lewy bodies, or TDP-43 inclusions are also not uncommon in AD
patients (Lane et al., 2018).

1.3.2.1.1

Genetic determinants of AD

The dichotomy between EOAD and LOAD loosely translates to whether the disease is
considered familial or not, with most EOAD cases considered as familial, and most
LOAD cases considered sporadic. Therefore, it is unsurprising that EOAD displays
heritability estimates of 90–100%. Yet, LOAD heritability remains unexpectedly high at
70–80% (Cacace, Sleegers, & Van Broeckhoven, 2016). However, even with such high
heritability, ~90% of EOAD cases remain genetically unexplained, as do a large majority
of LOAD cases.

1.3.2.1.1.1 Monogenic determinants of AD
There are three main genes — APP, presenilin 1 (PSEN1), and presenilin 2 (PSEN2) —
that in aggregate are known to account for 5–10% of EOAD cases, all of which were
identified by linkage analysis to contribute to the disease in an autosomal dominant
manner (Cacace et al., 2016). APP was the first gene associated with AD and the protein
product is thought to be involved in synaptic development (Priller et al., 2006). As
previously described, APP is also cleaved by secretases into by-products that eventually
contribute to amyloid-β plaque formation. Both rare SNVs and structural variants have
been identified as pathogenic in APP for EOAD, likely contributing to the phenotype
through the overproduction of amyloid-β-42 and resulting in increased amyloid plaque
pathology (Shao, Peng, & Wang, 2017). APP has also been associated with CAA,
characterized by cerebrovascular amyloid deposition and resultant dementia and/or
stroke. PSEN1 and PSEN2 encode proteins involved in the secretase in the
amyloidogenic pathway implicated in cleaving APP (Cacace et al., 2016). PSEN1 is the
most frequently mutated out of the three main EAOD genes, whereas variants within
PSEN2 are considered rarer. Within PSEN1 there have been a wide range of variants
identified, including SNVs and structural variants, and almost all are considered highly
penetrant; however, while both SNVs and structural variants have been associated with
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EOAD in PSEN2, penetrance is more variable and variable expressivity has been
observed (Cacace et al., 2016).
Of high importance, genetic risk of AD could not be discussed without describing APOE,
the strongest genetic risk factor for sporadic LOAD. The association was originally
discovered through linkage analysis and has been further replicated in many case-control
studies. Interestingly, APOE is associated with increased risk of EOAD, particularly in
individuals with a family history of AD (van Duijn et al., 1994). APOE encodes the apo E
glycoprotein, which is responsible for carrying and distributing cholesterol, both in the
periphery and the brain, and has roles in neuronal growth, nerve regeneration, and
immunoregulation. Notably, there are two variants within the gene, located at amino acid
positions 130 and 176 — or 112 and 158, respectively, if the pro-peptide sequence is
excluded — that give rise to three apo E isoforms: apo E2, apo E3, and apo E4 (Figure
1.8) (Zannis et al., 1982). While the wild-type gene is encoded by the E3 genotype, the
E4 genotype increases risk of AD in a dose dependent manner, with approximate
increased risks of three times in heterozygous carriers and 12 times in homozygous
individuals. The E4 genotype is relatively common in the general population, with an
MAF of ~0.14, although frequencies vary between ancestral populations (Heffernan,
Chidgey, Peng, Masters, & Roberts, 2016). In contrast, the less common E2 genotype
(MAF ~ 0.07) has been associated with protective effects against AD development.
Although the exact mechanism by which APOE contributes to AD risk is unclear, it is
seemingly involved in many potentially pathogenic pathways (Munoz, Garner, & Ooi,
2019). Not only has apo E been observed within amyloid-β plaques, but it may have a
direct role in amyloid-β fibril formation and amyloid plaque clearing within the brain.
The E4 isoform is less effective at preventing the fibril formation and potentially less
effective at clearing amyloid plaques (Munoz et al., 2019). However, apo E is also
observed within neurofibrillary tangles, and overexpression of apo E increases tau
hyperphosphorylation. Apo E4 also prevents synaptic protein expression and is
associated with increased α-synuclein pathology (Zhao et al., 2020; Zhao, Liu, Qiao, &
Bu, 2018).

55

Figure 1.8 Schematic of the apolipoprotein (apo) E protein, demonstrating the
location of the variants resulting in the differential apo E isoforms.
APOE encodes the apo E glycoprotein, which is responsible for carrying and distributing
cholesterol. Two variants within the gene, located at amino acid positions 130 and 176,
give rise to three apo E isoforms: apo E2, apo E3, and apo E4. E3 is considered the wildtype isoform, and E2 and E4 each have differential receptor binding affinity. Specifically,
the apo E4 isoform results in a domain interaction that reduces the protein’s binding
affinity, and is the greatest genetic risk factor for the development of Alzheimer’s
disease. Adapted from (Yu, Tan, & Hardy, 2014).
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1.3.2.1.1.2 Polygenic contributors to AD
Aside from APOE, there have been over 20 common variants identified through GWAS
associated with LOAD. Current efforts are being put forth to create an accurate,
replicable polygenic risk score to account for the potentially polygenic risk of AD;
however, NGS association studies have also since identified rare variants in GWAS
identified loci, as well as within other genes of potential interest, that may contribute
moderate risk of disease (Raghavan & Tosto, 2017).
Interestingly, PRSs have been created for AD with relatively large predictive power for
disease (Escott-Price, Myers, Huentelman, & Hardy, 2017; Escott-Price et al., 2015), but
it has since been determined that a large amount of the predictive power from these
scores is encompassed by the inclusion of the APOE E4 allele(s) (Escott-Price, Myers,
Huentelman, Shoai, & Hardy, 2019). Yet, recent analyses have demonstrated that even
when E4 carriers are excluded from PRS analyses, predictive power remains promising,
although only in cohorts of pathologically confirmed AD cases. In clinical cohorts of AD,
likely with an admixture of misdiagnosed individuals, the predictive power of the PRSs
in non E4 carriers is reduced (Escott-Price et al., 2019; Escott-Price et al., 2015). The
results are concerning, as the clinical utility of the currently available PRSs may not be
generally applicable in AD clinics or in the offices of general practitioners, which are
highly accessed by neurodegenerative disease patients living in rural areas.

1.3.2.2

Frontotemporal dementia (FTD)

FTD defines a collection of conditions, all characterized by atrophy of the frontal and
anterior temporal lobes, and resulting in progressive behavioural changes and/or language
dysfunction (Devenney, Ahmed, & Hodges, 2019). Overall, the disease displays a
prevalence in Ontario of 0.591 per 1,000 individuals over the age of 40 and 1.944 per
1,000 individuals over the age of 65 (Hogan et al., 2016; Ng et al., 2015). FTD subtypes
include: behavioural variant FTD (bvFTD), corticobasal syndrome (CBS), progressive
supranuclear palsy (PSP), and primary progressive aphasia (PPA). BvFTD displays an
average age of onset of ~58 years and is characterized by severe changes in social
conduct and personality, including apathy, lack of inhibition and empathy, mental
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rigidity, and deficits in executive function (Devenney et al., 2019). In contrast, CBS
involves asymmetric motor features, such as limb rigidity, dystonia, or myoclonus and
can sometimes present alongside other forms of FTD or dementia (Olney, Spina, &
Miller, 2017). PSP is largely defined by vertical supranuclear gaze palsy or slow vertical
saccades, as well as postural instability leading to falls, with onset after the age of 40
years. Patients may also present with the cognitive features common to many FTD subtypes, including personality changes, executive dysfunction, and reduced mental speed.
Similar to CBS, PSP can co-exist with the other FTD sub-types (Olney et al., 2017).
Finally, PPA is generally characterized by language impairment, but can be further
subdivided into non-fluent and semantic variants. The non-fluent variant encompasses
patients that present with severe difficulties with speech, whereas semantic variant
patients present with language-based difficulties and issues with semantic knowledge
(Olney et al., 2017).
It is also important to recognize the considerable overlap between FTD and ALS,
specifically in regards to neuropathology and genetic associations. As previously
described, between 40–50% of patients with ALS present with clinical features of FTD,
such as behavioural changes, language impairment, and impaired executive function
(Karch et al., 2018). It is also estimated that ~40% of FTD patients display a degree of
motor dysfunction. If certain diagnostic criteria are met, patients may actually be
diagnosed with concurrent ALS and FTD (ALS-FTD), accounting for ~15% of all FTD
cases (Bennion Callister & Pickering-Brown, 2014; Strong et al., 2017).
Over 90% of FTD cases present with protein inclusions composed of
hyperphosphorylated tau protein or ubiquitinated TDP-43; however, FUS positive
inclusions and ubiquitin proteosome pathology are also observed in rare cases (Devenney
et al., 2019). To some extent, neuropathology is dependent on FTD subtype, as well as
any genetic contribution to disease, although correlations are not perfect. The majority of
bvFTD cases present with heterogeneous inclusions containing at least one of:
hyperphosphorylated tau, ubiquitinated TDP-43, or FUS. In cases of CBS and PSP,
hyperphosphorylated tau is the predominant neuropathology, but in CBS, accumulation is
in the cortex and basal ganglia, and in PSP, accumulation is observed in the basal ganglia,
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brainstem, and cerebellum. Semantic variant PPA cases almost exclusively display TDP43 inclusion pathology, whereas non-fluent variant PPA may present with either
hyperphosphorylated tau or ubiquitinated TDP-43 (Devenney et al., 2019).

1.3.2.2.1

Genetic determinants of FTD

As previously stated, the genetic contributors to FTD influence patients’ differential
neuropathology and, in turn, the differential sub-types. Between 20–50% of FTD cases
are considered familial, although frequencies differ dependent upon the FTD sub-type
(Greaves & Rohrer, 2019). The remaining FTD cases are considered sporadic. Overall,
FTD is considered highly heritable, yet a genetic cause has been identified in <20% of
cases (Sieben et al., 2012).

1.3.2.2.1.1 Monogenic determinants of FTD
Three genes are able to account for the genetic predisposition to 60% of familial FTD
cases, including microtubule associated protein tau (MAPT), granulin precursor (GRN),
and C9orf72; the last of which refers to the hexanucleotide repeat expansion described in
Section 1.2.1.1.1. In fact, the C9orf72 expansion accounts for up to 25% of familial FTD
cases alone and has also been observed in cases of seemingly sporadic FTD and ALSFTD (Bennion Callister & Pickering-Brown, 2014).
MAPT was the first gene associated with familial FTD and was discovered through
linkage analysis (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini, Crowther,
Kamphorst, Heutink, & van Swieten, 1998). The gene encodes the protein tau — the
main component of hyperphosphorylated tau inclusions within neuron and glial cells in
FTD. Normally, tau is involved in the stability of microtubules; however, when mutated,
tau may become more abundant resulting in greater aggregation in the cytoplasm, may
have an increased rate of phosphorylation, or may undergo alternative splicing resulting
in imbalanced isoform ratios (Fenoglio, Scarpini, Serpente, & Galimberti, 2018). Carriers
of MAPT pathogenic, rare variants with FTD most commonly present with the bvFTD,
CBS, or PSP subtypes, and, unsurprisingly, carriers present with neuropathological
hyperphosphorylated tau inclusions (Olszewska, Lonergan, Fallon, & Lynch, 2016). CBS
and PSP have also been associated with common variation within MAPT, specifically in
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reference to the MAPT haplotype. MAPT falls within the largest region of LD across the
human genome, spanning ~1.8 Mb, inside of which 900 kb have been inverted, including
the entire MAPT gene resulting in differential haplotypes, namely H1 and H2 (Figure
1.9) (Caffrey & Wade-Martins, 2007). Due to the large amount of LD throughout the
region, the haplotype can be defined with only single SNPs that can be genotyped
through methods such as TaqMan allelic discrimination assay, as will be applied in
Chapter 2. Although the H1 haplotype is rather common in the general population, it has
been associated with both CBS and PSP. Within the H1 haplotype, duplicated regions
have also been discovered that can be defined by specific tagging SNPs, of which the
H1C sub-haplotype has been associated with PSP (Caffrey & Wade-Martins, 2007).
GRN encodes progranulin, a protein involved in growth regulation, wound repair, and
inflammation. Although variants within GRN are largely associated with familial FTD
cases, there have been pathogenic rare variants identified in the gene in seemingly
sporadic cases as well (Fenoglio et al., 2018). The variants result in haploinsufficiency, as
the majority of known pathogenic variants result in premature termination of the protein
and result in non-sense mediated decay. Missense variants have also been observed in
GRN in FTD patients, yet their mechanism of pathogenicity remains unclear. GRN
variants are associated with ubiquitinated TDP-43 inclusions and patients tend to have the
bvFTD or non-fluent PPA sub-types (Miller & Llibre Guerra, 2019).
There are many other genes that have been associated with FTD, and its subtypes, in
more rare instances, including TARDBP and FUS, indicating a large amount of genetic
overlap between FTD and ALS (Bennion Callister & Pickering-Brown, 2014). Although
monogenic inheritance of FTD is considered relatively uncommon, known Mendelian
variants sufficiently account for disease risk in many cases and are, therefore, important
markers to consider targeting in the development of novel therapeutics.
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Figure 1.9 The 900 kilobase (kb) inversion on chromosome 17 (17q21) that results in
two differential microtubule associated protein tau (MAPT) haplotypes.
MAPT falls within a ~1.8 megabase (Mb) region of linkage disequilibrium that includes
900 kb of inverted sequence, including the entire MAPT gene. The inversion results in
differential haplotypes, namely H1 and H2. The H1 haplotype has been previously
associated with subtypes of frontotemporal dementia. Adapted from (Caffrey & WadeMartins, 2007).
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1.3.2.2.1.2 Polygenic contributors to FTD
GWAS analyses are beginning to identify loci of interest associated with FTD, and
attempts are being made to produce accurate polygenic risk scores to account for a
portion of the remaining missing heritability (Ferrari et al., 2014; Hagenaars et al., 2018).
Unfortunately, similar to GWAS of ALS, the large sample sizes required for these
analyses have likely resulted in lower yield thus far, as FTD is considered a rarer type of
dementia (Manzoni & Ferrari, 2021). While recent GWASs of AD have included
>90,000 cases, the largest FTD GWAS to date has only included ~3,500 cases
(Hagenaars et al., 2018; Kunkle et al., 2019). Further research into the genetic
contributors to FTD with small to moderate phenotypic impact is warranted to account
for the obvious missing heritability of the disease.

1.3.2.3

Mild cognitive impairment

MCI is a prodromal stage of dementia, characterized by memory impairment that does
not disrupt daily functioning. Although some patients may not progress beyond the MCI
diagnosis, over 50% will continue on to develop AD, vascular dementia, or other forms
of dementia (Mitchell & Shiri-Feshki, 2009). As expected, MCI is highly heterogenous,
and cases can be largely divided into two subtypes: 1) amnestic and 2) non-amnestic.
Amnestic MCI is grossly characterized by memory impairment, whereas the nonamnestic form may present with intact memory, but impaired attention, language, or
executive functioning. The former is more likely to progress to a classical AD
presentation, while the latter may progress to other forms of neurodegeneration, such as
FTD or PD dementia (Giau, Bagyinszky, & An, 2019).

1.3.2.3.1

Genetic determinants of MCI

Due to the large amount of heterogeneity within the MCI diagnosis, neuropathology
varies. However, it is generally accepted that amyloid-β plaques and neurofibrillary tau
tangle loads correlate with the likelihood that MCI will progress to AD or other
dementias (Anderson, 2019). Similarly, the APOE E4 allele has been associated with
both increased risk of MCI development, as well as increased risk of progression from
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MCI to AD, yet any remaining genetic risk factors for MCI are undefined
(Elcoroaristizabal Martin et al., 2011; Fleisher et al., 2007).

1.3.3

Cerebrovascular disease (CVD)

Not only does the brain consume 20% of cardiac output and require 20% of the body’s
available oxygen and glucose, but it is not able to store energy for the long-term and,
therefore, requires a constant and dependable blood flow from its vascular system
(Lendahl, Nilsson, & Betsholtz, 2019). It is unsurprising that when issues arise within the
brain’s intrinsic vasculature, or when blood flow to the brain is restricted, damage can be
catastrophic. CVD is defined as any condition that affects the blood vessels within or the
blood flow to the brain and encompasses both acute events, such as ischemic or
hemorrhagic strokes, or CVD neuropathology, such as white matter hyperintensities,
CAA, and enlarged perivascular spaces. Although CVD may solely drive
neurodegenerative disease, as is the case with vascular dementia (VaD), it may also be a
concurrent pathology with existing neurodegenerative disease, or act as one of many
contributors to a neurodegenerative pathology, such as in AD or vascular PD (Seidel,
Giovannetti, & Libon, 2012).
VCI broadly defines all forms of dementia with a vascular component, ranging from
vascular MCI to VaD. The term can also encompass mixed pathologies, such as
concurrent vascular disease and AD pathology. Generally, any individual displaying
cognitive dysfunction along with the presence of CVD can be included under the VCI
umbrella (Dichgans & Leys, 2017). While the prevalence of CVD in individuals over the
age of 65 across Ontario is 37.8 per 1,000 individuals (Ng et al., 2015), it remains
difficult to define prevalence of VCI, as inclusion criteria may vary across clinical and
research cohorts. Additionally, it is not uncommon for cerebrovascular pathology and
acute events to go unnoticed by patients and clinicians until brain imaging is employed.
Yet, it is suggested that over 50% of dementia cases present with CVD features
(Schneider, Arvanitakis, Bang, & Bennett, 2007). Further, CVD is not uncommon when
considering motor/movement disorders (Chondrogianni et al., 2018; Mehanna &
Jankovic, 2013).
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Overall, it is continuously more accepted that neurodegenerative diseases are not only
characterized by neuronal cell loss, but also by cerebrovascular injury. In the context of
AD, approximately 40% of patients present with vascular changes and cerebral blood
flow is largely reduced in many patients, suggesting a mixed dementia pathology
(Lendahl et al., 2019). Further, blood-brain-barrier breakdown is common in AD, as well
as in MCI, resulting in greater levels of immune cells in the brain and neuroinflammation,
which is known to promote both neurodegenerative disease and CVD pathology.
Amyloid-β has also been observed to accumulate within the cerebrovasculature resulting
in CAA in more than 80% of AD cases (Lendahl et al., 2019). In contrast, there is much
less evidence for a role of CVD in FTD, although white matter changes in the frontal and
temporal lobes of FTD patients have been observed (Thal et al., 2015). And while
dementia is the first consideration when discussing CVD and neurodegenerative disease
co-morbidities, as stated above, motor/movement disorders are not excluded. Not only
have CVD risk factors been associated with subsequent diagnosis of PD, but vascular PD
has been estimated to account for between 3–12% of parkinsonism cases (Kummer et al.,
2019; Mehanna & Jankovic, 2013). Additionally, a few cases of ALS have now been
associated with cerebral arteriovenous malformations, and aspects of CVD, such as
atherosclerosis and ischemic heart disease, may be associated with greater risk of ALS
(Chondrogianni et al., 2018; Kioumourtzoglou et al., 2016).
When considering VaD, large and small cerebral vessel disease are considered causal,
rather than a co-pathology. Pathology of VaD is largely defined by diminished cerebral
blood flow, resulting in hypoxia, blood brain barrier dysfunction, and ultimately
neurotoxic effects and/or amyloid deposition. VaD can be further subclassified into: 1)
multi-infarct dementia, 2) strategic infarct dementia, 3) subcortical ischemic dementia,
hemorrhagic dementia, 4) hypoperfusion dementia, and 5) other arteriopathies, such as
CAA or CADASIL (Dichgans & Leys, 2017).

1.3.3.1

Genetic determinants of CVD and resultant
neurodegenerative disease

Compared to the specific neurodegenerative diseases outlined throughout Sections 1.2.1
and 1.2.2, few genetic determinants of VCI have been identified. Although, those that
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have been discovered have been found to either contribute to specific VaD diagnoses or
to co-pathologies encompassed by the VCI umbrella term.
The most frequent form of monogenic cerebral small vessel disease is CADASIL, caused
by heterozygous pathogenic variants in the Notch receptor 3 gene (NOTCH3) (Joutel et
al., 1996). Although clinically heterogeneous, most CADASIL patients present with
recurrent ischemic attacks, migraines with aura, cognitive decline and dementia, and, in
some cases, mood disorders. Identification of white matter hyperintensities (WMHs)
upon magnetic resonance imaging (MRI) is also a hallmark of the disease (Tikka et al.,
2014). The Notch3 protein — a transmembrane receptor in smooth muscle cells —
contains 34 extracellular epidermal growth factor (EGF)–like repeats, each containing
cysteine residues integral to the protein structure. Variants affecting these cysteine
residues are pathogenic for CADASIL, as they result in Notch3 protein misfolding and
aggregation in the smooth muscle cells, including those within the brain’s vasculature
(Joutel et al., 1997; Opherk et al., 2009). Cerebral autosomal recessive arteriopathy with
subcortical infarcts and leukoencephalopathy (CARASIL), although much rarer, presents
in a very similar manner to CADASIL; however, it is caused by homozygous pathogenic
variants in the high‐temperature requirement A serine peptidase 1 gene (HTRA1) (Hara et
al., 2009; Tikka et al., 2014). Interestingly, heterozygous variants within HTRA1 have
also been associated with cerebral small vessel disease, although presentation is less
severe than that of CARASIL (Bianchi et al., 2014; Y. Chen et al., 2013; Mendioroz et
al., 2010).
In addition to genes contributing to monogenic forms of VaD, there are also genes that
increase risk of stroke or other cerebrovascular accidents, such as collagen type IV alpha
1 (COL4A1) and collagen type IV alpha 2 (COL4A2). While these genes are pleiotropic
for multiple conditions, including glaucoma and myopathy, pathogenic variants in
COL4A1 and COL4A2 increase risk of hemorrhagic stroke. Other vascular conditions,
such as pseudoxanthoma elasticum (PXE) caused by autosomal recessive variants in the
ATP Binding Cassette Subfamily C Member 6 gene (ABCC6), can present with features
of CVD as well and are important to continue to investigate in respect to how they may
influence neurodegenerative disease pathology (Sunmonu, 2021). In fact, heterozygous
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variants in ABCC6 have also been observed in rare cases of PXE (Hu et al., 2003). Based
on the previous associations between CVD and neurodegeneration, it is possible that
variants within these genes may also contribute to increased risk of neurodegenerative
disease presentation.
There are also genes previously associated with neurodegeneration that have overlapping
influence with CVD. The most prominent example of this is APOE. Along with its strong
association with AD, the E4 allele has been associated with ischemic CVD, as well as
increased neuronal damage from CVD events (Laskowitz et al., 1997; McCarron,
Delong, & Alberts, 1999). Further, the apo E4 isoform contributes to the accumulation of
amyloid-β in the capillaries, resulting in increased rates of CAA in cases of AD, and the
risk variant has been associated with increased WMH volumes in AD patients (Love &
Miners, 2016). Recent analyses also suggest that APOE E4 contributes to blood-brainbarrier breakdown, resulting in cognitive decline independent of AD pathology
(Montagne et al., 2020). Interestingly, although the APOE E2 allele is typically
considered protective for AD, the allele is associated with increased WMH volume in
CADASIL patients, as well as increased CAA in parenchymal and meningeal
cerebrovasculature (Gesierich et al., 2016; Nelson et al., 2013).

1.3.4

Diagnosis and neurodegenerative disease heterogeneity

As can be gathered from the descriptions of different neurodegenerative diseases above,
presentation across the diagnoses is highly heterogeneous. Not only can patients within
one disease type, such as AD, present quite differently from one another, but patients
with different diagnoses often have overlapping features. Particularly, early in disease
presentation misdiagnosis can be quite common.
When considering motor/movement disorders, it is clearly recognized that patients also
often present with features of cognitive or behavioural dysfunction. Over 40% of patients
with ALS present with features of FTD, and common early features of PD include nonmotor phenotypes, such as cognitive impairment, psychiatric disorders, and sleep
disruptions (Kalia & Lang, 2015; Karch et al., 2018). In the early stages of disease, when
motor features are mild or not yet manifested, these cognitive features can lead to
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alternative diagnoses and mislead clinical care (Bicchi et al., 2015). Further, the
motor/movement disorders themselves are known to have overlapping features, as
parkinsonism has been observed in patients with ALS (Calvo et al., 2019). Although both
conditions have clearly defined diagnostic criteria — based on clinical examination,
nerve conduction studies, electromyography, and laboratory tests — if early signs of
disease are considered abnormal, as is quite common, appropriate tests may not be
ordered. Similarly, cognitive and behavioural disorders may present with features of
movement dysfunction, or overlapping cognitive features between the differential
diagnoses, perhaps to an even greater extent than the motor/movement disorders.
Misdiagnosis as AD is particularly common, possibly due to its high prevalence — if a
patient is displaying features of dementia that include memory impairment, AD is often
first assumed, rather than considering the possibility of FTD with memory dysfunction or
that the patient might have experienced silent CVD resulting in VCI (Beber & Chaves,
2013; Doran et al., 2007; Selvackadunco et al., 2019).
Unfortunately, current diagnostic processes are rather slow across neurodegenerative
diseases, allowing for further progression of pathology and associated symptoms before
potential interventions can be applied. For example, the average ALS patient will wait 9–
12 months for a diagnosis following initial onset of symptoms, which is quite striking for
a disease with a survival period of only 2–4 years (Hulisz, 2018; Mehta et al., 2017).
Additionally, by the time even early symptom onset occurs, irreversible neuropathology
changes may have begun 10–20 years before. In the case of PD, by the onset of motor
symptoms, it is estimated that more than 50% of dopaminergic neurons have already been
lost (Katsuno et al., 2018). As currently available treatments and interventions are only
able to marginally slow disease progression and manage symptoms, rather than
preventing progression or reversing damage, it is imperative that these are initiated as
soon as possible to preserve patient’s function ("The Need for Early Detection and
Treatment in Alzheimer's Disease," 2016).
Although there are many emerging methods for neurodegenerative disease diagnosis,
such as MRI algorithms and biomarker testing of cerebral spinal fluid or plasma
(Sancesario & Bernardini, 2018; Shen et al., 2020; X. Y. Zhang, Yang, Lu, Yang, &
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Zhang, 2017), definitive diagnosis requires postmortem neuropathological analysis.
Genetics may offer another avenue for definitive diagnosis, but current clinical genetic
tests for neurodegeneration screen only for variants known to cause the familial forms of
the diseases, limiting their utility. Comprehensibly, the basis for this is the lack of
understanding regarding the many genes that have now been linked to neurodegenerative
diseases and the high occurrence of uninterpretable variation during genetic screening (J.
S. Roberts, Patterson, & Uhlmann, 2020). However, it cannot be denied the profound
effect wide-spread, accurate genetic diagnostics would have in the field of
neurodegenerative disease. Not only would it offer definitive diagnosis for patients, but it
would also offer the ability for pre-emptive screening in family members interested in
knowing their risk of disease development.

1.3.5

Non-genetic risk factors for neurodegenerative disease

The most well-established risk factor for all neurodegenerative diseases is age. The root
of this association is likely multifaceted, as many cellular mechanisms are known to
breakdown with age. Suggested pathways include, but are not limited to: genomic
instability resulting in DNA damage, epigenetic changes such as increased DNA
methylation, mitochondrial dysfunction, cellular senescence, defects in telomere
maintenance, and a lack of stem cell rejuvenation (Hou et al., 2019). Further, there are
often prominent differences in risk between sexes for neurodegenerative disease
development, but the differences tend to be specific to the particular diagnosis. For
example, males have a greater risk of ALS, PD, and potentially FTD, while females have
a greater risk of AD. Presentation of the diseases can also differ between sexes
(Hanamsagar & Bilbo, 2016; Miller & Llibre Guerra, 2019).
There are a large number of environmental risk factors for neurodegenerative diseases
that may vary between diagnoses, as well. Across most diagnoses common risk factors
include traumatic brain injury, smoking, and chemical or heavy metal exposure
(Delamarre & Meissner, 2017; Hulisz, 2018; Killin, Starr, Shiue, & Russ, 2016).
Additionally, as described in Section 1.2.3, CVD is an imperative risk factor across all
neurogenerative diseases. Of course, it is important to have an understanding of how
environmental factors may influence risk of neurodegenerative disease development, as
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lifestyle modification may be able to mitigate risk to a certain degree. Yet, the large
amount of heritability attributable to neurodegeneration still suggests a dire need for
effective therapeutics to slow, cease, and reverse disease progression.

1.4
The Ontario Neurodegenerative Disease
Research Initiative
To date, many large consortia have been formed to study the factors contributing to and
progression of neurodegenerative diseases, such as the Alzheimer’s Disease
Neuroimaging Initiative (ADNI), the Parkinson Progression Marker Initiative (PPMI),
and Project MinE; yet these studies remain in their silos of specific diagnoses, studying
AD, PD, and ALS, respectively. Without consistent assessments, enrollment criteria, and
data processing, analyzing the participants across these studies remains difficult and they
cannot account for the large amounts of heterogeneity and overlap between
neurodegenerative diagnoses.
To gain a better understanding of the occurrence and progression of various
neurodegenerative diseases and their respective similarities and differences, the Ontario
Neurodegenerative Disease Research Initiative (ONDRI) was formed, funded through the
Ontario Brain Institute (OBI) (ondri.ca). The longitudinal, province-wide, observational
cohort study aims to characterize multiple neurodegenerative diseases, including: 1) AD;
2) ALS; 3) FTD (bvFTD, CBS, PSP, and PPA [non-fluent and semantic variants]); 4)
amnestic MCI; and 5) PD, as well as a cohort of individuals with CVD with or without
cognitive impairment (CVD ± CI). ONDRI takes a multimodal approach with multiple
assessment platforms and its novel study design provides a longitudinal nature of
evaluation, including follow-up and simultaneous analysis of patients across the five
phenotypes using the same phenotypic and genotypic markers. Goals of the study
included identifying markers that could be applied to early and accurate prediction tools
for neurodegeneration, as well as thoroughly analyzing the contribution of cerebral smallvessel pathology to neurodegenerative phenotypes. For the purposes of brevity, only
relevant details regarding the general experimental design, enrollment criteria, data
management, and assessment platforms will be outlined herein. Full details have been
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previously described by Farhan et al. and Sunderland et al. (S. M. K. Farhan et al., 2017;
Sunderland et al., 2020).
Participant recruitment took place between June 2014 and March 2017. Although ONDRI
originally aimed to enroll 600 participants across the various disease cohorts, final
enrollment was capped at 520 participants, including 41 AD participants, 40 ALS
participants, 161 CVD ± CI participants, 53 FTD participants, 85 MCI participants, and
140 PD participants. Upon original study design, the AD and MCI participants were
binned into a single AD/MCI cohort, but were later divided, which is reflected in certain
analyses in this Dissertation. AD participants included those with either amnestic and
non-amnestic presentation and MCI participants may have had either single- or multidomain amnestic presentation. Importantly, all AD/MCI participant MRI scans were
assessed by a research neurologist to confirm absence of significant cerebrovascular
pathology that may suggest non-Alzheimer cognitive impairment; if evidence of small
vessel disease was observed, participants were instead enrolled into the CVD ± CI cohort.
ALS participants may have had possible, probable, or definite ALS. Of the FTD
participants, 21 were diagnosed with bvFTD (39.6%), 3 with CBS (5.7%), 16 with PSP
(30.2%), 8 with non-fluent PPA (15.1%), and 5 with semantic variant PPA (9.4%). All
PD participants were considered idiopathic and may or may not have had cognitive
impairment. Full enrollment criteria and enrollment deviations were outlined by
Sunderland et al. (Sunderland et al., 2020).
All participants were assessed across seven platforms, including: 1) clinical; 2) genomics;
3) neuropsychology; 4) gait and balance; 5) eye tracking; 6) neuroimaging; and 7) retinal
imaging. There is also a neuropathology platform that is conducting neuropathological
analysis postmortem on select participants and a neuroinformatics platform that acts as a
structural backbone providing data processing, data structuring, and statistical support.
All platforms’ data are deposited in Brain-CODE (braincode.ca), allowing for a secure
and central location to collect, store, and share data. The use of this portal is imperative
as, in accordance with ONDRI’s agreement with the OBI and the Ontario Government,
all non-identifying data will be made available to the greater scientific community on
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request. It is the hope that this open-science effort will allow for eventual collaboration
with other consortium-based efforts to obtain larger sample sizes and to replicate results.

1.4.1

Genetic analysis of neurodegenerative disease patients

Largely, this Dissertation encompasses the work of the genomics platform of ONDRI,
specifically focusing on the data produced using the ONDRISeq targeted NGS panel.
However, multiple methods were employed within ONDRI to genetically characterize
participants, including the aforementioned ONDRISeq panel, the NeuroX array, repeatprimed PCR, TaqMan allelic discrimination assay, and Sanger sequencing.
ONDRISeq was custom-designed for the ONDRI study, and was used to sequence the
protein-coding regions of 80 genes that were previously associated with the
neurodegenerative diseases encompassed by ONDRI’s mandate (Table 1.2; Appendix
D). With this methodology, we are able to harness high-quality NGS data in a focused
and efficient manner. The design and validation of the ONDRISeq panel with multiple
concordance studies was previously described, for which the ONDRISeq panel was able
to identify novel, rare variants of possible clinical significance in 72.2% of 216 ONDRI
participants used for panel validation (S.M.K. Farhan et al., 2016). As described in
Section 1.1.3.2, WGS evaluates the entire genomic content of an individual, while WES
involves sequencing only the protein-coding regions of the genome. Targeted sequencing,
in contrast, focuses on specific regions of the genome based on relatively few specific
loci linked by common pathological mechanisms or known clinical phenotype. Therefore,
targeted sequencing can be an excellent approach when there is already a foundation of
candidate genes known to be associated with the disease of interest, as is the case with
neurodegenerative disease (Dilliott et al., 2018). Targeting specific regions of the genome
also allows for elimination of superfluous and irrelevant genetic variation that can cloud
or distract from data interpretation. While WGS and WES both produce high-quality
data, the large amount of data can be overwhelming, and at the time of the ONDRI
experimental design, cost for WGS and WES remained prohibitive.
To design ONDRISeq, 25 molecular genetics experts, including scientists and clinicians
within ONDRI, were consulted to select the 80 genes included on the panel (S.M.K.
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Farhan et al., 2016). Not only did the ONDRISeq panel include known monogenic genes,
such as SOD1, SNCA, APP, and NOTCH3, but the method also targeted genes with lessestablished genetic associations, such as those within known neurodegeneration pathways
and those identified through GWASs (Table 1.2). Detailed methodology of the
bioinformatics pipeline to process the data from the ONDRISeq panel is included in
Appendix J. Unfortunately, certain genes of interest had to be excluded from the
ONDRISeq panel due to technological limitations. For example, the GBA gene — which
has a pseudogene located downstream that causes NGS read misalignment — and the
C9orf72 repeat expansion could not be accurately assessed with ONDRISeq.
In addition to the ONDRISeq panel, all participants were genotyped using the NeuroX
genotype array. NeuroX consists of both the Illumina Human Exome array, as well as a
selection of variants located throughout the genome that have been previously associated
with neurological disease. The majority of the variants are rare (~200,000), with fewer
common variants (~25,000) (Nalls et al., 2015). Although the data produced from
NeuroX were not used for the purposes of this Dissertation, it is important to highlight
that the validation of the ONDRISeq panel relied heavily on this method, as it was able to
validate the calls of all 122 non-synonymous variants identified as part of the NGS
panel’s proof of concept analysis (S.M.K. Farhan et al., 2016).
In addition to the ONDRISeq panel and NeuroX array, all ONDRI participants were
genotyped for the two defining SNPs of the APOE genotype, rs429358(CT):p.Cys130Arg
and rs7412(CT):p.Arg176Cys, using TaqMan allelic discrimination assay. Although the
SNPs were also captured by the ONDRISeq panel and NeuroX array, the array’s results
were found to be of low quality, and it was necessary to confirm the allele calls obtained
using NGS with another methodology. Further, all participants were Sanger sequenced
for the protein-coding regions of the GBA gene.
Although 520 participants were enrolled in ONDRI, only 519 were included in the
ONDRI genomics platform, as one PD participant’s blood sample did not arrive at
Robarts Research Institute in London, ON for DNA isolation, and the participant was not
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able to provide a replacement sample upon follow up. Demographics of all participants
included in the ONDRI genomics analyses are outline in Table 1.3.
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Table 1.2 Genes included on the ONDRISeq next-generation sequencing gene panel,
broken down based on clinical diagnosis and mode of inheritance.
Neurodegenerative
disease

Clinical diagnosis
Early-onset AD

Mode of
inheritance
ADm
AR
ACD
ADm
AR

Alzheimer’s disease
(AD)

Late-onset AD
RF
Early-onset dementia
Juvenile-onset
dementia
Late-onset dementia
Early-onset ALS

Juvenile-onset ALS

Amyotrophic lateral
sclerosis (ALS)

ADm
AR
ADm
RF
ADm
AR
ADm
AR
X-Linked Dm

ADm
Late-onset ALS
AR
RF
X-Linked Dm
ADm
ALS-FTD

Cerebrovascular
disease with or
without cognitive
impairment
(CVD ± CI)ᶧ

Pseudoxanthoma
elasticum
Hemorrhage
Brain small vessel
disease
CADASIL
CARASIL
Aicardi-Goutieres
syndrome 5

RF
X-Linked Dm
ADm
AR
RF

Gene(s)
APP, PSEN1, PRNP,
PSEN2
APP
APOE
APOE, APP, SORL1
APOE, APP
ABCA7, BIN1, CD2AP,
CD33, CLU, CR1, MAPT,
MS4A4E, MS4A6A,
PICALM, PLD3, TREM2
CSF1R, DNMT1, ITM2B
TYROBP
CSF1R, DNMT1, ITM2B
TREM2
HNRNPA2B1, OPTN,
PFN1, SOD1, VAPB, VCP
OPTN, PNPLA6, SOD1
SETX, SOD1
ALS2, SETX, SIGMAR1
UBQLN2
ANG, ARHGEF28,
ATXN2, CHMP2B, DAO,
DCTN1, FIG4, FUS,
HNRNPA1, NEFH, PRPH,
SOD1, SQSTM1, TAF15,
TARDBP, VAPB
ARHGEF28, FUS, SOD1
CENPV, MAPT, UNC13A
UBQLN2
CHMP2B, FUS, SQSTM1,
TARDBP, UNC13A, VCP
MAPT
UBQLN2
ABCC6
ABCC6
COL4A1, COL4A2

ADm

COL4A1, COL4A2

ADm
AR

HTRA1, NOTCH3
HTRA1

AR
ADm

SAMHD1
TREX1
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Aicardi-Goutieres
syndrome 1
Vasculopathy, retinal,
with cerebral
leukoencephalopathy
and systemic
manifestations
Early-onset FTD

AR

TREX1

ADm

TREX1

ADm

TARDBP
CHMP2B, FUS, MAPT,
OPTN, SIGMAR1,
SQSTM1, TARDBP, VCP
OPTN
DCTN1
UBQLN2
HNRNPA2B1, VCP

ADm
FTD
Frontotemporal
dementia (FTD)
IBMPFD2
Progressive
supranuclear palsy
Ubiquitin-positive FTD

AR
RF
X-Linked Dm
RF
ADm

MAPT

ADm

GRN
HTRA2, LRRK2, PINK1,
SNCA, VPS35
FBX07, PANK2, PARK7,
PINK1, PLA2G6
ATP13A2, GCH1,
GIGYF2, HTRA2, LRRK2
UCHL1
PARK2, UCHL1
DNAJC13, EIF4G1,
HTRA2, LRRK2, PARK2,
VPS35
PLA2G6
ADH1C, ATP13A2,
ATXN2, GAK, GIGYF2,
HTRA2, LRRK2, MAPT,
MC1R, NR4A2, PM20D1,
RAB7L1
PARL

ADm
Early-onset PD

AR
RF

Juvenile-onset PD
Parkinson’s disease
(PD)

ADm
AR
ADm
AR

Late-onset PD
RF

-

BM

Abbreviations: ACD, autosomal co-dominant; ADm, autosomal dominant; AR, autosomal recessive; BM,
biological mechanistic association; CADASIL, cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy; CARASIL, cerebral autosomal recessive arteriopathy with subcortical
infarcts and leukoencephalopathy; IBMPFD2, inclusion body myopathy with Paget disease of the bone and
frontotemporal dementia; RF, risk factor; X-Linked Dm, X-linked dominant.
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Table 1.3 Demographics of the enrolled ONDRI participants that were included in
the genomics analyses.
Cohort
ONDRI
AD
ALS
CVD ± CI
FTD
bvFTD
nfPPA
PSP
MCI
PD

Cases
519
41
40
161
53
21
8
16
85
139

Mean age
(years ± sd)
68.9 ± 7.7
71.8 ± 8.0
62.0 ± 8.7
69.2 ± 7.4
67.8 ± 7.0
65.9 ± 8.8
68.4 ± 5.9
69.8 ± 6.0
70.6 ± 8.3
67.9 ± 6.3

Min. age
(years)
40.1
54.4
40.1
54.9
49.7
49.7
59.6
60.0
53.4
55.1

Max. age
(years)
87.8
87.8
77.2
85.4
80.9
80.9
75.1
80.1
87.2
85.9

Male:Female
345:174
24:17
24:16
110:51
34:19
14:7
5:3
10:6
45:40
108:31

Demographics of the FTD subtypes corticobasal syndrome and semantic variant primary progressive
aphasia cohorts are not displayed due to the small sample sizes of the groups (n ≤ 5), as they may
compromise confidentiality.
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; bvFTD, behavioural variant
frontotemporal dementia; CVD ± CI, cerebrovascular disease with or without cognitive impairment; FTD,
frontotemporal dementia; Max., maximum; MCI, mild cognitive impairment; Min., minimum; nfPPA, nonfluent primary progressive aphasia; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; sd,
standard deviation.
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1.5
1.5.1

Thesis outline
Overall aim and objectives

Genetic factors increase one’s risk of developing neurodegeneration considerably and
influence disease features. Yet, heretofore, many studies have aimed to identify the full
spectrum of genetic variation contributing to each individual neurodegenerative disease,
and they have failed to consider a holistic approach to studying neurodegeneration by not
taking into account the vast amount of clinical and pathological overlap between the
various diagnoses. It is imperative that we are able to gain a full understanding of the
genetic determinants contributing not only to risk of the diseases themselves, but to the
vast amount of heterogeneity observed within diagnoses, to gain a full understanding of
how genetic determinants influence all neurodegenerative diseases and their presentation.
By leveraging the unique study design of ONDRI and its rich dataset, efforts can be made
to elucidate the overlapping genetic determinants between the various neurodegenerative
diagnoses. Further, by focusing on the intrinsic goals of ONDRI we may establish an
understanding of the genetic contribution to cerebral small-vessel pathology and its
influence on neurodegenerative phenotypes.
The aim of my PhD research was to genetically characterize the full ONDRI cohort, and
leverage the data to gain a greater understanding of the genetic overlap between the
various neurodegenerative diseases, including AD, ALS, FTD, MCI, and PD, as well as
CVD, largely using the data generated with the ONDRISeq panel.
The first objective of my work was to identify associations between common genetic
variants of high phenotypic impact and the neurodegenerative diseases encompassed by
ONDRI’s mandate. Although the APOE genotype is a well-established risk factor for the
development of AD, it was imperative to replicate the association within the ONDRI
cohort to contribute to validation of the AD diagnoses, as well as assess whether the
genotype was contributing to any of the other disease cohorts. MAPT haplotype of each
ONDRI participant was also determined to assess contributions to disease presentation.
The details of these analyses, which compared variant frequencies in each ONDRI cohort
to a cognitively normal, elderly control cohort, are outlined in Chapter 2. The APOE
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genotype has also controversially been associated with deficits in various cognitive
domains within different individual neurodegenerative disease cohorts; therefore, I
leveraged ONDRI’s robust neuropsychology dataset to assess the contribution of the
APOE genotype to cognitive deficits in five domains, across the diagnoses. The analysis
and its results are included in Chapter 3.
The second objective of my PhD research was to assess the contribution of a spectrum of
rare genetic variants to the neurodegenerative diseases encompassed by ONDRI’s
mandate. As previously described, there exists a gap in the literature accounting for the
potential overlapping impact of genetic factors known to contribute to specific
neurodegenerative diagnoses within other neurodegenerative phenotypes. To begin
characterizing this heterogeneity, I identified all rare SNVs within the ONDRI samples in
the 80 genes previously associated with neurodegenerative disease using the NGS
targeted sequencing panel, ONDRISeq. I then performed rare variant association analyses
on both binned gene sets, as well as individual genes to identify signals of variant
enrichment and elucidate potential overlapping genetic factors across the
neurodegenerative diagnoses, which is presented in Chapter 4. In Chapter 5, I leveraged
the ONDRISeq NGS data to identify rare, large-scale CNVs within the ONDRI cohort
using a recently developed depth-of-coverage approach. Finally, to account for variation
that could not be captured using the ONDRISeq panel due to technical limitations,
Chapter 6 outlines the Sanger sequencing analysis of all exons of GBA in the ONDRI
participants and the identification of rare, nonsynonymous variants of interest within the
gene and associations with the individual neurodegenerative disease cohorts.
Finally, the third objective of my work was to identify associations between rare genetic
variants within ONDRI and the presentation and features of the neurodegenerative
disease patients. Along with the sequencing of GBA presented in Chapter 6, I also outline
a multivariate multiple regression analysis to assess the effects of GBA rare variants on
age of onset, generalized cognition, and motor impairment across all neurodegenerative
disease and CVD cohorts. Further, Chapter 7 highlights a novel association between
NOTCH3 rare variants and cerebrovascular disease burden in PD patients carrying
variants in the gene. Although only focusing on two genes for this objective, the analyses
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highlight a proof of concept that rare variants of possible moderate phenotypic impact
may influence the presentation of neurodegenerative diseases not typically associated
with the gene of interest, thereby accounting for some of the phenotypic heterogeneity
observed in these disease cohorts.

1.5.2

Hypothesis

Susceptibility to neurodegenerative diseases and their heterogenous intermediate
phenotypes display a complex genetic landscape with a combination of influence from
rare and common genetic variation, including small-scale SNVs and large-scale CNVs.

1.5.3

Summary

This Dissertation describes my research elucidating the genetic determinants of patients
with various neurodegenerative diseases, as well as patients with cerebrovascular disease.
Not only does my work aim to characterize the genetic factors contributing to disease
presentation overall, but it begins the important investigation into how genetics may
contribute to the heterogenous features of neurodegenerative disease. Importantly, the
research detailed herein also adds important data to ONDRI, which will become available
to the greater scientific community in the coming years. To achieve these goals, I utilized
the data generated using the ONDRISeq targeted NGS panel, which covers 80 genes
previously associated with neurodegenerative and cerebrovascular phenotypes, along
with other methodologies, such as Sanger sequencing, to account for the limitations of
the NGS panel. Not only did my work validate previously identified genetic associations
with the neurodegenerative diseases under study, such as the association between APOE
E4 and AD, but it identified novel genetic associations between neurodegenerative
disease associated genes and other neurodegenerative disease cohorts and patterns in
clinical presentation. Importantly, the work presented highlights the need for a greater
understanding of the complex genetic architecture contributing to neurodegeneration.
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2.1.

Abstract

Background/Objective: Apolipoprotein E (APOE) E4 is the main genetic risk factor for
Alzheimer’s disease (AD). Due to the consistent association, there is interest as to
whether E4 influences the risk of other neurodegenerative diseases. Further, there is a
constant search for other genetic biomarkers contributing to these phenotypes, such as
microtubule associated protein tau (MAPT) haplotypes. Here, participants from the
Ontario Neurodegenerative Disease Research Initiative were genotyped to investigate
whether the APOE E4 allele or MAPT H1 haplotype are associated with multiple
neurodegenerative diseases: 1) AD; 2) mild cognitive impairment (MCI); 3) amyotrophic
lateral sclerosis; 4) frontotemporal dementia (FTD); and 5) Parkinson’s disease, as well
as cerebrovascular disease (CVD) with or without cognitive impairment.
Methods and Results: Genotypes were mapped to their respective APOE allele and
MAPT haplotype calls for each participant and logistic regressions were performed to
identify associations with the disease cohorts. Our work confirmed the association of the
E4 allele with a dose-dependent increased presentation of AD, and an association
between the E4 allele alone and MCI; however, the other four diseases were not
associated with E4. Further, the APOE E2 allele was associated with decreased
presentation of both AD and MCI. No associations were identified between MAPT
haplotype and the disease cohorts, but following subtyping of the FTD cohort, the H1
allele was significantly associated with progressive supranuclear palsy.
Conclusion: This is the first study to concurrently analyze association of APOE isoforms
and MAPT haplotypes with five neurodegenerative diseases and CVD using consistent
enrollment criteria and broad phenotypic analysis.
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2.2.

Introduction

With the aging of populations, the burden of neurodegenerative diseases is increasing,
and substantial effort is directed towards identification of genetic biomarkers with the
objective of improved disease prediction and the long-term goal of discovering
therapeutic targets. In particular, molecular genetics efforts have focused on identifying
common single nucleotide polymorphisms (SNPs) that contribute to disease risk
(Lambert et al., 2013; Nalls et al., 2014; Simon-Sanchez et al., 2009). Although these
types of markers usually account for only a small proportion of disease risk, two closely
linked common SNPs on chromosome 19 have been identified to jointly impart a
relatively large effect on the risk of a particular neurodegenerative phenotype, namely the
apolipoprotein E (APOE) E4 allele and Alzheimer’s disease (AD) (Bertram, McQueen,
Mullin, Blacker, & Tanzi, 2007).
Apo E is found in chylomicrons, very low-density lipoproteins, intermediate-density
lipoproteins and high-density lipoproteins; it provides structural support to these particles
and also governs the catabolism of triglyceride rich lipoproteins through its role as a
receptor ligand. Importantly, apo E is the principal cholesterol carrier in the brain
(Mahley & Rall, 2000). There are three common protein isoforms of apo E — E2, E3,
and E4 — historically designated based on protein mobility in isoelectrophoretic focusing
gels (Kane & Gowland, 1986). At the DNA level, these three isoforms are encoded by
two nonsynonymous SNPs within the APOE gene, occurring at amino acid positions 130
and 176 (also numbered as 112 and 158, respectively, if the pro-peptide sequence is
excluded), and each involving cysteine or arginine as alternate residues (Zannis et al.,
1982). The E4 allele, which has arginine at both positions 130 and 176, is the most
common genetic risk factor for the development of late-onset AD and contributes to
disease risk in a dose-dependent manner (Ward et al., 2012). Meta-analyses show that
one and two copies of the E4 allele raise AD risk by ~3- to 4- and ~12-fold, respectively
(Corder et al., 1993; Saunders et al., 1993). Due to the replicated high risk association
from several meta-analyses of AD and APOE (Farrer et al., 1997; Liu et al., 2015; Ward
et al., 2012), researchers have attempted to determine whether the E4 allele is also
associated with other neurodegenerative diseases, including amyotrophic lateral sclerosis
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(ALS) (Y. J. Li et al., 2004; Mui, Rebeck, McKenna-Yasek, Hyman, & Brown, 1995),
frontotemporal dementia (FTD) (Agosta et al., 2009; Geschwind, Karrim, Nelson, &
Miller, 1998), and Parkinson’s disease (PD) (Ezquerra et al., 2008; Huang, Chen, &
Poole, 2004; Pankratz et al., 2006), as well as cerebrovascular disease with or without
cognitive impairment (CVD ± CI) (Baum et al., 2006; Chuang et al., 2010; Davidson et
al., 2006), so far with mixed and inconsistent results.
Another gene less consistently associated with AD risk is the microtubule associated
protein tau gene (MAPT), which encodes the protein tau (Myers et al., 2005). It remains
to be established whether the MAPT is associated with other neurodegenerative diseases.
Within the MAPT gene an ancestral inversion of ~900kb has resulted in two distinct
haplotypes, H1 and H2, and creates a large region of linkage disequilibrium. Apart from
the few associations found between H1 MAPT and AD, there has been debate as to
whether the haplotype is associated with PD (Seto-Salvia et al., 2011) and with the FTD
subtype progressive supranuclear palsy (Baker et al., 1999; Ferrari et al., 2017).
The Ontario Neurodegenerative Disease Research Initiative (ONDRI) is a multi-platform,
provincial-wide, observational cohort study aiming to characterize multiple attributes of
five neurodegenerative diseases, namely: 1) AD; 2) mild cognitive impairment (MCI); 3)
ALS; 4) FTD; and 5) PD, as well as CVD ± CI (S. M. K. Farhan et al., 2017). In addition
to genomic analysis, ONDRI incorporates a comprehensive phenotypic assessment on
each participant. The large dataset, combined with the consistent enrollment criteria
allows for the unique opportunity to assess the association of APOE genotype and MAPT
haplotype across the respective neurodegeneration phenotypes. Here, we aim to replicate
the known associations of the APOE E4 allele, APOE E4/4 genotype, and MAPT H1
haplotype with AD, in addition to assessing whether APOE E4 and MAPT H1 confer risk
to ALS, FTD, PD, and CVD ± CI within the ONDRI cohort.

2.3.
2.3.1.

Methods
Study participants

Blood samples were collected from 519 ONDRI participants after informed consent was
obtained, in accordance with the Research Ethics Boards at Hamilton General Hospital
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(Hamilton, Ontario, Canada); McMaster (Hamilton, Ontario, Canada); Parkwood
Hospital (London, Ontario, Canada); London Health Sciences Centre (London, Ontario,
Canada); The Ottawa Hospital (Ottawa, Ontario, Canada); University Health NetworkElizabeth Bruyère Hospital (Ottawa, Ontario, Canada); Baycrest Centre for Geriatric
Care (Toronto, Ontario, Canada); Centre for Addiction and Mental Health (Toronto,
Ontario, Canada); St Michael's Hospital (Toronto, Ontario, Canada); Sunnybrook Health
Sciences Centre (Toronto, Ontario, Canada); and Toronto Western Hospital (Toronto,
Ontario, Canada). Formal diagnoses and demographic data were obtained by participants’
clinicians upon enrollment in the study, in accordance with ONDRI standard operating
protocols (S. M. K. Farhan et al., 2017).

2.3.2.

DNA preparation and genotyping

Genomic DNA was isolated from blood samples collected from each participant as
described previously (S.M.K. Farhan et al., 2016). DNA samples were also obtained from
189 cognitively normal controls from the GenADA study (H. Li et al., 2008). All samples
underwent targeted next-generation sequencing using the ONDRISeq neurodegenerative
disease gene panel. Full methodology of DNA isolation, sequencing with the ONDRISeq
panel (S.M.K. Farhan et al., 2016), and raw sequencing data processing were previously
described (Dilliott et al., 2018).
Allele calls for the APOE risk alleles rs429358(CT):p.Cys130Arg and
rs7412(CT):p.Arg176Cys were extracted from the ONDRISeq data files and mapped to
their respective APOE genotype for each participant using a customized Annotate
Variation (Wang, Li, & Hakonarson, 2010) script. Allele calls and mapped genotypes
were validated with TaqMan allelic discrimination assay (Koch et al., 2002), as
previously described (S.M.K. Farhan et al., 2016).
TaqMan was also used to determine the MAPT haplotype of the ONDRI participants and
control samples. DNA samples were genotyped for the intronic SNP rs1800547, which is
not covered by the ONDRISeq panel. Based on a region of linkage disequilibrium, allele
calls were mapped to their respective MAPT haplotype (Lai et al., 2017).
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2.3.3.

Statistical analysis

Statistical analyses were performed using SAS v9.4 (SAS Institute, Cary, NC). The
Wilcoxon Mann-Whitney U test was utilized to determine the difference between the
ages of the control cohort compared to the five disease cohorts of interest. Chi-squared
analyses were used to determine the difference between the control cohort and disease
cohorts’ male:female ratios. Odds ratios and confidence intervals were obtained using
logistic regression, adjusting for participants’ age and sex.

2.4.
2.4.1.

Results
Study participants

Table 2.1 displays the demographics of the 519 ONDRI participants included in this
study, as well as the cognitively normal controls. Of the ONDRI participants, 83.0% selfreported their ethnicity as Caucasian. The ALS cohort had the lowest mean age (62.0 ±
8.7 years), and the control cohort had the highest mean age (74.0 ± 8.2 years), which was
significantly different from the mean age of the five ONDRI disease cohorts (p < 1.0x104

). Additionally, the male:female ratio of the control cohort was significantly different

from that of the overall ONDRI cohort (p < 1.0x10-4).
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Table 2.1 Demographics of the 519 ONDRI participants and 189 controls genotyped
for APOE and haplotyped for MAPT.
ONDRI
Cases
519
Mean Age
68.6 ± 7.7
(years ± sd)
Min. Age
40.1
(years)
Max. Age
87.8
(years)
Male:Female 345:174

AD/MCI
126

ALS
40

FTD
53

PD
139

CVD ± CI
161

Controls
189

71.0 ± 8.2

62.0 ± 8.7

67.8 ± 7.0

67.9 ± 6.3

69.2 ± 7.4

74.0 ± 8.2

53.4

40.1

49.7

55.1

54.9

48.0

87.8

77.2

80.9

85.9

85.4

92.0

69:57

24:16

34:19

108:31

110:51

77:112

Abbreviations: AD/MCI, Alzheimer’s disease/mild cognitive impairment; ALS, amyotrophic lateral
sclerosis; APOE, Apolipoprotein E gene; CVD ± CI, cerebrovascular disease with or without cognitive
impairment; FTD, frontotemporal dementia; MAPT, microtubule associated protein tau; Max, maximum;
Min, minimum; ONDRI, Ontario neurodegenerative disease research initiative; PD, Parkinson’s disease;
sd, standard deviation.
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2.4.2.

APOE genotype associations

Calls of the APOE alleles were obtained using the ONDRISeq panel and validated using
the TaqMan allelic discrimination assay with 100% concordance. Allele and genotype
frequencies were calculated for the disease cohorts and the controls (Table 2.2). As
expected, the AD/MCI cohort displayed the highest APOE E4 allele frequency (31.7%)
and E4/4 genotype frequency (14.3%), compared to 14.6% and 3.7%, respectively in
controls. The AD/MCI cohort also displayed the lowest APOE E2 allele frequency
(2.4%), compared to 10.3% in controls. The lowest APOE E4 allele and E4/4 genotype
frequencies were observed in the PD cohort (12.6% and 1.4%, respectively), differing
marginally from the respective frequencies in controls.
Allele and genotype calls were compared between each ONDRI disease cohort and the
control cohort, while adjusting for both age and sex of participants (Figure 2.1). The E4
allele was significantly associated with increased presentation of AD/MCI compared to
controls (OR = 2.76, 95% CI = 1.85–4.11, p < 1.0x10-4). Similarly, the E4/4 genotype
significantly increased the presentation of AD/MCI when compared to controls (OR =
4.13, 95% CI = 1.64–10.37, p = 2.5x10-3). As expected, the E2 allele was associated with
a significantly decreased presentation of AD/MCI when compared to controls after
adjusting for age and sex (OR = 0.21, 95% CI = 0.08–0.50, p = 5.0x10-4; Figure 2.2). No
association with APOE was found with the other four phenotypes in the ONDRI dataset.
The AD/MCI cohort was split into participants presenting with AD (n=41) and those
presenting with MCI (n = 85) and APOE analyses were repeated. The AD and MCI sub
cohorts displayed E4 allele frequencies of 46.3% and 24.7% and E4/4 genotype
frequencies of 26.8% and 8.2%, respectively. Indeed, the E4 allele was significantly
associated with both AD and MCI compared to controls (OR = 5.24, 95% CI = 3.07–
8.92, p < 1.0x10-4 and OR = 1.94, 95% CI = 1.22–3.07, p = 4.9x10-3, respectively) and
the E2 allele was significantly associated with decreased presentation of both AD and
MCI compared to controls (OR = 0.10, 95% CI = 0.01–0.77, p = 0.0268 and OR = 0.26,
95% CI = 0.10–0.68, p = 5.8x10-3, respectively). The E4/4 genotype was also
significantly associated with increased presentation of AD (OR = 10.36, 95% CI = 3.55–
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30.19, p < 1.0x10-4); however, the genotype did not significantly increase presentation of
MCI.
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Table 2.2 APOE allele and genotype frequencies in 519 ONDRI participants and 189 controls.
APOE Genotype [n (%)]
APOE Alleles [n (%)]
E2/2
E3/2
E4/2
E3/3
E4/3
E4/4
E2
E3
E4
AD/MCI
0
5 (4.0)
1 (0.8)
59 (46.8)
43 (34.1)
18 (14.3)
6 (2.4)
166 (65.9)
80 (31.7)
ALS
0
6 (15.0)
0
21 (52.5)
12 (30.0)
1 (2.5)
6 (7.5)
60 (75.0)
14 (17.5)
FTD 1 (1.9)
6 (11.3)
0
26 (49.0)
18 (34.0)
2 (3.8)
8 (7.5)
76 (71.7)
22 (20.8)
PD 1 (0.7) 19 (13.7)
3 (2.2)
86 (67.9)
28 (20.1)
2 (1.4)
24 (8.6)
219 (78.8)
35 (12.6)
CVD ± CI
0
21 (13.0)
2 (1.2)
100 (62.1)
34 (21.1)
4 (2.5)
23 (7.1)
255 (79.2)
44 (13.7)
Controls 2 (1.1) 29 (15.3)
6 (3.2)
110 (58.2)
35 (18.6)
7 (3.7)
39 (10.3)
284 (75.1)
55 (14.6)
All study participants were genotyped using both the ONDRISeq panel and TaqMan allelic discrimination assay.
Abbreviations: AD/MCI, Alzheimer’s disease/mild cognitive impairment; ALS, amyotrophic lateral sclerosis; APOE, Apolipoprotein E gene; CVD ± CI,
cerebrovascular disease with or without cognitive impairment; FTD, frontotemporal dementia; ONDRI, Ontario neurodegenerative disease research initiative;
PD, Parkinson’s disease.
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Figure 2.1 Forest plots of the relationship between APOE and risk of each of the
diseases encompassed by ONDRI.
Logistic regressions adjusting for participant age and sex analyzed the APOE E4 allele
and E4/4 genotype status of the ONDRI cohorts when compared to controls. A. Forest
plot of the APOE E4 allele and associated risk of each ONDRI disease cohort. B. Forest
plot of the APOE E4/4 genotype and associated risk of each ONDRI disease cohort.
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Figure 2.2 Forest plot of the relationship between the APOE E2 allele and risk of
each of the diseases encompassed by ONDRI.
Logistic regressions adjusting for participant age and sex analyzed the APOE E2 allele
status of the ONDRI cohorts when compared to controls.
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2.4.3.

MAPT haplotype associations

Allele calls of the intronic MAPT variant, rs1800547, were mapped to their respective
MAPT haplotype for each DNA sample. The ALS cohort had the highest frequencies of
H1 haplotype and H1/H1 diplotype (87.5% and 75.0%, respectively), whereas the FTD
cohort displayed the lowest frequencies (75.5% and 60.4%, respectively; Table 2.3).
There were no significant associations found between MAPT and any of the disease
phenotypes in ONDRI when compared to controls following adjustment for both age and
sex.
Due to its previous associations with the PSP subtype of FTD, the FTD cohort was split
into its respective subtypes, including behavioural variant FTD (bvFTD; n = 22),
corticobasal syndrome (CBS; n = 3), progressive non-fluent aphasia (PNFA; n = 8), PSP
(n=15), and semantic dementia (SD; n = 5), and MAPT analyses were repeated.
Interestingly, the SD sub cohort displayed the greatest MAPT H1 haplotype frequency
and the CBS sub cohort displayed the lowest, at 90.0% and 50.0% respectively.
Similarly, the SD sub cohort, along with the PSP sub cohort, displayed the greatest H1H1
diplotype frequency of 80.0%, while the CBS sub cohort displayed the lowest of 33.3%.
We also observed that the H1 haplotype was significantly associated with increased PSP
prevalence (OR = 7.46, 95% CI = 2.39–23.29, p = 5.0x10-4) following adjustment for age
and sex; however, the H1H1 diplotype did not display significant associations with PSP
presentation. In addition, there were no significant associations between MAPT and any
of the other FTD subtypes.
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Table 2.3 MAPT haplotype and diplotype frequencies in 519 ONDRI participants
and 189 controls.
MAPT Haplotype [n (%)]
MAPT Diplotype [n (%)]
H1
H2
H1/H1
H1/H2
H2/H2
AD/MCI
200 (79.4)
52 (20.6)
75 (59.5)
50 (39.7)
1 (0.8)
ALS
70 (87.5)
10 (12.5)
30 (75.0)
10 (25.0)
0
FTD
80 (75.5)
26 (24.5)
32 (60.4)
16 (30.2)
5 (9.4)
PD
227 (81.7)
51 (18.3)
93 (66.9)
41 (29.5)
5 (3.6)
VCI
264 (82.0)
58 (18.0)
108 (67.1)
48 (29.8)
5 (3.1)
Controls
293 (77.5)
85 (22.5)
111 (58.7)
71 (37.6)
7 (3.7)
All study participants were genotyped for the intronic SNP rs1800547 using TaqMan allelic discrimination
assay and results were mapped to their respective haplotype.
Abbreviations: AD/MCI, Alzheimer’s disease/mild cognitive impairment; ALS, amyotrophic lateral
sclerosis; CVD ± CI, cerebrovascular disease with or without cognitive impairment; FTD, frontotemporal
dementia; MAPT, microtubule associated protein tau gene; ONDRI, Ontario neurodegenerative disease
research initiative; PD, Parkinson’s disease.
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2.5.

Discussion

This is the first genetic characterization of the ONDRI cohort, which is important for
upcoming multimodal, multi-year, prospective observational studies of the five
phenotypes (e.g. APOE/MAPT-based stratification). The principal findings from the
current study are: 1) a dose-dependent association of the APOE E4 allele with AD and an
association between E4 and MCI; 2) an inverse association of the APOE E2 allele with
AD and MCI presentation; 3) a lack of associations between the APOE alleles and other
diseases included in the ONDRI mandate (ALS, FTD, PD or CVD ± CI); and 4) no
associations between any of the disease cohorts and the MAPT H1 haplotype, but an
association between H1 and the PSP subtype of FTD.
Our study design offers a unique opportunity to analyze individuals each with one of five
neurodegenerative diseases or CVD ± CI enrolled with strict inclusion criteria and
evaluated across a wide-range of platforms (S. M. K. Farhan et al., 2017). Because of this
robust workflow, we can investigate the effect of the APOE alleles and genotypes and
MAPT haplotypes across multiple diseases with common assessment. The control cohort
had a significantly older mean age than the ONDRI disease cohorts, as well as a
significantly different male:female ratio. For this reason, logistic regression was applied
to obtain odds ratios adjusted for both the age and sex of participants.
The E4 allele frequency in previously reported AD patients is 28–37%, while in controls
it is 8–14% (Farrer et al., 1997; Heffernan, Chidgey, Peng, Masters, & Roberts, 2016).
The results presented here are comparable to these literature values, with E4 allele
frequencies of 31.7% and 14.5% in the AD/MCI and control cohorts, respectively. More
specifically, we observed an APOE E4 allele frequency of 46.3% in individuals with AD
and 24.7% in individuals with MCI. Although the E4 allele frequency was significantly
increased in cohorts of MCI compared to controls, the increase is not as great as that seen
in those with AD only. Interestingly, the E4 allele has been shown to be a predictive risk
factor for the clinical conversion from MCI to AD (Elcoroaristizabal Martin et al., 2011;
Fleisher et al., 2007; Petersen et al., 2005), which, coupled with the increased E4 allele
frequency in the MCI sub cohort, may indicate that a portion of the individuals enrolled
in ONDRI with MCI will experience disease progression to AD. The longitudinal nature
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of the ONDRI study will permit follow up of the individuals with MCI to determine
whether their APOE status predicts possible progression to AD, and to evaluate the
phenotypic measures most severely affected by their status.
In accordance with previous literature (Corder et al., 1993), we identified that APOE E4
was associated with AD in a dose-dependent manner following adjustment for age and
sex. The presence of the E4 allele produced an approximately 5-fold increased risk of
having AD/MCI, which was marginally greater than estimates previously found.
However, we identified the E4/4 genotype to increase risk just over 10-fold, marginally
lower than the commonly reported 12-fold (Corder et al., 1993; Saunders et al., 1993).
The slight discrepancies are likely due to the modest number of individuals enrolled in
ONDRI with AD.
Previous studies have also suggested that the E2 allele decreases risk of AD, which we
also observed with our AD/MCI cohort (Corder et al., 1994; Farrer et al., 1997). It is
hypothesized that the stability provided by the cysteine-to-arginine variant at amino acid
176 may be contributing to this protective effect (Zhong & Weisgraber, 2009) and allows
the isoform to more effectively clear amyloid-β (Yang, Smith, Zhou, Gandy, & Martins,
1997), protect against synaptic degeneration (Dumanis et al., 2009), and facilitate antioxidant activity (Miyata & Smith, 1996). However, because of the small sample sizes
within ONDRI, no individuals in the AD/MCI cohort harboured the E2/2 genotype and
precise genotypic risk associations could not be evaluated. Due to this absence of
individuals with the E2/2 genotype in the AD/MCI cohort, it is expected that two copies
of the E2 allele would incrementally decrease the risk of the disease in a dose-dependent
manner, particularly in those with AD, but larger cohorts would be needed to validate this
hypothesis.
Although an association was not observed between MAPT H1 and the total FTD cohort,
we did observe an association between the haplotype and increased presentation of PSP,
as has been previously identified (Baker et al., 1999). Yet, we were not able to replicate
the previously observed increased prevalence of PSP associated with the H1H1 diplotype,
again possibly as a result of the modest number of individuals with PSP. Interestingly, the
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SD sub cohort of FTD displayed the highest MAPT H1 haplotype frequency and the same
H1H1 diplotype frequency as the PSP sub cohort, but was not significantly associated
with MAPT. We expect that the very low number of individuals enrolled in ONDRI with
SD may be driving factor in the lack of association observed here and believe that further
analysis into the association between MAPT H1 and SD is warranted with larger sample
sizes.
Due to the strong association between both the E4 allele and E4/4 genotype and AD
status, many studies have attempted to identify associations with other neurodegenerative
disorders (Verghese, Castellano, & Holtzman, 2011). However, these studies have
reported inconsistent results regarding the risk associated with APOE E4 and either onset
and/or progression of the other four diseases studied in ONDRI, namely ALS (Y. J. Li et
al., 2004; Mui et al., 1995), FTD (Agosta et al., 2009; Geschwind et al., 1998), PD
(Ezquerra et al., 2008; Huang et al., 2004; Pankratz et al., 2006), and CVD ± CI (Baum et
al., 2006; Chuang et al., 2010; Davidson et al., 2006). Within the ONDRI cohort, no
associations were identified for the other disease phenotypes. Similarly, no associations
were identified between the MAPT H1 haplotype or H1/H1 diplotype and any of the five
complete neurodegenerative disease cohorts or the CVD ± CI cohort. Absence of
associations could have been due to small sample sizes, and thus false negative
inferences, or to the true lack of a biological effect of E4 and H1 in these conditions.
Associations previously reported may have been due to the diagnostic challenges
associated with neurodegenerative diseases. Admixture of AD pathology in individuals
with other neurodegenerative diseases, including CVD associated neurodegenerative
diseases such as vascular dementia, may produce false positive associations with E4, and
co-pathologies within neurodegenerative diseases are far more common than previously
appreciated (Robinson et al., 2018). Due to the spectrum of overlapping features that can
be observed across neurodegenerative phenotypes it will be important to identify those
that are associated with the APOE E4 allele and MAPT H1 haplotype to better understand
patient prognosis. Future analyses will utilize ONDRI’s robust assessment of structural
and cognitive measures to identify whether common phenotypes across the various
diseases are influenced by APOE and MAPT.
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While ONDRI is unique in terms of the number of different clinical conditions evaluated
simultaneously within the process, there is still a limitation due to modest sample sizes.
Larger cohorts may produce results that align more closely with those previously
reported. Additionally, an important limitation to this study is the lack of correlation with
cognitive status within the disease cohorts. Assessments of cognitive impairment are
ongoing, and future studies will incorporate these measures from the participants in order
to assess the effects of the APOE E4 allele and MAPT haplotype on cognitive status
within all five disease cohorts.

2.6.

Conclusion

In conclusion, E4 allele carriers in the ONDRI study displayed a dose-dependent
increased risk of AD/MCI, specifically in those diagnosed with AD, which is consistent
with current APOE literature. Similarly, this study was concordant with recent evidence
that the APOE E2 allele decreases risk of AD/MCI. Further, the MAPT H1 haplotype was
significantly associated with the PSP subtype of FTD. The work also confirmed that risks
of the other four diseases evaluated within ONDRI, namely ALS, FTD, PD and CVD ±
CI are not associated with the E4 allele or E4/4 genotype and that none of the complete
disease cohorts are associated with the MAPT H1 haplotype or H1/H1 diplotype. To our
knowledge this is the first study to analyze APOE genotypes and MAPT haplotypes
across these five neurodegenerative diseases and CVD using common enrollment criteria
and comprehensive phenotypic analysis. Future studies will investigate the structural and
cognitive symptoms of neurodegeneration influenced by the E4 allele and H1 haplotype
and the contributions of other genetic factors to these phenotypes.
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Chapter 3 – Association of apolipoprotein E variation with
cognitive impairment across multiple neurodegenerative
diagnoses.
The work presented in Chapter 3 has been edited from the original publication in
Neurobiology of Aging for brevity and consistency throughout the entire Dissertation.
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3.1.

Abstract

Background/Objective: For many years, there has been uncertainty regarding how
apolipoprotein E (APOE) E2 and E4 variants may influence overlapping features of
neurodegeneration, such as cognitive impairment. We aimed to identify whether the
APOE variants are associated with cognitive function across various neurodegenerative
and cerebrovascular diagnoses (n=513).
Methods and Results: Utilizing a comprehensive neuropsychology battery, multivariate
multiple regression was used to assess the influence of APOE carrier status and disease
cohort on performance across five cognitive domains. Irrespective of disease cohort, E4
carriers had significantly lower performance in verbal memory and visuospatial domains
than those with E3/3, while E2 carriers’ cognitive performance was not significantly
different. However, E2 carriers with frontotemporal dementia (FTD) performed
significantly worse than those with E3/3 in the attention/working memory, executive
function, and visuospatial domains.
Conclusion: Our results highlight that the influence of APOE variation on cognition is
complex, in some cases varying based on diagnosis and possibly underlying disease
pathology.
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3.2.

Introduction

Apolipoprotein E (APOE) is located on chromosome 19q13 and encodes a lipoprotein
component responsible for the transportation of cholesterol, both in plasma and within
the central nervous system. The formed apo E protein exists as one of three isoforms —
E3, otherwise considered the wild-type isoform, E2, and E4 — defined by two single
nucleotide polymorphisms within the gene at amino acid positions 130 and 176 (Zannis
et al., 1982). Importantly, the APOE E4 allele displays a high-risk association with
sporadic Alzheimer’s disease (AD), in a dose dependent manner (Ward et al., 2012).
Previously, we analyzed the contribution of the variant to multiple neurodegenerative
phenotypes (Dilliott et al., 2019). Consistent with previous studies, we reported an
association with AD. We also observed an association between E4 and amnestic mild
cognitive impairment (MCI) presentation; however, we did not observe associations
between APOE and the other neurodegenerative diseases under study, including
amyotrophic lateral sclerosis (ALS), cerebrovascular disease (CVD; previously referred
to as vascular cognitive impairment), frontotemporal dementia (FTD), or Parkinson’s
disease (PD).
While the association between APOE and sporadic AD is well established, the exact
mechanism of pathology is not fully understood. Apo E is an amyloid-β (Aβ) chaperone
and modulates its metabolism, aggregation, and deposition by directly binding to the Aβ
peptide (T. C. Dickson, Saunders, & Vickers, 1997; Kanekiyo, Xu, & Bu, 2014), and
controlling its production by regulating neuronal cholesterol levels (Osenkowski, Ye,
Wang, Wolfe, & Selkoe, 2008). However, these functions are influenced by the isoform
of apo E. Apo E4 has been found to promote Aβ oligomer aggregation and prevent its
clearance, thereby resulting in Aβ accumulation into amyloid plaques (Deane et al., 2008;
T. Hashimoto et al., 2012; Liu et al., 2017). In addition to its effects on Aβ, apo E4 has
also been proposed to contribute to neurodegenerative disease pathology by increasing
tau aggregates in brains with existing Aβ pathology (Farfel, Yu, De Jager, Schneider, &
Bennett, 2016), as well as tau phosphorylation in mouse models (Brecht et al., 2004; Shi
et al., 2017), indicating that the isoform may also play a role in the presentation of
tauopathies. Similarly, in individuals with Lewy body disease, apo E4 was associated
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with increased α-synuclein pathology, irrespective of tau and Aβ, suggesting a role in
synucleinopathies as well (D. W. Dickson et al., 2018). In contrast, although apo E2 is
well known for its reduced binding affinity for the low-density lipoprotein receptor,
causing hyperlipoproteinemia type III when inherited in the homozygous state (Rall,
Weisgraber, Innerarity, & Mahley, 1982), the isoform was also associated with increased
tau pathology in mouse models of FTD (Zhao et al., 2018).
Although a large amount of effort has been put forth in determining the contribution of
APOE genotypes to neurodegenerative disease development and pathology, how the
variants influence features of disease has long been a source of uncertainty (Swartz,
Black, & St George-Hyslop, 1999), and still remains to be fully elucidated. In particular,
how APOE may contribute to overlapping features of neurodegeneration — such as
cognitive impairment ― remains unclear with previous analyses reporting conflicting
results. Specifically, researchers have reported that the E4 allele is associated with
reduced performance on measures of verbal and episodic memory, executive function,
and speed of processing in healthy elderly cohorts (O'Donoghue, Murphy, Zamboni,
Nobre, & Mackay, 2018); memory and attention in probable AD patients (M. Hashimoto
et al., 2001; Lehtovirta et al., 1996; Marra et al., 2004; van der Vlies et al., 2007);
executive function in amnestic MCI patients (Seo et al., 2016); and memory, attention,
and executive function in patients with PD (Mata et al., 2014). However, other studies
have reported no difference in cognition between APOE E4 carriers and non-carriers in
healthy elderly cohorts (O'Donoghue et al., 2018), or AD (Lehtovirta et al., 1996; van der
Vlies et al., 2007; Wolk, Dickerson, & Alzheimer's Disease Neuroimaging, 2010) and PD
(Mengel et al., 2016) patients.
In contrast, the APOE E2 allele — commonly accepted as protective against the
development of AD (Dilliott et al., 2019) — has been associated with increased risk of
FTD, specifically tauopathies, such as progressive supranuclear palsy (PSP) and
corticobasal degeneration (CBD) (Verpillat et al., 2002; Zhao et al., 2018). It is also
associated with an increased co-occurrence of FTD with a primary diagnosis of ALS
(ALS-FTSD) (Chio et al., 2016). To date, studies have also presented inconsistent
findings regarding the relationship between APOE status and ischaemic stroke outcomes
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(Klages, Fisk, & Rockwood, 2005; Pendlebury et al., 2020; Verghese, Castellano, &
Holtzman, 2011), including emerging evidence of a potentially complex interaction
between APOE E4, cerebrovascular burden, and cognition that may offer a new lens
through which to examine the effect of APOE status in these groups (Mirza et al., 2019).
The Ontario Neurodegenerative Disease Research Initiative (ONDRI) is a prospective
longitudinal cohort study with the aim of developing deep phenotypes of 1) AD; 2) ALS;
3) CVD; 4) FTD; 5) amnestic MCI; and 6) PD, and understanding potential
cerebrovascular disease contributors to neurodegeneration (Farhan et al., 2017;
Sunderland et al., 2020). The ONDRI protocol includes a comprehensive
neuropsychological battery (McLaughlin et al., 2020) and well-established clinical
diagnostic criteria, affording the opportunity to examine APOE variants cross-sectionally
in rigorously characterized cohorts using converging information across genetics,
clinical, and neuropsychological platforms. In doing so, we overcome limitations of other
studies that report APOE associations using a) a singular disease cohort that are unable to
identify overlapping features of neurodegeneration and b) cognitive characterizations
based on a restricted set of domains and sub-clinical standards for determining
impairment (i.e., use of a single test to label a domain as impaired) that may
underestimate the nature of and degree of cognitive impairment.
In this paper, we aimed to identify whether carriers of the APOE E2 or E4 variants
display differing cognitive function across multiple domains compared to those with the
wild-type APOE E3/3 genotype across neurodegenerative and cerebrovascular diseases.

3.3.
3.3.1.

Methods
Study participants

In total, 520 participants previously clinically diagnosed with a neurodegenerative or
cerebrovascular disease were recruited into ONDRI from 14 tertiary care centers across
Ontario. Diseases included: 1) AD; 2) ALS; 3) CVD; 4) FTD (including behavioural
variant FTD [bvFTD], corticobasal syndrome [CBS], PSP, and primary progressive
aphasia (PPA, including non-fluent and semantic variant); 5) amnestic MCI; and 6) PD.
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Based on the Montreal Cognitive Assessment (MoCA) administered during an initial
study screening visit, the CVD and PD cohorts aimed to include a mix of individuals with
(<26) and without (≥26) cognitive impairment. MoCA scores across disease cohorts are
outlined in Table 3.1. Ethics approval was obtained from each of the participating sites.
Descriptions of the inclusion/exclusion criteria of ONDRI participants were previously
reported (Farhan et al., 2017; Sunderland et al., 2020). All participants provided informed
written consent.
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Table 3.1 Distribution of general cognition in all enrolled ONDRI participants, as
determined by MoCA score.
Total number of
Mean MoCA
Cohort
Max. MoCA Min. MoCA
participants
(score ± sd)
ONDRI
520ᶧ
24.4 ± 3.4
30
13
AD
41
20.9 ± 2.8
26
15
ALS
40ᶧ
25.5 ± 2.8
30
19
CVD
161
25.2 ± 3.0
30
18
FTD
53
21.5 ± 3.9
29
13
MCI
85
23.5 ± 2.7
30
18
PD
140ᶧᶧ
25.8 ± 2.6
30
18
ᶧOne participant did not complete MoCA testing.
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CVD ± CI, cerebrovascular
disease with or without cognitive impairment; FTD, frontotemporal dementia; Max., maximum; MCI, mild
cognitive impairment; Min., minimum; MoCA, Montreal Cognitive Assessment; ONDRI, Ontario
neurodegenerative disease research initiative; PD, Parkinson’s disease; sd, standard deviation.
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3.3.2.

APOE genotyping

Participant blood samples were obtained and genomic DNA was isolated from blood and
subsequently sequenced using ONDRISeq, a custom-designed next-generation
sequencing gene panel that targets 80 genes previously associated with the disease
cohorts in ONDRI (Dilliott et al., 2018; Farhan et al., 2016).
APOE genotypes were obtained from the ONDRISeq data using a customized Annotate
Variation (ANNOVAR) script to extract allele calls for the APOE variants
rs429358(CT):p.Cys130Arg and rs7412(CT):p.Arg176Cys and map to the respective
genotype for each participant (Dilliott et al., 2019; Dilliott et al., 2018). All APOE
genotypes were subsequently validated using a TaqMan allelic discrimination assay.
Genotypes were used to bin participants into three groups based on carrier status: 1) E2
carriers (E2/2, E3/2); 2) E3/3; and 3) E4 carriers (E4/3, E4/4). All participants harbouring
an E4/2 genotype were excluded from the study.

3.3.3.

Neuropsychology assessment

Participants completed a comprehensive neuropsychological battery (McLaughlin et al.,
2020) that included 23 measures from 14 neuropsychological tests across five cognitive
domains: 1) attention/working memory; 2) executive function; 3) language; 4) verbal
memory; and 5) visuospatial abilities (Table 3.2). Cognitive domains and associated test
measures were grouped together based on general neuropsychology conventions (Lezak,
Howieson, Loring, Hannay, & Fischer, 2004) and consensus agreement among the
ONDRI Clinical Neuropsychologists.
Domain scores were created by averaging the standardized residuals of a linear model for
each raw test score with age, sex, years of education, and, where necessary, assessment
version as main effects, across variables within a domain. All timed scores were
multiplied by -1 such that faster response times (higher scores) reflected better
performance.
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Prior to creating domain scores, missing neuropsychology data were imputed using a
regularized iterative principal component analysis (PCA) process from the missMDA
package in R (Josse & Husson, 2016). Briefly, using the standardized residuals starting
values were imputed and a PCA was performed. From the PCA, a set of fitted values was
derived, and a new PCA was performed using the fitted values as updated imputed
values. The number of components retained for calculating the fitted values was
determined based on the minimum mean square predicted error of the observed values.
The process was repeated until the overall change in fitted values was negligible.
Starting values were the observed variable mean (adjusted for age, sex, and years of
education of the participant) for values missing for reasons unrelated to the participant,
and the extreme score when the participant was unable to complete the task because of
difficulty understanding the task instructions or performing the task as intended.
Both the APOE and Neuropsychology datasets underwent rigorous quality assurance and
quality control processes to ensure accuracy (Dilliott et al., 2018; McLaughlin et al.,
2020; Sunderland et al., 2019).
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Table 3.2 Binning strategy of the neuropsychological tests into cognitive domains.
Attention and Working
Cognitive Domain
Executive Function
Language
Memory
Trail Making Test – Part
B (time)

Boston Naming – 15
Item (pro-rated)

Trail Making Test – Part A
(time)

DKEFS: Interference
(time)

TAWF: Verb Naming

WAIS-III: Digit Span
Forward (longest span)

DKEFS: Inhibition/
Switching (time)

WAIS-III: Digit Span
Backward (longest span)

DKEFS: Letter Fluency

Neuropsychological Symbol Digit Modality Test
Tests (coding)

WAIS-III: Digit Span Total
DKEFS: Color naming
(time)

BDAE: Semantic
Probe
WASI-II: Vocabulary

Verbal Memory
RAVLT: Immediate
RAVLT: Long-delay
RAVLT:
Recognition
Discrimination

Visuospatial
Awareness
Judgement of Line
Orientation
VOSP: Incomplete
Letters
BVMT-R: Copy Trial
(raw)

DKEFS: Category
Fluency
WASI-II: Matrix

DKEFS: Word reading
(time)
Abbreviations: BDAE, Boston Diagnostic Aphasia Examination; BVMT-R, Brief Visuospatial Memory Test-Revised; DKEFS, Delis-Kaplan Executive Function
System; RAVLT, Rey Auditory Verbal Learning Test; VOSP, Visual Object and Space Perception Battery; WAIS-III, Wechsler Adult Intelligence Scale – Third
Edition; WASI-II, Wechsler Abbreviated Scale Intelligence – Second Edition.
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3.3.4.

Statistical analysis

A multivariate multiple regression model was used to estimate effects across the five
cognitive domains as a function of APOE carrier status and disease cohort, while
accounting for interactions between the two predictor variables (Johnson & Wichern,
2001). Wilks’ lambda assessed predictor contributions of the five parallel equations,
where significance indicated that the predictor contribution was non-zero for at least one
of the five cognitive domains. To determine the extent to which domain(s) a predictor
contributed, the individual coefficients were examined.
Participant APOE carrier statuses were transformed into dummy variables with E3/3 as
the reference category. Participant disease cohorts were transformed with weighted-effect
coding, using the wec R package (v0.4-1) (Nieuwenhuis et al., 2017). With weightedeffect coding, the point of reference is the sample mean of all participants, regardless of
cohort. While the parameter for one cohort (in this case, CVD was chosen) must be
excluded from the model to avoid statistical redundancy, the coefficient estimate can still
be calculated (te Grotenhuis et al., 2017a, 2017b). Significance for the multivariate
multiple regression model was measured at an alpha-level of 5.0e-2, although nonsignificant trends were reported in the results at p < 7.5e-2.
Statistical analyses were performed using the R statistical software 3.6.0 (R Core Team,
2014) in R Studio 1.1.463 and data visualization was performed using the ggplot2 R
package (v3.3.s) (Wickham, 2009).

3.4.
3.4.1.

Results
Study participants

In total, 519 of the 520 participants enrolled in ONDRI were included in the genetic
analysis, as one participant did not complete the genomics assessment. Of the 519, six
with the APOE E4/2 genotype were excluded. Of the 513 participants remaining, we
identified that 292 (56.9%) participants harboured the E3/3 genotype, 59 (11.5%)
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participants were APOE E2 carriers, and 162 (31.6%) participants were APOE E4 carriers
(Table 3.3). Neuropsychology data were imputed using a regularized iterative PCA for
176 missing values (1.5% of all cells) across 100 participants (19.5%) that were
distributed amongst the six cohorts.
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Table 3.3 Demographics and APOE carrier status of the ONDRI participants included in the APOE cognitive impairment
analysis.
Participants included
Mean age
APOE E2
APOE E4
Cohort
Male:Female
APOE E3/3
in APOE analysis
(years ± sd)
carriers
carriers
ONDRI
513
68.6 ± 7.6
341:172
292 (56.9%)
59 (11.5%)
162 (31.6%)
AD
40
71.9 ± 8.1
23:17
14 (35.0%)
0
26 (65.0%)
ALS
40
62.0 ± 8.7
24:16
21 (52.5%)
6 (15.0%)
13 (32.5%)
CVD
159
69.2 ± 7.4
109:50
100 (62.9%)
21 (13.2%)
38 (23.9%)
FTD
53
67.8 ± 7.1
34:19
26 (49.1%)
7 (13.2%)
20 (37.7%)
bvFTD
21
65.9 ± 8.8
14:7
11
0
10
nfPPA
8
68.4 ± 5.9
5:3
4
1
3
PSP
15
69.7 ± 6.2
10:6
6
6
4
MCI
85
70.6 ± 8.3
45:40
45 (52.9%)
5 (5.9 %)
35 (41.2%)
PD
136
67.8 ± 6.4
106:30
86 (63.2%)
20 (14.7%)
30 (22.1%)
APOE E2 carriers are those harbouring the E3/2 or E2/2 genotypes, whereas APOE E4 carriers are those harbouring the E4/4 or E4/3 genotypes. Individuals
harbouring the APOE E4/2 genotype were excluded from the cognitive analysis. The patient diagnosed with bvFTD and PSP was included in the PSP cohort.
Demographics and APOE carrier status of the CBS and svPPA cohorts are not displayed due to the small sample sizes of the groups (n ≤ 5).
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; APOE, Apolipoprotein E gene; bvFTD, behavioural variant frontotemporal
dementia; CBS, corticobasal syndrome; CVD ± CI, cerebrovascular disease with or without cognitive impairment; FTD, frontotemporal dementia; MCI, mild
cognitive impairment; nfPPA, non-fluent primary progressive aphasia; ONDRI, Ontario neurodegenerative disease research initiative; PD, Parkinson’s disease;
PSP, progressive supranuclear palsy; sd, standard deviation; svPPA, semantic variant primary progressive aphasia.
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3.4.2.

Influence of APOE across all neurodegenerative diseases

All coefficient estimates and standard errors obtained by the multivariate multiple
regression model are summarized in Table 3.4. A Wilks’ lambda test on the multivariate
multiple regression analysis confirmed contribution to the model from APOE carrier
status (Λ = 0.937, p = 3.58e-4), disease cohort (Λ = 0.705, p < 2.20e-16), and their
interaction (Λ = 0.874, p = 1.81e-2).
Figure 3.1 shows the magnitude of difference in cognition of participants carrying E4 or
E2 in relation to E3 homozygotes across ONDRI as a whole and all disease cohorts
individually for each cognitive domain. To better illustrate these changes, disease effects
were removed.
Combining all participants in a single group revealed that APOE E4 carriers had
significantly lower performance in verbal memory (p = 9.22e-3; Figure 3.1I) and
visuospatial abilities (p = 2.20e-2; Figure 3.1J) compared to those with the APOE E3/3
genotype. In contrast, APOE E2 carriers displayed similar cognitive performance across
domains to those with the APOE E3/3 genotype.
Including an interaction term in the model also allowed us to compare cognitive
performance of the two APOE variant carrier groups (E4 and E2) to the APOE E3/3
carriers in each individual disease cohort to identify differences between APOE carrier
status and disease group.
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Table 3.4 Coefficient estimates (SE) of z-score transformed cognitive domain scores for participants in each neurodegenerative
disease cohort, and in the total cohort, based on APOE carrier status obtained using multivariate multiple regression.
Attention and
Executive
Visuospatial
Cognitive Domain
Language
Verbal Memory
Working Memory
Function
Abilities
Intercept
0.013 (0.040)
-0.012 (0.044)
-0.020 (0.050)
0.057 (0.047)*
0.056 (0.043)
APOE E2
-0.041 (0.097)
-0.0801 (0.107)
0.081 (0.121)
0.014 (0.114)
-0.147 (0.104)
APOE E4
-0.036 (0.070)
-0.029 (0.077)
-0.024 (0.087)
-0.215 (0.082)*** -0.173 (0.0752)*
AD
-0.222 (0.170)
-0.340 (0.188)
-0.730 (0.211)*** -0.475 (0.199)**
-0.070 (0.182)
AD x APOE E2
NA
NA
NA
NA
NA
AD x APOE E4
0.056 (0.196)
0.049 (0.217)
0.384 (0.245)
-0.419 (0.230)
-0.158 (0.211)
ALS
0.076 (0.140)
0.181 (0.155)
-0.004 (0.175)
0.062 (0.165)
0.080 (0.151)
ALS x APOE E2
0.482 (0.294)
0.623 (0.325)
0.447 (0.366)
0.054 (0.345)
0.279 (0.315)
ALS x APOE E4
-0.116 (0.228)
-0.199 (0.252)
0.058 (0.284)
0.219 (0.238)
0.166 (0.245)
FTD -0.642 (0.124)***
-0.767 (0.137)*** -0.854 (0.154)*** -0.649 (0.145)***
-0.213 (0.133)
FTD x APOE E2
-0.827 (0.268)**
-0.605 (0.296)*
0.779 (0.334)*
0.260 (0.314)
-1.051 (0.287)***
FTD x APOE E4
-0.100 (0.187)
-0.076 (0.207)
0.190 (0.233)
0.486 (0.219)*
0.145 (0.201)
MCI
0.050 (0.091)
0.005 (0.101)
0.135 (0.113)
-0.190 (0.107)
-0.085 (0.098)
MCI x APOE E2
0.328 (0.304)
0.175 (0.336)
0.036 (0.379)
0.574 (0.357)
0.385 (0.327)
MCI x APOE E4
0.052 (0.134)
0.132 (0.148)
-0.101 (0.167)
-0.093 (0.157)
0.081 (0.144)
PD
0.230 (0.064)
0.238 (0.070)***
0.184 (0.079)*
0.254 (0.075)***
0.086 (0.068)
PD x APOE E2
-0.062 (0.135)
-0.238 (0.150)
-0.224 (0.169)
-0.265 (0.159)
0.033 (0.145)
PD x APOE E4
-0.021 (0.133)
-0.080 (0.147)
-0.155 (0.166)
0.113 (0.156)
-0.227 (0.143)
CVD +/- CI
0.027 (0.057)
0.090 (0.064)
0.239 (0.072)
0.205 (0.067)
0.040 (0.062)
CVD +/- CI x APOE E2
0.119 (0.130)
0.209 (0.143)
-0.183 (0.162)
0.014 (0.152)
0.148 (0.139)
CVD +/- CI x APOE E4
0.023 (0.117)
0.017 (0.129)
-0.166 (0.146)
-0.048 (0.137)
0.080 (0.125)
APOE carrier statuses were transformed into dummy variables with E3/3 as the reference. Participant disease cohorts were transformed using weighted-effect
coding using the CVD ± CI cohort as the reference. The model was rerun using the ALS cohort as the reference in the weighted-effect coding to obtain
coefficient estimates for the CVD ± CI cohort, as displayed below the line. *p-value < 0.05; **p-value < 0.005; ***p-value < 0.0005.
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; APOE, Apolipoprotein E gene; CVD ± CI, cerebrovascular disease with or without
cognitive impairment; FTD, frontotemporal dementia; MCI mild cognitive impairment; PD, Parkinson’s disease; SE, standard error.
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3.4.3.

Influence of APOE in the individual disease cohorts

Considering individual disease cohorts, direction of association based on the APOE E4
allele was not uniform across disease cohorts. E4 carrier status was significantly
associated with better verbal memory performance in the FTD cohort relative to those
harbouring the E3/3 genotype (p = 2.72e-2; Figure 3.1I). In contrast, in the AD cohort
poorer verbal memory performance by APOE E4 carriers approached significance (p =
6.97e-2; Figure 3.1I). No other differences of interest were observed between APOE E4
and E3/3 across disease cohorts.
The only significant interaction effect of APOE E2 was observed in the FTD cohort. FTD
patients harbouring the E2 allele performed significantly better in the language domain (p
= 2.00e-2; Figure 3.1C), yet significantly worse in the attention/working memory (p =
2.12e-3; Figure 3.1A), executive function (p = 4.17e-2; Figure 3.1B), and visuospatial
domains (p = 2.37e-4; Figure 1E), compared to patients harbouring the E3/3 genotype. In
the ALS cohort, better executive function performance by APOE E2 carriers approached
significance (p = 5.58e-2; Figure 3.1B).
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Figure 3.1 Estimates based APOE variant carrier status in the neurodegenerative
disease cohorts encompassed by ONDRI with respect to performance on
neuropsychology tests binned into cognitive domains.
From the neuropsychology core dataset, 23 raw scores were binned into five cognitive
domains, raw scores were standardized into z-scores, and mean z-scores were derived for
each cognitive domain per participant. Multivariate multiple regression analysis was used
to model performance across the cognitive domains as a function of APOE carrier status,
disease cohort, and interactions between the predictor variables. Estimates for differences
between groups were calculated based on the intercept, coefficient estimates from APOE
carrier status, and coefficient estimates from the APOE carrier status and disease cohort
interaction effect. *p-value < 0.05; **p-value < 0.005; ***p-value < 0.0005.
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; APOE,
Apolipoprotein E gene; CVD ± CI, cerebrovascular disease with or without cognitive
impairment; E2, E2 carriers; E3, E3/3 carriers; E4, E4 carriers; FTD, frontotemporal
dementia; MCI mild cognitive impairment; ONDRI, Ontario Neurodegenerative Disease
Research Initiative; PD, Parkinson’s disease.
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3.5.

Discussion

Here, we investigated the influence of the APOE E4 and E2 alleles on cognitive
functioning in multiple cognitive domains across neurodegenerative and cerebrovascular
disease cohorts.
Generally, carriers of the E4 allele had an estimated significantly lower performance in
the verbal memory and visuospatial domains than those with E3/3. Multiple studies have
reported associations between the APOE E4 allele and poor memory performance,
including adults who were considered cognitively normal for their age (Baxter, Caselli,
Johnson, Reiman, & Osborne, 2003; Caselli et al., 2009; Caselli et al., 2007). Combined
with the results that we observed across all participants regardless of cohort in the verbal
memory domain, this suggests that APOE E4 may influence memory performance
regardless of disease status, independent of age and sex. Two hypotheses have been put
forth in the literature to account for these findings (O'Donoghue et al., 2018). The first
suggests that APOE E4 carriers are in a prodromal stage of AD, with the Apo E4 isoform
increasing the deposition of early-AD pathology, such as Aβ and tau, thereby indirectly
influencing memory function. The second hypothesis suggests that the Apo E4 isoform
directly influences cognition, in a mechanism unrelated to AD pathology – possibly via a
role of Apo E in synaptic plasticity and neurotoxicity. Perhaps both mechanisms
contribute, but this must be further elucidated (O'Donoghue et al., 2018). Our data
showed an intriguing exception in the FTD cohort, where participants with E4 performed
better than those with the E3/3 genotype; a reverse effect than what was observed in the
E4 group effect. Yet, FTD patients carrying an E4 allele still performed below the group
average for APOE E4 carriers across all ONDRI samples in the verbal memory domain
(Table 3.4). In addition, while we observed poorer performance in E4 carriers in
comparison to E3/3 AD patients, the interaction term did not reach statistical
significance, as we expected it to (M. Hashimoto et al., 2001; Lehtovirta et al., 1996;
Marra et al., 2004; van der Vlies et al., 2007). Due to the high proportion of E4 carriers in
the AD cohort (65%) and the large influence from an AD diagnosis and E4 individually
(β = -0.475, p = 1.73e-2 and β = -0.215, p = 9.22e-3, respectively), there may not have
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been enough power to achieve statistical significance despite the relatively large
interaction estimate (β = -0.419).
In the FTD cohort, carriers of the APOE E2 allele performed significantly worse in
multiple cognitive domains, including attention/working memory, executive function,
and visuospatial abilities. Zhao et al. identified an association between APOE E2 and
increased neurofibrillary tau pathology (Zhao et al., 2018), which is a hallmark of certain
subtypes of FTD — including PSP, CBD, and FTD with tau pathology ― and is a risk
factor for increased cognitive impairment (Koga et al., 2017). Further, the APOE E2/2
genotype was previously directly associated with increased risk of PSP and CBD (Zhao
et al., 2018) and the E2 allele with increased risk of ALS-FTSD (Chio et al., 2016).
Within ONDRI, of the seven FTD patients carrying an E2 allele, five were diagnosed
with PSP (the Richardson phenotype, PSP-RS) and one was diagnosed with both bvFTD
and PSP (Table 3.3). Individuals with PSP often present with a high degree of cognitive
impairment, particularly in executive function and speed of processing, verbal fluency,
and visuospatial abilities (Bak, Crawford, Hearn, Mathuranath, & Hodges, 2005).
Therefore, it is possible that we observed an increased presence of the PSP subtype ―
and cognitive impairment ― as a result of increased neurofibrillary tau pathology in
individuals carrying APOE E2. Unfortunately, neuropathology data are currently
unavailable for ONDRI patients to assess tau pathology; however, the PSP-RS phenotype
is highly predictive of underlying tau pathology (Kovacs et al., 2020). In contrast, E2
carriers in the FTD cohort performed significantly better than patients with APOE E3/3
on memory measures. No other disease cohorts displayed significant interaction effects
on cognitive function between the E2 allele and disease diagnosis; however, the effects
could not be assessed in the AD cohort due to a lack of E2 carriers. This observation was
expected as the E2 allele is commonly accepted as protective against AD (Dilliott et al.,
2019).
We recognize this study’s limitations, including the relatively modest sample sizes of the
individual disease cohorts, which limited the ability to further analyze the subtypes of
heterogenous diseases, as was observed in the FTD cohort. Despite this, a goal of the
analysis was to evaluate across all neurodegenerative diagnoses and account for
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overlapping disease features. The cross-cohort analysis was made possible by ONDRI’s
rigorous and consistent enrollment criteria and cross-platform assessment. It is important
for this study to be replicated with larger sample sizes, particularly of FTD patients.
Limitations were also introduced by not accounting for progression of the ONDRI
patient’s cognitive impairment over time and the lack of access to post-mortem
neuropathology to confirm diagnoses, although these analyses may be revisited in the
future if data are available. Finally, we utilized a theory-based framework derived from
published guidelines to reduce our neuropsychological measures into five cognitive
domains. This theory-driven data reduction approach has inherent limitations, such that
some tests may not contribute solely to one domain and there is debate as to how tests
should be binned; however, the use of a comprehensive assessment was prioritized as
previous analyses on APOE have mostly utilized only a limited number of tests
accounting for fewer cognitive domains per investigation or introducing single test
biases.

3.6.

Conclusion

In summary, our study allowed for simultaneous analysis of the influence of APOE on
multiple cognitive domains across various neurodegenerative diseases and CVD with
rigorous data collection and a comprehensive neuropsychological assessment protocol.
Considering all neurodegenerative and cerebrovascular disease patients as a group, we
identified an association between the APOE E4 allele and worse performance on
measures of verbal memory and visuospatial processing. Further, we identified a
potential association between the APOE E2 allele and poor performance on measures of
attention/working memory, executive function, and visuospatial abilities in patients with
FTD, which may add to the previously observed associations between the variant and
PSP and tau pathology. Future work incorporating the longitudinal ONDRI
neuropsychology data will be imperative for understanding how APOE influences disease
progression. Additionally, including other biomarkers obtained in ONDRI, such as
neuroimaging data, may further elucidate the mechanisms by which APOE influences
cognition across the disease cohorts. Gaining a greater understanding of the contributions
of genetic risk factors, such as APOE variation to features of neurodegenerative disease,
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may present the opportunity for genetic testing to become a progression prediction tool
for these typically heterogenous phenotypes.
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4.1.

Abstract

Background/Objective: Genetic factors contribute to neurodegenerative disease, with
high heritability estimates across diagnoses; however, a large portion of this genetic
influence remains poorly understood. Many previous studies have attempted to fill the
gaps by performing linkage analyses and association studies in individual disease cohorts
but have failed to consider the clinical and pathological overlap observed across
neurodegenerative diseases and the potential for genetic overlap between the phenotypes.
Here, we leveraged rare variant association analyses (RVAA) to elucidate the genetic
overlap among multiple neurodegenerative diagnoses, including Alzheimer’s disease,
amyotrophic lateral sclerosis, frontotemporal dementia (FTD), mild cognitive
impairment, and Parkinson’s disease (PD), as well as cerebrovascular disease, using the
data generated with a custom-designed neurodegenerative disease gene panel in the
Ontario Neurodegenerative Disease Research Initiative (ONDRI).
Methods and Results: As expected, only ~3% of ONDRI participants harboured a
monogenic variant likely driving their disease presentation. Yet, when genes were binned
based on previous disease associations, we observed an enrichment of putative loss-offunction variants in PD genes across all ONDRI cohorts. Further, individual gene-based
RVAA identified significant enrichment of rare, non-synonymous variants in PARK2 in
the FTD cohort, and in NOTCH3 in the PD cohort.
Conclusion: The results indicate that there may be greater heterogeneity in the genetic
factors contributing to neurodegeneration than previously appreciated. Although the
mechanisms by which these genes contribute to disease presentation must be further
explored, we hypothesize they may be a result of rare variants of moderate phenotypic
effect contributing to overlapping pathology and clinical features observed across
neurodegenerative diagnoses.
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4.2.

Introduction

Neurodegenerative diseases are characterized by neuronal degeneration resulting in
cognitive decline and/or motor dysfunction. Mainly manifesting in late adulthood,
neurodegenerative diseases are often tightly correlated with the deposition of protein
aggregates, such as amyloid-β and neurofibrillary tau tangles in Alzheimer’s disease
(AD) and α-synuclein in Parkinson’s disease (PD) (Kovacs, Botond, & Budka, 2010).
Although diagnoses are typically based on clinical presentation, definitive diagnosis
requires post-mortem pathologic analysis to identify the pathogenic protein aggregates in
situ. Further, neurodegenerative disease presentation is highly heterogeneous, and it is
increasingly accepted that diagnoses exist along a spectrum, with a greater amount of
mixed pathology — and overlapping clinical features — than previously thought (Kovacs
et al., 2013).
Genetic factors are known to increase risk of neurodegeneration and influence expression
of disease features (Bocchetta et al., 2016); however, only ~10% of neurodegenerative
disease patients are considered to have familial forms of disease, a fraction of which are
caused by known rare, highly penetrant genetic variants. Similarly, while genome-wide
association studies (GWASs) have identified many common GWAS-significant single
nucleotide polymorphisms (SNPs) in neurodegenerative disease cohorts and thus have
advanced the field considerably (Lambert et al., 2013; Nalls et al., 2014; Simon-Sanchez
et al., 2009), such variants account for only a small amount of heritable risk (Keller et al.,
2014; Ridge, Mukherjee, Crane, & Kauwe, 2013; Singleton & Hardy, 2016). Even after
considering the collective effects of both Mendelian large-effect rare mutations and
common disease-associated SNPs, a considerable portion of heritability across
neurodegenerative diseases remains unexplained (Ciani et al., 2019; Ridge et al., 2013;
Van Damme, 2018).
Recent studies have reported enrichment of rare variants in genes typically considered
only in early-onset, familial neurodegenerative disease cases in cohorts with sporadic
forms of disease, likely constituting a moderate effect on disease risk. For example, rare
variants have been identified in patients with late-onset sporadic AD in amyloid precursor
protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) (Cruchaga et al., 2012);
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in patients with both late- and early-onset sporadic PD in α-synuclein (SNCA), parkin
RBR E3 ubiquitinated protein ligase (PARK2), leucine-rich repeat kinase 2 (LRRK2), and
VPS35 retromer complex component (VPS35) (Lesage & Brice, 2012; Robak et al.,
2017); and in patients with both familial and sporadic ALS in superoxide dismutase
(SOD1), FUS RNA binding protein (FUS), and DnaJ heat shock protein family (Hsp40)
member C7 (DNAJC7) (S. M. K. Farhan et al., 2019). In addition, the explanation for
heterogeneity of phenotypic expression of neurodegeneration among individuals with
identical rare variants is unclear, as is the potential influence of genetic factors on the
overlapping clinical and pathological features of different neurodegenerative diagnoses.
Such gaps in knowledge reinforce how much remains to be learned regarding genetic risk
of neurodegeneration, even with respect to known neurodegenerative disease genes.
While rare variants likely account for at least a portion of the missing heritability of
neurodegenerative diseases, as well as the phenotypic heterogeneity between diseases,
they remain difficult to detect. Rare variants with large effect sizes are individually very
uncommon and require large samples sizes to obtain the statistical power necessary for
detection — even some of the largest GWASs, with sample sizes >100,000, are still
unable to detect rare disease-associated variants. However, by binning variants into genebased groupings of their original disease associations — or by analyzing each gene
individually — rare variant association analyses (RVAAs) may identify gene-disease
associations and explain additional disease risk even with modest sample sizes (Lee,
Abecasis, Boehnke, & Lin, 2014).
Here, we utilize targeted next-generation sequencing (NGS) data coupled with a RVAAbased binning strategy to identify the contribution of rare genetic variants in participants
from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) to multiple
neurodegenerative disease phenotypes, including: 1) AD; 2) amnestic MCI; 3) ALS; 4)
frontotemporal dementia (FTD); and 5) PD, as well as cerebrovascular disease (CVD) (S.
M. K. Farhan et al., 2017; Sunderland et al., 2020). By binning variants into diseaseassociation-based gene groupings and individual gene-based groupings, and comparing
variant enrichment to that of a cognitively normal, elderly control cohort, we seek to
identify whether rare variants significantly contribute to disease presentation in ONDRI
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participants. Furthermore, by studying six phenotypes concurrently, we can determine
whether associations exist across disease phenotypes, and whether these might account
for the overlapping features often observed across neurodegenerative diseases.

4.3.
4.3.1.

Methods
Study participants

In total, 520 individuals passed ONDRI preliminary screening (S. M. K. Farhan et al.,
2017). Of those, 519 participants had a blood sample collected, from which genomic
DNA was extracted. Study ethics approval was obtained from the Research Ethics Boards
at Baycrest Centre for Geriatric Care (Toronto, Ontario, Canada); Centre for Addiction
and Mental Health (Toronto, Ontario, Canada); Elizabeth Bruyère Hospital (Ottawa,
Ontario, Canada); Hamilton General Hospital (Hamilton, Ontario, Canada); McMaster
(Hamilton, Ontario, Canada); London Health Sciences Centre (London, Ontario,
Canada); Parkwood Hospital (London, Ontario, Canada); St Michael's Hospital (Toronto,
Ontario, Canada); Sunnybrook Health Sciences Centre (Toronto, Ontario, Canada); The
Ottawa Hospital (Ottawa, Ontario, Canada); and University Health Network-Toronto
Western Hospital (Toronto, Ontario, Canada). All participants provided written, informed
consent in accordance with the Research Ethics Boards and regulatory requirements.
DNA was also obtained from 189 cognitively normal control genomic DNA samples
from the GenADA study (Li et al., 2008).

4.3.2.

DNA preparation and sequencing

All DNA samples were sequenced using the targeted NGS panel, ONDRISeq, on the
Illumina MiSeq Personal Genome Sequencer (Illumina, San Diego, CA, United States)
and raw sequencing data were processed with a custom bioinformatics workflow. Briefly,
FASTQ files were imported into CLC Bio Genomics Workbench v10 (CLC Bio, Aarhus,
Denmark) to perform pre-processing and variant annotation, which produced a variant
calling format (VCF) file and binary alignment map (BAM) file for each participant.
Detailed methodology outlining DNA isolation, DNA sequencing, and sequencing
analysis has been previously described (Dilliott et al., 2018).
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4.3.3.

Identification of variants likely contributing to Mendelian
disease

ONDRISeq VCF files of the ONDRI cases were imported into VarSeq® (Golden Helix,
Bozeman, MT, United States) and variants were annotated with sequence ontologies.
Minor allele frequencies (MAFs) were obtained from the Genome Aggregation Database
(gnomAD v.2.0.1v3 non-neuro) (Karczewski et al., 2020). Rare (MAF < 0.01),
nonsynonymous variants were prioritized. Further assessment of variants was performed
to identify those in genes known to contribute to Mendelian forms of the patient’s disease
of diagnosis and those classified as pathogenic or likely pathogenic in ClinVar (Landrum
et al., 2014), Online Mendelian Inheritance in Man (OMIM) ("Online Mendelian
Inheritance in Man, OMIM®,"), and/or the Alzforum Mutation Database ("Alzforum
Mutations,"). All identified variants were considered those likely to be contributing to
Mendelian forms of disease.
All samples were genotyped for chromosome 9 open reading frame 72 (C9orf72) using
both amplicon length analysis and repeat-primed polymerase chain reaction (PCR), as
previously described (Xi et al., 2012). Harbouring > 30 repeats is a commonly accepted
genetic cause of ALS and FTD (Xi et al., 2015; Xi et al., 2012), and therefore was the
cutoff used to determine those with pathogenic repeat expansions.

4.3.4.

Ancestry matching and estimation

The ONDRISeq VCF files of all cases and controls were merged and filtered to include
only SNPs within exonic and splicing regions with a MAF > 0.005 in the Genome
Aggregation Database (gnomAD v.2.0.1v3) using VarSeq®. Variants that were located
on the sex chromosomes or within the MAPT gene were excluded, due to potential
influence from the cohort’s sex distribution and a common haplotype variation found
across the gene, respectively. The filtered, merged VCF was processed with a bash-based
tool that contains a collection of scripts necessary to run region-based RVAA,
“Exautomate” (Davis, Dron, Robinson, Hegele, & Lizotte, 2019), to produce PLINK
compatible MAP and PED files. SNP & Variation Suite v8.8.3 (SVS; Golden Helix Inc.)
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was used to perform linkage disequilibrium (LD) pruning (threshold = 0.5) and a
principal component analysis (PCA) was performed to identify the genetic ancestry.
In accordance with standard quality control in genomic studies, a logistic regression
analysis was performed within R on the generated principal components to identify
individuals with divergent ancestries to minimize false discoveries due to population
stratification. A multidimensional outlier analysis (multiplier = 1.5) was performed
within SVS using the significant components to identify outlier samples based on
ancestral variation and batch effects, which were not included in the RVAAs described
below.
To predict the genomic ancestry of the samples, we used the whole genome sequences
from the 1000 Genomes Project (1000G; N = 2693), which are binned into ancestral
groups, including: African, Admixed American, East Asian, European, and South Asian
(Auton et al., 2015). The 1000G VCFs were merged and filtered to include only SNPs
within the exonic and splicing regions captured by the ONDRISeq panel with an MAF >
0.005 in gnomAD. The resulting filtered merged VCF was processed using “Exautomate”
to produce MAP and PED files and a PCA was performed using the SNPRelate
Bioconductor R package (v1.22.0; LD pruning threshold = 0.5) (Zheng, Gogarten,
Laurie, & Weir, 2015). The SNP loadings from this PCA and the PED file of the ONDRI
cases and controls were used to project the ONDRI cases and controls onto the
components of the 1000G PCA (Zheng et al., 2012).

4.3.5.

Rare variant association analysis

The VCF files of all ancestry matched ONDRI cases and controls were imported into the
variant annotation software, VarSeq®. Variants were annotated with sequence
ontologies, MAFs from gnomAD, and in silico prediction scores from Combined
Annotation Dependent Depletion (CADD; v1.3) (Kircher et al., 2014), Sorting Intolerant
from Tolerant (SIFT) (Kumar, Henikoff, & Ng, 2009), and Polymorphism Phenotyping
v2 (PolyPhen-2) (Adzhubei et al., 2010). Variants were prioritized and variants with a
sequence ontology of nonsense, stop-loss, splicing acceptor, splicing donor, frameshift,
or missense, and a MAF < 0.01 in the Exome Aggregation Consortium (ExAC v1.0) were
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included in subsequent analyses. Both heterozygous and homozygous variants were
retained for RVAAs. Variants were binned into three groups: 1) putative loss-of-function
variants (LOF; including nonsense, stop-loss, frameshift, splice acceptor, and splice
donor sequence ontologies); 2) missense variants; and 3) possibly deleterious missense
variants (including missense variants with either a CADD Phred ≥ 20 or a likely
damaging/damaging prediction from both SIFT and PolyPhen-2). Carriers of these
variants were considered ‘variant positive’ and ‘variant negative’, respectively.
Variants were also binned into groups based on the previous disease association of the
gene in which the variant was located. In total, the 80 genes encompassed by the
ONDRISeq panel were binned into four disease-association groups: 1) AD/MCIassociated genes; 2) ALS/FTD-associated genes; 3) PD-associated genes; and 4) CVDassociated genes based on the most well-established previous disease association, as
determined by Farhan et al. (Figure 4.1) (S.M.K. Farhan et al., 2016).
RVAAs were performed using multinomial logistic regression models. A model was
produced for each variant subgroup (putative LOF, missense, and possibly deleterious
missense) to compare the number of variant-positive individuals in each of the ONDRI
disease cohorts to the cognitively normal control cohort, while correcting for age and sex.
In addition, participants were weighted to better reflect disease prevalence in the general
elderly population, accounting for potential inference bias as a result of the nonprobability sampling mechanism ("2020 Alzheimer's disease facts and figures," 2020;
"Chapter 3: Mapping Connections: An understanding of neurological conditions in
Canada – Scope (prevalence and incidence)," 2014; Hogan et al., 2016; Mehta et al.,
2018; Ng et al., 2015; Roberts & Knopman, 2013). The brglm2 R package (v0.6.2)
(Kosmidis, 2020) was used to fit the regression models and apply a mean bias reduction
(Kosmidis, Kenne Pagui, & Sartori, 2020) that accounts for the low variant positive
counts.
A gene-based RVAA, the optimal unified Sequence Kernel Association Test (SKAT-O),
was also performed using the script package “Exautomate” (Davis et al., 2019). This
method identified specific genes covered by ONDRISeq with an increased frequency of
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nonsynonymous, rare variants (MAF < 0.01, ExAC) in the disease cohorts compared to
controls, and in the disease cohorts compared to each other. To maximize sample sizes,
the AD and amnestic MCI cohorts were combined for SKAT-O analyses. As SKAT-O
was not able to account for multi-nucleotide variants, follow-up analyses were performed
on SKAT-O results with a detected signal using Firth logistic regression, adjusting for
age and sex, using the brglm2 R package. Genes that had total rare variant counts
between the two cohorts of <5, or with zero rare variants in one of the cohorts were
excluded from analyses.
Analyses were performed using R statistical software 3.6.0 (Team, 2014) in R Studio
1.1.463 and data visualization was performed using the ggplot2 R package (v3.3.s)
(Wickham, 2009). Significance for all regression analyses was measured at an alpha-level
of p < 0.050, although regression results with p < 0.075 were still reported.
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Figure 4.1 Binning of genes included on the ONDRISeq next-generation sequencing
panel based on their previous disease associations for use in the rare variant
association analyses.
Genes were binned based on the most well-established previous disease association, as
determined by Farhan et al. (S.M.K. Farhan et al., 2016).
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4.4.
4.4.1.

Results
Variants likely contributing to Mendelian disease

In the total cohort of 519 ONDRI cases (Table 4.1), seven participants harboured nonsynonymous rare variants likely contributing to a Mendelian form of disease with each
harbouring a unique variant of interest (Table 4.2), including one participant with AD,
two participants with CVD, one participant with MCI, and three participants with PD,
each harbouring a unique variant of interest (Table 4.3). Further, seven participants
carried pathogenic repeat expansions within C9orf72 (Table 4.2), including four
participants with ALS, two participants with FTD, and one participant with AD. Overall,
monogenic variants were observed at a frequency of ~3% both before and after ancestral
outlier analysis (0.027 [0.015–0.045] and 0.030 [0.016–0.052] in the total ONDRI cohort
and ancestry matched cohort, respectively). All participants were retained for subsequent
analyses.
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Table 4.1 Demographics of the total ONDRI cohorts and cognitively normal control cohort at baseline and the demographics
of the cohorts following multivariate outlier analysis.
Total Participants
Ancestry Matched Participants
Cohort Samples Mean age (years ± sd) Male:Female Samples
Mean age (years ± sd) Male:Female
ONDRI
519
68.6 ± 7.6
341:172
396
68.7 ± 7.9
268:128
AD
41
71.8 ± 8.0
24:17
33
71.4 ± 7.9
19:14
ALS
40
62.0 ± 8.7
24:16
32
61.9 ± 9.2
23:9
CVD
161
69.2 ± 7.4
109:50
124
69.6 ± 7.6
87:37
FTD
53
67.8 ± 7.1
34:19
39
67.5 ± 7.3
25:14
MCI
85
70.6 ± 8.3
45:40
59
71.9 ± 8.3
29:30
PD
139
67.8 ± 6.4
106:30
109
67.5 ± 6.3
85:24
Controls
189
74.0 ± 8.2
77:112
164
74.0 ± 7.9
68:96
The common variation (MAF > 0.005) captured by the ONDRISeq next-generation sequencing panel was used to perform principal component analysis on the
ONDRI cases and controls accounting for variance introduced by differential ancestry and batch effects. Multivariate outlier analysis was performed using the
first 8 principal components. Ancestry matched refers to all samples that were not removed by the outlier analysis.
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CVD, cerebrovascular disease; FTD, frontotemporal dementia; MCI, mild cognitive
impairment; ONDRI, Ontario neurodegenerative disease research initiative; PD, Parkinson’s disease; sd, standard deviation.
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Table 4.2 ONDRI participants harbouring rare variants likely contributing to Mendelian forms of neurodegenerative disease
and cerebrovascular disease.
Total Participants
Ancestry Matched Participants
Monogenic
C9orf72
Monogenic
C9orf72
Cohort
Samples
Samples
rare variants
expansion
rare variants
expansion
ONDRI
519
7
7
396
5
7
AD
41
1
1
33
1
1
ALS
40
0
4
32
0
4
CVD
161
2
0
124
1
0
FTD
53
0
2
39
0
2
MCI
85
1
0
59
1
0
PD
139
3
0
109
2
0
Ancestry matched refers to all samples that were not removed by the outlier analysis following principal component analysis on common variation (MAF >
0.005) captured by the ONDRISeq next-generation sequencing panel. Monogenic rare variants refers to individuals harbouring variants with a MAF < 0.01 in
gnomAD v.2.1.1 (non-neuro) in a gene known to contribute to Mendelian forms of the disease of patient diagnosis and that was classified as likely
pathogenic/pathogenic in ClinVar, OMIM, and/or the AlzForum mutations database. C9orf72 expansions refers to individuals harbouring the G4C2-expansion,
which were genotyped using amplicon length analysis and repeat primed PCR; all expansions were > 60 repeats in length.
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; C9orf72, chromosome 9 open reading frame 72 gene; CVD, cerebrovascular
disease; FTD, frontotemporal dementia; MCI, mild cognitive impairment; ONDRI, Ontario neurodegenerative disease research initiative; PD, Parkinson’s
disease.
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Table 4.3 Nonsynonymous rare variants likely contributing to Mendelian forms of neurodegenerative disease and
cerebrovascular disease identified in the total ONDRI cohort.

1

34.0
13.9
35
31.0
23.5

Previous
disease
association
AD1
PD2
PD3
CADASIL4
CADASIL5

Participants
harbouring
variant (cohort)
1 (AD)
1 (PD)
1 (PD)
1 (CVD)
1 (CVD)

1.40e-4

14.1

AD6

1 (MCI)

8.28e-5

4.9

PD7

1 (PD)

Gene

cDNA alteration

Protein
alteration

Reference
SNP identifier

Sequence
ontology

MAF
(gnomAD)

CADD
Phred

APP
GCH1
LRRK2
NOTCH3
NOTCH3

c.2137G>A
c.671A>G
c.6055G>A
c.544C>T
c.580T>C

p.Ala713Thr
p.Lys224Arg
p.Gly2019Ser
p.Arg182Cys
p.Cys194Arg

rs63750066
rs41298442
rs34637584
rs28933697
rs1568361818

2.88e-5
4.70e-5
2.26e-4
4.70e-5
NA

PSEN1

c.118_120delGAC

p.Asp40del

rs759538127

SNCA

c.150T>G

p.His50Gln

rs201106962

Missense
Missense
Missense
Missense
Missense
In-frame
deletion
Missense
2

(Armstrong, Boada, Rey, Vidal, & Ferrer, 2004; Carter et al., 1992; Pera et al., 2013); (Leuzzi et al., 2002; Saunders-Pullman et al., 2004; Trender-Gerhard et
al., 2009); 3(Di Fonzo et al., 2005; Zabetian et al., 2006); 4(Joutel et al., 2001; Joutel et al., 1997); 5(Kalimo, Ruchoux, Viitanen, & Kalaria, 2002); 6(Nygaard,
Lippa, Mehdi, & Baehring, 2014); 7(Khalaf et al., 2014)
Nonsynonymous rare variants likely contributing to Mendelian forms of neurodegenerative disease were considered variants with a MAF < 0.01 in gnomAD
v.2.1.1 (non-neuro) in a gene known to contribute to Mendelian forms of the disease of patient diagnosis and that was classified as likely pathogenic/pathogenic
in ClinVar, OMIM, and/or the AlzForum mutations database.
Abbreviations: AD, Alzheimer's disease; APP, amyloid precursor protein gene; CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy; CADD Phred, combined annotation dependent depletion Phred; cDNA, coding DNA; COL4A2, collagen type IV alpha 2 chain
protein; CVD, cerebrovascular disease; GCH1, GTP cyclohydrolase 1 gene; LRRK2, leucine rich repeat kinase 2 gene; MAF, minor allele frequency; MCI, mild
cognitive impairment; NA, not applicable; NOTCH3, notch receptor 3 gene; PD, Parkinson’s disease; PSEN1, presenilin 1 gene; SNCA, α-synuclein gene; SNP,
single nucleotide polymorphism.
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4.4.2.

Principal component analysis

Ancestry of the ONDRI cases and cognitively normal control samples was estimated by
projecting their SNP loadings onto a PCA of the 1000G population (Figure 4.2). The
large degree of overlap observed between the ONDRI cases, as well as the cognitively
normal controls, and the European cohort of the 1000G population suggests that the
participants within our study were largely of European descent. To produce a
homogenous genetic dataset, which minimizes any false discoveries due to population
stratification in accordance with standard genomics quality control best practices, we
performed a logistic regression of the ONDRI case and control principal components and
identified the first eight components as significantly contributing to variance in the
samples. Following multidimensional ancestral outlier analysis and outlier removal, the
data consisted of 396 ONDRI cases and 164 cognitively normal controls (Table 4.1).
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Figure 4.2 Ancestry estimate of the ONDRI cases and cognitively normal control cohort using a principal component analysis
(PCA) of data from the 1000 Genomes Project.
Whole genome sequencing VCFs from 1000G were merged and filtered to include SNPs (MAF > 0.005, gnomAD) within the exonic
and splicing regions captured by the ONDRISeq panel. A PCA was run using the SNPRelate Bioconductor R package (LD pruning
threshold = 0.5). SNP loadings from the PCA were used to project the ONDRI cases and controls onto the components to estimate the
participant’s ancestries. Abbreviations: ONDRI, Ontario Neurodegenerative Disease Research Initiative; PC, principal component.
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4.4.3.

Disease association based RVAA

All regression coefficients and standard errors obtained by the multinomial logistic
regression models are summarized in Appendix E. Combined analysis of
neurodegenerative disease cohorts revealed that ONDRI participants were significantly
more likely to carry a putative LOF variant in PD-associated genes in comparison to the
normal controls (OR = 7.322, p = 0.031; Figure 4.3). Interestingly, similar significant
associations were observed within many individual disease cohorts when compared to
controls, including for the AD (OR = 12.307, p = 0.023), ALS (OR = 127.744, p =
0.013), and FTD (OR = 51.832, p = 0.031) cohorts. Although not significant, the
remaining disease cohorts displayed trends towards association in the same manner,
including the CVD (OR = 10.698, p = 0.071), MCI (OR = 6.273, p = 0.053), and PD (OR
= 30.821, p = 0.061) cohorts (Figure 4.3).
In addition, ALS and MCI cases were significantly more likely to carry rare putative LOF
variants in ALS/FTD-associated genes, compared to the control cohort (OR = 33.169, p =
0.045 and OR = 2.905, p = 0.044, respectively; Figure 4.3). The ALS cases were also
more likely to carry rare putative LOF variants in AD- and CVD-associated genes,
although results were not significant (OR = 25.572, p = 0.072 and OR = 57.857, p =
0.074, respectively; Figure 4.3).
No differences in odds of carrying rare missense variants or possibly deleterious missense
variants were observed between the participants in the neurodegenerative disease cohorts
and the controls (Appendix F).
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Figure 4.3 Rare variant association analysis comparing the enrichment of putative
loss-of-function (LOF) rare variants in four disease-associated gene groupings in the
ONDRI cohorts compared to cognitively normal controls.
Multinomial logistic regressions adjusted for age, sex, and disease prevalence were
performed to analyze enrichment of putative LOF variants (including nonsense, stop loss,
frameshift, splice acceptor, and splice donor sequence ontologies) identified in the 80
genes encompassed by the ONDRISeq panel, which were binned into four diseaseassociated gene groupings: AD associated genes, ALS/FTD associated genes, CVD
associated genes, and PD associated genes, across the ONDRI cohorts compared to the
control cohort. Only ancestry matched participants were included in the analyses. The
brglm2 R package was used to fit the regression model and apply a mean bias reduction
accounting for the low variant positive counts. *p-value < 0.05. Abbreviations: AD,
Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CVD, cerebrovascular disease;
FTD, frontotemporal dementia; LOF, loss-of-function; MCI mild cognitive impairment;
ONDRI, Ontario Neurodegenerative Disease Research Initiative; PD, Parkinson’s
disease.

168

4.4.4.

Gene-based RVAA using SKAT-O

Following gene-based RVAA using SKAT-O, 11 genes were identified to be likely
enriched in nonsynonymous rare variants in the ONDRI cohorts compared to the controls
that also had sufficient total rare variant counts for subsequent analysis. Firth logistic
regression, which was used to accommodate for the limitations of SKAT-O, revealed
significant differences in nonsynonymous rare variant enrichment in three genes in the
ONDRI cohorts compared to the controls (Table 4.4), including charged multivesicular
body protein 2B (CHMP2B) across the combined neurodegenerative disease ONDRI
cohort (OR = 0.080, p = 0.0008), neurofilament heavy chain (NEFH) in the CVD cohort
(OR = 0.360, p = 0.036), and PARK2 in the FTD cohort (OR = 11.602, p = 0.023).
Similarly, SKAT-O revealed 6 genes likely enriched in nonsynonymous rare variants in
the individual ONDRI disease cohorts compared to each other that also had sufficient
total rare variant counts for subsequent analysis. Firth logistic regression identified two
genes with a significantly different enrichment of nonsynonymous rare variants in one
cohort when compared to another (Table 4.5), including an enrichment of variants in
Notch receptor 3 (NOTCH3) in the PD cohort compared to the combined AD and MCI
cohort (OR = 2.986, p = 0.009), and an enrichment of variants in NEFH in the combined
AD and MCI cohort compared to the CVD cohort (OR = 0.272, p = 0.011).
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Table 4.4 Gene-based rare variant association analyses using Firth logistic regression comparing rare variant enrichment in
the ONDRI cohorts compared to the control cohort, in genes identified as having differing enrichment by SKAT-O.
Previous disease Odds Lower Upper
Cohort
Gene
P-value
association
ratio
CI
CI
ONDRI
ABCA7
AD
1.630 0.768 3.460
0.204
ONDRI CHMP2B
ALS/FTD
0.080 0.018 0.351
0.0008
AD/MCI ABCA7
AD
2.042 0.862 4.838
0.105
AD/MCI
SETX
ALS/FTD
2.085 0.744 5.843
0.162
CVD
NEFH
ALS/FTD
0.360 0.138 0.936
0.036
CVD
PARK2
PD
3.129 0.397 24.669
0.279
CVD
PINK1
PD
2.278 0.382 13.600
0.366
CVD
SETX
ALS/FTD
0.567 0.213 1.512
0.257
FTD
ALS2
ALS/FTD
3.543 0.708 17.721
0.123
FTD
PARK2
PD
11.602 1.395 96.519
0.023
PD
ABCA7
AD
2.155 0.831 5.590
0.114

Due to limitations of SKAT-O and to account for the effects of age and sex, a Firth logistic regression was performed on each gene identified by SKAT-O to
compare the enrichment of rare variants in the respective ONDRI cohorts in comparison to a cognitively normal control cohort. Only ancestry matched
participants were included in the analyses. Genes that had total rare variant counts <5, or with zero rare variants in one of the cohorts were excluded from
analyses. Statistical analyses were performed using the R statistical software 3.6.0 in R Studio 1.1.463. *p-value < 0.05; **p-value < 0.005; ***p-value < 0.0005.
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CI, confidence interval; CVD, cerebrovascular disease; FTD, frontotemporal
dementia; MCI, mild cognitive impairment; ONDRI, Ontario neurodegenerative disease research initiative; PD, Parkinson’s disease; SKAT-O, the optimal
unified Sequence Kernel Association Test.
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Table 4.5 Gene-based rare variant association analyses using Firth logistic regression comparing rare variant enrichment
between the individual ONDRI cohorts, in genes identified as having differing enrichment by SKAT-O.
Reference Comparison
Previous disease Odds Lower Upper
PGene
Cohort
Cohort
association
ratio
CI
CI
value
AD/MCI
PD
NOTCH3
CVD
2.986 1.310 6.806
0.009
AD/MCI
CVD
NEFH
ALS/FTD
0.272 0.100 0.739
0.011
CVD
FTD
NEFH
ALS/FTD
2.392 0.630 9.092
0.200
PD
CVD
ALS2
ALS/FTD
3.092 0.442 21.630 0.256
PD
FTD
PARK2
PD
2.563 0.592 11.085 0.208

Due to limitations of SKAT-O and to account for the effects of age and sex, a Firth logistic regression was performed on each gene identified by SKAT-O to
compare the enrichment of rare variants between the individual ONDRI disease cohorts. Only ancestry matched participants were included in the analyses. Genes
that had total rare variant counts <5, or with zero rare variants in one of the cohorts were excluded from analyses. Statistical analyses were performed using the R
statistical software 3.6.0 in R Studio 1.1.463. *p-value < 0.05; **p-value < 0.005; ***p-value < 0.0005.
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CI, confidence interval; CVD, cerebrovascular disease; FTD, frontotemporal
dementia; MCI, mild cognitive impairment; ONDRI, Ontario neurodegenerative disease research initiative; PD, Parkinson’s disease; SKAT-O, the optimal
unified Sequence Kernel Association Test.
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4.5.

Discussion

As previously described, a large amount of missing heritability remains across
neurodegenerative diagnoses and little is known regarding the contribution of rare genetic
factors to the heterogenous presentation of these diseases. Due to the established
infrequency of Mendelian forms of neurodegenerative phenotypes (Ghasemi & Brown,
2018; Reed, Bandres-Ciga, Blauwendraat, & Cookson, 2019; Takada, 2015; Van
Cauwenberghe, Van Broeckhoven, & Sleegers, 2016), it was not surprising that few
ONDRI participants harboured monogenic variants likely driving their disease
presentation, including seven carriers of likely monogenic non-synonymous, rare variants
— defined as variants previously reported as pathogenic within relevant mutations
databases and the literature in respect to the participant’s diagnosis — and seven carriers
of the pathogenic C9orf72 repeat expansion. Yet, the low frequency of monogenic
variants observed in our cohorts has highlighted the need to investigate the contribution
of rare variants in genes previously associated with neurodegeneration to the presentation
of the entire spectrum of neurodegenerative and CVD diagnoses utilizing RVAA.
Associations between specific neurodegenerative diagnoses and known
neurodegeneration genes were identified with SKAT-O and subsequent logistic
regression, as well as with disease-association based RVAA. Our principal findings
included associations between: 1) nonsynonymous rare variants in PARK2 and the FTD
cohort; 2) nonsynonymous rare variants in NOTCH3 and the PD cohort; 3) rare, putative
LOF variants in PD-associated genes across the entire ONDRI cohort; and 4) rare,
putative LOF variants in ALS/FTD-associated genes in the ALS and MCI cohorts.
Nonsynonymous rare variants in PARK2 were enriched in the FTD cohort. While PARK2
is well-established to be associated with autosomal recessive familial PD (Abbas et al.,
1999) and potentially with autosomal dominant sporadic PD (Jeon, Kim, Lee, Hattori, &
Mizuno, 2001; Tan et al., 2005), it has not been previously associated with FTD.
However, both PD and FTD are influenced by lysosome dysfunction, which can be
exacerbated by mutated PARK2 (Wallings, Humble, Ward, & Wade-Martins, 2019). The
variants identified in the FTD cohort were all of heterozygous zygosity, and two had been
previously reported as variants of uncertain significance in ClinVar (i.e. p.Arg402Cys
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and p.Pro437Leu). Although the variants may have contributed to the FTD diagnoses in
our cohort, it remains possible that the variants had a moderate phenotypic effect and/or
decreased penetrance. If so, our result may be consistent with some of the heterogeneity
and overlap often seen across neurodegenerative disease presentations, therefore
highlighting the potential impact of unexpected rare variation to features of disease,
which is an area of neurogenetics that must be further explored.
One example of how rare variants may contribute to intermediate phenotypes of
neurodegeneration, rather than a diagnosis itself, is demonstrated for rare variants in
NOTCH3 among participants with PD. Typically, rare variants within NOTCH3 are
associated with a monogenic subtype of CVD called cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).
Leukoencephalopathy associated with CADASIL can be manifested as white matter
hyperintensities seen on T2-weighted MRI scans. We previously observed that PD
participants harbouring rare NOTCH3 variants had double the volume of white matter
hyperintensities than those that did not (Dilliott et al., 2020). Herein, we did not observe
an association between PD and NOTCH3 when compared to the controls, but the history
of CVD in the control cohort was unknown. An association was observed between PD
and NOTCH3 when compared to the combined AD and MCI cohort, which was of
particular interest as ONDRI excluded participants from the AD and MCI cohorts who
had significant evidence of vascular pathology (Sunderland et al., 2020). Therefore, this
result seemingly supports the hypothesis that rare NOTCH3 variation may be contributing
to cerebrovascular features within patients with PD (Dilliott et al., 2020).
The gene-based RVAA also identified CHMP2B as having significantly fewer variants in
the entire ONDRI cohort compared to controls, and NEFH as having significantly fewer
variants in the CVD cohort compared to the controls or the combined AD/MCI cohort.
These results could be interpreted as protection against neurodegenerative diseases and
cerebrovascular phenotypes from rare variants in CHMP2B and NEFH, respectively.
However, the association within CHMP2B was likely driven by a single splicing variant
(c.34+8C>T) harboured by the only three ONDRI participants with rare CHMP2B
variants and five of the eight controls with rare CHMP2B variants. The variant had a
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MAF in ExAC of 2.80E-3 and was previously reported in ClinVar as benign. It is
possible that the variants in CHMP2B and NEFH may have gain-of-function protective
effects, explaining the unexpected signal; however, functional assays are needed for
confirmation. Based on the large amount of influence from single variants in these
potentially protective results, specifically in the case of CHMP2B, and no previously
established protective effects for either gene within the literature, further interpretation
remains unclear.
No ‘expected’ rare variant associations were observed between the individual
neurodegenerative disease cohorts and genes previously associated with the disease
cohorts in the gene-based analysis. For example, there were no associations between rare
variants in APP, PSEN1, or PSEN2 with the combined AD and MCI cohort. Although
this was unsurprising due to the low frequency of monogenic variants we identified in the
ONDRI cohorts (Table 1.2), it suggests there may be other genetic determinants driving
disease presentation and progression. So, to maximize analytic power, we also assessed
rare variant frequency in groups of genes, based on the disease with which the genes have
been most commonly associated. Across all neurodegenerative diagnoses, rare, putative
LOF variants in PD-associated genes were enriched when compared to the control cohort.
Although unsurprising in the PD cohort, this interesting trend was observed in all five
remaining neurodegenerative disease cohorts individually, as well as in the combined
ONDRI cohort.
When we examined the individual genes that contributed to the association, eight of the
13 putative LOF PD-associated variant positive participants (61.5% of variant positive
participants) harboured variants in melanocortin 1 receptor (MC1R). Specifically, the
putative LOF variants in MC1R were identified in the CVD, FTD, MCI, and PD cohorts,
as well as in one control participant. MC1R on chromosome 16 encodes a receptor
typically involved in the regulation of melanin pigment within the skin, but is also
expressed in the periaqueductal gray matter of the brain (Xia, Wikberg, & Chhajlani,
1995). The gene was originally associated with PD in a study by Tell-Marti et al. (TellMarti et al., 2015), in which a common missense variant (p.Arg160Trp) was associated
with the disease in a Spanish population. Previous research has also suggested an
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association between both red hair and melanoma — for which MC1R variants are a risk
factor — and PD (Chen, Feng, Schwarzschild, & Gao, 2017; Liu, Gao, Lu, & Chen,
2011). The MC1R protein was also found to be neuroprotective in dopaminergic neurons,
which are integral to PD pathology. Unfortunately, the association between MC1R and
PD is controversial, with multiple studies unable to replicate the finding (Gan-Or et al.,
2016; Lorenzo-Betancor, Wszolek, & Ross, 2016), and to date, no strong evidence
linking MC1R variation to any other neurodegenerative disease exists.
We also observed a significant enrichment of rare, putative LOF variants in ALS/FTDassociated genes in the ALS and MCI cohorts. No single gene stood out in the analysis
and it is important to recognize that the number of participants in each cohort harbouring
rare putative LOF variants was low, so we are cautious to not draw conclusions from
these results given the small sample sizes. However, it cannot be discounted that the
enrichment signal within the MCI cohort may suggest the participants’ potential to
progress to FTD, rather than AD. Typically, we anticipate that amnestic MCI patients
will progress to an AD phenotype or will not progress at all, yet the possibility remains
that presentation will develop into a variant of FTD and follow up of the MCI
participants in ONDRI remains imperative.
Our study did have limitations that deserve comment. The analysis was largely limited by
modest sample sizes, particularly after accounting for variance resulting from differential
ancestry and batch effects. Combined with the inherent rarity of the variants, the number
of variant-positive participants in each cohort remained small. Yet, the study still
identified interesting signals that are reasonable contenders for replication within larger
cohorts and hypothesis generating for further analyses. Further, apart from basic
demographic information and Montreal Cognitive Assessment scores to define the
control cohort as cognitively normal upon enrollment, no further data were available.
Therefore, it is unclear whether control participants had any history of CVD without
cognitive impairment and analyses may not have been sensitive to signals from the CVDassociated genes on the ONDRISeq panel, as highlighted by the association between
NOTCH3 and PD when compared to the AD/MCI cohort, but not the controls. Our
analyses were also limited to individuals of probable European ancestry and replication in
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other populations is necessary. Finally, our results were restricted to the 80 genes covered
by our custom, targeted NGS panel (S.M.K. Farhan et al., 2016) and identification of
novel genes associated with neurodegenerative disease was not possible. Despite this, we
still identified associations between specific neurodegenerative diagnoses and known
neurodegeneration genes, such as the enrichment of PARK2 variants in FTD.

4.6.

Conclusion

Our analyses allowed us to observe considerable heterogeneity in the genetic contribution
underlying neurodegenerative disease presentation. While we could not conclude that the
rare variants observed were driving diagnoses in all instances, it is reasonable to assume
that some of the variability observed in neurodegenerative disease presentation may be
driven by the rare variants in ‘atypical’ neurodegenerative disease genes. Future analyses
are required to replicate our findings; however, our study demonstrates the potential for
RVAA as an approach to identify genes in which rare variants may have moderate and
somewhat unanticipated phenotypic effects in certain neurodegenerative disease cohorts,
either by directly influencing disease pathology or by potentially contributing to the
overlapping features across neurodegenerative disease. Overall, this may suggest a more
complex genetic architecture of neurodegeneration than the familiar simple monogenic
model of inheritance in which a variant fully explains a clinical phenotype.
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across the neurodegenerative disease spectrum.
The work presented in Chapter 5 has been edited from the original manuscript that is
being prepared for submission for brevity and consistency throughout the entire
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5.1.

Abstract

Background/Objective: Neurodegenerative diseases are a range of conditions affecting
the aging population that are caused by neuronal loss and result in heterogenous
presentations of motor impairment and cognitive and/or behavioural dysfunction.
Although genetic factors are known to contribute to neurodegenerative disease
susceptibility, there remains a large amount of heritability unaccounted for across the
diagnoses. Copy number variants (CNVs) throughout the genome contribute to these
phenotypes, but their presence and influence on disease state remains relatively
understudied. Here, we addressed this gap by leveraging the recent improvements in the
bioinformatics analysis of next-generation sequencing and applying a depth of coverage
approach to detect CNVs in 80 genes previously associated with neurodegenerative
disease within participants of the Ontario Neurodegenerative Disease Research Initiative
(ONDRI).
Methods and Results: In total, we identified and validated four CNVs in the ONDRI
cohort, including: 1) a heterozygous deletion of exon 5 in OPTN in an Alzheimer’s
disease participant; 2) a duplication of exons 1–5 in PARK7 in an amyotrophic lateral
sclerosis participant; 3) a duplication of >3 Mb, which encompassed ABCC6, in a
cerebrovascular disease (CVD) participant; and 4) a duplication of exons 7–11 in
SAMHD1 in a mild cognitive impairment participant. We also identified two duplications
with high confidence in the genes ABCA7 and ATP13A2, each carried by an additional
CVD participant. To our knowledge, all six CNVs were novel with respect to their
association with the disease phenotype of the carrier.
Conclusion: The identification of CNVs across our study of neurodegenerative disease
suggest that a portion of the apparent missing heritability of the phenotypes may be due
to these structural variants, and thus their assessment is imperative for a thorough
understanding of the genetic spectrum of neurodegeneration.
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5.2.

Introduction

Neurodegenerative diseases are a collection of progressive conditions characterized by
neuronal degeneration and protein aggregation within the brain. Although typically
defining behavioural and/or cognitive phenotypes, such as Alzheimer’s disease (AD),
frontotemporal dementia (FTD), and mild cognitive impairment (MCI) or motor
phenotypes, such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD),
the umbrella term may also encompass neurodegenerative phenotypes that result from, or
present alongside, cerebrovascular disease (CVD).
Age is the strongest risk factor for neurodegeneration; however, another important risk
factor encompasses genetic variation that contributes to the diseases. It is known that
genetic factors increase one’s risk of developing neurodegenerative disease considerably,
with relatively high heritability estimates across the various diagnoses (Cacace, Sleegers,
& Van Broeckhoven, 2016; Greaves & Rohrer, 2019; Mejzini et al., 2019). However, our
existing understanding of the genetic contributors to neurodegenerative disease fails to
reach these estimates, leaving a large amount of missing heritability (Cacace et al., 2016;
Hagenaars et al., 2018; Keller et al., 2012; Mejzini et al., 2019).
Copy number variants (CNVs) are large-scale deletions or duplications of DNA of at
least 50 base pairs in length. While CNVs are generally common across the human
genome (Redon et al., 2006), when encompassing genes, these structural variants often
have large phenotypic impacts, including affecting gene expression, organization, and
dosage (Stranger et al., 2007). CNVs have been shown to contribute to neurodegenerative
disease presentation, including in individuals with AD (Cuccaro, De Marco, Cittadella, &
Cavallaro, 2017; Ghani et al., 2012; Hooli et al., 2014); ALS (Morello et al., 2018); and
PD (Nuytemans, Theuns, Cruts, & Van Broeckhoven, 2010). Yet studies identifying
these variants in neurodegenerative disease cohorts are sparse, potentially due to the
previous intricacies of accurately detecting CNVs. It is therefore hypothesized that some
of the missing heritability of neurodegeneration may be accounted for by these largescale variants.
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Recently, the development of new bioinformatics algorithms have made the identification
of CNVs more accessible, with the ability to detect variants using next-generation
sequencing (NGS) and a depth of coverage (DOC) assessment (Iacocca et al., 2017).
Here, we leveraged this approach to identify CNVs across the participants of the Ontario
Neurodegenerative Disease Research Initiative (ONDRI), a multi-cohort study aiming to
characterize a selection of neurodegenerative diseases, including AD, ALS, FTD, MCI,
and PD, as well as CVD and its potential influence on neurodegeneration. Previously, the
ONDRI cohort was genetically sequenced using the ONDRISeq NGS targeted panel,
which covers 80 genes known to contribute to neurodegenerative disease (Dilliott et al.,
2018; S.M.K. Farhan et al., 2016). Following the identification of CNVs using a DOC
approach, we also aimed to validate a subset of CNVs to determine appropriate metrics
by which DOC analysis can define CNVs of high confidence when evaluating
ONDRISeq data.

5.3.
5.3.1.

Methods
Study participants

ONDRI enrolled 520 individuals that passed preliminary screening and were each
clinically diagnosed with one of the following conditions: 1) AD; 2) ALS; 3) CVD; 4)
FTD; 5) MCI; and 6) PD. Research ethics board approval was obtained from each
participating site. Descriptions of the inclusion/exclusion criteria of ONDRI participants
were previously reported (S. M. K. Farhan et al., 2017; Sunderland et al., 2020). All
participants provided informed written consent. Clinical diagnoses and demographic data
were obtained during participant screening and baseline assessment. When possible,
participants provided clinical longitudinal follow-up assessment yearly, for up to three
years (S. M. K. Farhan et al., 2017; Sunderland et al., 2020).

5.3.2.

Next-generation targeted sequencing

Of the 520 enrolled participants, 519 participants had a blood sample collected, from
which genomic DNA was extracted. DNA was also obtained from 189 cognitively
normal elderly controls from the GenADA study (Li et al., 2008).
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All ONDRI participant and control DNA samples were subjected to targeted NGS using
the ONDRISeq neurodegenerative disease gene panel, as previously described (Dilliott et
al., 2018). DNA samples were pooled and paired-end NGS was performed using the
MiSeq Personal Genome Sequencer (Illumina, San Diego, CA, United States) and MiSeq
Reagent Kit v3. Raw sequencing data FASTQ files were imported into CLC Bio
Genomics Workbench v10 (CLC Bio, Aarhus, Denmark) to perform pre-processing and
variant annotation, which produced a variant calling format (VCF) file and binary
alignment map (BAM) file for each participant. Read mapping was performed using the
human reference genome GRCh37/hg19.

5.3.3.

Copy number variant detection

The CNV Caller tool, an application within VarSeq® (v1.4.3; Golden Helix, Bozeman,
MT), was used to detect CNVs from ONDRISeq-generated data. The CNV Caller tool
employs a normalized depth of coverage algorithm, such that an increase in sample
coverage in comparison to a set of reference samples suggests a gain of copy number, and
a decrease in coverage suggests a loss of copy number.
The ONDRISeq browser extensible data (BED) file was imported into VarSeq®, as well
as the VCF and BAM files of the 189 control samples from which the algorithm selected
48 samples to use as a reference set with the lowest percent difference in coverage data
compared to each ONDRI sample. The algorithm excluded control samples in the
reference set if they displayed a >20% difference in coverage compared with the samples
of interest. The matched reference sets also corrected for GC-content bias and accounted
for any regions exhibiting inaccurate mapping. By comparing to the reference set, the
CNV Caller tool was used to identify CNVs across the 519 ONDRI participants. A DOC
ratio and z-score were computed for each target region covered by the NGS panel within
each ONDRI sample. The DOC ratios measured the normalized DOC of the sample of
interest compared to the normalized mean DOC of the reference set, whereas z-scores
measured the number of standard deviations of each target region’s DOC from the
normalized mean DOC of the reference set. In addition to the DOC algorithm, the CNV
Caller tool examined single nucleotide polymorphism (SNP) heterozygosity by
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examining variant allele frequencies across target regions to provide further evidence for
suspected CNVs, as previously described (Iacocca et al., 2017). The CNV Caller tool
assigned each suspected CNV an average DOC ratio, average z-score, and a p-value.
CNVs detected using ONDRISeq data are referred to as “potential CNVs”.

5.3.4.

Deletion confirmation using breakpoint analysis

To verify the presence of a partial optineurin (OPTN) gene deletion, primers were
designed to flank regions surrounding putative deletion breakpoints and used for PCR
amplification of the mutant allele. The Expand 20kbplus PCR system was used for DNA
amplification (Roche, Basel, Switzerland). Forward (F3) and reverse (R1) primers
flanking the deletion junction were: F3 5’-GTGACTCCATCACTCTGAACCTCC and
R1 5’-CGAGTCTTCCTTCACATACGTGCC. Gel electrophoresis of the PCR product
provided a visual confirmation of the mutant allele.
Once deletion breakpoints were identified, confirmation primers (P1:5’TCCCTTGACATTTGCAGTGGAATC, P2: 5’ACTGAGAGAACAGACAAGGTCAAC, P4: 5’GGTCACTTAGGGAACAAGATAGTC) spanning proximal and distal breakpoints were
designed for PCR and Sanger sequencing to verify the deletion breakpoint sequences for
the wild type and mutant alleles. Thirty seconds of extension time for PCR cycles were
used to achieve amplification of the normal allele using primer pair P1 and P2, while
primer pair P1 and P4 amplified the mutant allele. Electropherograms were analyzed
using the Applied Biosystems SeqScape Software version 2.6 (Thermo Fischer Scientific,
Waltham, MA, USA) with the reference sequence obtained from the National Center for
Biotechnology Information (NCBI) GenBank database
(https://www.ncbi.nlm.nih.gov/genbank/).

5.3.5.

Duplication confirmation using whole exome sequencing

To validate the presence of potential CNV duplications detected using the ONDRISeq
data, six samples each with at least one potential duplication were selected for wholeexome sequencing (WES). DNA samples were sent to the McGill University and
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Genome Quebec Innovation Centre (MUGQIC) for WES using the HiSeq 4000
instrument (Illumina) and Roche Nimblegen chemistry (Roche, Basel, Switzerland).
FASTQ files were again imported into CLC Bio Genomics Workbench v10 (CLC Bio) to
perform pre-processing and variant annotation to produce a VCF file and BAM file for
each participant.
VCF and BAM files of the six ONDRI participants and the BED file that defined the
Roche Nimblegen chemistry target regions were imported into VarSeq®, along with VCF
and BAM files from WES of eight reference samples obtained from cognitively normal
individuals diagnosed with atrial fibrillation and sequenced on the same HiSeq 4000 run
at the MUGQIC as the six ONDRI cases. Five reference samples were selected by the
algorithm based on similarity of the normalized coverage to the samples of interest, as
described above. Again, the CNV Caller tool applied a DOC approach and computed a
DOC ratio, z-score, and p-value for each detected CNV.

5.4.
5.4.1.

Results
Study participants and ONDRISeq copy number variant
analysis

Using the VarSeq® CNV Caller tool, at least one potential CNV was detected in 44 of
the total 519 ONDRI participants screened (8.5%). A total of 47 potential CNVs were
detected among the 44 participants, including 37 duplications and ten heterozygous
deletions (Appendix G). The CNVs ranged in size from 150 to 74,407 bp.

5.4.2.

Deletion confirmation using breakpoint analysis

Of the ten potential heterozygous deletions identified, one was chosen for breakpoint
analysis based on our high confidence in the variant call, as determined by the metrics
produced by the CNV Caller algorithm (DOC ratio = 0.487; z-score = -6.851; p = 1.10E12). Specifically, the chosen heterozygous deletion encompassed exon 5 of OPTN.
Sanger sequencing across the CNV breakpoints confirmed the presence of a 4,969 bp
deletion in OPTN that encompassed all of exon five, with proximal and distal breakpoints
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at chr10: 13,152,598 and chr10: 13,157,566, respectively (Figure 5.1). The deletion was
carried by subject 1, who was diagnosed with AD (Table 5.1). The remaining nine
heterozygous deletions did not undergo breakpoint analysis due to lower confidence in
the reliability of the CNV calls, as determined by the CNV’s individual metrics and/or
relatively short span.
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Figure 5.1 Validation of single-exon deletion in OPTN of subject 1 with Alzheimer’s
disease (AD).
(A) Screen capture of ONDRISeq-generated data from subject 1 processed by the
VarSeq® v1.4.3 CNV Caller tool identified a potential heterozygous deletion, as
indicated by a drop in DOC ratio. The bottom section shows the OPTN gene and location
of primers used to confirm and sequence across the breakpoint. (B) Sanger sequencing
results for the deletion junction. Results from a cognitively normal control are presented
on the top, with results from subject 1 on the bottom. Internal sequence missing in the
deleted allele is written in grey. (C) Gel electrophoresis of PCR products across the
deletion breakpoint. The top gel shows amplification products generated using F3 and
R1. The normal sequence distance between primer pair F3 and R1 generated a product
size of 6116 bp; however, PCR amplification of subject 1’s genomic DNA using F3 and
R1 generated a product size of 1147 bp, suggesting a 4969 bp deletion. The bottom gel
contains amplification products generated using primer pairs (i) P1, located in the
proximal side of the suspected breakpoint, and P2, located within the deleted fragment, as
well as (ii) P1 and P4, located on the distal side of the suspected breakpoint. Both the
normal control (N) and proband (P) demonstrate amplification (367 bp) for the proximal
primer pair. Amplification (291 bp) with P1 and P4 is seen in the proband, but not the
normal control. For individuals without the deletion, the span between P1 and P4 would
be too large to amplify under standard conditions; thus, if amplification occurred, it
confirms the presence of a large deletion between the primer pair.
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Table 5.1 Demographics and clinical data of the six ONDRI participants identified to have CNVs of high confidence in the 80
neurodegenerative disease genes covered by the ONDRISeq panel.
Diagnosis
ASO (years)
Sex
MoCA
Other
relevant
clinical
information

Relevant
family
history

Subject 1

Subject 2

Subject 3

Subject 4

Subject 5

Subject 6

AD
73
Male
19

ALS
55
Male
26

CVD
70
Male
29

MCI
57
Female
23

CVD
73
Male
26

CVD
63
Male
30

Exhibited cataracts in
both eyes. No
evidence of motor
impairment reported.

Exhibited slight kinetic
tremor; fasciculation of
the torso, arms, and legs;
brisk deep tendon reflex;
and diffuse denervation of
the lower motor neurons.
No signs of parkinsonism
were reported (H&Y = 0).

Experienced right-sided,
anterior, large-artery
atherosclerosis. Exhibited
coronary artery disease,
hypertension, and high
cholesterol and previously
had undergone coronary
artery bypass graft surgery.

Although symptom
onset was 15 years
ago, the subject has
not progressed to
AD. No history of
significant CVD.

Experienced rightsided, anterior,
small-artery
occlusion. Exhibited
hypertension, atrial
fibrillation, and
diabetes.

N/A

N/A

Both parents and one
sibling exhibited heart
disease.

N/A

N/A

Experienced right sided,
posterior, large-artery
atherosclerosis. Exhibited
hypertension and high
cholesterol. No signs of
parkinsonism were reported
(H&Y = 0) or other motor
symptoms.
Mother experienced
peripheral vascular disease,
father experienced a stroke,
and one half-sibling was
diagnosed with ALS.

Duplication of all exons
Duplication of
Heterozygous
Duplication of the
Duplication of exons
Duplication of exon 16
of ABCC6 as well as 42
exons 7–11 in
deletion of exon 5
latter part of exon
1–5 in PARK7
in ATP13A2
in OPTN
16 in ABCA7
other genesa
SAMHD1
Span (bp)
9,810
8,802
276
707
4,969b
3,233,228c
~chr16:15,185,138–
~chr1:8,021,464–
~chr20:35,539,371– ~chr19:1,047,628
~chr1:17,319,874–
Genomic chr10: 13,152,598–
13,157,566
–1,047,903
region
8,031,273
35,548,172
17,320,580
18,418,365c
Validation
Breakpoint
WES
WES
WES
N/A
N/A
-6.851
DOC ratio
6.816
6.371
5.872
9.287
7.175
0.487
z-score
1.455
1.482
1.474
3.221
1.430
1.10E-12
p-value
0
0
1.70E-21
3.14E-13
2.02E-8
Clinical data was obtained during participant screening and baseline analysis. Span, genomic region, DOC ratio, z-score, and p-value were based on the
ONDRISeq CNV analysis, unless otherwise indicated. aOther genes encompassed by the duplication are outlined in Table 5.2. bThe span presented is based on
the breakpoint analysis of the heterozygous duplication. cThe span and genomic region presented is based on the WES analysis of the duplication.
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; ASO, age of symptom onset; bp, base pairs; chr, chromosome; CNV, copy number
variant; CVD, cerebrovascular disease; DOC, depth of coverage; H&Y, Hoehn and Yahr; MCI, mild cognitive impairment; MoCA, Montreal Cognitive
Assessment; N/A, not applicable; WES, whole exome sequencing.
CNV
Identified
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5.4.3.

Duplication confirmation using whole-exome sequencing

Of the participants harbouring the 37 potential duplications, six were identified as CNVs
of relatively high confidence, as determined by their DOC ratios, z-scores, and p-values.
Following WES of the samples and subsequent analysis with the CNV Caller tool, we
identified and validated three participants as carriers of large-scale duplications (Table
5.1). Subject 2 was diagnosed with ALS and harboured a duplication spanning 9,810 bp
that encompassed the first five exons of parkinsonism associated deglycase (PARK7).
Subject 3 was diagnosed with CVD and harboured a duplication encompassing the
entirety of ATP binding cassette subfamily C member 6 (ABCC6), which was detected
using the ONDRISeq analysis; however, WES revealed the duplication also encompassed
42 other neighbouring genes, including 15 protein-coding genes, 12 pseudogenes, 11
microRNA encoding genes, and 4 non-coding RNA genes (Table 5.2). In total, the
duplication spanned over 3 Mb. Finally, subject 4 was diagnosed with MCI and
harboured a duplication of exons 7–11 of SAM and HD domain containing
deoxynucleoside triphosphate triphosphohydrolase 1 (SAMHD1).
One of the six samples sent for WES exhibited unmappable and incorrectly mapped
reads, failing to pass the quality control standards of the CNV Caller tool algorithm.
Validation of the duplication carried by this individual remains inconclusive.
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Table 5.2 Genes encompassed by the >3 Mb duplication harboured by Subject 3.
Gene type
Genes
MIR1972-1; MIR6511B2; MIR3180-4; MIR6506; MIR484;
MicroRNA
MIR3179-2; MIR3670-2; MIR3180-2; MIR6511A2; MIR6770-2;
encoding genes
MIR6511A3;
Non-coding RNA
LOC100505915; PKD1P6-NPIPP1; PKD1P1; LOC102723692
encoding genes
PDXPC1; NTAN1; RRN3; NPIPA5; MPV17L; C16orf45;
Protein-coding
KIAA0430; NDE1; MYH11; FOPNL; ABCC1; ABCC6;
genes
NOMO3; NPIPA7; XYLT1; NPIPA8
LOC728138; NPIPP1; PKD1P6; RNU6-213P; RPL15P20;
Pseudogenes RPL17P40; PKD1P2; LOC100133127; LOC441750;
LOC100421029; RPL7P47; LOC100133137
Whole-exome sequencing confirmation of a full gene duplication of ABCC6 revealed that the duplication
also encompassed 42 other neighbouring genes.
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5.4.4.

Copy number variants of high confidence

Based on the ONDRISeq analysis average DOC ratios, average z-scores, and p-values of
the CNVs that we were both able and unable to validate, we identified two additional
CNVs of high confidence (Table 5.1). The first duplication encompassed part of exon 16
of ATP binding cassette subfamily A member 7 (ABCA7) and had an average DOC ratio
of 3.221 and average z-score of 9.961. It was found in subject 5, who was diagnosed with
CVD. The second duplication encompassed all of exon 16 of ATPase cation transporting
13A2 (ATP13A2), with a DOC ratio of 1.430 and an average z-score of 7.175, and was
found in subject 6, who was also diagnosed with CVD. Although these CNVs have not be
formally validated, the CNV Caller tool metrics suggest that they are true positives.
Importantly, none of the confirmed CNVs, nor the CNVs of high confidence, were
identified in any of the 189 cognitively normal elderly control samples. The six CNV
carriers did not harbour additional pathogenic single nucleotide variants in the
neurodegenerative disease associated genes encompassed by ONDRISeq relevant to their
diagnoses. Clinical case information of subjects 1–6 can be found in Table 5.1.

5.5.

Discussion

Of the 519 individuals diagnosed with neurodegenerative disease and/or CVD enrolled in
the ONDRI study, we identified 44 individuals (8.5%) with potential CNVs in the 80
neurodegenerative disease associated genes covered by the ONDRISeq panel, of which
six CNVs, each in a different participant (1.2%), were validated or determined to be of
high confidence. Breakpoint analysis confirmed the presence of a heterozygous deletion
in OPTN harboured by an individual with AD, and WES confirmed the presence of
duplications in PARK7, ABCC6, and SAMHD1, in individuals diagnosed with AD, CVD,
and MCI, respectively. We were also able to identify two additional CNVs from the 44
detected that were deemed to be CNVs of high confidence, which were duplications in
ABCA7 and ATP13A2 also in individuals diagnosed with CVD. To our knowledge, all six
CNVs were novel with respect to each carrier’s diagnosis.
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Among the validated CNVs, the heterozygous deletion of exon 5 in OPTN was the only
CNV we confirmed using Sanger-based breakpoint analysis, and it was identified in a
participant with AD. OPTN encodes optineurin, and pathogenic variants in the gene are
associated with both autosomal dominant, adult-onset glaucoma and ALS (Maruyama et
al., 2010; Schilter, Reis, Sorokina, & Semina, 2015). Interestingly, two studies have
reported similar heterozygous deletions of exon 5 of OPTN in Japanese ALS cohorts
(Iida et al., 2012; Maruyama et al., 2010). It has been hypothesized that there may be a
relationship between OPTN, glaucoma, and AD, due to the high rate of co-morbidity
between glaucoma and AD, as well as the observation of optineurin in neurofibrillary tau
tangles — a hallmark of AD pathology (Liu & Tian, 2011). Yet, AD patients with
pathogenic OPTN variants have not been previously observed. Herein, subject 1
exhibited gradual cognitive decline but did not demonstrate ALS-associated motor
symptoms. Although no glaucoma diagnosis was documented and the participant’s
intraocular pressure was within the normal range for both eyes (10–21 mm Hg) at
baseline and upon one-year follow-up, the participant did report vision loss and presented
with cataracts at baseline assessment. It remains unclear whether the observation of the
partial OPTN heterozygous deletion suggests a novel relationship between the gene and
AD, or whether the variant may be contributing to the participant’s ocular phenotypes.
We confirmed the presence of a duplication spanning exons 1–5 of PARK7 in a
participant diagnosed with ALS, although breakpoints could not be determined using
WES. PARK7, otherwise referred to as DJ-1, encodes a conserved protein belonging to
the peptidase C56 family and is thought to help inhibit aggregation of α-synuclein — a
hallmark of PD pathology — as well as protect neurons against oxidative stress and cell
death (Lev, Roncevic, Ickowicz, Melamed, & Offen, 2006). Mutations in PARK7 cause
autosomal recessive early-onset PD (EOPD) (Bonifati et al., 2003). Previously,
duplications of the first five exons of PARK7 have been associated with EOPD (Macedo
et al., 2009), and small-scale variants in the gene have been associated with autosomal
recessive Guamanian ALS/EOPD, which presents with a heterogeneous symptoms
including muscular atrophy, cognitive decline, and tremor or rigidity (Annesi et al., 2005;
Hanagasi et al., 2016). However, no previous associations of PARK7 duplications have
been reported in patients diagnosed with ALS alone. While the participant presented
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herein did report slight tremors at baseline, which progressed to moderate tremors upon
three-year follow-up based on the MDS Unified Parkinson's Disease Rating Scale (MDSUPDRS), they had no further clinical signs of parkinsonism and had a Hoehn and Yahr
score of zero both at baseline and follow-up. Yet the involvement of PARK7 in ALS
cannot be ruled out, as the DJ-1 protein is involved in sensing oxidative stress (Lev et al.,
2006), and PARK7 variants may therefore increase risk of oxidative stress, which is
implicated as a major component in ALS pathologic mechanisms (Barber & Shaw, 2010).
Our study is the first to report a case in which a structural variant affecting PARK7 may
have a role in a non-parkinsonism condition; however, functional analyses are required
for further investigation of this relationship.
Furthermore, a CVD participant presented with a full-gene duplication of ABCC6.
Confirmation of the duplication using WES found the CNV actually spanned over 3 Mb
encompassing 43 total genes. Pathogenic variants within ABCC6, including CNVs, cause
pseudoxanthoma elasticum (PXE), a rare autosomal recessive disorder characterized by
elastic tissue fragmentation and arterial calcification (Bergen et al., 2000; Kringen et al.,
2015; Ringpfeil, Lebwohl, Christiano, & Uitto, 2000). It is not uncommon for PXE
patients to present with cerebral artery calcification, and studies have shown that
ischemic CVD is highly prevalent in patients with PXE (Kauw et al., 2017; Pavlovic et
al., 2005). Here, the participant carrying the ABCC6 duplication exhibited symptoms
characteristic of PXE, including hypertension, atherosclerosis, stroke, mood disorders,
and ocular features such as cataracts. The participant also reported that all immediate
family members had a history of heart disease, albeit segregation analysis of the
duplication was not possible. Although the specific CNV we identified has not been
previously reported, a full gene duplication of ABCC6 was reported in gnomAD (v2.1.1
non-neuro; https://gnomad.broadinstitute.org/) (Karczewski et al., 2020). The duplication
was identified in 18 gnomAD samples (allele frequency = 1.08E-3); however, all
individuals were under the age of 60 years, and it remains unclear whether any of the
individuals presented with features of CVD. To our knowledge, this is the first reporting
of a large-scale duplication involving ABCC6 in an individual with CVD. Although this
CNV spanned 42 other genes (Table 5.2), there is currently no evidence suggesting that
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structural variation of these other genes contributed to the participant’s disease
presentation.
We also identified and validated a duplication of exons 7–11 in SAMHD1 in a subject
with MCI, and identified duplications of high confidence in exon 16 of both ABCA7 and
ATP13A2 in two different participants with CVD. Previous studies have associated large
duplication events in ABCA7 and SAMHD1 with developmental delay and autism (Coe et
al., 2014; Cooper et al., 2011); however, no reports of neurodegenerative symptoms have
been made in patients demonstrating similar CNVs. Additionally, small-scale
duplications within exon 16 of ATP13A2 have been linked to Kufor-Rakeb syndrome, a
juvenile-onset condition characterized by parkinsonism and dementia, although full
duplications of exon 16 have not been previously described (Ramirez et al., 2006).
Subject 6, who harboured the ATP13A2 duplication, was diagnosed with CVD and did
not present with clinical features of PD at baseline, nor upon two-year follow-up. Further
evaluation of these CNVs will be needed to gain a better understanding of their
contribution to neurodegeneration and CVD.
Although we have high confidence in the presence of six CNVs across the ONDRI
participants, we were able to confirm the exact breakpoints of only one, namely the
deletion of exon 5 in OPTN. Identification of CNVs using NGS is limited to only
determine which NGS probes are affected by the structural variant, thereby requiring
further analysis to determine CNV breakpoints. However, breakpoint analysis remains
challenging for duplications, as it is unclear whether the duplicated sequence will appear
in tandem with the original sequence, or will be inserted unpredictably into a distal region
of the genome. Therefore, we were unable to determine the exact location of the
identified duplications and whether they may be interrupting other important genomic
sequences that could contribute to the neurodegenerative phenotypes. Further, 41 CNVs
identified using DOC analysis of ONDRISeq data remain unvalidated with average DOC
ratios, average z-scores, and p-values of unknown confidence. Confirmation of these
CNVs using alternative methods will be required. Despite these limitations, DOC CNV
detection with targeted NGS continues to produce comprehensive, high-quality data,
while remaining more time- and cost-effective than the ‘gold-standard’ Sanger
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sequencing or multiplex ligation-dependent probe amplification (MLPA) approaches
(Iacocca et al., 2017).

5.6.

Conclusion

In summary, we were able to identify potentially pathogenic, novel CNVs with high
confidence in 6 individuals who were diagnosed with neurodegenerative disease or CVD.
Further, we present an additional 41 potential CNVs that will be candidates for future
replication studies. Although functional analyses are still required to determine how the
CNVs may contribute to pathologic mechanisms of disease, the results highlight the need
for further investigation into structural variants and their impact on neurodegenerative
and cerebrovascular phenotypes, as they may account for a portion of the missing
heritability observed across the individual diagnoses. Assessing the full spectrum of
potential variants that can contribute to the disease states is imperative for a complete
understanding of the genetic etiology of these highly prevalent and progressive
conditions, which, in due course, will contribute to more accurate genetic diagnostic
screening and therapeutic targeting.
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6.1.

Abstract

Background/Objective: Pathogenic homozygous variants in GBA are well known to
cause Gaucher’s disease, while heterozygous variants are the most common genetic risk
factor for Parkinson’s disease (PD). However, it is increasingly recognized that some
neurodegenerative diseases may show overlap in terms of both clinical expression and
underlying pathology, suggesting overlap of underlying genetic risk factors. Yet GBA has
not been assessed in cohorts with neurodegeneration other than classic synucleinopathies.
Here, we aimed to assess rare, likely pathogenic GBA variants across the six disease
cohorts encompassed by the Ontario Neurodegenerative Disease Research Initiative
(ONDRI), and determine whether GBA variants were associated with disease
presentation.
Methods and Results: We found that likely pathogenic GBA variants were significantly
enriched in the PD cohort versus other ONDRI disease cohorts. However, we observed a
high frequency of GBA variants across the entire sample, including among participants
with Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal
dementia (FTD), mild cognitive impairment (MCI), and cerebrovascular disease with or
without cognitive impairment (CVD ± CI), compared to previously reported control
cohorts, potentially indicative of underlying Lewy body co-pathologies previously
unrecognized in the ONDRI participants. We also identified novel collections of rare
variants in GBA exons five and six across all ONDRI disease phenotypes. However, GBA
variant status was not associated with clinical phenotypes across the cohorts.
Conclusion: Our findings indicate that diverse neurodegenerative diagnoses may have
common underlying genetic risk factors — in this case, rare GBA variants — which could
help with understanding the pathogenesis of these diseases and possible interventions.
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6.2.

Introduction

The glucosylceramidase beta gene (GBA), located on chromosome 1q21, encodes the
lysosomal enzyme glucocerebrosidase (GCase) that cleaves glucosylceramide within the
cell membrane. Bi-allelic pathogenic GBA mutations cause Gaucher’s disease, an
autosomal recessive disorder characterized by a range of non-neurological and
neurological features, including dementia and parkinsonism. Moreover, mono-allelic or
heterozygous GBA variants are a common risk factor for developing Parkinson’s disease
(PD), with 5–25% of affected individuals carrying a pathogenic GBA variant (Sidransky
et al., 2009). Pathogenic variants in GBA are also enriched in cohorts of patients with
Lewy body disease (Mata et al., 2008; Shiner et al., 2016).
PD is a widely prevalent neurodegenerative disease characterized by both motor
symptoms, such as bradykinesia, resting tremor, postural instability, and rigidity, and
non-motor symptoms, such as cognitive impairment, depression, autonomic dysfunction,
impaired sleep, and hyposmia, although presentation is highly heterogeneous (Poewe et
al., 2017). A signature brain pathology of PD is the presence of Lewy bodies —
intraneuronal inclusions containing aggregates of α-synuclein — the accumulation of
which may lead to neurotoxicity and depending on distribution can contribute to
dementia in PD patients (Burre, Sharma, & Sudhof, 2015; Poewe et al., 2017).
Although exactly how GBA variation contributes to the risk of PD development is
unknown, a few hypotheses are being explored. First, GCase is a lysosomal hydrolase
involved in the endolysosomal pathway, often implicated in PD pathology (Klein &
Mazzulli, 2018), and its substrate, glucocerebroside, can accumulate in dopaminergic
neurons, leading to cellular stress and possible interruption of dopamine production.
Additionally, dysregulated GCase has also been associated with accumulation of αsynuclein (Mazzulli et al., 2011). Compared to patients with idiopathic PD, GBA PD
patients tend to develop onset of clinical symptoms at an earlier age, have a greater motor
decline, and are more likely to present with non-motor symptoms, such as cognitive
impairment (Blauwendraat, Nalls, & Singleton, 2020; Gan-Or, Liong, & Alcalay, 2018).
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GBA is currently considered to be an important target for PD and Lewy body disease
therapeutics, with one small positive open label trial of a GCase pharmacological
chaperone published and several phase 2 clinical trials underway (ClinicalTrials.gov:
NCT02941822; NCT02914366; NCT04588285) (Mullin et al., 2020); yet it remains
unclear whether variants within the gene contribute to other neurodegenerative diagnoses.
Furthermore, the substantial overlap between features of non-PD neurodegenerative
diseases and the frequent co-occurrence of neuropathology — including α-synuclein
(Cairns et al., 2015) — suggests potentially common genetic mechanisms such as GBA.
As GBA has not been systematically studied in neurodegenerative diseases other than
synucleinopathies its involvement in the presentation of various neurodegenerative
diseases is not known (Gan-Or et al., 2018).
To study the association of GBA variants with a range of neurodegenerative phenotypes,
we used Sanger sequencing to identify all likely pathogenic non-synonymous rare
variants in GBA harboured by individuals from the Ontario Neurodegenerative Disease
Research Initiative (ONDRI) affected by: PD, Alzheimer’s disease (AD), amyotrophic
lateral sclerosis (ALS), frontotemporal dementia (FTD), mild cognitive impairment
(MCI), and cerebrovascular disease with or without cognitive impairment (CVD ± CI).
Furthermore, we investigated the relationship between GBA variants and clinical features
in these patient cohorts.

6.3.
6.3.1.

Methods
Study participants

ONDRI enrolled 520 participants with neurodegenerative disease who provided informed
consent, most of whom were in the early stages of disease progression (Farhan et al.,
2017; Sunderland et al., 2020). Of those participants, 519 provided blood samples, from
which genomic DNA was isolated as previously described (Dilliott et al., 2018). Study
ethics approval was obtained from the Research Ethics Boards at all recruitment sites. All
participants provided written, informed consent in accordance with the Research Ethics
Boards and regulatory requirements. Clinical data were obtained upon participant
enrollment including demographics, ages of symptom onset, Montreal Cognitive
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Assessment (MoCA), and Movement Disorder Society-Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS).
Using the MDS-UPDRS, axial scores were calculated to represent motor severity across
the disease cohorts. The score encompassed the summation of subscales, including those
pertaining to difficulties with speech, swallowing, turning over in bed, freezing of gait,
arising from chairs, gait, postural stability, and generalized posture (MDS-UPDRS
subsections: 2.1, 2.3, 2.9, 2.13, 3.9, 3.10, 3.11, 3.12, and 3.13) (Bohnen et al., 2017;
O'Gorman Tuura, Baumann, & Baumann-Vogel, 2018). Although there is no single scale
fully appropriate for this purpose across diagnoses, the MDS-UPDRS was available for
most participants and, aside from freezing of gait, all other metrics encompassed in the
subscales can be observed in the full range of neurodegenerative diseases.

6.3.2.

Sanger sequencing

All exons of GBA were Sanger sequenced in the ONDRI participants. Briefly,
polymerase chain reaction (PCR) amplifications were carried out, yielding three
amplicons that contained: 1) exons 1–4; 2) exons 5–7; and 3) exons 8–11; the most
highly specific of previously published primers were used to provide specificity for
isolating GBA (Mata et al., 2016). Sanger sequencing of each exon of GBA was
performed using previously established primer sets (Mata et al., 2016). All 11 exons of
GBA were sequenced, including 100 base pairs at each intron-exon boundary. Primer
sequences are listed in Appendix H.

6.3.3.

Variant annotation and prioritization

Variants were mapped to their genomic, mRNA, and protein coding positions using the
NG_009783.1, NM_000157.4, and NP_000148.2 reference sequences, respectively
(https://www.ncbi.nlm.nih.gov/gene/). Minor allele frequencies (MAFs) were obtained
using the Genome Aggregation Database (gnomAD; v2.1 non-neuro; N = 114,704)
(Karczewski et al., 2020). In silico predictions of variant deleteriousness were obtained
from Combined Annotation Dependent Depletion Phred scoring (CADD Phred) (Kircher
et al., 2014) and variant pathogenicity was investigated using ClinVar
(https://www.ncbi.nlm.nih.gov/clinvar/).
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All non-synonymous and splicing region variants were prioritized to identify those most
likely to be pathogenic. Variants were first prioritized to include only those that were
rare, with a MAF < 0.01 in gnomAD. Variants were further prioritized to identify those
with at least one of the following: a) a CADD Phred score >15; b) a classification of
likely pathogenic or pathogenic in ClinVar; or c) a sequence ontology of putative loss-offunction (frameshift, splice-site donor, splice-site acceptor, and nonsense variants). All
prioritized variants were referred to as “likely pathogenic variants.” Individuals who did
and did not harbour likely pathogenic variants were referred to as “variant positive” and
“variant negative,” respectively.

6.3.4.

Statistical analyses

To determine whether individuals with the GBA likely pathogenic variants were more
likely to be diagnosed with PD than one of the other ONDRI diseases, we used logistic
regression, adjusted for age and sex.
The contribution of GBA variant status to clinical outcomes was also compared between
variant positive and variant negative participants across the ONDRI cohorts. A
multivariate multiple regression model was used to estimate the influence of GBA variant
status within the disease cohorts, adjusting for age and sex, on age of symptom onset,
total MoCA score, and MDS-UPDRS axial score (Johnson & Wichern, 2001). The
interaction terms between the two predictor variables of interest were included to identify
any disease-specific effects of GBA carrier status. To use the sample mean of all
participants, regardless of cohort, as a point of reference, disease cohorts were
transformed using weighted-effect coding with the wec R package (v0.4-1) (Nieuwenhuis
et al., 2017) as previously described (Dilliott et al., 2021; Te Grotenhuis et al., 2017). A
multivariate regression, assessing the clinical outcomes between variant positive and
variant negative participants in only the PD cohort confirmed results in the singular
disease cohort. Wilks’ lambda assessed predictor contributions across the three clinical
outcomes, where significance indicated that the corresponding predictor contribution was
non-zero for at least one of the three outcomes.
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Significance for the regression analyses was evaluated at an alpha-level of 0.05. All
statistical analyses were performed using the R statistical software 3.6.0 (R Core Team,
2014) in R Studio 1.1.463 and data visualization was performed using GraphPad Prism 9.

6.4.
6.4.1.

Results
Likely pathogenic GBA variants

GBA was successfully sequenced in 515 of the 519 participants (Table 6.1), although
data from at least one exon was missing for 12 of the sequenced participants (Appendix
I). Of the sequenced participants, 195 (38%) harboured at least one of 47 unique GBA
variants. Following variant prioritization, 74 participants were found to harbour at least
one of 18 unique GBA likely pathogenic heterozygous variants (Table 6.2; Figure 6.1).
Eight of the likely pathogenic variants were exclusively found within exons 5 and 6 and
were each identified in a relatively high number of ONDRI participants (n = 4–46),
resulting in ONDRI-wide MAFs ranging from 0.008–0.089, although each variant had an
MAF in gnomAD ≤ 8.17E-05. Therefore, the variants were considered common among
ONDRI participants. Further, 47 participants across all ONDRI cohorts harboured at least
two of these variants together, hereafter referred to as complex variants (Figure 6.1). Of
the seven identified complex variants, one consisted of two rare likely pathogenic
variants (c.681T>G, p.N227K and c.689T>G, p.V230G), which was exclusively present
in 15 PD participants. An additional two complex variants were each identified in a
single PD patient. The remaining four complex variants were found within patients across
the five other ONDRI cohorts, excluding PD (Table 6.3).
Aside from the variants present within exons five and six, the most common variants
found within the ONDRI cohort were c.C1223T, p.T408M and c.A1226G, p.N409S,
which were present in ten and nine participants, respectively (ONDRI-wide MAFs =
0.019 and 0.017, respectively; Table 6.2).
Although GBA likely pathogenic variants were identified in all ONDRI cohorts, logistic
regression confirmed that participants carrying GBA likely pathogenic variants were more
likely to be in the PD cohort compared to the AD, ALS, CVD, FTD, and MCI cohorts
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combined (OR = 1.793 [1.061–3.031], p = 0.0293). However, GBA complex variants
were not found to display the same associations (OR = 1.614 [0.852–3.057], p = 0.1416).
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Table 6.1 Demographics of the 515 ONDRI participants successfully sequenced for GBA and their clinical outcomes.
Participants
Percent
Age
Participants with Age of onset
MoCA
Axial score
[n (%)]
male (%) (mean ± sd)
clinical data (n)
(mean ± sd)ᶧ (mean ± sd)ᶧ (mean ± sd)ᶧ
AD
GBA (+)
4 (9.8%)
100
72.8 ± 4.7
4
68.3 ± 7.2
20.0 ± 2.9
1.75 ± 2.9
GBA (-)
37 (90.2%)
54.1
71.7 ± 8.3
35
67.0 ± 8.6
21.0 ± 2.7
1.31 ± 2.0
ALS
GBA (+)
6 (15.4%)
50
65.8 ± 6.1
4
65.1 ± 4.3
24.5 ± 2.9
3.75 ± 4.9*
GBA (-)
33 (84.6%)
60.6
61.3 ± 9.2
26
59.4 ± 9.5
25.7 ± 2.9
7.73 ± 5.7
CVD ± CI
GBA (+)
15 (9.3%)
73.3
67.5 ± 6.9
15
65.2 ± 8.0
25.5 ± 2.1
1.07 ± 1.8
GBA (-) 146 (90.7%)
67.8
69.4 ± 7.5
145
67.3 ± 8.5
25.2 ± 3.1
1.77 ± 2.5
FTD
GBA (+)
8 (15.7%)
62.5
69.6 ± 5.0
8
65.3 ± 5.7
23.1 ± 3.5
7.12 ± 7.8
GBA (-)
43 (84.3%)
62.8
67.4 ± 7.5
42
62.5 ± 7.7
21.1 ± 4.0
5.57 ± 7.1
MCI
GBA (+)
12 (14.3%)
75
69.9 ± 7.1
10
68.9 ± 6.6
23.4 ± 3.6
1.00 ± 2.2
GBA (-)
72 (85.7%)
50
70.8 ± 8.5
63
67.0 ± 9.5
23.3 ± 2.7
0.86 ± 1.6
PD
GBA (+)
28 (20.1%)
71.4
66.9 ± 6.4
28
61.3 ± 6.6
25.7 ± 2.7
4.89 ± 3.5
GBA (-) 111 (79.9%)
79.3
68.1 ± 6.3
111
61.6 ± 6.7
25.9 ± 2.5
4.45 ± 3.4
Clinical data were not available for all participants. ᶧdenotes clinical variables calculated based on the sample sizes outlined in “Participants with clinical data.”
Axial scores were derived from the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale part three (MDS-UPDRS) with lower scores referring
to less motor impairment. Multivariate multiple linear regression was used to assess the association between GBA variant status and age of symptom onset,
MoCA scores, and axial scores. *p-value < 0.05.
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CVD ± CI, cerebrovascular disease with or without cognitive impairment; FTD,
frontotemporal dementia; GBA, glucosylceramidase beta gene; MCI, mild cognitive impairment; MoCA, Montreal Cognitive Assessment; n, sample size; PD,
Parkinson’s disease; sd, standard deviation.
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Table 6.2 Rare, likely deleterious variants identified within the GBA gene harboured by ONDRI participants.
Protein
Reference
Sequence
MAF
CADD
ClinVar
Variant
Exon
alteration
SNP identifier
ontology
(gnomAD) Phred
(LP/P)
c.115+1G>A
NA
rs104886460
2
Splice Donor 7.42E-05
32.0
GD and PD
c.C475T
p.R159W
rs439898
5
Missense
NA
25.1
GD
c.T667C
p.W223R
rs61748906
6
Missense
9.63E-06
22.0
GD
c.T681G
p.N227K
rs381418
6
Missense
8.17E-05
13.25
GD
c.680_681delinsGG
p.N227R
NA
6
Missense
NA
NA
Phenotype NP
c.T689G
p.V230G
rs381427
6
Missense
1.44E-05
13.40
GD*
c.T703C
p.S235P
rs1064644
6
Missense
9.61E-06
14.61
GD
c.G721A
p.G241R
rs409652
6
Missense
3.84E-05
23.5
GD
c.T754A
p.F252I
rs381737
6
Missense
4.36E-05
22.5
GD and PD*
LBD, PD, and
c.G887A
p.R296Q
rs78973108
7
Missense
4.36E-05
25.90
GD
c.C1073T
p.P358L
NA
8
Missense
NA
26.9
NA
c.C1223T
p.T408M
rs75548401
8
Missense
5.89E-03
22.2
PD*
c.A1226G
p.N409S
rs76763715
9
Missense
1.86E-03
23.8
LBD, PD, GD
c.T1249G
p.W417G
rs1450426641
9
Missense
NA
27.80
NA
Frameshift
c.1265–1319del
p.L422Pfs3X
NA
9
NA
NA
NA
deletion
c.T1448C
p.L483P
rs421016
10
Missense
1.28E-03
23.6
NA
c.G1483C
p.A495P
rs368060
10
Missense
1.44E-04
17.68
NA
c.G1495C
p.V499L
rs369068553
10
Missense
5.77E-05
18.57
GD

Number of
carriers
1
29
4
19
28
46
31
31
32
1
1
10
9
1
1
2
1
1

*Phenotype not explicitly listed as likely pathogenic or pathogenic in ClinVar, but the ClinVar entry includes many publications that indicate potential
pathogenicity of the phenotype. “Phenotype NP” refers to the variant having a ClinVar designation of likely pathogenic or pathogenic, but no definitive
phenotype being specified.
Abbreviations: CADD Phred, Combined annotation dependent depletion Phred score; GBA, glucosylceramidase beta gene; GD, Gaucher’s disease; gnomAD,
Genome Aggregation Database (v2.1 non-neuro); MAF, minor allele frequency; LBD, Lewy body dementia; LP, likely pathogenic; NA, not applicable; NP, not
provided; ONDRI, Ontario Neurodegenerative Disease Research Initiative; PD, Parkinson’s disease; P, pathogenic; SNP, Single nucleotide polymorphism.
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Table 6.3 Complex variants identified within GBA exons five and six harboured by ONDRI participants according to disease
cohort.
Variant carriers in ONDRI
Complex Variant
AD
ALS
CVD ± CI
FTD
MCI
PD
c.681T>G, p.N227K; c.689T>G, p.V230G

0

0

0

0

0

15

c.475C>T, p.R159W; c.680_681delinsGG, p.N227R;
c.689T>G, p.V230G; c.703T>C, p.S235P;
c.721G>A, p.G241R; c.754T>A, p.F252I

1

4

9

4

7

0

c.475C>T, p.R159W; c.680A>G, p.N227S;
c.689T>G, p.V230G; c.703T>C, p.S235P;
c.721G>A, p.G241R; c.754T>A, p.F252I

0

0

0

0

1

0

c.681T>G, p.N227K; c.689T>G, p.V230G;
c.703T>C, p.S235P; c.721G>A, p.G241R;
c.754T>A, p.F252I

0

0

0

0

0

1

c.681T>G, p.N227K; c.689T>G, p.V230G;
c.754T>A, p.F252I

0

0

0

0

0

1

c.681T>G, p.N227K; c.703T>C, p.S235P;
c.721G>A, p.G241R; c.754T>A, p.F252I

0

0

1

0

0

0

c.475C>T, p.R159W; c.667T>C, p.W223R;
c.680_681delinsGG, p.N227R;
c.689T>G, p.V230G; c.703T>C, p.S235P;
c.721G>A, p.G241R; c.754T>A, p.F252I

0

0

1

0

2

0

Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CVD ± CI, cerebrovascular disease with or without cognitive impairment; FTD,
frontotemporal dementia; GBA, glucosylceramidase beta gene; MCI, mild cognitive impairment; ONDRI, Ontario Neurodegenerative Disease Research
Initiative; PD, Parkinson’s disease.

215

Figure 6.1 Schematic of the likely pathogenic variants identified in GBA across 515 ONDRI participants.
GBA variation was assessed using gold-standard Sanger sequencing. Variants were prioritized to identify those that were nonsynonymous, rare (MAF < 0.01, gnomAD v2.1 non-neuro), and displayed at least one of the following: a) a CADD Phred score >15;
b) a classification of likely pathogenic or pathogenic in ClinVar or Franklin; or c) a sequence ontology of putative loss-of-function
(frameshift, splice-site donor, and nonsense variants). Each box in the schematic represents an exon of GBA. “Component of complex
variant” refers to variants that were identified in exons five and six in various combinations with each other in a relatively high
number of ONDRI participants. Figure was made using https://proteinpaint.stjude.org/.

216

6.4.2.

Associations with clinical outcomes

Data for all three clinical outcomes were available for 491 of the ONDRI participants
who had been sequenced for GBA (Table 6.1). The Wilks’ lambda test confirmed that the
contribution of the disease cohort and GBA variant status interaction was significant (Λ =
0.928, p = 0.0021); among participants in the ALS cohort, variant positive status
negatively associated with MDS-UPDRS axial scores (β = -4.670, SE = 1.870, p =
0.0129). There were no further associations between GBA variant status and the clinical
outcomes within the ONDRI cohorts, nor any associations between GBA complex variant
status and the clinical outcomes.

6.5.

Discussion

Here, we evaluated the contribution of GBA genetic variation across a spectrum of
neurodegenerative disease and CVD phenotypes. We found that: 1) GBA-likely
pathogenic variants were associated with diagnosis and enrollment in the PD cohort
compared to the other ONDRI disease cohorts; 2) GBA likely pathogenic variants were
still identified across all ONDRI disease cohorts; 3) there were intriguing clusters of GBA
likely pathogenic variants in exons five and six — referred to as “complex variants” —
across all ONDRI participants; and 4) there was not an obvious relationship between
GBA and clinical phenotypes across the neurodegenerative cohorts.
Of the 18 likely pathogenic variants identified, eight were previously associated with
only Gaucher’s disease, one was previously associated with only PD, and four were
previously associated with both Gaucher’s disease and PD (Table 6.2). Individuals
carrying GBA likely pathogenic variants were more likely to be in the PD cohort of
ONDRI compared to the remaining five ONDRI disease cohorts. Nonetheless, likely
pathogenic variants were identified across all study participants. Thus, the variants may
represent novel genetic associations for neurodegenerative disease.
Although control samples sequenced with the same methodology were unavailable for
these analyses, all variants were considered rare in the gnomAD non-neurological cohort
(MAF < 0.01) and previous reports have suggested that the frequency of heterozygous
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likely pathogenic/pathogenic GBA variants range from 0–4.0% in elderly control cohorts,
dependent on ancestry and spectrum of variants screened (Sato et al., 2005; Sidransky et
al., 2009). By comparison, the cohort with the lowest GBA variant frequency in ONDRI
was the CVD ± CI cohort with a frequency of 9.3%, over double that of the highest
frequency in previously reported controls (Sato et al., 2005; Sidransky et al., 2009),
leaving us to hypothesize that the GBA likely pathogenic variants identified herein are
likely contributing to the spectrum of neurodegenerative diseases.
The markedly high frequency of GBA likely pathogenic variants across all ONDRI
disease cohorts suggests possible undetected pathologic connections between these
disease cohorts. Importantly, when GBA is mutated, decreased function of the encoded
GCase — a lysosomal hydrolase — causes lysosomal dysfunction, a pathway implicated
in the pathologic mechanism of many neurodegenerative diseases (Root, Merino,
Nuckols, Johnson, & Kukar, 2021), and suggests the variants we observed in GBA may
be contributing to disease risk across the neurodegenerative diagnoses. Additionally,
pathogenic GBA variants were previously associated with increased prominence of Lewy
bodies in PD patients, as well as increased risk of Lewy body dementia (Mata et al.,
2008; Nalls et al., 2013). Many cases of co-pathology between various neurodegenerative
diagnoses and Lewy body dementia have been identified — including Lewy bodies and
general α-synuclein aggregation in patients with AD (Cairns et al., 2015; Savica et al.,
2019), ALS (Ayaki et al., 2018; Doherty, Bird, & Leverenz, 2004), and FTD (Forrest et
al., 2019) — which can remain undetected until post-mortem pathologic analysis.
Patients with confirmed AD and Lewy body dementia co-pathology are significantly
more likely to carry GBA mutations than controls (Tsuang et al., 2012). Therefore, while
it remains possible that the GBA variants increase vulnerability to multiple
neurodegenerative diseases through common pathogenic mechanisms such as lysosomal
dysfunction, the variants may also suggest a higher admixture of co-pathology than was
previously appreciated. Post-mortem analyses will be necessary for validation of this
hypothesis.
Of the GBA variants identified, a particularly interesting — and relatively novel —
pattern arose in exons five and six, resulting in seven distinct complex variants identified
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across 47 participants. One of the complex variants was observed in 15 patients with PD,
namely the combination of p.N227K and p.V230G. While the variant p.N227K has
previously only been associated with Gaucher’s disease (Germain, Puech, Caillaud,
Kahn, & Poenaru, 1998; Stone et al., 2000), p.V230G has been associated with Gaucher’s
disease and has also been observed in individuals with PD and with Lewy body dementia
(Du, Ding, Chen, Guo, & Wang, 2018; Mitsui et al., 2009). Whether both variants or only
one are contributing to PD development remains to be determined. Interestingly, both
variants were also observed in combination with other GBA variants in ONDRI
participants in other disease cohorts, as well as in the two other PD participants carrying
complex variants.
Four complex variants were only identified in the AD, ALS, CVD, FTD, and MCI
cohorts. Although the complex variants found among the ONDRI participants have not
been previously reported in the specific combinations identified, similar patterns of
complex variants in exons five and six have been observed on occasion in patients with
both Gaucher’s disease (Sheth et al., 2019) and PD (Mitsui et al., 2009). Yet, the high
frequency and complex patterns of these variants in ONDRI subjects remains novel.
Importantly, a pseudogene located downstream of GBA — glucosylceramidase beta
pseudogene 1 (GBAP) — might affect primer alignment during sequencing, resulting in
false positive variant calls. However, because exons 5 through 7 were amplified together
in a single fragment with highly specific PCR primers, and no complex variants included
likely pathogenic variants in exon 7, despite the exon’s dissimilarity of sequence with
GBAP, we are confident that the results are not due to artefacts related to sequencing of
the pseudogene. The Sanger sequencing method employed was limited in its ability to
discern whether the identified variants within each complex variant were in cis or trans,
although variants in trans — i.e. compound heterozygous variants — might have been
expected to result in Gaucher’s disease. The self-reported ethnicities and family disease
histories of all participants harbouring the complex variants were reviewed and no
distinct patterns stood out. It has previously been proposed that other complex variants
within GBA, particularly within exons 9 and 10, could be the result of small-scale
rearrangements between GBA and GBAP, which may be a potential mechanism
underlying the complex variants we observed herein (Eyal, Wilder, & Horowitz, 1990).
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Ultimately, whether the complex variants indicate a rearrangement and how they may
contribute to the spectrum of neurodegenerative diseases must be further explored.
Although we expected GBA variation might be associated with clinical phenotypes, such
as earlier symptom onset, lower cognitive performance, and increased motor impairment,
no definitive differences were observed between variant positive and variant negative
ONDRI participants. Surprisingly, these results were similarly not observed within the
PD cohort when assessed alone (Blauwendraat et al., 2020; Gan-Or et al., 2018), although
follow up analyses with longitudinal data are necessary to determine whether variant
positive participants will progress through their disease course differently than those
variant negative. The absence of association was potentially a result of our relatively
small sample sizes. The only significant result observed among quantitative intermediate
traits was a lower axial score, corresponding to less motor impairment, in GBA variant
positive participants with ALS compared with variant negative participants. However,
only four ALS participants were variant-positive and standard deviation of the axial score
was relatively large, so we are cautious not to draw conclusions from this result. Further
analysis of the contribution of GBA variation to the clinical spectrum of various
neurodegenerative diseases using larger sample sizes is required.
We recognize that this analysis has a few limitations. Control samples were not available
for the analyses to compare GBA variant enrichment in the ONDRI cohorts to healthy
elderly individuals. Yet all of the GBA likely pathogenic variants reported herein were
rare in the general population and estimates of variant frequencies in other studies’
control samples were readily available (Sato et al., 2005; Sidransky et al., 2009). Further,
the entire GBA gene could not be sequenced in four ONDRI participants, and individual
exons could not be sequenced in 12 additional participants. At least one clinical metric
was missing for 24 participants who were subsequently excluded from the intermediate
phenotype analysis. The majority of missing variables were due to lack of relevant
variables from the MDS-UPDRS Part 3 (95.8% of missing data), and most of the
individuals missing the clinical data were from the AD, MCI, or ALS cohorts (91.7% of
participants missing data). Finally, a subset of likely pathogenic variants has not been
previously associated with PD, or other neurodegenerative diseases, and functional
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analyses are required to validate the variants’ pathogenicity; however, a portion of these
variants has been previously associated with Gaucher’s disease, and the remaining
variants were determined to be putative loss-of-function variants, or have an in silico
prediction indicating they are likely deleterious (CADD Phred score > 15).

6.6.

Conclusion

The analyses presented herein demonstrate that potentially deleterious GBA variation
may be more prevalent among various neurodegenerative conditions than previously
known. Although individuals with GBA likely pathogenic variants were significantly
more likely to be in the PD cohort than the other ONDRI disease cohorts, variant
frequencies in all ONDRI cohorts were remarkably high in contrast to previously
reported elderly control cohorts (Sato et al., 2005; Sidransky et al., 2009). We
hypothesize that this enrichment of GBA variation may indicate underlying Lewy body
co-pathologies previously unrecognized among ONDRI participants or common
pathogenic mechanisms such as lysosomal dysfunction. We also report a relatively high
frequency of complex variants observed in GBA exons 5 and 6 across the
neurodegenerative disease and CVD cohorts, which may indicate small-scale
rearrangements with the GBA pseudogene and warrant further exploration. Our findings
highlight the complexity and overlap of genetic factors contributing to various
neurodegenerative diagnoses.
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7.1.

Abstract

Background/Objective: White matter hyperintensities (WMH) on MRI may influence
clinical presentation in patients with Parkinson’s disease (PD), although their significance
and pathophysiological origins remain unresolved. Studies examining WMH have
identified pathogenic variants in NOTCH3 as an underlying cause of inherited forms of
cerebral small vessel disease.
Methods and Results: We examined NOTCH3 variants, WMH volumes, and clinical
correlates, in 139 PD participants in the Ontario Neurodegenerative Disease Research
Initiative (ONDRI) cohort. We identified 13 PD participants (~9%) with rare (<1% of
general population), non-synonymous NOTCH3 variants. Bayesian linear modelling
demonstrated a doubling of WMH between variant negative and positive participants (3.1
vs. 6.9mL), with large effect sizes for periventricular WMH (d=0.8) and lacunes (d=1.2).
Negative correlations were observed between WMH and global cognition (r=-0.2).
Conclusion: The NOTCH3 rare variants in PD may significantly contribute to increased
WMH burden, which in turn may negatively influence cognition.
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7.2.

Introduction

White matter hyperintensities (WMH), commonly associated with aging and cerebral
small vessel disease (Wardlaw et al., 2013), have been observed on MRI of Parkinson’s
disease (PD) patients (Bohnen & Albin, 2011); however, their exact role in clinical
presentation and disease progression remains controversial. Although some studies
demonstrate WMH to be significantly associated with greater burden of motor
dysfunction, mild cognitive impairment, and progression to dementia (Dunet et al., 2019;
Foo et al., 2016; Kandiah et al., 2013; Slawek et al., 2013; Toda, Iijima, & Kitagawa,
2019), other studies have found no independent association beyond that of normal aging
(Acharya, Bouchard, Emery, & Camicioli, 2007; Hanning et al., 2019; Mak et al., 2015;
Pozorski et al., 2019; Ten Harmsen et al., 2018; Vesely, Antonini, & Rektor, 2016).
Cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy (CADASIL) is a monogenic form of cerebral small vessel disease
with hallmark signs of WMH. CADASIL is caused by heterozygous pathogenic
mutations in the Notch Receptor 3 gene (NOTCH3) located on chromosome 19p13
(Joutel et al., 1996), which encodes a transmembrane receptor in smooth muscle cells and
pericytes (Joutel et al., 2000). The protein’s extracellular domain comprises 34 epidermal
growth factor (EGF)-like repeats that each have six cysteines forming disulphide bonds
integral to Notch3’s tertiary structure and overall function (Sakamoto, Chao, Katsube, &
Yamaguchi, 2005). Traditionally, pathogenic variants for CADASIL were considered
those that occurred in an EGF-like repeat — most commonly, EGF-like repeats 1–6 —
and contributed to the loss or gain of a cysteine residue (Joutel et al., 1997). These
variants disrupt disulphide bridging, leading to protein misfolding, and ultimately Notch3
protein aggregation in smooth muscle cell walls, including within the brain’s vasculature
(Joutel et al., 2010; Opherk et al., 2009). However, NOTCH3 variants pathogenic for
diffuse WMH and the CADASIL phenotype have also been discovered within EGF-like
repeats not affecting cysteine residues (Muino et al., 2017). In addition, variants outside
the 34 EGF-like repeats may contribute to milder cerebrovascular disease (Schmidt et al.,
2011). There is also evidence that some CADASIL patients can present with late-onset,
slowly progressive parkinsonism. In general, these cases are not levodopa responsive,
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have more falls, and display greater levels of cognitive impairment (Ragno et al., 2013).
However, the contribution of NOTCH3 variants to idiopathic PD has not been previously
described.
Here we examine the presence of NOTCH3 variants and WMH volumes, along with their
clinical correlates, in PD participants from the Ontario Neurodegenerative Disease
Research Initiative (ONDRI) cohort.

7.3.
7.3.1.

Methods
Study participants and clinical assessments

Participants were recruited from ONDRI (http://ondri.ca/) (S. M. K. Farhan et al., 2017),
a multi-centre cohort study that included PD participants who met criteria for idiopathic
PD defined by the United Kingdom’s Parkinson’s Disease Society Brain Bank clinical
diagnostic criteria at the time of enrollment (Hughes, Daniel, Kilford, & Lees, 1992).
Participants had a good and sustained response to dopaminergic therapy and had a Hoehn
and Yahr stage 1–3 in the “on” medication state. Study participants gave written
informed consent in accordance with each site’s institutional Research Ethics Board.
Standard clinical and demographic assessments including the Movement Disorder
Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) (Goetz et al., 2008),
the Montreal Cognitive Assessment tool (MoCA) (Nasreddine et al., 2005), hemoglobin
A1C (HbA1C), high- and low-density lipoproteins (HDL/LDL), seated/standing systolic
and diastolic blood pressure (BP), hip/waist ratio, and clinical history of diabetes and
hypertension, were all collected and underwent thorough quality control processes
(Sunderland et al., 2019).

7.3.2.

Genetic analysis

Blood-derived genomic DNA samples were sequenced using ONDRISeq, a customdesigned next-generation sequencing panel that targets 80 genes associated with
Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, PD, and/or
cerebrovascular disease (e.g. NOTCH3). Importantly, the ONDRISeq panel has been
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previously validated (S.M.K. Farhan et al., 2016), and detailed sequencing and quality
control methodology has been described (Dilliott et al., 2018).
Variants identified within NOTCH3 with an allelic depth of at least 10x were prioritized
if they were nonsynonymous in sequence ontology, were of either heterozygous or
homozygous zygosity, and appeared at a minor allele frequency (MAF) of less than 1%
in the Exome Aggregation Consortium database (ExAC) (Lek et al., 2016). Variants were
further prioritized if they displayed evidence of being likely deleterious, either with an in
silico Combined Annotation Dependent Depletion (CADD) Phred score of >20 (top 1%
of deleterious variants in the human genome) or if previously associated with disease by
the Human Gene Mutation Database (HGMD) (Stenson et al., 2014) or ClinVar
(Landrum et al., 2016). Individuals that carried at least one prioritized NOTCH3 variant
are hereafter referred to as NOTCH3 variant positive, whereas those who did not carry a
variant are referred to as NOTCH3 variant negative.
Due to the association between the apolipoprotein E (APOE) E2 allele and increased
WMH volume in individuals with CADASIL (Gesierich et al., 2016), APOE genotypes
were obtained from the ONDRISeq data. A customized ANNOVAR script was used to
extract calls for the APOE variants rs429358(CT):p.Cys130Arg and
rs7412(CT):p.Arg176Cys and map to the respective APOE genotype for each participant,
as previously described (Dilliott et al., 2019).

7.3.3.

Neuroimaging

Harmonized with the Canadian Dementia Imaging Protocol (Duchesne et al., 2019), 3T
MRI was performed at each ONDRI site and included the following sequences: 3D T1weighted (T1), T2-weighted fluid attenuated inversion recovery (FLAIR), and an
interleaved T2-weighted (T2) and proton density. MRI scans were fully evaluated by a
neuroradiologist (S.S.) for incidental findings. MRI-based volumetrics were acquired
using previously published methods, which included quantification of WMH volumes
and an individualized measure of head size obtained from the supra-tentorial intracranial
volume (ST-TIV) (Ramirez et al., 2020; Ramirez et al., 2014).
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7.3.4.

Statistical analysis

Our primary aims were to determine the prevalence of NOTCH3 variants in the ONDRI
PD cohort, and to test the hypothesis that WMH volumes were significantly higher in the
participants with NOTCH3 variants, after controlling for hypertension, diabetes, age, sex
and the presence of the APOE E2 allele (Adib-Samii, Brice, Martin, & Markus, 2010).
Individual differences in head size and the highly skewed distribution of WMH volumes
were adjusted for with a natural log transform and ST-TIV volumes (DeCarli et al., 2005;
Ramirez et al., 2016). To account for conventional risk factors and presence of the APOE
E2 allele (Raz, Yang, Dahle, & Land, 2012), we found significant bivariate associations
with age, male sex, and clinical history of hypertension and diabetes (odds ratios ranging
from 0.72 to 1.41). Based on associations between these variables, we calculated an
aggregate of the presumed risk factors. In order to estimate the magnitude of association
between NOTCH3 variation and WMH volume, we fit a Bayesian linear model (Sturtz,
Ligges, & Gelman, 2005). Graphical diagnostics were examined to ensure successful
convergence of the simulation. Thus, the outcome measure was log-transformed, headsize adjusted total WMH volume. Regressor variables included an aggregate of the risk
factors, an APOE E2 allele indicator variable, and a NOTCH3 variant indicator variable.
An uninformative prior normal distribution (μ = 0, σ = 1,000) was specified for each of
the intercept and regression coefficients and a gamma distribution for residual variance.
Cohen’s d and Cramér's ф (for categorical variables) effect sizes according to NOTCH3
status were estimated for MRI-derived whole brain volumetrics and clinical measures
(HbA1C, HDL/LDL, BP, hip/waist). Across the entire sample, Pearson r correlations
between WMH and tremor, postural instability/gait, and motor phenotype (tremor
dominant vs. postural instability/gait disorder) were also examined (Stebbins et al.,
2013). Statistical analyses were performed using the R package and R2WinBUGS
package (R Core Team, 2014; Sturtz et al., 2005). Data visualization was performed
using RStudio version 1.2.1335 (RStudio, Inc., Boston, MA) and ITKSnap (Yushkevich
et al., 2006).
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7.4.
7.4.1.

Results
Study participants and NOTCH3 variants

ONDRI enrolled 139 PD participants that had blood samples obtained for DNA isolation.
Participant demographics, MRI-derived whole brain volumetrics, clinical measures, and
effect sizes according to NOTCH3 status are compared in Table 7.1.
In total, 13 of the 139 (9%) PD participants harboured rare, non-synonymous, likely
deleterious NOTCH3 variants. Twelve participants each harboured a single variant, and
one participant harboured two variants (c.3704A>T: p.His1235Leu and c.6201dupC:
p.Gly2068Argfs). In total, there were thirteen unique variants, with only one variant
identified in two different individuals (Table 7.2). Eight of the prioritized variants were
previously associated with disease according to HGMD or ClinVar. Importantly, three of
the variants were cysteine modifying — one identified in EGF-like repeat 14 and two
identified in EGF-like repeat 31.
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Table 7.1 Study participant demographics, raw whole brain volumetrics obtained
from MRI, and clinical measures commonly associated with vascular risk.
NOTCH3
NOTCH3
Effect
Variant Negative Variant Positive
Size †
Demographics
N
126
13
-Sex, M/F
99/27
9/4
0.07
Age
67.7 (6.4)
69.4 (6.3)
0.27
Education, years
15.5 (2.7)
15.5 (2.5)
0.02
MoCA
25.7 (2.6)
27.1 (1.9)
0.13
Modified Rankin Score
1.7 (0.7)
1.6 (0.7)
0.53
Whole brain volumetrics
Total Intracranial Capacity, mL
1313.7 (126.1)
1335.1 (139.4)
0.17
White matter, mL
446.0 (61.3)
446.8 (65.0)
0.01
Gray matter, mL
573.6 (47.3)
583.0 (46.8)
0.20
Sulcal cerebrospinal fluid, mL
251.2 (53.1)
257.6 (54.5)
0.12
Ventricular cerebrospinal fluid, mL
38.2 (19.6)
38.2 (17.9)
0.00
Periventricular WMH, mm3
4079.0 (5140.9)
8379.2 (8473.1)
0.78*
Deep WMH, mm3
484.4 (764.3)
657.8 (909.1)
0.22
Lacunes, mm3
82.5 (183.1)
485.0 (947.2)
1.22*
Enlarged PVS, mm3
52.3 (52.9)
59.6 (80.8)
0.13
Clinical measures
TD/PIGD Ratio (MDS-UPDRS)a
1.1 (0.2)
1.1 (0.2)
0.15
Blood glucose: HbA1C, %
5.7 (0.8)
5.7 (0.3)
0.07
Cholesterol, mmol/L
4.6 (1.1)
4.6 (1.1)
0.01
b
Low density lipoprotein, mmol/L
2.6 (0.9)
2.5 (0.8)
0.12
High density lipoprotein, mmol/L
1.4 (0.4)b
1.6 (0.4)
0.45
b
Cholesterol/HDL ratio
3.4 (0.9)
2.9 (0.4)
0.59
BP Systolic (seated)
131.1 (20.0)
136.6 (19.5)
0.28
BP Diastolic (seated)
78.0 (10.6)
78.0 (8.3)
0.01
BP Systolic (standing)
126.1 (20.4)
126.2 (15.3)
0.00
BP Diastolic (standing)
78.3 (11.6)
76.3 (8.3)
0.17
Hip/Waist Ratio
1.8 (3.9)a
2.2 (5.5)
0.04
Note that raw volumes are reported for transparency, statistical analyses were performed on risk adjusted,
head-size adjusted, normalized values.
† Cohen's d for continuous variables, Cramér's ф for the sex variable. Large effect sizes are bold and
highlighted with an asterisk (*).
a
Tremor dominant (TD) vs postural instability/gait difficulty (PIGD) ratio. 34
b
Data available in 125/126 individuals.
Abbreviations: MoCA, Montreal Cognitive Assessment tool; PVS, perivascular spaces; MDS-UPDRS,
Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; HbA1C, hemoglobin A1C; BP,
blood pressure.
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Table 7.2 Prioritized non-synonymous rare variants identified within the NOTCH3 gene carried by 13 individuals with PD.

1

cDNA
Alteration

Protein
Alteration

Reference SNP
Identifier

c.884T>G
c.1490C>T
c.1732C>T
c.1931T>A
c.2978C>T
c.3664T>G
c.3691C>T
c.3704A>T
c.4552C>A
c.5510G>A
c.5854G>A
c.6025C>T

p.Leu295Arg
p.Ser497Leu
p.Arg578Cys
p.Val644Asp
p.Thr993Met
p.Cys1222Gly
p.Arg1231Cys
p.His1235Leu
p.Leu1518Met
p.Arg1837His
p.Val1952Met
p.Arg2009Trp

rs143117018
rs114207045
rs769773673
rs148046938
rs371278091
rs199638166
rs201680145
rs55882518
rs141320511
rs138265894
rs115582213
rs151322770

6
9
11
12
18
22
22
22
25
30
32
33

7
12
14
16
25
31
31
NA
NA
NA
NA
NA

c.6201dupC

p.Gly2068Argfs

NA

33

NA

Exon EGFr

22.9
23.3
30
24.2
26.5
25.6
30
14.8
27.8
35
34
33

Previous
Disease
Association
NA
WML1
CADASIL2,3
WML4
NA
CADASIL5
CADASIL2,5
WML1
WML1
NA
AD modifier6
NA

Participants
Harbouring
Variant
1
1
1
1
1
1
1
1
1
1
2
1

32

NA

1

Sequence
Ontology

MAF
(ExAC)

CADD
Phred

Missense
Missense
Missense
Missense
Missense
Missense
Missense
Missense
Missense
Missense
Missense
Missense
Frameshift
insertion

1.89E-04
5.69E-03
4.12E-05
7.00E-04
8.28E-06
7.41E-05
9.88E-04
3.95E-03
3.17E-03
8.48E-04
8.47E-03
4.12E-05
NA

(Schmidt et al., 2011); 2(Joutel et al., 1997); 3(Yoon et al., 2015); 4(Ungaro et al., 2009); 5(Rutten et al., 2016); 6(Guerreiro et al., 2012).
Abbreviations: AD, Alzheimer’s disease; CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; cDNA,
coding DNA; EGFr, epidermal growth factor-like repeat; ExAC, Exome Aggregation Consortium; MAF, minor allele frequency; NA, not applicable; WML,
white matter lesions. Previous disease associations were defined based on the Human Gene Mutation Database.
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7.4.2.

Associations between NOTCH3 and cerebrovascular burden

Periventricular WMH volumes were greater in the NOTCH3 variant positive group
(8379.2mm3 vs. 4079.0mm3, Cohen’s d = 0.78). Lacunar volumes were also greater in
the NOTCH3 variant positive group (485.0 mm3 vs. 82.6mm3, Cohen’s d = 1.22). The
FLAIR MRI of a NOTCH3 variant positive PD participant with diffuse WMH is shown
in Figure 7.1.
There was an association between the aggregate risk factor and WMH volumes (Figure
7.2). There were two NOTCH3 variant positive participants — one harbouring c.884T>G:
p.Leu295Arg and one harbouring c.1931T>A: p.Val644Asp — with high aggregate risk
factor and relatively low WMH. They might be expected to exert a negative bias on the
estimate of the magnitude of association between NOTCH3 and WMH. In order to
estimate the strength of evidence for a conditional association between NOTCH3 and logadjusted WMH, we calculated Bayes factor using the BayesFactor package in R. The
magnitude of the multiplicative effect of NOTCH3 on WMH volume was about 2.2
(between 1.2 and 3.7, 95% probability). An approximate doubling of total WMH volume
between NOTCH3 variant negative (mean ~3.1 mL) and NOTCH3 variant positive (mean
~6.9 mL) was determined at the midpoint of the aggregate risk factor.
Scatter plots showing log WMH volumes (head size corrected) versus clinical factors for
the entire PD sample are shown in Figure 7.3. There was an inverse correlation between
WMH volume and global cognition (r=-0.19, C.I: -0.32, -0.02), but no other significant
associations were demonstrated.
Upon follow-up, comprehensive clinical assessment resulted in the revision of the original
diagnosis of one NOTCH3 variant negative participant who was subsequently removed
from the study. Re-analysis of the data did not significantly impact the findings: epsilon
changed from 0.8–1.3, to 0.8–1.4; medians and credible regions describing associations
between NOTCH3, risk score, and APOE E2 and head-size adjusted total WMH volume
were unchanged.
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Figure 7.1 Axial view of fluid-attenuated inversion recovery (FLAIR) MRI showing
multiple diffuse WMH (bright) in a NOTCH3 variant positive Parkinson’s disease
participant from the Ontario Neurodegenerative Disease Research Initiative
(ONDRI).
White matter hyperintensities (WMHs) are indicated by the red arrows.
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Figure 7.2 Scatter plot of WMH (head-size adjusted) versus aggregate risk score.
NOTCH3 variant positive participants are indicated in red; non-parametric smoothers
(solid) and additive linear fit (dotted) are superimposed.
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Figure 7.3 Scatter plots showing head-size corrected log WMH volume (x-axis) by
global cognition (A), tremor (B), motor phenotype (tremor dominant vs. postural
instability/gait disorder; C), and postural instability/gait (D).
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7.5.

Discussion

The main finding of this study was that PD participants carrying prioritized NOTCH3
variants had double the WMH volumes compared to NOTCH3 variant negative
participants. These findings were based on data adjusted for head size, age, vascular risk
factors and the presence of the APOE E2 allele. To our knowledge, this is the first report
suggesting that rare NOTCH3 variants may be relevant in the neuropathology associated
with idiopathic PD.
The 13 unique NOTCH3 variants identified have not undergone functional analysis to
confirm pathogenicity. However, using a non-synonymous, rare variant prioritization
strategy, along with pathogenicity predictions based on in silico analysis or previous
association with disease, we aimed to select variants most likely to contribute to disease
presentation. Only one variant had a CADD Phred score below 20 (top 1% of deleterious
variants) and eight of the variants were previously identified in individuals with
CADASIL, WMH or Alzheimer’s disease. Yet, ten of the variants were not cysteinemodifying and six were located outside of the EGF-like repeats, both of which would be
atypical for CADASIL-related variants. Previously, it was hypothesized that these
atypical NOTCH3 variants may contribute to more mild presentations of CADASIL and
cerebrovascular disease (Muino et al., 2017; Ragno et al., 2013; Ungaro et al., 2009).
Rather than contributing to the patients’ PD pathology directly, NOTCH3 variants may
modify disease presentation by influencing WMH burden, but further analysis is
required.
Three individuals carried cysteine-modifying NOTCH3 variants within an EGF-like
repeat that have been previously associated with the CADASIL phenotype (Rutten et al.,
2016; Yoon et al., 2015). These participants were individually analyzed and only one
(carrier of c.3691C>T: p.Arg1231Cys) stood out as having more severe cerebrovascular
burden, consistently appearing in the top 10 worst cases of total, periventricular and deep
WMH, and with a higher burden of lacunes and enlarged perivascular spaces.
Interestingly, the individual with the greatest amount of vascular burden carried a variant
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in EGF-like repeat 25 that is not cysteine-altering (c.2978C>T: p.The993Met) and has not
been previously associated with disease. Further, this individual harboured an APOE
E3/3 genotype. Additional analysis regarding the pathogenicity of this NOTCH3 variant
is needed.
Although the sample size and variability limited our statistical ability to analyze
differences in periventricular/deep WMH, lacunes, and enlarged perivascular spaces
(PVS), the effect sizes shown in Table 7.1 suggest NOTCH3 variant positive participants
had greater burden of periventricular (8.4mL vs. 4.1mL, Cohen’s d = 0.78) but not deep
WMH, and lacunes (485mm3 vs. 82.6mm3, Cohen’s d = 1.22) but not PVS. Apart from
some limited case reports (Mestre et al., 2014), previous studies have not examined
lacunes and PVS burden in PD. Future studies with larger sample sizes are needed to
validate these observations in our study sample.
The inverse correlation between WMH and cognition across the entire sample lends some
support to previous studies that suggest WMH influence the cognitive presentation of PD;
however, in the absence of a control group and long-term follow-up data, our correlations
should be interpreted with caution. A recent cross-sectional analysis of the Dutch
PROPARK cohort (n=163) demonstrated a relationship between visuospatial functioning
and periventricular WMH in PD patients (de Schipper et al., 2019), while a retrospective
analysis of a different Dutch cohort (n=204) found no relationship with self-reported
cognition (Ten Harmsen et al., 2018). Longitudinally, the PPMI study reported that
higher baseline WMH burden was associated with future cognitive decline and cortical
thinning over a four year period (Dadar et al., 2018), while the DeNoPa study reported no
modifying effects on cognitive function with a two year follow-up period (Hanning et al.,
2019). Another smaller study found various relationships with WMH and brain atrophy,
but age-adjustment eliminated the correlations, further emphasizing the well-established
finding that WMH are an age-related phenomenon (Acharya et al., 2007). The
heterogeneity of these reports is further aggravated by the difficulty interpreting findings
from studies using different cognitive assessments tools and approaches to measure
WMH burden (Dunet et al., 2019; Vesely et al., 2016).

240

The main strength of our study was the ability to draw data from ONDRI’s study design.
ONDRI implemented a standardized multi-centre, multi-platform approach which
enabled the volumetric analysis of MRI-based neurovascular biomarkers and genomic
information using validated quantification methods in their respective fields. As
previously mentioned, the main limitations include the limited statistical power, the lack
of a normative sample, and the cross-sectional nature of the study.

7.6.

Conclusion

Here, we present the first report of rare NOTCH3 variants potentially influencing
cerebrovascular sub-phenotypes in individuals with idiopathic PD. As ONDRI’s
longitudinal data becomes available, serial MRI processing and long-term disease
tracking, combined with a more comprehensive analysis of the neuropsychological
profile of our participants, will be possible. The findings reported here should encourage
further studies on the occurrence of NOTCH3 variants in PD and their clinical, imaging
and pathological correlates.
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Chapter 8 – Discussion
8.1.

Overview

Within this Dissertation, I have comprehensively characterized the genetic contributors to
various neurodegenerative diseases, including: 1) Alzheimer’s disease (AD); 2)
amyotrophic lateral sclerosis (ALS); 3) frontotemporal dementia (FTD); 4) mild
cognitive impairment (MCI); and 5) Parkinson’s disease (PD), as well as their genetic
overlap with cerebrovascular disease (CVD). Throughout this work I have contributed a
vast amount of data to the Ontario Neurodegenerative Disease Research Initiative
(ONDRI) and leveraged the data I produced using the ONDRISeq next-generation
sequencing (NGS) targeted gene panel to elucidate the genetic contributors to the
participants’ diagnoses. Specifically, I assessed the contribution of common genotypes
and haplotypes, rare single nucleotide variants (SNVs), and copy number variants
(CNVs) to the various diagnoses and their clinical intermediate phenotypes to gain a
greater understanding of the spectrum of genetic variation that can contribute to disease
presentation.

8.2.

Summary of research findings

Throughout this Dissertation, I have genetically characterized 519 participants from
ONDRI. A summary of the relevant genetic contributors to each ONDRI disease cohort,
as determined by the analyses presented herein are summarized in Figure 8.1.
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Figure 8.1 Summary of the relevant genetic factors carried by participants of the
Ontario Neurodegenerative Disease Research Initiative (ONDRI) that were found to
be associated with the disease cohorts.
In total, genetic characterization was performed on 519 participants enrolled in ONDRI,
including individuals diagnosed with: 1) Alzheimer’s disease (AD); 2) amyotrophic
lateral sclerosis (ALS); 3) frontotemporal dementia (FTD); 4) mild cognitive impairment
(MCI); 5) Parkinson’s disease (PD); and 6) cerebrovascular disease with or without
cognitive impairment (CVD ± CI). To identify contributors to disease presentation, all
participant DNA samples underwent targeted next-generation sequencing using the
ONDRISeq panel, TaqMan genotyping to define MAPT haplotypes, repeat-primed PCR
to identify C9orf72 repeat expansions, and Sanger sequencing to identify variants within
the gene GBA.
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“APOE E4 carrier” refers to individuals harbouring at least one copy of the APOE E4
allele within the AD or MCI cohorts. “C9orf72 expansion” refers to individuals with ALS
or FTD harbouring a pathogenic repeat expansion in C9orf72. “CNV” refers to
individuals harbouring a copy number variant (CNV) of high confidence in a gene
encompassed by the ONDRISeq panel. “Enriched rare variant” refers to individuals
harbouring a variant within a gene or gene set found to be association with the cohort of
interest using rare variant association analysis. “GBA variant” refers to individuals
harbouring a likely pathogenic variant in GBA; GBA variation within all cohorts was
assessed based on the relatively high number of likely pathogenic variants identified
across ONDRI participants and despite the lack of comparison to a control cohort.
“MAPT H1 carrier” refers to individuals diagnosed with FTD harbouring at least one
copy of the H1 MAPT haplotype. “Monogenic rare variants” refers to individuals
harbouring a rare single nucleotide variant known to cause the disease of interest.
“Polygenic” refers to individuals carrying multiple genetic factors likely contributing to
their disease presentation.
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8.2.1.

Common genetic contributors to neurodegenerative
diseases and their intermediate phenotypes

Although it is generally accepted that common genetic variants tend to contribute small
phenotypic effects to disease risk, there are a few prominent examples of these variants
that have moderate-to-large impact on risk of neurodegenerative disease. The most
notable example is the apolipoprotein E (APOE) genotype. The results described in
Chapters 2 and 3 highlight the contribution of common genetic variants to various
neurodegenerative diseases and cerebrovascular disease, as well as to clinical
intermediate phenotypes of the diagnoses (Dilliott et al., 2019; Dilliott et al., 2021).
As described in Chapter 1, Section 1.2.2.1.1, APOE genotype is the strongest genetic risk
factor for the development of AD. There are three possible genotypes — E3, E2, and E4
— corresponding to the wild-type allele, protective allele for AD, and risk allele for AD,
respectively (Bertram, McQueen, Mullin, Blacker, & Tanzi, 2007). Due to its high
importance in the risk of AD, it was imperative that all ONDRI participants were
genotyped for APOE and that we replicated the association between AD and E4 in the
study cohort as a means to validate the AD diagnoses across the patient cohort. Further,
various previous studies have attempted to identify whether APOE variation is associated
with any other neurodegenerative diseases. ONDRI’s concurrent and consistent
assessment of multiple diagnoses offered a unique opportunity to pursue this analysis,
and specifically to determine whether APOE E4 or E2 conferred risk to other
neurodegenerative diagnoses. The results of this analysis were included in Chapter 2.
Within the AD cohort, 65.9% of participants carried at least one copy of the E4 allele.
Unsurprisingly, the allele accounted for the largest percentage of genetic explanation
across any single ONDRI disease cohort (Figure 8.1). When allele frequencies were
compared to a cognitively normal, elderly control cohort, I identified an expected dosedependent association between the APOE E4 allele and AD presentation, such that the E4
allele itself increased odds of AD presentation by 5.24 (p < 1.0E-4) and the E4/4
genotype increased odds of AD presentation by 10.36 (p < 1.0E-4). I also identified an
association between MCI presentation and the E4 allele, with an increased odds of MCI
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presentation by 1.94 (p = 4.9E-3). No other ONDRI cohorts showed any association with
the APOE E4 allele.
I also analyzed the APOE E2 allele, as previous studies had shown a protective effect of
the variant for AD presentation. Indeed, I was able to again replicate this result in the
ONDRI cohort. The allele was associated with a significantly decreased odds of
presenting with either AD or MCI (OR = 0.10, p = 2.7E-2 and OR = 0.26, p = 5.8E-3,
respectively), when compared to the cognitively normal, elderly control cohort.
Interestingly, no AD or MCI participants in the ONDRI study harboured an E2/2
genotype. While the genotype is considered relatively uncommon in the general
population, this observation may also have been due to the incremental decrease in AD or
MCI risk that would result from two copies of the allele.
Although the results of the study were not novel and acted as validation of previous work,
to our knowledge, it was the first study to concurrently analyze APOE genotypes across
such a broad spectrum of neurodegenerative diagnoses and cerebrovascular disease
phenotypes. Further, our results acted as an important validation of the accurate diagnosis
of the ONDRI AD and MCI participants, as the APOE allele frequencies we observed
were relatively similar to those previously reported in the literature (Farrer et al., 1997;
Heffernan, Chidgey, Peng, Masters, & Roberts, 2016). APOE genotypes are also an
important variable for future analyses within ONDRI, as is it often a critical correction
factor due to its associations with AD and intermediate phenotypes of neurodegeneration
and cerebrovascular disease. For example, in the study of the influence of rare Notch
receptor 3 (NOTCH3) genetic variants in PD in Chapter 7, the analysis was corrected for
the presence of the APOE E2 allele. Pathogenic NOTCH3 variants are typically
associated with a monogenic cerebrovascular disease called Cerebral Autosomal
Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL),
and we studied whether variants in the gene could also modify the presentation of PD
patients, specifically by increasing their cerebrovascular disease burden. Importantly,
APOE E2 has been previously associated with increased white matter hyperintensity
(WMH) volume in CADASIL patients; therefore, it was an important correction factor in
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our analysis of PD patients, as well. I anticipate that the APOE genotype data will be a
critical component in ONDRI analyses for years to come.
While we did not observe any novel associations between APOE and the other
neurodegenerative diseases encompassed by ONDRI’s mandate, I also aimed to
determine whether variation in the gene may influence the clinical presentation of
neurodegenerative disease patients. As previously described, there is considerable
overlap among presenting features of various neurodegenerative diseases, such as those
with motor impairments (PD and ALS) presenting with cognitive dysfunction (Kalia &
Lang, 2015; Karch et al., 2018). And even within single neurodegenerative cohorts,
presentations can be highly heterogenous between patients (Beber & Chaves, 2013;
Doran et al., 2007; Selvackadunco et al., 2019). The rigorous assessment of ONDRI
participants, particularly with a detailed neuropsychology battery, offered a unique
opportunity to assess whether APOE E2 or E4 variants contributed to differing
functioning across multiple cognitive domains in the ONDRI cohorts, as presented in
Chapter 3.
Irrespective of disease cohort, I found that E4 carriers had significantly lower
performance in verbal memory and visuospatial domains than those with the E3/3
genotype (p = 9.2E-3 and p = 2.2E-2, respectively). Although the results may be
suggesting that the participants carrying the E4 allele are in a prodromal stage of AD with
increased deposition of early-AD pathology, the influence of APOE E4 on cognition
appears to be irrespective of AD pathology, rather relative to synaptic plasticity or
neurotoxicology. The influence of the E4 allele on verbal memory was also compounded
in the AD cohort, with an interaction observed between the diagnosis and the allele,
although power limitations likely prevented this result from reaching statistical
significance (p = 6.8E-2). In contrast, the E2 allele did not display significant association
with cognition across the ONDRI cohorts, although E2 carriers in the FTD cohort
displayed significantly worse attention/working memory, executive function, and
visuospatial abilities (p = 2.1E-3, p = 4.2E-2, and p = 2.4E-4, respectively). Interestingly,
the majority of the E2 carriers in the FTD cohort were diagnosed with the progressive
supranuclear palsy (PSP) subtype, which presents with a hallmark of tau pathology, as
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well as a relatively high degree of cognitive dysfunction. APOE E2 has been previously
associated with increased tau pathology and so whether the association we observed
between E2 and lower cognition in the FTD cohort was a direct effect or whether it was
indicative of an increase in tau pathology — and resultant PSP — remains unclear.
Nonetheless, my results demonstrate the complex influence of APOE on cognition and
highlight that genetic factors may be contributing to the vast heterogeneity observed
across the presentation of patients with identical diagnoses.
The results presented in Chapter 2 also display the distribution of microtubule-associated
protein tau (MAPT) haplotypes across the ONDRI cohort. MAPT is located within a large
region of linkage disequilibrium (LD), inside of which a 900 kb portion of the genome
has been inverted, resulting in two haplotypes of MAPT, specifically H1 and H2.
Interestingly, I did not identify any associations between the haplotypes and any of the
full ONDRI cohorts in comparison to the cognitively normal, elderly control cohort,
irrespective of previous associations identified between H1 and AD, PD, and FTD
(Ferrari et al., 2017; Myers et al., 2005; Seto-Salvia et al., 2011). However, there was an
association between the H1 haplotype and the presentation of PSP. Again, these results
were not novel, but replicated a previously observed association with the phenotype
(Baker et al., 1999). Within the H1 haplotype, there have also been duplicated regions
identified that define MAPT sub-haplotypes. Due to the small sample sizes of ONDRI,
we chose not to pursue further genotyping to define these sub-haplotypes, as statistical
analyses would have had markedly limited power. Therefore, it remains unknown
whether the lack of associations between MAPT and AD or PD were merely a
consequence of not further defining the common variants under study.
Although the results of Chapter 2 did not identify novel associations between APOE or
MAPT and the neurodegenerative diseases or CVD, the lack of associations were an
important addition to the literature. The associations that I replicated between APOE
variation and AD/MCI and MAPT and PSP acted as a proof of concept for the strength of
the analysis and integrity of the approach and study design; the findings allow us to
confidently rule out any further associations of moderate to large phenotypic impact with
the genes, which have been controversially proposed previously in the literature (Baum et
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al., 2006; Huang, Chen, & Poole, 2004; Myers et al., 2005). Furthermore, Chapter 3
demonstrates the importance in considering known neurodegenerative disease associated
genes, such as APOE, not only when studying disease risk, but also when endeavoring to
account for the large amount of heterogeneity among the clinical features of
neurodegeneration.

8.2.2.

Rare genetic contributors to neurodegenerative diseases
and their intermediate phenotypes

Throughout the literature, it is well documented that rare monogenic variants contribute a
relatively large amount of risk to neurodegenerative diseases; however, across the
spectrum of diagnoses, a large amount of missing heritability remains. Not only is this
missing heritability likely due to rare variants of small to moderate phenotypic effect that
are difficult to identify using traditional linkage analysis or genome-wide association
analysis (GWAS) approaches, but the presence and influence of structural variants
remain relatively understudied in neurodegeneration. Throughout Chapters 3–7, I
assessed the contribution of rare genetic factors to the diseases encompassed by the
ONDRI mandate, particularly to fill the gap of the potential overlapping impact of rare
genetic factors to multiple neurogenerative diagnoses.
I began by assessing the number of ONDRI participants that carried rare, small-scale
variants such as SNVs and repeat expansions that were likely causes for Mendelian forms
of disease. Unsurprisingly, only ~3% of participants harboured either pathogenic SNVs
in a gene covered by the ONDRISeq panel or a pathogenic chromosome 9 open reading
frame 72 (C9orf72) repeat expansion. The ALS cohort had the highest frequency of these
variants, with four participants carrying a pathogenic repeat expansion in C9orf72,
equating to a frequency of 10% across the cohort (Figure 8.1). Although this frequency is
relatively low compared to the 40–60% typically observed in familial cohorts of ALS, it
is relatively similar to the 5–10% frequency estimates of cohorts with sporadic ALS
(Umoh et al., 2016). Within ONDRI, the majority of ALS participants were considered to
be sporadic cases, with only two participants self-reporting a family history of the
disease, one of whom carried the C9orf72 repeat expansion. In fact, the low frequency of
familial cases was observed across all ONDRI cohorts, and many participants presented
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with later-onset, more mild forms of the disease as a result of the strict enrollment criteria
(Sunderland et al., 2020). Therefore, it was expected that the frequency of participants
carrying monogenic rare variants would remain relatively low.
Nonetheless, sporadic forms of neurodegeneration are also known to have a genetic
component, with heritability estimates of up to 80% (Cacace, Sleegers, & Van
Broeckhoven, 2016; Keller et al., 2012; Mejzini et al., 2019), although much of the
genetic risk is largely unexplained. I hypothesized that some of the missing heritability of
these conditions may result from the lack of analysis across neurodegenerative disease
cohorts and consideration of pleiotropic genes. To assess this possibility, I performed rare
variant association analyses (RVAAs) to identify genes, and sets of genes, covered by the
ONDRISeq panel that were enriched for rare variants across the neurodegenerative
diseases and CVD.
Using an individual gene-based RVAA approach, I identified a novel association between
nonsynonymous rare variants in Parkin RBR E3 ubiquitin protein ligase (PARK2) and the
FTD cohort (OR = 11.602 [1.395–96.519], p = 2.3E-2). Typically, pathogenic variants in
PARK2 cause autosomal recessive familial PD; however, variants within the gene
specifically contribute to lysosomal dysfunction — a pathogenic mechanism known to
contribute to both PD and FTD (Wallings, Humble, Ward, & Wade-Martins, 2019).
Therefore, the finding may suggest that the variants are indeed contributing to increased
risk of FTD. An association was also identified between nonsynonymous rare variants in
NOTCH3 and the PD cohort (OR = 2.986 [1.310–6.806], p = 9.0E-3). Homozygous rare
variants in NOTCH3 cause CADASIL, a Mendelian disease characterized by small vessel
damage and dementia; although, there is evidence that some CADASIL patients present
with a late-onset, slowly progressive parkinsonism (Ragno et al., 2013; Ragno et al.,
2016). Together with the RVAA results, this may suggest that NOTCH3 rare variants
increase risk of PD.
To maximize analytic power, I also created gene sets based on the most well-established
previous disease associations of the genes encompassed by the ONDRISeq panel.
Interestingly, an association was observed between rare, putative loss-of-function (LOF)
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variants in PD-associated genes and the entire ONDRI cohort (OR = 7.322 [1.196–
44.826], p = 3.1E-2). The association of putative LOF variants in PD-associated genes
was largely driven by variants in the gene melanocortin 1 receptor (MC1R). While the
gene has been controversially associated with increased risk of PD (Gan-Or et al., 2016;
Lorenzo-Betancor, Wszolek, & Ross, 2016; Tell-Marti et al., 2015), it has also been
associated with red hair and melanoma (Chen, Feng, Schwarzschild, & Gao, 2017).
Although the MC1R protein is neuroprotective within dopaminergic neurons, it remains
unclear how the variants may contribute to pleiotropic risk across neurodegenerative
diseases and CVD. An association was also observed between rare, putative LOF variants
in ALS-associated genes and the ALS and MCI cohorts. The association between the
genes and ALS was anticipated, but the association with MCI remained novel. Caution
was taken so as to not draw inappropriately large conclusions from the results, since
sample sizes of variant positive participants and controls were small. However, it was
still recognized that the association between putative LOF variants in ALS-associated
genes and MCI may suggest potential for a portion of the participants in the MCI cohort
to progress to FTD, rather than the anticipated AD.
The ONDRISeq data was further leveraged to identify large-scale CNVs, such as
deletions and duplications, among the ONDRI participants. Heretofore, these structural
variants have remained under-studied across neurodegenerative disease and CVD cohorts
due to the previous technological challenges involved in their detection. I hypothesized
that some of the missing heritability of the diseases may be accounted for by undetected
CNVs. Recent bioinformatics advances allowed for the utilization of a depth-of-coverage
(DOC) method for CNV detection, which I applied in Chapter 5. Following DOC
analysis of the ONDRISeq data across all ONDRI participants, we applied breakpoint
analysis to confirm the presence of a heterozygous deletion in optineurin (OPTN)
harboured by an individual with AD, as well as WES to confirm the presence of
duplications in parkinsonism associated deglycase (PARK7), ATP binding cassette
subfamily C member 6 (ABCC6), and SAM and HD domain containing deoxynucleoside
triphosphate triphosphohydrolase 1 (SAMHD1), in individuals diagnosed with ALS,
CVD, and MCI, respectively (Figure 8.1). I also identified two additional duplications of
high confidence in ATP binding cassette subfamily A member 7 (ABCA7) and ATPase
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cation transporting 13A2 (ATP13A2) each in an individual with CVD. Although all
CNVs identified were novel, and functional analyses are required to confirm their
pathogenicity, the identification of CNVs in genes previously associated with
neurodegeneration and cerebrovascular disease across the ONDRI cohorts highlights the
need for further analysis of the impact of structural variants to these phenotypes.
The glucosylceramidase beta (GBA) gene could not be adequately evaluated with
traditional NGS techniques applied using the ONDRISeq panel due to a pseudogene
located 16 kb downstream, namely glucosylceramidase beta pseudogene 1 (GBAP).
However, we were able to capture the full coding sequence of the gene by applying a
gold-standard Sanger sequencing approach with carefully designed primers. From the
GBA sequences of all ONDRI participants, variants were identified and prioritized to
identify those most likely to be pathogenic. Unfortunately, controls were unavailable for
this analysis, preventing the ability to perform traditional RVAA. Yet the analysis was
still able to yield novel results, as displayed in Chapter 6. Interestingly, I identified likely
pathogenic, rare GBA variants, not only in the PD cohort, but in all other cohorts of
ONDRI as well (Figure 8.1). In fact, the cohort with the lowest variant frequency —
namely the CVD cohort with a frequency of 9.3% of participants carrying a variant —
still had a frequency that was more than double that of the of the highest frequencies in a
previously reported control cohort (~4%) (Sidransky et al., 2009). Across the ONDRI
cohorts, there were also 47 participants identified that harboured distinctive collections of
variants, referred to as “complex variants,” within exons 5 and 6 of GBA, which may
have resulted from small-scale rearrangements with GBAP. The relatively high frequency
of variants across the ONDRI cohorts may suggest that GBA is indeed contributing to risk
of multiple neurodegenerative diseases. The results may also suggest that GBA variant
carriers within ONDRI not diagnosed with PD have unrecognized α-synuclein copathology, as GBA variants are also known to increase the presence of Lewy bodies, the
main component of which are aggregates of α-synuclein (Mata et al., 2008; Nalls et al.,
2013). In turn, the co-pathology may be influencing the presentation of the individuals,
and therefore may account for some of the heterogeneity between patients observed in the
presentation of neurodegenerative disease and CVD.
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In an effort to determine whether the likely pathogenic GBA variants influenced disease
presentation, I assessed the difference in age of symptom onset, general cognition, and
basic motor phenotype in the variant positive individuals in comparison to those variant
negative, but no conclusions could be drawn from the analysis. Nevertheless, with the
relatively high frequencies of GBA variation observed across the ONDRI cohorts, it will
be important to continue assessing the influence the variants may have on clinical
presentation of the participants. For example, in a similar manner to the analysis of
APOE’s influence on cognition presented in Chapter 3, utilizing the rich
neuropsychology dataset may allow for a more sensitive analysis of how GBA variation
influences cognition across multiple domains. Similarly, the gait performance data may
allow for a more robust analysis of motor phenotypes across the ONDRI cohorts.
As with the differential possible interpretations of the GBA data, the RVAA results from
Chapter 4 may also not be suggesting pleiotropic effects of the genes significantly
enriched for rare variants. Rather, the enrichment of variants in these genes may actually
be a result of rare variants of moderate phenotypic effect that influence overlapping
clinical features of disease between the diagnoses. As previously stated, this is an area of
neurodegenerative disease and CVD research that remains relatively understudied, yet
understanding the factors influencing differential presentation of neurodegeneration and
CVD is imperative for a full appreciation of the genetic factors that influence these
complex phenotypes.
An excellent example of rare genetic variation contributing to different intermediate
phenotypes of neurodegenerative disease was encompassed in the comprehensive
analysis of NOTCH3 in the PD cohort. Upon early analysis of the PD participants’
ONDRISeq NGS data, I observed a relatively high frequency of likely pathogenic rare
variation within the NOTCH3 gene, with 13 participants carrying a nonsynonymous, rare
variant of interest (~9%). As explained previously, heterozygous pathogenic variants in
NOTCH3 are causative for CADASIL, a monogenic form of vascular dementia (VaD).
Therefore, the identification of potentially pathogenic rare variants in the NOTCH3 gene
in PD participants was notable. Further collaboration with the ONDRI imaging platform,
outlined in Chapter 7, resulted in an analysis through which we identified a doubling of
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WMHs volumes in NOTCH3 variant positive participants, compared to variant negative
participants. Additionally, NOTCH3 genetic variation was associated with significantly
increased periventricular WMHs and increased lacune volumes. Although small sample
sizes likely limited the ability to identify differences in generalized cognition or motor
phenotypes and the genetic variants, we hypothesize that the increased WMHs observed
in the PD participants harbouring NOTCH3 variants likely contribute to differential
disease presentation, warranting further analysis.
The association between NOTCH3 and cerebrovascular phenotypes in PD patients was
also supported by the results of the gene-based RVAAs performed in Chapter 4. As
described, NOTCH3 was found to be enriched for rare variants in the PD cohort, albeit in
comparison to the combined AD and MCI cohorts rather than the cognitively normal
control cohort. Importantly, while the control cohort was known to be cognitively
normal, whether they had any form of CVD remained unknown. In contrast, the AD and
MCI cohorts’ enrollment criteria excluded any participants with significant evidence of
vascular pathology (Sunderland et al., 2020), which resulted in the combined cohort
likely acting as a more appropriate control for the detection of enriched variants in a
VaD-associated gene. The result seemingly supports the observations in Chapter 7 and
suggests that rather than contributing to PD pathogenesis, NOTCH3 rare variants may be
altering the presentation of the PD participants carrying the variants.
Similarly, it cannot be denied that the association between PARK2 and FTD observed in
Chapter 4 may actually be a result of variants of moderate phenotypic effect and/or
decreased penetrance influencing intermediate features of disease, rather than directly
contributing to FTD risk. As this possibility demonstrates, the novel genetic associations
I have identified throughout my Dissertation are hypothesis generating and the
comprehensive ONDRI dataset will allow for unique cross-platform assessments to
further elucidate how the genetic variants may be contributing to disease risk and
differential disease presentation. Overall, my work has provided an important tangible
contribution to the elucidation of the entire spectrum of genetic variation contributing to
neurodegenerative disease and CVD phenotypes.
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8.2.3.

Contributions to the goals of ONDRI

Upon its conception, ONDRI set out with goals to identify markers applicable to early
and accurate diagnostic and progression prediction tools for neurodegeneration, as well as
to thoroughly analyze the contribution of cerebral small-vessel pathology to
neurodegenerative phenotypes. The work I have presented throughout this Dissertation
clearly demonstrates progress towards both of these goals. Additionally, my PhD work
has encompassed data generation that will be continue to be made available through the
ONDRI consortium, allowing for continued analysis and, potentially, further discoveries
in the field of neurodegeneration.
The data collected through ONDRI are stored in a secure database, run by the Ontario
Brain Institute (OBI), called Brain-CODE (braincode.ca). The centralized portal was
designed to house the data produced by more than 160 researchers located at over 20
clinical sites across Ontario. Not only has Brain-CODE allowed for effective
collaboration, but all non-identifying data will be made available to the greater scientific
community on request through this portal. Therefore, it was imperative that all data being
produced through ONDRI go through rigorous data cleaning and standards checks prior
to upload to Brain-CODE. Upon completion of my PhD, the work presented herein will
have contributed to four genomic platform datasets — collectively encompassing over
675,000 data points — which contain the APOE genotypes, MAPT haplotypes, C9orf72
repeat expansions, ONDRISeq panel annotated small-scale variants, ONDRISeq panel
CNVs, and GBA small-scale variants. These data will continue to be accessed by ONDRI
researchers for further genomics analyses, as well as by collaborators from across the
globe.
In addition to the data produced through my PhD, this Dissertation also reflects
successful steps towards the goals of ONDRI. In particular, ONDRI was designed with
its unique cross-disease and cross-platform approach, in hopes of breaking down the silos
typically observed in the field of neurodegenerative disease research. While Chapters 2,
4, 5, and 6 demonstrated cross-disease analyses with the study of APOE, rare variant
enrichment, CNVs, and GBA variation, respectively, Chapter 7 demonstrated crossplatform analyses in the study of neuroimaging metrics in reference to NOTCH3
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variation. Most notably, Chapter 3 clearly demonstrates the application of both crossdisease and cross-platform analysis and can act as a proof of concept for the unique study
design of ONDRI moving forward.
Finally, ONDRI aimed to gain a better understanding of the contribution of cerebral small
vessel disease to neurodegenerative phenotypes. Although without functional analyses
the results of the RVAA analysis and NOTCH3 rare variant analysis in PD cannot make
definitive pathologic connection between the NOTCH3 variants and CVD in PD patients,
the results still suggest an important co-pathology for the participants carrying these
variants. Furthermore, the novel findings may now be further explored to better
understand how the increased small vessel disease influences the presentation of
neurodegenerative disease patients with NOTCH3 variants. Therefore, my results
represent the first large step in achieving one of the core goals of ONDRI.

8.3.

Dissertation strengths and limitations

Throughout this Dissertation, study-specific strengths and limitations have been
presented within each relevant data chapter. Here, I will present strengths and limitations
relevant to all data and analyses included in Chapters 2–7 in context to the overall results
of the Dissertation.

8.3.1.

Strengths

A distinct strength of this Dissertation is the unique study design of ONDRI. Upon
conceptualization of the consortium, priority was placed on the interdisciplinary research
model. It was well known that there were many experts in their respective fields studying
neurodegenerative diseases and treating neurodegenerative disease patients, but many
have traditionally remained in their respective silos. Further, the large size of the
province of Ontario posed a challenge to the coordination of collaborative efforts without
detailed protocols in place. ONDRI brought together experts in the field, including both
scientists and clinicians, for a concerted effort to tackle the large amount left to be
understood regarding neurodegenerative and cerebral small vessel diseases. Priority was
placed on recruiting a diverse cohort of participants from throughout the province to
effectively represent the general population, and on deeply phenotyping participants to
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gain an all-encompassing depiction of neurodegenerative disease presentation. Further,
the longitudinal nature of evaluation would allow for investigation into the progression of
individuals diagnosed with these incurable diseases.
Throughout my Dissertation, I leveraged ONDRI’s study design to perform analyses
across the neurodegenerative disease cohorts. Not only was this quite novel in the field of
neurogenetics, but it allowed for the unique opportunity to identify overlapping genetic
risk factors concurrently for all diseases of interest. Many previous studies have only
focused on single disease cohorts, or multiple disease cohorts, but then only applied
GWAS-based methodology, thereby limiting utility (Karch et al., 2018). In contrast, the
work I reported in Chapters 2–6 encompassed five neurodegenerative diagnoses, as well
as cerebrovascular disease, and greatly expanded the range of applied methodologies in
order to gain a deeper understanding of the full spectrum of genetic variants contributing
to these phenotypes. In Chapters 2, 4, 5, and 6, I sought to identify novel gene-disease
associations within known neurodegenerative disease genes. This approach proved
successful based on the novel associations found between PARK2 rare variation and
FTD, NOTCH3 rare variation and PD, and all neurodegenerative diseases and LOF
variants in PD-associated genes. I also identified CNVs in genes that were not typically
associated with the diagnoses of the individuals carrying the large-scale variants, as well
as a large amount of likely pathogenic GBA variation occurring across all ONDRI
cohorts. Additionally, I took advantage of ONDRI’s unique study design by driving
strong collaborative projects with other ONDRI platforms, as displayed in Chapters 3 and
7, which ultimately resulted in the identification of novel associations between APOE and
cognitive impairment (Dilliott et al., 2021), as well as between NOTCH3 and small vessel
disease in PD patients (Dilliott et al., 2020).
Another strength of this Dissertation was the use of the ONDRISeq NGS targeted gene
panel. The custom-designed panel allowed for the sequencing of 80 genes previously
associated with the neurodegenerative and cerebral small vessel diseases encompassed by
ONDRI’s mandate. From these data, we accurately extracted the genotyping data
necessary to map APOE genotypes, identify rare variants of various pathogenicity, and
capture large-scale CNVs. Upon validation of the ONDRISeq panel, its strengths were
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highlighted, as we observed that variant calls using the NGS method were more reliable
than those obtained from the NeuroX microarray, as confirmed using Sanger sequencing
(S.M.K. Farhan et al., 2016). Furthermore, although NeuroX captured >250,000 SNVs
exome-wide (Nalls et al., 2015), ONDRISeq allowed for the identification of novel
variants, which may be contributing to disease presentation, as well as the subsequent
gene-based binning and RVAAs. During the conceptualization of ONDRI, wholegenome sequencing (WGS) and whole-exome sequencing (WES) methodologies were
also explored; however, the costs remained prohibitive, and the computational power
necessary for data processing posed a challenge at the time. In contrast, ONDRISeq
offered a targeted approach to further explore genes known to contribute to
neurodegenerative and cerebrovascular phenotypes in diseases not typically associated
with the genes. Combined with the cross-cohort strengths of the ONDRI design,
ONDRISeq allowed for analyses to detect genes that may have pleiotropic effects across
diseases or may contribute to overlapping disease features, without the noise and added
statistical power reduction that would be introduced by unrelated genetic loci captured by
WGS or WES.

8.3.2.

Limitations

Expectedly, this Dissertation is not without its limitations that must be considered when
interpreting the results and conclusions presented. The most fundamental limitation is the
relatively modest sample sizes of the ONDRI cohort. Upon study conception, ONDRI
aimed to recruit 600 participants evenly distributed across the six disease cohorts (S. M.
K. Farhan et al., 2017). However, neurodegenerative disease studies often experience
difficulties in patient recruitment, particularly when a large degree of engagement is
expected from the enrolled individuals. Due to the deep phenotyping performed on each
participant, and the longitudinal nature of the follow up, enrolling in ONDRI proved to be
a substantial commitment on the part of the participants and their essential study partners.
Obtaining the intended cohort proved difficult. Further, ONDRI had strict enrollment
criteria that each participant was required to meet, including successfully completing an
analysis by magnetic resonance imaging (MRI), which proved to be burdensome for
many participants, particularly those with cognitive and/or behavioural phenotypes that

264

were relatively advanced. Even so, attaining the intended 600 participants would still
have left a relatively small sample for subsequent genetic analyses. Typically, genetic
analyses require larger sample sizes in order to provide enough statistical power to
identify novel genetic associations, especially when studying rare variants. To mitigate
this limitation, I prioritized the RVAAs to bin variants into larger groups to maximize
power. Yet, in some instances, lack of significant results may have occurred due to
ONDRI’s small sample sizes. Additionally, the available sample sizes limited in the
ability to further sub-classify participants in an attempt to gain a clearer understanding of
potential neurodegenerative disease sub-phenotypes. A clear example of this is evident in
Chapter 3, in which I was unable to further elucidate whether the contribution of APOE
E2 to cognitive dysfunction in FTD was a result of the PSP sub-phenotype, which
represented an exceedingly small subgroup (Dilliott et al., 2021). Nonetheless, the work
presented throughout this Dissertation offers a proof of concept for the overall strategy
and analytic approaches, which can be applied to larger sample sizes in the future.
Additionally, the demanding recruitment model of ONDRI, and the existing ethnic
distribution of elderly Ontarians in the general population, resulted in inherent biases
within our total cohort. Most notably, the ONDRI cohort displayed a large bias to
individuals of European descent, as displayed in Chapter 4. This resulted in the inability
to assess genetic factors likely contributing to the phenotypes of interest in individuals of
diverse ancestral backgrounds, which remains a long-standing concern in the field of
genomics (Sirugo, Williams, & Tishkoff, 2019). Further, the demands of being involved
in our study introduced biases towards individuals with milder disease presentation, as
well as towards individuals with attainment of greater education levels and of higher
socioeconomic status (Sunderland et al., 2020). Finally, our cohort displayed an apparent
male bias, which we have hypothesized may have been a result of the need for a study
partner — a role that, according to anecdotal evidence, females in a heterosexual
domestic partnership with the participant were most willing to serve.
Select analyses presented throughout this Dissertation were also limited by the available
control cohort. Unfortunately, ONDRI did not include an internal control cohort in its
study design; however, the genomics platform sought out control samples for the
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purposes of our analyses. We obtained 189 control samples from cognitively normal,
elderly individuals recruited by the GenADA study (Li et al., 2008). We subsequently
sequenced the samples using ONDRISeq, and genotyped the samples using the NeuroX
array and TaqMan allelic discrimination assays to validate the APOE genotypes and
obtain the MAPT haplotypes. But due to financial constraints, we were unable to perform
Sanger sequencing of GBA on the control samples, resulting in no control cohort for the
study presented in Chapter 6. Furthermore, the control cohort samples from the GenADA
study had limited phenotypic data, only comprised of age, sex, and Montreal Cognitive
Assessment (MoCA) score. Therefore, I was unable to use the controls for cross-platform
ONDRI analyses, including those presented in Chapters 3 and 7. It also remained
unknown whether the control cohort had underlying neurodegenerative pathology, yet
remained asymptomatic, as neuropathology can appear many years prior to
neurodegenerative symptom onset (Katsuno, Sahashi, Iguchi, & Hashizume, 2018).
Finally, the lack of phenotypic data on the controls resulted in uncertainty regarding how
appropriate the cohort was for analyses of cerebral small vessel disease and its associated
genes. While the controls were considered cognitively normal, it was not known whether
any had experienced CVD. An example of how this may have impacted analyses is
demonstrated in the RVAA results presented in Chapter 4, in which an association
between NOTCH3 rare variation and PD was observed when compared to the combined
AD and MCI cohorts, but not when compared to the control cohort.
Some variables also remained unknown among the ONDRI participants, such as their
underlying neuropathology. Until neuropathological analyses can be performed on our
participants — either through post-mortem analysis or potentially through emerging
methods of plasma biomarker assessment (Shen et al., 2020) — diagnoses remain
presumptive. As described in Chapter 1, Section 1.2.4, although clinical diagnoses are
possible, the rates of misdiagnoses remain relatively high. ONDRI attempted to mitigate
these issues with strategies such as excluding participants from the AD and MCI cohorts
who had displayed significant amount of cerebral small vessel disease, but it remains
unclear whether those participants indeed had AD or MCI, or whether they were
experiencing a form of VaD. During enrollment, there were also instances of patient
enrollment that may not have fully complied with inclusion criteria — for example, some
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participants were enrolled in the PD cohort with large stroke volumes and others with
staging below the inclusionary cut-off. Additionally, some individuals enrolled in the
original vascular cognitive impairment (VCI) cohort were subsequently found not to have
objective cognitive impairment upon completion of the neuropsychology battery, and this
resulted in the cohort being reclassified as CVD ± CI. If ONDRI did contain
misdiagnosed participants, it may have introduced noise into the genetic analyses and
prevented true associations from being detected, particularly when combined with the
reduced statistical power as a consequence of ONDRI’s small sample sizes.
It is also important to recognize the limitations of the ONDRISeq panel; although, it was
considered a strength of the studies presented herein as described in Section 8.2.1.
ONDRISeq was designed by an expert panel of scientists and clinicians in 2012–2013,
and, at the time, it was considered to include all relevant genes known or thought to
contribute to neurodegenerative disease and VaD phenotypes. However, in the near
decade since these design decisions were made, the panel is now recognized to be
missing more recently discovered genes of importance, including those identified through
GWAS, such as ADAM metallopeptidase domain 10 (ADAM10) and angiotensin I
converting enzyme (ACE) that are associated with AD (Kunkle et al., 2019), and those
identified through RVAA, such as DnaJ heat shock protein family (Hsp40) member C7
(DNAJC7) that is associated with ALS (S. M. K. Farhan et al., 2019). Additionally,
targeted gene panels are by design limited to evaluate only specific regions of the
genome, which impairs the ability to discover novel loci that have previously not been
associated with the diseases under study. The ONDRISeq panel also did not include
probes covering intronic or intergenic SNPs, previously associated with
neurodegenerative disease or CVD through GWAS analysis, thereby limiting the ability
to assess the contributions of common variation of small to moderate phenotypic effect to
the diseases encompassed by ONDRI’s mandate. The inclusion of associated SNPs on the
ONDRISeq panel may have allowed for the design of novel, or the assessment of
previously designed, polygenic risk scores (PRSs) within the ONDRI cohorts.
Finally, two important caveats must be considered when interpreting the results of the
studies presented throughout this Dissertation. The first caveat is that the analyses were
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only comprised of a discovery cohort, and results were not replicated. Replication cohorts
are particularly important in genomics studies to account for the possibility of spurious
associations resulting from random chance or not controlling for variables of importance
(Kraft, Zeggini, & Ioannidis, 2009). However, as previously described, recruitment of
neurodegenerative disease patients for large-scale studies remains a challenge, and by
introducing our results into the literature without internal replication, we offer the
opportunity for other research groups to replicate our findings in their own study cohorts.
The second caveat is that the novel genetic associations presented throughout the
Dissertation have not yet been validated with functional analyses to verify the genedisease associations and identify the pathologic mechanisms involved. Although
considered beyond the scope of my PhD work, these follow-up studies will be imperative
to validate the results. For example, it will be important to further explore the relationship
between NOTCH3, CVD, and PD to determine whether the NOTCH3 variants are only
modifying disease presentation, or whether they are directly contributing to the PD
phenotype through a vascular mechanism.

8.4.

Applications and future directions

The work I have presented contributes to the elucidation of the genetic determinants of
neurodegenerative diseases and CVD, including identifying genetic risk factors for
disease presentation and investigating how genetic factors may influence the
heterogeneous features of neurodegeneration. The knowledge I have generated can be
combined with the existing literature to direct further neurogenetic studies and can be
applied towards clinical applications to improve the diagnosis, progression prediction,
and treatment of patients.

8.4.1.

Genomics-based diagnostic tools

As we continue to gain a better understanding of the genetic factors that contribute to
neurodegenerative phenotypes, we may be able to begin addressing some pervasive
issues in neurodegenerative diagnostics. Unfortunately, many neurodegenerative
diagnostic processes remain relatively slow, allowing the often quickly developing
disease states to further progress prior to being able to intervene with the few therapeutics
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available to slow disease progression (Hulisz, 2018; Katsuno et al., 2018). As
therapeutics currently available cannot completely prevent disease progression or reverse
damage, it is imperative that treatments are initiated as soon as possible to preserve
patient’s function. Further, misdiagnosis is relatively common due to the large amount of
phenotypic overlap between neurodegenerative diagnoses (Beber & Chaves, 2013; Doran
et al., 2007). Definitive diagnoses currently require post-mortem neuropathologic
analysis; however, genomics could also offer an avenue of definitive diagnoses as we
continue to expand our understanding of genetic risk of disease.
Currently, genetic sequencing is suggested in the diagnostic pathways of some earlyonset familial cases of neurodegenerative disease, yet even individuals with seemingly
sporadic forms of disease may harbour underlying genetic variation driving their disease
presentation (Bennion Callister & Pickering-Brown, 2014; Maraganore et al., 2006;
Mejzini et al., 2019; Sidransky et al., 2009). Therefore, it may be beneficial to expand
genetic analysis to a greater number of neurodegenerative disease cases. It is also
imperative that a wide range of genetic variant types are considered, particularly
structural variation, which was identified as being of potential importance in Chapter 5,
yet can be overlooked in clinical genetic diagnostics.

8.4.2.

Influence of genetic variation on neurodegenerative disease
progression

Gaining a greater understanding of the genetic spectrum of neurodegeneration and CVD
may also allow for more accurate progression prediction. Currently, it remains unclear
how individuals may progress through their disease upon diagnoses, as features of
disease can vary widely from patient to patient. However, as the results of Chapter 7
displayed, genetics may provide a lens through which progression could be predicted,
although my analyses only found that genetic variation contributes to features of disease
presentation at a single point in time. ONDRI includes a longitudinal nature of
assessment, following participants for up to three years. It will be important for further
analyses to prioritize the use of the longitudinal ONDRI data to study how genetic
variants may influence disease progression, including the degree to which individuals
may progress and at what rate.
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It will also be interesting to investigate whether certain genetic variants increase the risk
of relatively atypical presentation, such as the co-occurrence of cognitive and/or
behavioral impairments in individuals diagnosed with a form of motor impairment. In
this manner, in combination with genetic diagnostic tools, progression predications tools
may be developed, such that an individual’s entire genetic profile can not only offer an
accurate diagnosis, but can predict the clinical features a patient might experience, as
well as how quickly those phenotypes may develop. Ultimately, in the study of such
complex diseases, this will be an important component for future personalized medicine
efforts.

8.4.3.

Identification of novel gene-disease relationships

Although novel gene-disease associations were identified using RVAA in Chapter 4, it is
recognized that these associations remain to be replicated, which may be possible through
collaborative efforts with other consortia, such as the Parkinson’s Progression Marker
Initiative (PPMI), and validated using functional studies. My analysis, as well as previous
studies, focused on gene-wide approaches to prevent analytic biases in the RVAAs;
however, it is important to consider that variant frequencies can vary within genes and
variant enrichment may be localized to functional domains in the encoded protein
(Richardson et al., 2016). Therefore, it may be beneficial to repeat the RVAA performed
herein, but instead specifically prioritize rare variants that are located within the
functional domains of proteins. If a gene were to exhibit similar rare variant frequencies
between cases and controls, but different distributions of variants, specifying the analysis
using a domain-based approach may detect additional novel gene-disease relationships.
Similarly, as described in Section 8.2.2, a limitation of this Dissertation was a result of
the use of ONDRISeq and its inability to identify novel neurodegenerative disease and/or
CVD associated genes. However, ONDRI is currently pursuing WGS of all ONDRI
participants, with the exception of the CVD ± CI cohort, as well as a relatively small (n ≈
50) elderly control cohort. Ideally, this would allow for exome-wide RVAAs to be
performed, although the low statistical power resulting from the small sample sizes of
ONDRI and the control cohort will remain a limitation. Yet, the use of the data could
offer the opportunity to identify novel gene-disease associations, again applying both
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gene-wide and domain-based enrichment analyses. One opportunity to maximize
statistical power could be by applying a gene-set approach by binning genes into
functional sets, based on the pathways in which they may contribute to neurodegenerative
pathology, such as a set of genes encoding mitochondria-associated proteins, based on
their potential involvement in ALS or PD (Khalil & Lievens, 2017; Park, Davis, & Sue,
2018). This could mitigate the effects of genes unrelated to the neurodegenerative
phenotypes and their potential influence on power reduction. If significant signals were
observed in these gene sets, the genes may be further explored to identify whether a
single gene was driving the association.

8.4.4.

Cerebrovascular changes in neurodegenerative disease

One of the pillars of ONDRI’s rationale and design was to gain a greater understanding
of the contribution of cerebral small vessel disease to neurodegenerative disease risk and
presentation. It is now well recognized that the co-occurrence of cerebrovascular injury
with neurodegeneration is relatively common (Kummer et al., 2019; Lendahl, Nilsson, &
Betsholtz, 2019; Thal et al., 2015), but the exact mechanisms by which CVD may
contribute to pathology remains unclear. Here, I initiated these efforts in the analysis of
NOTCH3 genetic variation, WMH volume, and PD in Chapter 7, which now offers an
opportunity for expansion. WMHs are also not uncommon among other
neurodegenerative diseases, such as AD and FTD, but their effects on disease features are
not fully understood (Brickman, Muraskin, & Zimmerman, 2009; Kandel et al., 2016;
Woollacott et al., 2018). Further, multiple genes on the ONDRISeq panel have been
previously associated with various features of CVD burden. ONDRI’s simultaneous
analysis of patients across multiple neurodegenerative phenotypes using consistent
assessment offers the unique opportunity to extend the novel NOTCH3 finding across
multiple disease cohorts and genes. Efforts are currently underway to assess the influence
of rare, likely pathogenic variants within all CVD-associated genes of the ONDRISeq
panel (Appendix D) on CVD defining brain volumetrics across all ONDRI cohorts in
collaboration with the imaging platform. Functional analyses will remain imperative to
confirm that variants within the CVD genes are influencing features of cerebrovascular
pathology within the participants, and to determine whether the small vessel damage is
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contributing to the diseases’ pathogenic mechanisms or to differential disease
presentation.

8.4.5.

Estimation of gene-environment interactions

Although genetic factors contribute a clear risk to neurodegenerative disease and CVD
presentation, it is also important to recognize the large amount of influence from
environmental factors to the risk of neurodegeneration. The most important risk factor for
the diagnoses is age, potentially due to mechanisms involving DNA damage, epigenetic
changes such as increased DNA methylation, mitochondrial dysfunction, cellular
senescence, and telomere maintenance (Hou et al., 2019). However, these cellular
pathways are also highly influenced by genetic factors (Atzmon et al., 2010; Coutts et al.,
2019; Larsen, Hanss, & Kruger, 2018), leading to a potential for interaction between risks
associated with both aging and genetic variation. In fact, brains of neurodegenerative
disease patients have displayed age-correlated variable gene expression (Cao, ChenPlotkin, Plotkin, & Wang, 2010), suggesting important gene-environment interactions,
and certain pathogenic mutations causative of neurodegeneration have displayed agedependent effects (Ho et al., 2020; Longo et al., 2017). Similar gene-environment
interactions have been observed in relation to pesticide exposures and other
environmental toxins (Casarejos et al., 2006; Liu et al., 2017).
This Dissertation did not address the potential for significant interactions between genetic
and environmental risk factors, yet in order for the entire spectrum of neurodegenerative
and cerebral small vessel disease risk to be assessed, we must obtain a comprehensive
understanding of the genetic influences on disease. The novel genetic associations I
identified demonstrate that there are still important discoveries to be made to contribute
to the greater analysis of gene-environment interactions. Further, the identification of
potentially pathogenic variation in individuals with unexpected diagnoses, such as the
GBA variation observed across the non-PD diagnoses of ONDRI, may suggest that there
are other genetic and/or environmental factors contributing to the differential phenotypes
of these patients. Therefore, studying the potential influence from both environmental
and genetic risk factors may prove itself necessary to truly understand disease risk
moving forward.
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8.4.6.

Development of novel therapeutic targets

A common goal for those studying the genetic determinants of neurodegeneration is
addressing the considerable need for appropriate therapeutic targets and the development
of treatments that may halt disease development or prevent its onset. Although there have
been many attempts at this across neurodegenerative diagnoses, to date there remains few
substantial breakthroughs in this quest. It is well-established that 85% of clinical trials
fail, and neurodegenerative diseases are no exception to this rate (Olanow, Kieburtz, &
Schapira, 2008; Oxford, Stewart, & Rohn, 2020; Petrov, Mansfield, Moussy, & Hermine,
2017; Wong, Siah, & Lo, 2019). By gaining a greater understanding of the breadth of
genetic variation that may contribute to disease risk, we may identify novel therapeutic
targets specific to the underlying genetic risk factors.
Furthermore, it is important to recognize that many of these efforts are currently
underway, such as clinical trials of drugs specific to individuals diagnosed with PD that
carry pathogenic GBA variation or individuals diagnosed with AD carrying the APOE E4
genotype (Schneider & Alcalay, 2020; Yang, Kantor, & Chiba-Falek, 2021). However,
the trials have yet to involve patients with different diagnoses, even though a substantial
amount of genetic overlap has been observed across the diseases. A clear example of this
overlap is displayed in Chapter 6, in which a relatively high frequency of likely
pathogenic GBA variation is observed across all ONDRI cohorts. By applying these
findings, if the clinical trials were to prove successful, it will be absolutely crucial that we
gain a full understanding of the genetic overlap between neurodegenerative diseases and
potential co-pathologies, as therapies may be useful to patients with seemingly different
diagnoses.

8.5.

Conclusions

Through the genetic analyses of individuals with neurodegenerative disease and CVD
from the ONDRI study, I have contributed to the delineation of the complex genetic
architecture of the phenotypes. My work has demonstrated the wide range of genetic
variants that contribute to neurodegeneration and cerebral small vessel diseases and the
potential overlap of genetic risk that has not previously been well defined. Specifically, I
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leveraged the ability to concurrently evaluate patients with different neurodegeneration
diagnoses using the ONDRISeq targeted NGS panel to characterize common genotypes
and haplotypes, rare SNVs, and CNVs contributing to disease presentation and features.
Chapters 2 and 3 demonstrated the important influence of APOE, not only to AD and
MCI risk, but to cognitive impairment across all disease cohorts. Chapter 4 highlighted
potentially novel gene-disease relationships and, along with Chapters 5 and 6,
demonstrated that there may be a greater amount genetic overlap between
neurodegenerative and cerebrovascular diagnoses than previously appreciated. Finally,
the results of Chapter 7 supported the theory that aside from rare variants of high
phenotypic effect that can drive diagnoses within a Mendelian model, there may also be
rare variants of moderate phenotypic effect that are influencing neurodegenerative
presentation and contributing to the large amount of phenotypic heterogeneity observed
between patients with the same diagnoses and the phenotypic overlap between those with
different diagnoses. Although I have applied robust methodologies to maximize the
utility of the limited sample sizes within ONDRI, replication of the novel findings and
functional analyses of novel variation are required to fully elucidate their contribution to
disease pathogenesis. Nonetheless, to my knowledge, this Dissertation represents the first
compendium to date of analyses of genetic associations across this number of
neurodegenerative diseases at once with such deep, consistent phenotyping of
participants. As the view of neurodegenerative diseases continues to evolve to consider
diagnoses as sitting on a spectrum with mixed pathologies and overlapping etiologies,
genetic factors will continue to become an ever more important indicator of presentation
risk, particularly in regards to features and progression of disease.
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Appendix D. Genes included on the ONDRISeq targeted next-generation sequencing panel.
Chromosomal
Affected protein
location
Amyotrophic lateral sclerosis/frontotemporal dementia
Gene

RefSeq
Transcript

Associated phenotype

Mode of inheritance

ALS2
ANG
ARHGEF28

2q33.1
14q11.2
5q13.2

Alsin
Angiogenin
Rho guanine nucleotide
exchange factor 28

NM_020919
NM_001145
NM_001080479

ALS2
ALS9
ALS and FTD

AR (HZ), juvenile onset
ADm, late onset
AR (HZ) and ADm, late
onset

ATXN2
CENPV

12q24.12
17p11.2

Ataxin 2
Centromere protein V

NM_002973
NM_181716

ALS13
ALS

ADm, late onset
Genetic association, late
onset

CHMP2B
DAO
DCTN1

3p11.2
12q24.11
2p13.1

CHMP family member 2B
D-amino acid oxidase
Dynactin 1

NM_014043
NM_001917
NM_004082

ADm, late onset
ADm, late onset
ADm, late onset

FIG4

6q21

FIG4 homolog, SAC1 lipid
phosphatase domain
containing

NM_014845

ALS17, FTD
ALS, schizophrenia
ALS, HMN7B, Perry
syndrome
ALS11, CMT disease, YV
syndrome

FUS

16p11.2

Fused in sarcoma

NM_004960

ALS6, FTD, HET4

GRN

17q21.31

Granulin precursor

NM_002087

FTD, NCL

HNRNPA1

12q13.13

Heterogeneous nuclear
ribonucleoprotein A1

NM_002136

ALS20, inclusion body
myopathy with early-onset
Paget disease with/without
FTD 3

ADm, late onset; AR
(HZ and CH), infantile
onset; AR (HZ and CH),
infantile onset
AR (HZ), ADm, late
onset
ADm, late onset; AR
(HZ), juvenile onset
ADm, late onset; ADm,
early onset
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HNRNPA2B1

7p15.2

Heterogeneous nuclear
ribonucleoprotein A2/B1

NM_031243

MAPT/STH

17q21.31

Microtubule-associated
protein tau

NM_001123066

NEFH

22q12.2

Neurofilament protein, heavy
polypeptide

NM_021076

Inclusion body myopathy
with early-onset Paget
disease with/without FTD 2
ALS, FTD with
parkinsonism, PD, AD,
Pick disease, supranuclear
palsy, tauopathy
ALS1

OPTN

10p13

Optineurin

NM_001008211

ALS12, glaucoma

ADm, early onset

AR (HZ) and AD, early
onset
ADm, earlier onset
AR (HZ and CH), early
onset

ADm, late and early
onset

ADm, late onset

PFN1
PNPLA6

17p13.2
19p13.2

Profilin 1
Patatin-like phospholipase
domain-containing protein 6

NM_005022
NM_001166111

PRPH
SETX

12q13.12
9q34.13

Peripherin
Senataxin

NM_006262
NM_015046

9p13.3

Sigma nonopioid
intracellular receptor 1

NM_001282208

ALS18
Spastic paraplegia,
Boucher-Neuhauser
syndrome
ALS1
ALS4, spinocerebellar
ataxia 1
ALS16, FTD

21q22.11

Superoxide dismutase 1

NM_000454

ALS1

AR (HZ and CH), ADm,
age of onset varies from
6–94 years old

Sequestosome 1
TAF15 RNA polymerase II,
TATA box binding protein
associated factor

NM_001142298
NM_139215

Paget disease of bone
Chondrosarcoma

ADm, late onset

Tar DNA-binding protein
Ubiquilin 2

NM_007375
NM_013444

ALS10, FTD
ALS15, FTD

ADm, late onset
X-linked, juvenile and
late onset

SIGMAR1
SOD1

SQSTM1
TAF15

5q35.3
17q12

TARDBP
UBQLN2

1p36.22
Xp11.21

ADm, late onset
ADm and AR, juvenile
onset
AR (HZ); ADm, early
onset
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UNC13A

19p13.11

Unc-13 homolog A (C.
elegans)

NM_001080421

ALS

Genetic association, late
onset

VAPB

20q13.33

Vesicle-associated
membrane protein (VAMP)associated protein B and C

NM_004738

ALS, spinal muscular
atrophy (Finkel type)

ADm, early and late
onset

Valosin-containing protein

NM_007126

ALS14, FTD, inclusion
body myopathy with earlyonset Paget disease
with/without; FTD1

ADm, early onset

VCP

9p13.3

Alzheimer’s disease/mild cognitive impairment
ABCA7

19p13.3

ATP-binding cassette,
subfamily a, member 7

NM_019112

AD

Genetic association, late
onset

APOE

19q13.32

Apolipoprotein E

NM_001302688

ACD, ADm, AR (HZ
and CH), late onset

APP

21q21.3

Amyloid-β A4 precursor
protein

NM_000484

AD2, lipoprotein
glomerulopathy, sea-blue
histiocyte disease, macular
degeneration
AD 1, cerebral amyloid
angiopathy

BIN1

2q14.3

Bridging integrator 1

NM_001320642

AD

Genetic association, late
onset

CD2AP

6p12.3

CD2-associated protein

NM_012120

AD

Genetic association, late
onset

CD33 antigen

NM_001772

AD

Genetic association, late
onset

ADm and AR (HZ),
early and late onset

CD33

19q13.41

CLU

8p21.1

Clusterin

NM_001831

AD

Genetic association, late
onset

CR1

1q32.2

Complement component;
receptor 1

NM_000651

AD

Genetic association, late
onset
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CSF1R

5q32

Colony-stimulating factor 1
receptor

NM_001349736

HDLS with dementia

ADm, early and late
onset

DNMT1

19p13.2

DNA methyltransferase 1

NM_001130823

HSN1E with dementia

ITM2B

13q14.2

NM_021999

Dementia

MS4A4E

11q12.2

NM_011545418

AD

MS4A6A

11q12.2

NM_152852

AD

Genetic association, late
onset

PICALM

11q14.2

Integral membrane protein
2B
Membrane-spanning 4domains, subfamily A,
member 4E
Membrane-spanning 4domains, subfamily A,
member 6A
Phosphatidylinositol-binding
clathrin assembly protein

ADm, early onset
dementia
ADm, early and late
onset
Genetic association, late
onset

NM_007166

AD

Genetic association, late
onset

PLD3

19q13.2

Phospholipase D family,
member 3

NM_012268

AD19

Genetic association, late
onset

PSEN1

14q24.2

Presenilin 1

NM_000021

ADm, early onset

PRNP
PSEN2

20p13
1q32.13

Prion protein
Presenilin 2

NM_000311
NM_000447

SORL1

11q24.1

Sortilin-related receptor

NM_003105

AD3, dilated
cardiomyopathy, FTD, Pick
disease, acne inversa
Dementia
AD4, dilated
cardiomyopathy
AD

TREM2

6p21.1

Triggering receptor
expressed on myeloid cells 2

NM_018965

Genetic association, late
onset

TYROBP

19q13.12

Tyro protein tyrosine kinasebinding protein

NM_003332

AD Nasu-Hakola disease
(dementia and psychotic
symptoms)
Nasu-Hakola disease
(dementia and psychotic
symptoms)

Parkinson’s disease

ADm, early onset
ADm, early onset
ADm, combined gene
burden, late onset

AR (HZ), juvenile onset
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ADH1C

4q23

Alcohol dehydrogenase 1C,
gamma polypeptide

NM_000669

PD, alcohol dependence
protection

Genetic association, late
onset

ATP13A2
(PARK9)

1p36.13

ATPase, type 13A2

NM_022089

PD, ceroid lipofuscinosis,
dementia

DNAJC13

3q22.1

DNAJ/HSP40 homolog,
subfamily C, member 13

NM_001329126

PD

Genetic association,
early onset and late
onset
ADm, late onset

EIF4G1

3q27.1

Eukaryotic translation
initiation factor 4-gamma

NM_182917

PD18

ADm, late onset

FBXO7

22q12.3

F-box only protein 7

NM_012179

PD15

GAK

4p16.3

Cyclin G-associated kinase

NM_005255

PD

AR (HZ and CH), early
onset
Genetic association, late
onset

GCH1

14q22.2

GTP cyclohydrolase I

NM_000161

PD, dystonia

Genetic association,
early onset

GIGYF2

2q37.1

GRB10-interacting GYP
protein 2

NM_015575

PD11

Genetic association,
early and late onset

HTRA2

2p13.1

HTRA serine peptidase 2

NM_013247

PD13

LRRK2

12q12

Leucine-rich repeat kinase 2

NM_198578

PD8

MC1R

16q24.3

Melanocortin 1 receptor

NM_002386

PD; melanoma, UV
induced skin damage

ADm and genetic
association, early and
late onset
ADm and genetic
association, early and
late onset
Genetic association, late
onset

NR4A2

2q24.1

Nuclear receptor subfamily
4, group A, member 2

NM_006186

PD

Genetic association, late
onset

PANK2

20p13

Pantothenate kinase 2

NM_001324191

Neurodegeneration

AR (HZ and CH), early
onset
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PARK2
(PRKN)

6q26

Parkin

NM_004562

PD2

AR (HZ and CH),
juvenile onset;
heterozygotes have late
onset
AR (HZ and CH), early
onset
NA

PARK7(DJ1)

1p36.23

Oncogene DJ1

NM_007262

PD7

PARL

3q27.1

Presenilin-associated
rhomboid-like protein

NM_018622

PINK1

1p36.12

Pten-induced putative kinase
1

NM_032409

PD (based on biological
mechanisms, no linkage
confirmed)
PD6

PLA2G6

22q13.1

Phospholipase A2, group VI

NM_001349867

PD14, NBIA2A, NBIA2B

AR (HZ and CH), early
and late onset

PM20D1

1q32

Peptidase M20 domain,
containing 1

NM_152491

PD16

Genetic association, late
onset

RAB7L1

1q32.1

RAB7-like 1

NM_001135663

PD

SNCA
UCHL1

4q22.1
4p13

α-synuclein
Ubiquitin carboxyl-terminal
esterase L1

NM_000345
NM_004181

PD1, PD4, LBD
PD5, neurodegeneration
with optic atrophy

Genetic association, late
onset
ADm, early onset
ADm, AR (HZ),
juvenile-onset

VPS35

16q11.2

Vacuolar protein sorting 35

NM_018206

PD17

ADm, early and late
onset

ATP-binding cassette,
subfamily C, member 6

NM_001171

AR (HZ), infantile
onset; AR; ADm

Collagen type IV, alpha-1

NM_001845

Arterial calcification;
pseudoxanthoma elasticum;
pseudoxanthoma elasticum
forme fruste
Angiopathy, brain small
vessel disease,
porencephaly 1,

AR (HZ and CH), ADm,
early onset

Vascular cognitive impairment
ABCC6

16p13.11

COL4A1

13q34

ADm, infantile onset
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COL4A2

13q34

Collagen type IV, alpha-2

NM_001846

HTRA1

10q26.13

HTRA serine peptidase 1

NM_002775

NOTCH3

19p13.12

Notch homology protein 3

NM_000435

SAMHD1

20q11.23

SAM domain and HD
domain 1

NM_015474

TREX1

3p21.31

3-prime repair exonuclease 1

NM_016381

intracerebral haemorrhage
susceptibility
Porencephaly 2,
intracerebral haemorrhage
susceptibility
CARASIL syndrome,
macular degeneration
Infantile myofibromatosis
2, CADASIL
Aicardi-Goutieres
syndrome 5, Chilblain
lupus 2
Aicardi-Goutieres
syndrome 1, Chilblain
lupus, Vasculopathy,
retinal, with cerebral
leukodystrophy

ADm, infantile onset

AR (HZ), early onset
ADm, early onset
AR (HZ and CH), AD,
infantile onset
AD, AR (HZ and CH),
juvenile onset

Age of onset was classified as ‘late onset’ if greater than 65 years of age. Figure adapted from Farhan, S., Dilliott, A., Ghani, M. et al. (2016) The ONDRISeq
panel: custom-designed next-generation sequencing of genes related to neurodegeneration. npj Genomic Med 1, 16032.
https://doi.org/10.1038/npjgenmed.2016.32
Abbreviations: ACD, autosomal co-dominant; AD, Alzheimer’s disease; ADm, autosomal dominant; ALS, amyotrophic lateral sclerosis; AR, autosomal
recessive; CARASIL syndrome, cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy; CADASIL, cerebral autosomal
dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CH, compound heterozygous; CMT disease, Charcot-Marie-Tooth disease; FTD,
frontotemporal dementia; HDLS, leukoencephalopathy, diffuse hereditary, with spheroids; HET4, hereditary essential tremor, 4; HMN7B, neuropathy, distal
hereditary motor, type VIIB; HSN1E, hereditary sensory neuropathy type 1E; HZ, homozygous; LBD, Lewy body dementia; NCL, neuronal ceroidlipofuscinoses; NBIA2A, neurodegeneration with brain iron accumulation 2A; NBIA2B, neurodegeneration with brain iron accumulation 2B; NGS, Nextgeneration sequencing; PD, Parkinson’s disease; YV syndrome, Yunis–Varon syndrome.
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Appendix E. Regression coefficients (standard error) of the multinomial logistic
regressions used for rare variant association analyses in Chapter 4.
AD/MCI
ALS/FTD
Associated
Associated
Genes
Genes
Putative loss-of-function variants
ONDRI 0.423 (0.534)
0.725 (0.576)
Cohort

CVD
Associated
Genes

PD
Associated
Genes

-0.194 (0.822)

1.991 (0.924)*

AD
ALS

-0.560 (1.601)
3.242 (1.805)

0.646 (1.014)
3.502 (1.747)*

1.007 (1.233)
4.058 (2.272)

2.510 (1.107)*
4.850 (1.947)*

CVD

0.904 (1.039)

1.156 (1.039)

0.680 (1.499)

2.370 (1.313)

FTD

2.415 (1.591)

2.713 (1.607)

2.790 (2.049)

3.948 (1.833)*

MCI

0.626 (0.575)

1.066 (0.529)*

-1.125 (1.862)

1.836 (0.950)

PD

2.039 (1.555)

2.420 (1.531)

2.196 (1.910)

3.428 (1.832)

Missense variants
ONDRI

0.047 (0.206)

-0.183 (0.205)

-0.116 (0.217)

-0.051 (0.208)

AD
ALS
CVD
FTD

0.240 (0.384)
0.291 (1.113)
-0.088 (0.442)
0.065 (0.986)

-0.239 (0.386)
-0.048 (1.115)
-0.384 (0.440)
0.045 (0.987)

-0.355 (0.425)
0.441 (1.125)
-0.248 (0.477)
0.258 (1.013)

-0.350 (0.384)
-0.383 (1.119)
0.047 (0.443)
-0.109 (1.001)

MCI

0.107 (0.228)

-0.056 (0.228)

-0.028 (0.237)

-0.065 (0.230)

PD

0.242 (0.873)

-0.339 (0.876)

0.229 (0.909)

-0.083 (0.885)

Possibly deleterious missense variants
ONDRI

-0.209 (0.235)

-0.056 (0.216)

-0.141 (0.236)

0.123 (0.210)

AD
ALS
CVD
FTD
MCI
PD

0.146 (0.420)
1.010 (1.134)
-0.222 (0.513)
0.478 (1.024)
-0.109 (0.262)
0.171 (0.943)

0.275 (0.391)
0.345 (1.145)
-0.306 (0.480)
0.299 (1.009)
0.133 (0.237)
0.043 (0.905)

-0.709 (0.512)
0.615 (1.158)
-0.189 (0.523)
0.263 (1.069)
-0.137 (0.261)
0.489 (0.934)

-0.526 (0.439)
0.324 (1.134)
0.302 (0.444)
0.670 (1.003)
0.381 (0.230)
0.178 (0.907)

Multinomial logistic regressions adjusted for age, sex, and disease prevalence were performed to analyze
enrichment of rare variants identified in the 80 genes encompassed by the ONDRISeq panel. The brglm2 R
package was used to fit the regression model and apply a mean bias reduction accounting for the low
variant positive counts. *p-value < 0.05.
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CVD, cerebrovascular
disease; FTD, frontotemporal dementia; MCI mild cognitive impairment; ONDRI, Ontario
Neurodegenerative Disease Research Initiative; PD, Parkinson’s disease.
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Appendix F. Rare variant association analysis comparing the enrichment of rare missense variants in four disease-associated
gene groupings in the ONDRI cohorts compared to cognitively normal controls presented in Chapter 4.

Multinomial logistic regressions adjusted for age, sex, and disease prevalence were performed to analyze enrichment of (a)
missense variants, and (b) possibly deleterious missense variants identified in the 80 genes encompassed by the ONDRISeq panel,
which were binned into four disease-associated gene groupings: AD associated genes, ALS/FTD associated genes, CVD associated
genes, and PD associated genes, across the ONDRI cohorts compared to the control cohort. Only ancestry matched participants
were included in the analyses. The brglm2 R package was used to fit the regression model and apply a mean bias reduction
accounting for the low variant positive counts. Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CVD,
cerebrovascular disease; FTD, frontotemporal dementia; MCI mild cognitive impairment; ONDRI, Ontario Neurodegenerative
Disease Research Initiative; PD, Parkinson’s disease.
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Appendix G. Copy number variants (CNVs) detected by the VarSeq® v1.4.3 CNV Caller tool in 519 ONDRI participants in 80
neurodegenerative disease genes covered by the ONDRISeq panel in Chapter 5.
Subject
1
2
3
4
5
6
7
7
7
8
9
10
11
12
13
14
15
16
17
18
18
19
20
21
22

Phenotype
AD
ALS
CVD
MCI
CVD
CVD
CVD
CVD
CVD
AD
CVD
CVD
PD
CVD
PD
CVD
ALS
FTD
CVD
CVD
CVD
CVD
PD
PD
PD

CNV State
Het Deletion
Duplicate
Duplicate
Duplicate
Duplicate
Duplicate
Duplicate
Het Deletion
Duplicate
Duplicate
Het Deletion
Duplicate
Duplicate
Duplicate
Duplicate
Duplicate
Duplicate
Het Deletion
Duplicate
Duplicate
Duplicate
Duplicate
Duplicate
Duplicate
Duplicate

Gene
OPTN
PARK7
ABCC6
SAMHD1
ABCA7
ATP13A2
ABCA7
LRRK2
PRPH
ABCA7
TREM2
COL4A2
UNC13A
SQSTM1
ABCA7
CLU
DNMT1
TREM2
ATP13A2
CENPV
PSEN2
NOTCH3
GCH1
UCHL1
ALS2

Exon(s)
5
1–5
1–31
7–11
16
16
4–5
9
7–8
15–16
4
2
36
0
16–17
8
35–36
4
28
1
1
3–4
5
0–1
34

Span (bp)
2357
9810
74407
8802
276
707
611
170
453
630
156
220
530
532
1627
395
678
156
700
972
578
641
621
150
2127

Z-score
-6.851
6.816
6.371
5.872
9.961
7.175
4.156
-3.990
3.991
4.454
-3.753
4.212
6.097
6.045
4.163
4.731
6.623
-3.980
5.397
5.323
4.559
3.901
6.382
4.799
4.658

Ratio
0.487
1.455
1.482
1.474
3.221
1.430
1.357
0.636
1.338
1.845
0.678
1.382
1.356
1.712
1.748
1.405
1.319
0.653
1.493
1.441
1.350
1.351
1.322
2.454
1.380

p-value
1.10E-12
0
0
1.70E-21
3.14E-13
2.02E-08
3.51E-07
4.09E-05
6.34E-05
4.63E-07
7.30E-07
7.34E-07
8.18E-07
8.62E-07
9.65E-07
1.72E-06
2.14E-06
3.77E-06
4.39E-06
5.14E-06
9.32E-05
5.44E-06
8.90E-06
9.01E-06
1.07E-05

Validation
Yes (BA)
Yes (WES)
Yes (WES)
Yes (WES)
N/A
N/A
No (WES)
N/Aa
No (WES)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/Ab
N/A
N/A
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23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
38
40
41
42
43
44

MCI
CVD
MCI
CVD
CVD
CVD
AD
ALS
CVD
CVD
CVD
CVD
ALS
CVD
MCI
AD
CVD
CVD
MCI
PD
MCI
PD

Duplicate
Duplicate
Het Deletion
Duplicate
Duplicate
Duplicate
Duplicate
Duplicate
Duplicate
Duplicate
Het Deletion
Duplicate
Duplicate
Duplicate
Duplicate
Duplicate
Het Deletion
Duplicate
Duplicate
Het Deletion
Het Deletion
Het Deletion

TAF15
NOTCH3
GAK
ABCC6
PNPLA6
CD2AP
UNC13A
COL4A2
SOD1
UNC13A
NEFH
NOTCH3
UCHL1
NOTCH3
TARDBP
ABCA7
SIGMAR1
ATP12A2
PNPLA6
UNC13A
ABCC6
ABCA7

15
4–6
20–23
3
1–3
1
36
7
1-2
35
1
21–24
7–8
3–4
1
13–16
1
1
2–5
8
3–4
8

210
944
623
265
375
960
530
3715
4765
2216
571
1756
2361
641
622
1925
351
700
232
506
629
222

4.235
3.946
-5.521
4.652
3.722
3.853
5.228
3.817
3.541
4.415
-5.899
3.884
3.981
3.543
5.506
3.568
-3.757
5.030
5.132
-4.214
-3.744
-4.021

1.513
1.304
0.567
1.786
1.596
1.407
1.304
1.314
2.019
1.374
0.564
1.322
1.301
1.323
1.426
1.388
0.538
1.460
1.421
0.598
0.516
0.451

1.26E-05
1.33E-05
1.35E-05
1.40E-05
1.48E-05
1.85E-05
2.72E-05
2.87E-05
3.13E-05
3.21E-05
3.22E-05
3.29E-05
3.55E-05
3.63E-05
4.24E-05
5.11E-05
5.76E-05
6.29E-05
7.97E-05
8.88E-05
9.89E-05
9.94E-05

N/A
No (WES)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

For multi-exon CNVs, the reported ratio and Z-score values are averaged across each affected region. A response of “No” in respect to validation indicated that
the WES did not identify the CNV that had been identified using the ONDRISeq panel. aThe WES performed did not have probes adequately covering exon 9 of
LRRK2. bWES exhibited unmappable and incorrectly mapped reads, failing to pass the quality control standards of the CNV Caller tool algorithm.
Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; BA, breakpoint analysis; bp, base pairs; CNV, copy number variant; CVD,
cerebrovascular disease; FTD, frontotemporal dementia; Het, heterozygous; MCI, mild cognitive impairment; N/A, not applicable; PD, Parkinson’s disease;
WES, whole exome sequencing.

306

Appendix H. Polymerase chain reaction (PCR) and Sanger sequencing primers used
to capture the sequence of GBA in Chapter 6.
Target PCR Primer
Exon(s)
Direction
FWD
1
2
3–4
REV
FWD
5–6
7
REV
FWD
8
9
10–11
REV

Sequencing
Primer Direction
FWD
REV
FWD
REV
FWD
REV
FWD
REV
FWD
REV
FWD
REV
FWD
REV
FWD
REV

Primer Sequence
GCCTCACTTCCTGTGTCATG
TTCCCACCCATTTCAACTTC
GTGGGCCTTGTCCTAATGAA
CAAAGGACTATGAGGCAGAA
CAAGGGGTGAGGAATTTTGA
ACGAAAAGTTTCAATGGCTCT
GCAAGTGATAAGCAGAGTCC
CTAGGTTGAGGGTTGGGACA
AGGCTGTTCTCGAACTCCTG
AGTTTGGGAGCCAGTCATTT
TGTGTGCAAGGTCCAGGATCAG
CTGGACAGGAAGGGCTTCTG
GCAACTCTGGGGAACCA
CATTGGGGTTTTCTGTTGCT
CAGGAGTTATGGGGTGGGTC
TTCTAGGGGCCTCCAGCC

The primers listed were used for PCR amplifications, yielding three amplicons that contained: 1) exons 1–
4; 2) exons 5–7; and 3) exons 8–11; the most highly specific of previously published primers were used to
provide specificity for isolating GBA (Mata et al. Mov Disord, 2016). All 11 exons of GBA were Sanger
sequenced, including 100 base pairs at each intron-exon boundary.
Abbreviations: FWD, forward; GBA, glucosylceramidase beta gene; PCR, polymerase chain reaction; REV,
reverse.
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Appendix I. GBA exons unable to be sequenced in ONDRI participants stratified by
disease cohort presented in Chapter 6.
Region unable to be
sequenced
Exons 1–4; 9–11
Exon 2
Exons 2–4; 8–11
Exons 3–4
Exon 4

AD
(n=41)
0
0
0
0
0

Number of ONDRI participants
ALS CVD ± CI FTD
MCI
PD
(n=39) (n=161) (n=51) (n=84) (n=139)
0
0
0
0
1
1
1
0
0
0
0
0
0
0
1
0
4
1
2
0
0
0
0
1
0

Abbreviations: AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; CVD ± CI, cerebrovascular
disease with or without cognitive impairment; FTD, frontotemporal dementia; GBA, glucosylceramidase
beta gene; MCI, mild cognitive impairment; ONDRI, Ontario Neurodegenerative Disease Research
Initiative; PD, Parkinson’s disease.
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Appendix J. Targeted next-generation sequencing and bioinformatics pipeline to
evaluate genetic determinants of constitutional disease.
The work presented in Appendix J. has been used with permission from the Journal of
Visualized Experiments. The video component of this article has accumulated over
20,000 views and can be found at: https://www.jove.com/v/57266/targeted-nextgeneration-sequencing-bioinformatics-pipeline-to

Dilliott A.A., Farhan S.M.K., Ghani M., Sato C., Liang E., Zhang M., McIntyre A.D.,
Cao H., Racacho L., Robinson J.F., Strong M.J., Masellis M., Bulman D.E., Rogaeva
E., Lang A., Tartaglia C., Finger E., Zinman L., Turnbull J., Freedman M., Swartz R.,
Black S., the ONDRI Investigators, and Hegele R.A. (2018). Targeted next-generation
sequencing and bioinformatics pipeline to evaluate genetic determinants of
constitutional disease. J Vis Exp, (134): e57266.
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Abstract
Next-generation sequencing (NGS) is quickly revolutionizing how research into the
genetic determinants of constitutional disease is performed. The technique is highly
efficient with millions of sequencing reads being produced in a short time span and at
relatively low cost. Specifically, targeted NGS is able to focus investigations to genomic
regions of particular interest based on the disease of study. Not only does this further
reduce costs and increase the speed of the process, but it lessens the computational
burden that often accompanies NGS. Although targeted NGS is restricted to certain
regions of the genome, preventing identification of potential novel loci of interest, it can
be an excellent technique when faced with a phenotypically and genetically
heterogeneous disease, for which there are previously known genetic associations.
Because of the complex nature of the sequencing technique, it is important to closely
adhere to protocols and methodologies in order to achieve sequencing reads of high
coverage and quality. Further, once sequencing reads are obtained, a sophisticated
bioinformatics workflow is utilized to accurately map reads to a reference genome, to call
variants, and to ensure the variants pass quality metrics. Variants must also be annotated
and curated based on their clinical significance, which can be standardized by applying
the American College of Medical Genetics and Genomics Pathogenicity Guidelines. The
methods presented herein will display the steps involved in generating and analyzing
NGS data from a targeted sequencing panel, using the ONDRISeq neurodegenerative
disease panel as a model, to identify variants that may be of clinical significance.
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Introduction
As defining the genetic determinants of various conditions takes on a higher priority in
research and in the clinic, next-generation sequencing (NGS) is proving to be a highthroughput and cost-effective tool to achieve these goals1,2,3. For almost 40 years, Sanger
sequencing had been the gold standard for identifying genetic variants4; however, for
diseases with genetic heterogeneity or unknown genetic etiology, many possible
candidate genes must be evaluated, often concurrently. In this context, Sanger sequencing
becomes expensive and time-consuming. However, NGS involves massive parallel
sequencing of millions of DNA fragments, allowing for a cost and time efficient
technique to simultaneously detect a wide range of genetic variation across various
regions of the genome.
There are three types of NGS for sequencing DNA: 1) whole-genome sequencing
(WGS), 2) whole-exome sequencing (WES), and 3) targeted sequencing5. WGS evaluates
the entire genomic content of an individual, while WES involves sequencing only the
protein-coding regions of the genome6. Targeted sequencing, in contrast, focuses on
specific regions of the genome based on relatively few specific genes linked by common
pathological mechanisms or known clinical phenotype. Either the exons or introns, or any
intergenic regions of a gene or specific group of genes can be specified using this
approach. Therefore, targeted sequencing can be an excellent approach when there is
already a foundation of candidate genes known to be associated with the disease of
interest. Targeting specific regions of the genome allows for elimination of superfluous
and irrelevant genetic variation that can cloud or distract from clinical interpretation.
While WGS and WES both produce a large amount of high-quality data, the amount of
data can be overwhelming. Not only does this large amount of data require
computationally intensive bioinformatics analysis, but data storage can frequently present
problems7. This challenge of data storage also adds additional costs to both WGS and
WES, which is often not initially considered when calculating the expense of sequencing.
Further, although it is decreasing, the cost of WGS and WES remain relatively high.
Targeted sequencing can be a more cost-efficient option, particularly when sequencing of
a large number of individuals is required.
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The Ontario Neurodegenerative Disease Research Initiative (ONDRI) is a multi-platform,
provincial-wide, observational cohort study characterizing five neurodegenerative
diseases, including: 1) Alzheimer's disease and mild cognitive impairment, 2)
amyotrophic lateral sclerosis, 3) frontotemporal dementia, 4) Parkinson's disease, and 5)
vascular cognitive impairment8. The ONDRI genomics subgroup is aiming to elucidate as
part of the baseline characterization of this cohort the often discounted, yet extremely
important genetic landscape of these phenotypically and genetically heterogeneous
diseases. Neurodegenerative diseases are thus appropriate candidates for NGS
methodologies and for targeted sequencing in particular.
We have custom-designed a targeted NGS panel, ONDRISeq, to sequence 528
participants involved in ONDRI for the protein-coding regions of 80 genes that have been
previously associated with the five diseases of interest. With this methodology, we are
able to harness the high-quality NGS data in a focused and efficient manner. The design
and validation of the ONDRISeq panel with multiple concordance studies has been
previously described, for which the ONDRISeq panel was able to identify novel, rare
variants of possible clinical significance in 72.2% of 216 cases used for panel validation9.
Although NGS technology has advanced rapidly and remarkably in recent years, many
researchers face a challenge when processing the raw data into a list of usable, annotated
variants10. Further, interpretation of the variants can be complex, especially when faced
with many that are rare or novel11.
Here, we describe in a step-by-step manner, the methodology of targeted NGS and the
associated bioinformatics workflow required for resequencing, variant calling, and
variant annotation using the ONDRISeq study as an example. After the generation of
NGS data, raw sequencing files must be aligned to the human reference genome in order
to accurately call variants. Variants must then be annotated in order to perform
subsequent variant curation. We will also explain our implementation of the American
College of Medical Genetics' Standards and Guidelines to accurately classify variant
pathogenicity.
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Protocol
For the purposes of ONDRI, ethics protocols and informed consent were obtained based
on the Research Ethic Boards at Baycrest Centre for Geriatric Care (Toronto, Ontario,
Canada); Centre for Addiction and Mental Health (Toronto, Ontario, Canada); Elizabeth
Bruyère Hospital (Ottawa, Ontario, Canada); Hamilton General Hospital (Hamilton,
Ontario, Canada); London Health Sciences Centre (London, Ontario, Canada); McMaster
(Hamilton, Ontario, Canada); The Ottawa Hospital (Ottawa, Ontario, Canada); Parkwood
Hospital (London, Ontario, Canada); St Michael's Hospital (Toronto, Ontario, Canada);
Sunnybrook Health Sciences Centre (Toronto, Ontario, Canada); and University Health
Network-Toronto Western Hospital (Toronto, Ontario, Canada).
1. DNA Isolation from Human Blood Samples
1.1. Collect samples from sequencing participants in accordance with
appropriate ethics protocols and informed consent.
1.1.1. To obtain DNA of high quality, draw blood samples for the purposes of
extraction.
NOTE: DNA can also be extracted from saliva or buccal cells, ensuring that
an appropriate DNA extraction kit is used.
1.1.2. If extracting from blood, to obtain a high yield of DNA, collect the sample
in three 4 mL EDTA K2 tubes, providing a sample of total volume ~12 ml.
1.1.3. Centrifuge blood samples for 20 min at 750 x g to fraction into an upper
phase of plasma, thin, middle phase of leukocytes, and a bottom phase of
erythrocytes.
1.2. Remove the plasma from the blood sample by pipetting it off the top of the
sample with a disposable transfer pipette. Appropriately discard the plasma or
dispense into multiple 500 µL aliquots for storage at -80 °C for future
biochemical analyses. Ensure that a new, sterile pipette is used for each sample.
1.3. Extract DNA from the blood sample with a blood extraction kit12 (Table of
Materials) according to manufacturer's instructions.
NOTE: If a sample of the volume described above is obtained, ~3 mL of
leukocytes will be obtained to use in the DNA extraction.
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1.4. Measure initial DNA concentration in ng/µL using a full-spectrum
spectrophotometer13 (Table of Materials), according to manufacturer's
instructions.
1.5. Proceed directly to step 2. Alternatively, store DNA at 4 °C.
2. Sequencing Library Preparation
2.1. Perform serial dilutions on the DNA samples over the course of three days to
obtain a final concentration of 5.0 ± 1.0 ng/µL.
2.1.1. Dilute 1 M Tris buffer pH 8.5 to 10 µM with deionized water.
NOTE: The volume diluted will depend on the number of DNA samples that
will need to be diluted in the subsequent steps.
2.1.2. If performing the DNA dilution directly after step 1.4, proceed to the
following step. If not on the same day, measure the DNA concentration as
was done in step 1.4.
2.1.3. Based on the concentration measured, dilute 40 µL of the DNA to ~10
ng/µL using 10 µM Tris buffer pH 8.5 and allow the sample to sit overnight
at 4 °C.
2.1.4. Measure DNA concentration with a fluorometer14 appropriate for the
quantification of DNA (Table of Materials), according to manufacturer's
instructions.
NOTE: The concentration of the sample should be >10 ng/µL because of the
lower sensitivity of the spectrophotometer used previously.
2.1.5. Based on the concentration measured, dilute 20 µL of the DNA to 10
ng/µL using 10 µM Tris buffer pH 8.5 and allow the sample to sit overnight
at 4 °C.
2.1.6. Measure DNA concentration with the fluorometer14, according to
manufacturer's instructions.
2.1.7. Based on the concentration measured, dilute 10 µL of the DNA to 5 ng/µL
using 10 µM Tris-HCl pH 8.5 and allow the sample to sit overnight at 4 °C.
2.2. Prepare sequencing library according to manufacturer's instructions with
the targeted NGS panel's appropriate target enrichment kit15 (Table of
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Materials). Ensure that the enrichment kit is appropriate for the NGS
platform being used.
2.2.1. Follow manufacturer's instructions16 regarding the plexity and pooling of
libraries.
NOTE: For ONDRISeq, libraries are composed of 12 DNA samples, pooled
in sets of two, and run on the NGS desktop instrument (Table of Materials).
The number of samples that can be run in a single reaction will depend on
the sequencing kit and platform used.
2.2.2. To achieve higher quality sequencing data, perform the optional step to
validate the DNA library quality following tagmentation, described in
manufacturer's instruction of the target enrichment kit15.
2.2.2.1.

Analyze each library in triplicate to ensure the quality of the

library yield.
2.2.3. If pooling libraries, measure DNA concentration with the fluorometer14,
according to manufacturer's instructions. Use this concentration to determine
the volume of each DNA library to pool to obtain the equimolar ratios
recommended by the target enrichment kit being used.
3. Next-generation Sequencing
3.1. Sequence the library according to the NGS desktop instrument's reagent kit
manufacturer's instructions17,18 (Table of Materials).
3.1.1. Prepare a sample sheet according to manufacturer's instructions18 using the
appropriate NGS technology software (Table of Materials), which will be
imported into the NGS desktop instrument's workflow.
NOTE: For the purposes of ONDRISeq, the application option chosen is
'other', with only the FASTQ files requested (Figure J.1). Subsequent steps
will process these FASTQ files, to allow for full customization of alignment
and quality parameters. However, if targeted sequencing is chosen, some
NGS instruments are able to process the sequencing data into VCF files
themselves. The manufacturer's instructions18 may be consulted for a full
selection of options.
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3.1.2. If using a cloud-based computing environment19 (Table of Materials), log
in when setting up the sequencing run. Do this after clicking "Sequencing"
on the NGS desktop instrument home page.
3.1.3. Following library denaturation18 according to the manufacturer's
instructions, measure DNA library concentration with the fluorometer14.
3.1.4. Validate the DNA library quality using an appropriate automated
electrophoresis system and DNA quality analysis kit20 (Table of Materials),
as per manufacturer's instructions.
3.1.5. To convert the DNA concentration from ng/µL to nM, use the following
formula16

NOTE: Average library size will be specific to target enrichment kit being
used, and can be obtained from the electrophoresis trace observed in step
3.1.4.
3.1.6. Dilute the sequencing library to a final concentration of 6–20 pM, as
appropriate, and volume of 600 μL, according to manufacturer's
instructions21.
NOTE: The exact concentration needed is dependent on the sequencing kit
used. Consult the enrichment kit manufacturer to determine the proper
loading concentration.
3.1.7. Dilute, denature, and include a positive control sequencing library21,
according to the manufacturer's instructions.
3.1.8. Keep a log of every sequencing run, which includes the DNA library
concentration loaded (pM), the percentage of positive control added, reagent
cartridge barcode, application chosen in step 3.1.1, number of index reads,
enrichment kit used, read length(s), and the sample sheet name.
NOTE: The run time of the NGS desktop instrument will depend on the
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instrument, enrichment kit, and read lengths chosen (4–56 h for the
sequencer used in this experiment22).
3.2. Upon completion of the sequencing run, access the "Run Folder", which includes
all outputs, by navigating to the NGS desktop instrument home page and clicking
"Manage Files". Move the files to a local drive for later access. For a separate
option, on a computer, find the files within the cloud-based computing
environment19 by selecting "Runs" on the navigation panel. Select the
appropriate sequencing run to navigate to the Run Summary page. Select
"Download" to obtain data from the cloud. From the dialog box that appears,
select the FASTQ files as the file type to download and click "Download".
3.3. From the Run Summary page of the cloud-based computing
environment19,23, navigate to "Charts" to analyze the quality of the
sequencing run with the various figures produced by the computing
environment. Refer to the manufacturer's instructions23 for details
regarding each figure produced.
3.3.1. From the Run Charts page, find the figure labeled "Data by Cycle". Under
chart, select "Intensity" and under channel select "All Channels". Ensure that
this signal intensity plot produced is similar to that produced by sequencing
runs performed in the past with the same enrichment kit and NGS desktop
instrument.
NOTE: This reflects the percentage of intensity shown by each base across
all 150 cycles. The figure can vary widely depending on the enrichment kit
used, which is why it must be compared to past sequencing runs of the same
panel.
3.3.2. Select the "Indexing QC" tab within the run navigation panel to find the
indexing quality control (QC) histogram, which is on the right-hand side of
the page. Ensure that a relatively uniform distribution of % Reads Identified
(PF) is observed across all samples.
NOTE: If any samples have a much lower % Reads Identified (PF) than the
rest of the samples, note that the quality of the sequencing data may be
affected.
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3.4. From the Run Summary page of the cloud-based computing environment,
navigate to the quality metrics by clicking "Metrics" within the run
navigation panel.
NOTE: Metrics cut-offs will depend on the sequencing platform and enrichment
kit being used. There are many metrics that can be utilized based on
manufacturer's instructions23, with the following steps highlighting three that are
highly recommended for quality control.
3.4.1. Under "DENSITY (K/MM2)" ensure the cluster density is within the range
recommended by the enrichment kit being used (in this case 1,200–1,400
K/mm2).
3.4.2. Under the total "%≥Q30" ensure that the value is ≥85%, reflecting the
quality of the sequencing reads.
NOTE: If lower than this threshold of 85%, note that the quality of the
sequencing may be compromised.
3.4.3. Under "ALIGNED (%)" ensure that the value is similar to the % of
positive control that was included in the sequencing run.
NOTE: This acts as a measure of positive control, such that only this
percentage of total reads were found to align to the positive control genome.
If 1% positive control was used it would be expected that the Aligned (%)
would be ~1–5%.
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Figure J.1: Screenshot of the NGS technology software's (Table of Materials)
sample sheet creator application options.
For the purposes of ONDRISeq, the FASTQ only application is used. However, if the
user would like other files produced, such as VCF files, it is recommended that an
application within the targeted resequencing category is used.
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4. Resequencing and Variant Calling
4.1. For data pre-processing, select appropriate software to align the raw FASTQ files
to the human reference genome and to call variants (Table of Materials).
4.2. Import FASTQ sequencing reads into the data pre-processing software.
NOTE: For the purposes of ONDRISeq, the 48 FASTQ files produced from a
single sequencing run of 24 samples are imported and processed through the
software. The number of samples processed at once can vary depending on the
needs of the researcher and size of the NGS panel.
4.2.1. Within the "Navigation Area", right click and select "New Folder". Name
the folder such that there is clarity as to the sequencing run that was
performed.
4.2.2. From the toolbar at the top, select "Import". From the dropdown list of
sequencing platforms shown chose the platform with which the sequencing
was performed.
NOTE: For the purposes of ONDRISeq, "Illumina" is chosen. However, if
using a different sequencing platform consult the manufacturer's instructions
for the remainder of the FASTQ importing steps24.
4.2.3. In the dialog box, navigate to and select the FASTQ files from the
sequencing run that is being processed. Ensure that the files being imported
are stored in and imported from the local drive, if using a computer with
multiple servers.
4.2.4. From the "General options" of the dialog box, click the box beside "Paired
reads" if sequencing used paired end chemistries.
NOTE: In this case, there should also be two FASTQ samples imported for
each sample - one forward and one reverse.
4.2.5. From the Paired read information of the dialog box, select "Paired-end
(forward-reverse)" if the forward read FASTQ file appears before the reverse
read in the file list. If the files appear in the opposite order, select "Mate-pair
(reverse-forward)". Set the paired read minimum distance to 1 and maximum
distance to 1000, to allow for the detection of small scale structural
rearrangements within the sample sequences.
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4.2.6. From the "Illumina options" of the dialog box, select "Remove failed
reads", to remove the reads that failed sequencing. If the NGS desktop
instrument de-multiplexed the data before exporting the FASTQ files do not
select the "MiSeq de-multiplexing" box.
4.2.7. From the "Quality score" dropdown list, select the NGS Pipeline that was
utilized for sequencing. Select "Next" at the bottom of the dialog box.
NOTE: The pipeline used will affect the format of the FASTQ file quality
scores. For more information about which pipeline to select, consult the
manufacturer's instructions24.
4.2.8. From the new dialog box, select “Save” and “Create subfolders per bath
unit to put each sample's FASTQ files into their own individual folder.
Select "Next" at the bottom of the dialog box.
4.2.9. From the new dialog box, choose the folder that was created in step 4.2.1.
This is where the FASTQ files will be imported. Select "Finish" at the
bottom of the dialog box and wait until the FASTQ files are imported. Click
the "Processes" tab to see the status of the file import.
4.3. Design a workflow within the software to perform resequencing and variant
calling, according to manufacturer's instructions.
NOTE: This workflow can vary based on the needs of the researcher, but the
following steps encompass what is included for the purposes of ONDRISeq
(Figure J.2). The steps in this workflow can be applied to other NGS
resequencing and variant calling software as appropriate. All bioinformatics
processing for the purposes of ONDRI is performed in reference to human
reference genome GRCH37/hg19, for consistency of data processing and
analysis.
4.3.1. Map the sequencing reads to the reference genome.
4.3.1.1.

When configuring, choose the reference genome as appropriate,

ensuring that it is the same reference genome that is used for all
bioinformatics steps.
4.3.1.2.

From the masking mode drop-down list select "No masking" so

that no regions of the reference sequence are masked.
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4.3.1.3.

Use the default mapping options assigned by the software. Review

the manufacturer's instructions24 to verify that this is acceptable based
on the purposes of the research.
4.3.2. Include in the workflow local realignment to the human reference genome
to resolve any read mapping errors, particularly surrounding insertiondeletion variants.
4.3.2.1.

Use the default local realignment options assigned by the software.

Review the manufacturer's instructions24 to verify that this is acceptable
based on the purposes of the research.
4.3.3. Remove duplicated mapped reads produced by PCR within the NGS
protocol to reduce the effect of the PCR amplification bias, which may
produce false positives25.
4.3.3.1.

Set the "Maximum representation of minority sequence (%)",

based on the needs of the research.
NOTE: A lenient setting, as used for the purposes of ONDRISeq, is
5%; however, the software's default setting is more stringent 20%.
When two reads are very similar, this setting determines if the sequence
with fewer read counts should be considered a sequencing error from
the PCR amplification bias. Therefore, by setting 5%, the minority read
count must be ≤ 5% of the majority read count to be corrected to be
identical to the majority read.
4.3.4. Export statistics for the target regions in the form of a coverage summary
text file from the read tracks generated in step 4.3.3. Ignore non-specific
matches and broken pairs in the settings. Choose a destination on the local
drive for these files.
4.3.5. Export a binary sequence alignment map (BAM) file for each sample from
the read tracks generated in step 4.3.3. This contains sequence alignment
data, if needed in future analyses. Choose a destination on the local drive for
these files.
4.3.6. Choose a method of variant detection to call variants within the sequence.
NOTE: When assumptions can be made about the ploidy of the samples, it is
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recommended that a fixed ploidy variant detection algorithm be used, as is
used for the purposes of ONDRISeq. If this assumption cannot be made,
refer to the manufacturer's instructions24 to determine the best algorithm for
the purposes of the research.
4.3.6.1.

When configuring, from the fixed ploidy variant parameters

options set the ploidy as appropriate for the sample organism. Set the
"required variant probability", or the probability that a variant has been
correctly called in order for it to be retained, at 90.0%.
4.3.6.2.

Use the following recommended settings for the general filters:

"Minimum coverage" of 10x, "Minimum count" of 2, "Minimum read
frequency" of 20%, "Ignore broken pairs", ignore nonspecific matches
based on "Reads", and "Minimum read length" of 20.
NOTE: These parameters are based on the purposes of ONDRISeq.
Refer to the manufacturer's instructions24 to ensure they are appropriate
for the research being done.
4.3.6.3.

Use the following recommended settings for the noise filters:

"Base quality filters" with a "Neighbourhood radius" mapping quality
score of 5, "Minimum central quality" mapping score of 20, and
"Minimum neighbourhood quality" mapping score of 15; a "Read
direction filter" of 5.0%; and "Relative read direction filter" of 1.0%
significance.
NOTE: These parameters are based on the purposes of ONDRISeq.
Refer to the manufacturer's instructions24 to ensure they are appropriate
for the research being done.
4.3.7. Filter the variants that have been called based on their overlap with the
targeted panel's target regions as specified by the Browser Extensible Data
(BED) file, allowing only variants occurring within the genomic regions
selected for the targeted NGS panel to be retained.
NOTE: The BED file will be unique to the targeted NGS panel that is being
utilized, based on the regions of the genome that the panel is able to cover.
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4.3.8. Export a variant report in a variant calling format (VCF) file from the
variant track produced in step 4.3.7. Choose a destination on the local drive
for these files.
4.3.9. Save and install the workflow according to manufacturer's instructions24,
to make it available in the software's "Toolbox". Ensure the workflow is
named such that it is clear in the future what NGS panel it is appropriate for.
4.3.9.1.

In the dialog box with the "Exporting reference data" options

during installation, set all options to "Bundle".
4.3.9.2.

In the dialog box with the "Install location" options during

installation, click "Install the workflow on your local computer".
4.4. Run imported FASTQ sequencing read files through the customized
bioinformatics workflow designed in step 4.3, according to manufacturer's
instructions24.
4.4.1. Identify the workflow designed in step 4.3 in the software's "Toolbox" and
double-click it.
4.4.2. Within the dialog box that appears, locate the folders of FASTQ files that
were imported in step 4.2 within the "Navigation Area". Highlight all folders
by selecting them within the "Navigation Area" and then click the box
beside "Batch". Use the right-facing arrow to move the files to "Selected
elements". Click "Next" at the bottom of the dialog box.
4.4.3. Within the dialog box, review the "Batch overview" to ensure the correct
FASTQ files were selected and then click "Next".
4.4.4. Review the following steps of the workflow within the dialog box to
ensure the correct files and export locations were selected when designing
the workflow in step 4.3: "Map Reads to Reference"; Remove Duplicate
Mapped Reads"; "Create Statistics for Target Regions"; "Export BAM";
"Export Tab delimited text"; "Filter Based on Overlap"; and "Export VCF"
4.4.5. Within the final step in the dialog box -"Result handling"- select the
option "Save in input folder". Click "Finish" at the bottom of the dialog box.
NOTE: This means that the files produced for each sample will be placed

324

into the same folder that stores the FASTQ file within the data preprocessing software.
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Figure J.2: Workflow for the resequencing and variant calling of FASTQ files within the data pre-processing software (Table
of Materials) customized for the purposes of ONDRISeq.
The steps in the workflow can be applied to other NGS resequencing and variant calling software based on the needs of the researcher.
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5. Variant Annotation
5.1. Download and customize the Annotate Variation (ANNOVAR)26 script to
perform variant annotation upon the VCF file of each sample.
5.1.1. Download the following databases from ANNOVAR to be included as
annotations: 1) RefSeq27 (August 2015 update); 2) dbSNP13828 (September
2014 update); 3) the Exome Aggregation Consortium29 (ExAC, version 0.3
November 2015 update); 4) the National Heart, Lung, and Blood Institute
Exome Sequencing Project European Cohort30 (ESP, March 2015 update); 5)
the 1000 Genomes Project European Cohort31 (1KGP, August 2015 update);
6) ClinVar32 (March 2016 update); and 7) Combined Annotation Dependent
Depletion33 (CADD), Sorting Intolerant from Tolerant34 (SIFT), and
PolyPhen-235.
NOTE: Genome coordinates and all databases referenced by ANNOVAR
referred to human genome build GRCh37/hg19. Additionally, the database
versions listed are those used for the purposes of ONDRISeq, when
downloading the databases use the most up to date versions available.
5.1.2. If desired, customize ANNOVAR to output the complete list of annotated
variants, as well as a reduced compilation of annotated variants using the -filter operation26.
NOTE: The reduced list can be customized based on the needs of the
researcher. For the purposes of ONDRISeq, the reduced list of annotated
variants does not include variants that occur further than 15 bases from the
nearest exon or any variants with a minor allele frequency (MAF) >3% in
any of the three databases: 1) ExAC; 2) ESP; and 3) 1KGP. This step is
highly recommended.
5.1.3. If desired, customize ANNOVAR to single out specific allele calls based
on the needs of the researcher26.
NOTE: For the purposes of ONDRISeq, ANNOVAR assesses the
sequencing calls made for the APOE risk alleles rs429358(C>T):p.C130R
and rs7412(C>T):p.R176C in order to output the overall APOE genotype, of
which there are six possible combinations, including: 1) E2/E2; 2) E3/E2; 3)
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E4/E2; 4) E3/E3; 5) E4/E3; 6) E4/E4. Of these six
possible APOE genotypes, E4/E4 is the most commonly accepted genetic
risk factor for developing late-onset Alzheimer’s disease36.
5.2. Query disease mutation databases (Table of Materials) to determine if
variants have been previously associated with disease, with reasonable
evidence. Consider any variants that have not been previously reported as a
novel variant.
5.2.1. Assess the ANNOVAR annotations from ClinVar, such that the diseaseassociated variants include any classified as likely pathogenic or pathogenic.
5.3. Process splicing variants through the in silico prediction tools Splicing-based
Analysis of Variants37 (SPANR) and Human Splicing Finder38 (HSF, version
3.0).
5.4. If processing a large number of samples, compare the variant calls within each
sample to determine which variants are shared by various samples. Do this
manually or with a custom-designed script, allowing for the detection of possible
sequencing artifacts and contamination events.
NOTE: For the purposes of ONDRI, a custom script is used to annotate the
ANNOVAR output files by comparing them to one another. The script
incorporates an annotation, per variant, with the subject ID of any other samples
harboring the same variant, otherwise termed the variant's history in the study
cohort.
5.5. Classify variants based on the American College of Medical Genetics (ACMG)
Pathogenicity Guidelines39, assigning each variant a classification as one of the
following: 1) pathogenic; 2) likely pathogenic; 3) variant of uncertain
significance; 4) likely benign; or 5) benign.
NOTE: For the purposes of ONDRI, an in-house designed Python script is used
to perform ACMG classification on a semi-automated basis. Although not used
for this study, InterVar40 is a similarly designed tool that can be utilized in an
analogous manner.

328

5.6. Sanger sequence any variants with a sequencing coverage of <30x and/or
variants that have been identified in > 10% of the study cohort to validate that
they are not sequencing artifacts41.

Representative Results
The methodologies described herein were applied to 528 participant DNA samples from
individuals that have been enrolled in ONDRI. Samples were run on the ONDRISeq
panel in 22 runs of 24 samples per run. Overall, sequencing data were determined to be of
high quality with a mean sample coverage of 78 ± 13x and all individual runs expressed a
mean sample coverage >30x. Further, on average, 94% of all target regions were covered
at least 20x (Table J.1).
A mean 95.6% of reads were mapped to the reference sequence and all ONDRISeq runs
had >90% of reads mapped (Table J.1). Of the mapped reads, 92.0% had a Phred score
≥Q30, with only one run having <80% of mapped reads meeting this quality metric.
However, this run still displayed a mean coverage of 79x and 93% of target regions were
covered at least 20x.
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Table J.1: Sequencing quality metrics for 22 runs on ONDRISeq.
Parameter

Mean (±sd) Best performance Poorest performance

Cluster Density (x103/mm2) 1424 (±269)

1347

1835

Total Reads (106) 43.1 (±6.0)

48.7

47.4

Mapped Reads (106) 40.1 (±6.0)

47.1

25.7

Mapped Reads (%) 95.6 (±1.3)

96.8

92.6

92

68.3

99

51

Phred Quality Score ≥Q30 (%) 92.0 (±6.0)
Sample Coverage (x)

78 (±13)
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Case Study: Identification of rare variants in a PD patient.
To demonstrate the utility of our targeted NGS workflow, we present the example of a 68
year-old, male, Parkinson's disease patient. The DNA sample was run on the NGS
desktop instrument (Table of Materials) using the ONDRISeq panel alongside 23 other
ONDRI samples. The run displayed a cluster density of 1,555 x 103/mm2. The patient's
particular sample displayed a mean coverage of 76x, with 93.9% of the target regions
covered at least 20x.
After performing variant calling and annotation with the custom bioinformatics
workflow, the patient was found to harbor 1351 variants within the exons and
surrounding 250 bp of the 80 genes included on the ONDRISeq panel. However, the
ANNOVAR pipeline was able to reduce the number of variants by considering variant
sequence ontology and MAF, as described above. This produced a list of seven variants
that underwent manual curation (Figure J.3). From these seven variants, two were
identified as having possible clinical significance. This process is specific to the needs of
ONDRI and was done by identifying those that are relatively rare in the general
population and are nonsynonymous in ontology thereby causing a change in the protein.
Whether the variant had been previously associated with disease, the in silico predictions
of deleteriousness to the protein and the ACMG pathogenicity classification of the
variants were also utilized in this process.
The first identified from the reduced list was a heterozygous variant,
namely LRRK2:c.T3939A, resulting in the nonsense variant p.C1313*. LRRK2 encodes
the protein Leucine-Rich Repeat Kinase 2, which possesses both GTPase and kinase
activity42. Further, mutations within this gene are known to be among the leading causes
of familial Parkinson's disease43. This variant introduces a premature stop codon
within LRRK2, thereby losing amino-acid residues 1,314–2,527. This prevents the
translation of the protein's Ras of complex proteins (Roc), C-terminal of Roc (COR), and
protein kinase domains, which are involved in functioning as an atypical Rho GTPase,
GTP binding protein, and protein kinase, respectively, and was predicted to be damaging
by the in silico analysis generated by CADD (CADD Phred = 36). This variant is also

331

rare with a MAF of 0.004% and 0.01% in ExAC and ESP, respectively, and is absent
from the 1000G database. Additionally, this is the only patient out of all 528 sequenced
who carries this variant, which is novel since it has not been previously described in
disease mutation databases (Table of Materials). The confidence of the variant call was
confirmed by its deep coverage of 109x. Finally, the variant was assessed with the
AMCG Standards and Guidelines for pathogenicity and was classified as being
pathogenic.
The patient also carried a second heterozygous variant, NR4A2:c.C755A, resulting in the
missense change p.P252Q. The protein encoded by NR4A2, Nuclear Receptor Subfamily
4 Group A Member 2, is a transcription factor involved in the generation of dopaminergic
neurons44 and mutations within this gene have been previously associated with
Parkinson's disease45. The substitution of the non-polar proline to the polar glutamine was
predicted to be damaging by the in silico prediction analysis generated by CADD (CADD
Phred = 21.1), but not by the analysis generated by SIFT or PolyPhen-2. The variant is
rare, with a MAF of 0.004% in ExAC and absence from both ESP and 1000G. The
variant was also identified in an ONDRI participant diagnosed with vascular cognitive
impairment, but has not been previously described in disease mutation databases. This
variant had coverage of only 18x, however, Sanger sequencing will be performed in order
to ensure its validity within the sequence. Finally, the variant was determined to be of
uncertain significance when assessed with the ACMG Standards and Guidelines for
pathogenicity.
The ONDRISeq panel and bioinformatics pipeline is also able to determine
the APOE genotype of each sample. This patient was determined to have
the APOE genotype E3/E3.
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Figure J.3: Example of a reduced output from ANNOVAR displaying manually curated, annotated variants.
The reduced ANNOVAR output from the case study of a 68-year-old, male, patient with Parkinson's disease. Annotated variants are
curated to identify those that are most likely to be of clinical significance, as denoted by the red boxes.

333

Discussion
In the path from DNA sample extraction to identifying variants that may be of interest
when considering a patient's diagnosis, disease progression, and possible treatment
options, it is important to recognize the multifarious nature of the methodology required
for both sequencing and proper data processing. The protocol described herein is an
example of the utilization of targeted NGS and subsequent bioinformatic analysis
essential to identify rare variants of potential clinical significance. Specifically, we
present the approach taken by the ONDRI genomics subgroup when using the
ONDRISeq custom-designed NGS panel.
It is recognized that these methods were developed based on a specific NGS platform and
that there are other sequencing platforms and target enrichment kits that may be used.
However, the NGS platform and desktop instrument (Table of Materials) was chosen
based on its early US Food and Drug Administration (FDA) approval46. This
authorization reflects the high-quality sequencing that can be performed with the NGS
protocols of choice and the reliability that can be placed on the sequencing reads.
Although obtaining accurate sequencing reads with the depth of coverage is very
important, the bioinformatics processing required for final rare variant analysis is vital
and can be computationally intensive. Due to the many sources of errors that may occur
within the sequencing process, a robust bioinformatics pipeline must correct for the
various inaccuracies that can be introduced. They may arise from misalignments in the
mapping process, amplification bias introduced by PCR amplification in the library
preparation, and the technology producing sequencing artifacts47. No matter the software
used to perform read mapping and variant calling, there are common ways to reduce
these errors including local realignment, removal of duplicate mapped reads, and setting
proper parameters for quality control when calling variants. Additionally, the parameters
chosen during variant calling may vary based on what is most appropriate for the study at
hand11. The minimum coverage and quality score of a variant and the surrounding
nucleotides that were applied herein were chosen as to create a balance between

334

appropriate specificity and sensitivity. These parameters have been validated for the
ONDRISeq panel based on variant calling concordance with three separate genetic
techniques, as previously described, including: 1) chip-based genotyping; 2) allelic
discrimination assay; and 3) Sanger sequencing9.
Following accurate variant calling, in order to determine those of potential clinical
significance, annotation and curation are essential. Due to its open access platform,
ANNOVAR is an excellent tool for both annotation and preliminary variant screening or
elimination. Beyond being easily accessible, ANNOVAR can be applied to any VCF file,
no matter what sequencing platform is used, and is customizable based on the needs of
the research26.
After annotation, variants must be interpreted to determine if they should be considered
to be of clinical significance. Not only does this process become complex, but it is often
prone to subjectivity and human error. For this reason, the ACMG has set guidelines to
assess the evidence for pathogenicity of any variant. We apply a non-synonymous, rare
variant-based manual curation approach, which is constructed based on these guidelines
and safeguarded by individually assessing each variant that is able to pass through the
pipeline with a custom-designed Python script that classifies the variants based on the
guidelines. In this way, each variant is assigned a ranking of pathogenic, likely
pathogenic, uncertain significance, likely benign, or benign, and we are able to add
standardization and transparency to the variant curation process. It is important to
recognize that the specifics of variant curation, beyond the bioinformatics pipeline, will
be individualized based on the needs of the research, and was therefore beyond the scope
of the methodologies presented.
Although the methods presented here are specific to ONDRI, the steps described can be
translated when considering a large number of constitutional diseases of interest. As the
number of gene associations increase for many phenotypes, targeted NGS allows for a
hypothesis driven approach that can capitalize on the previous research that has been
done in the field. Yet, there are limitations to targeted NGS and the methodology
presented. By only focusing on specific regions of the genome, the areas of discovery are
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limited to novel alleles of interest. Therefore, novel genes or other genomic loci beyond
those covered by the sequencing targets, which could be revealed with WGS or WES
approaches, will not be identified. There are also regions within the genome that can be
difficult to accurately sequence with NGS approaches, including those with a high degree
of repeated sequences48 or those that are rich in GC content49. Fortunately, when utilizing
targeted NGS, there is a priori a high degree of familiarity with the genomic regions
being sequenced, and whether these might pose technical challenges. Finally, detection of
copy number variants from NGS data at present is not standardized50. However,
bioinformatics solutions to these concerns may be on the horizon; new computational
tools may help to analyze these additional forms of variation in ONDRI patients.
Despite its limitations, targeted NGS is able to obtain high-quality data, within a
hypothesis-driven approach, while remaining less expensive than its WGS and WES
counterparts. Not only is this methodology appropriate for efficient and directed research,
the clinical implementation of targeted NGS is growing exponentially. This technology is
being used to answer many different questions regarding the molecular pathways of
various diseases. It is also being developed into an accurate diagnostic tool at relatively
low cost when opposed to WES and WGS. Even when compared to the gold-standard
Sanger sequencing, targeted NGS can outcompete in its time- and cost-efficiency. For
these reasons, it is important for a scientist or clinician who receives and uses NGS data,
for instance, delivered as text in a laboratory or clinical report, to understand the complex
"black box" that underlies the results. The methods presented herein should help users
understand the process underlying the generation and interpretation of NGS data.
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Table of Materials
Name

Company

Catalog Number

Comments

4 mL EDTA K2 tubes

Fisher Scientific

02-689-4

1 M Tris Buffer

Bio Basic Canada
Inc.

SD8141

Gentra Puregene Blood
Kit

Qiagen

158389

1,000 mL Kit. This is the blood extraction kit, referred to in step
1.3.

NanoDrop-1000
Spectrophotometer

Thermo Fisher
Scientific

ND-2000

Replaced by the NanoDrop-2000 Spectrophotometer. This is the
full-spectrum spectrophotometer, referred to in steps 1.4 and 2.1.2.

Qubit 2.0 fluorometer

Invitrogen

Q32866

This is a fluorometer appropriate for the quantification of DNA,
referred to in steps 2.1.4, 2.1.6, 2.2.3, and 3.1.3.

Nextera Rapid Custom
Capture Enrichment Kit

Illumina, Inc.

FC-140-1009

Specifically designed for the ONDRISeq panel, sequencing the
exons of 80 genes, resulting in 971,388 base pairs of sequence in
paired-end reads of 150 bases in length; 288 samples per kit. This is
the target enrichment kit, referred to in steps 2.2, 2.2.2, 2.2.3, 3.1.5,
3.1.6, 3.4.1, and the Discussion.

2100 BioAnalyzer

Agilent
Technologies

G2939BA

This is an automated electrophoresis system, referred to in step
3.1.4.

High Sensitivity DNA
Reagent Kit

Agilent
Technologies

5067-4626

110 Samples per kit; This is a DNA quality analysis kit, referred to
in step 3.1.4.

MiSeq Reagent Kit v3

Illumina, Inc.

MS-102-3003

600 Cycle Kit; This is the NGS desktop instrument reagent kit,
referred to in step 3.1.
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MiSeq Personal
Genome Sequencer

Experiment Manager

BaseSpace

CLC Genomics
Workbench 10.1.1

Illumina, Inc.

SY-410-1003

This is a NGS desktop instrument, referred to in steps 2.2.1, 3.1,
3.1.1, 3.1.2, 3.1.8, 3.2, 4.2.6, the Representative Results, and the
Discussion.

Illumina, Inc.

This is NGS technology software, referred to in step 3.1.1
and Figure J.1.
https://support.illumina.com/sequencing/sequencing_software/exper
iment_manager/downloads.html

Illumina, Inc.

SW-410-1000

This is a cloud-based computing environment, referred to in steps
3.1.2, 3.2, 3.3, 3.3.1, 3.3.2, 3.4, 3.4.1, 3.4.2 and 3.4.3.
https://basespace.illumina.com/

832000

Open source options for data pre-processing are also available that
can model the workflow used in this protocol. This is the software
used for data pre-processing, referred to throughout step 4 and
in Figure J.2.

Qiagen

http://annovar.openbioinformatics.org/en/latest/userguide/download/

Annotate Variation

RefSeq

National Center for
Biotechnology
Information

https://www.ncbi.nlm.nih.gov/refseq/

dbSNP138

National Center for
Biotechnology
Information

https://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi?view
+summary=view+summary&build_id=138

Exome Aggregation
Consortium

Broad Institute

http://exac.broadinstitute.org/
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National Heart, Lung,
and Blood Institute
Exome Sequencing
Project European
Cohort

University of
Washington and the
Broad Institute

http://evs.gs.washington.edu/EVS/

ClinVar

National Center for
Biotechnology
Information

https://www.ncbi.nlm.nih.gov/clinvar/

Combined Annotation
Dependent Depletion

University of
Washington and
Hudson-Alpha
Institute for
Biotechnology

http://cadd.gs.washington.edu/

Sorting Intolerant from
Tolerant

J. Craig Venter
Instutite

http://sift.jcvi.org/

PolyPhen-2

Brigham and
Women's Hospital,
Harvard Medical
School

http://genetics.bwh.harvard.edu/pph2/

Human Gene Mutation
Database

Qiagen

This is a disease mutation database, referred to in step 5.2 and the
Representative Results. https://portal.biobase-international.com/cgibin/portal/login.cgi?redirect_url=/hgmd/pro/start.php

Splicing-based
Analysis of Variants

Frey lab, University
of Toronto

http://tools.genes.toronto.edu/

Human Splicing Finder

Aix Marseille
Université

http://www.umd.be/HSF3/HSF.shtml

834050
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Other materials
Centrifuge
Disposable transfer
pipets
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INVITED PRESENTATIONS AND SEMINARS
1. Neurodegeneration Genetics Seminar, Farhan Lab, McGill University, Montréal,
QC (Visiting Speaker)
“Rare variant enrichment across neurodegenerative and cerebrovascular
diseases.” | May 27, 2021
2. ONDRI Friends and Family Day, London, ON (Provincial, Audience: General Public)
“Investigating genetics’ role in neurodegenerative disease.” | September 17,
2019
3. Alzheimer’s Society of London and Middlesex Scholarship Research Showcase,
Alzheimer’s Society of London and Middlesex, London, ON (Provincial, Audience:
General Public)
“Investigating genetics’ role in neurodegenerative disease.” | May 29, 2019
4. ONDRI Friends and Family Day, Toronto, ON (Provincial, Audience: General
Public)
“Investigating genetics’ role in neurodegenerative disease.” | February 20,
2019
5. London Regional Genomics Centre and Illumina’s NextSeq Launch, Robarts
Research Institute, London, ON (Local)
“Identifying rare disease-causing mutations using whole-exome
sequencing.” | September 26, 2016

PLATFORM PRESENTATIONS
1. Neuroscience Research Day, Western University, London, ON (Provincial;
Competitive) | February 19, 2021
*Award-winning
2. Robarts Research Retreat, Western University, London, ON (Institutional;
Competitive) | June 19, 2020
3. Leena Peltonen School of Human Genomics, Les Diablerets, Switzerland
(International; Competitive) | August 20, 2019
4. 8th Annual Canadian Human and Statistical Genetics Meeting, Montebello, QC
(National; Competitive) | June 17, 2021
5. ONDRI Scientific Retreat, Toronto, ON (Provincial) | May 27, 2019
6. Biochemistry Spring Menten Symposium, Western University, London, ON
(Institutional) | May 3, 2019
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7. Biochemistry Graduate Student Spring Symposium, Western University, London,
ON (Institutional) | June 13, 2018
8. London Health Research Day, London, ON (Local; Competitive) | May 10, 2018
9. Molecular Medicine Data Club, Robarts Research Institute, Western University,
London, ON (Institutional) | May 2, 2018
10. ONDRI Workshop, Toronto, ON (Provincial) | October 3, 2017
11. Robarts Research Retreat, Western University, London, ON (Institutional;
Competitive) | June 20, 2017
12. Molecular Medicine Data Club Three Minute Theses, Robarts Research Institute,
Western University, London, ON (Institutional) | May 31, 2017
13. ONDRI Workshop, Mississauga, ON (Provincial) | April 20, 2017

POSTER PRESENTATIONS
1. Biochemistry Fall Symposium, Western University, London, ON (Institutional) |
December 10, 2020
2. American Society of Human Genetics Meeting, Virtual (International) | October
27–30, 2020
3. American Society of Human Genetics Meeting, Houston, TX (International) |
October 17, 2019
4. 8th Annual Canadian Human and Statistical Genetics Meeting, Montebello, QC
(National) | June 18, 2019
5. Department of Medicine Resident Research Day, Western University, London,
ON (Institutional) | May 10, 2019
6. London Health Research Day, London, ON (Local) | April 30, 2019
7. American Society of Human Genetics Meeting, San Diego, CA (International) |
October 19, 2018
8. Schulich Clinician Scientist Trainee Symposium, Western University, London, ON
(Institutional) | August 14, 2018
9. International Symposium on Atherosclerosis, Toronto, ON (International) | June
10, 2018
10. Robarts Research Retreat, Western University, London, ON (Institutional) | June 1,
2018
11. Department of Medicine Resident Research Day, Western University, London,
ON (Institutional) | May 11, 2018
12. American Society of Human Genetics Meeting, Orlando, FL (International) |
October 17, 2017
13. Robarts Research Retreat, Western University, London, ON (Institutional) | June
20, 2017
14. 8th Annual Canadian Human and Statistical Genetics Meeting, Quebec City, QC
(National) | April 23, 2017
15. London Health Research Day, London, ON (Local) | March 28, 2017
16. Harold Stewart Research Showcase, Western University, London, ON
(Institutional) | January 20, 2017
17. ONDRI Annual Workshop, London, ON (Provincial) | October 17, 2016
18. Robarts Research Retreat, Western University, London, ON (Institutional) | June
13, 2016
19. Department of Medicine Resident Research Day, Western University, London,
ON (Institutional) | May 26, 2016
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20. Harold Stewart Research Showcase, Western University, London, ON
(Institutional) | January 22, 2016

TEACHING EXPERIENCE
Graduate Teaching Assistantships – Western University, London, ON
MEDSCI 4931G: Selected Topics in Medical Sciences
January 2021 – April 2021
MEDSCI 3900G: Medical Science Laboratory

January 2020 – April 2020

MEDSCI 4900F/G: Advanced Medical Science Laboratory
BIOCHEM 3380G: Biochemistry Laboratory
BIOCHEM 3382A: Biochemical Regulation

September 2019 – April 2020
September 2018 – April 2019
January 2018 – April 2018
January 2017 – April 2017

September 2017 – December 2017
September 2016 – December 2016

MENTORING AND LEADERSHIP EXPERIENCE
▪
▪
▪

Summer Research Assistant Mentor (6)
May 2017 – August 2021
Western University, London, ON
Undergraduate Thesis Student Mentor (8)
September 2016 – April 2021
Western University, London, ON
Schulich Graduate Students’ Council Chair
March 2019 – May 2021
Schulich School of Medicine and Dentistry, Western University, London, ON

INTERVIEWS AND MEDIA RELATIONS
▪
▪
▪
▪

Impact Stories, The Ontario Neurodegenerative Disease Research Initiative
“ONDRI Scholars Promoting Novel Scientific Discoveries.” | October 2020
The Collaborator, Schulich School of Medicine and Dentistry
“Solving a genetic puzzle.” | November 2019
The Collaborator, Schulich School of Medicine and Dentistry
“On a mission to increase diversity and inclusion in the world of science.” |
April 2019
Trainee Q&A, Robarts Research Institute Discovery Newsletter
“The research gene.” | October 2017

